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This document is dedicated to the memories of Michael W. Shannon, MD, MPH (1953-2009) and Kathryn R. 
Mahaffey, PhD (1943-2009). 
Dr. Shannon was a gifted scientist, a respected leader in medicine and public health, and a tireless advocate 
for prevention of childhood lead poisoning. His contributions to the scientific literature documenting unrec­
ognized sources of exposure and describing innovative management protocols did much to improve the lives 
of countless children both in the United States and around the world. 
Dr. Mahaffey’s early work to ensure that blood samples collected during the National Health and Nutrition 
Examination Surveys increased understanding of lead poisoning and contributed to the identification of lead 
in gasoline and paint as primary routes of lead exposure in children. She was actively involved in preventing 
lead exposure in children for over 35 years and provided invaluable assistance with this document. 
The thoughtful contributions of Drs. Shannon and Mahaffey to the CDC Advisory Committee on Childhood 
Lead Poisoning Prevention will be deeply missed. 
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Lead exposure during pregnancy and breastfeeding can result in lasting adverse health effects independent 
of lead exposure during other life stages. However, to date there has been limited guidance available for clini­
cians and the public health community regarding the screening and management of pregnant and lactating 
women exposed to high levels of lead. Recognizing the need for national recommendations, the Centers 
for Disease Control and Prevention and the Advisory Committee on Childhood Lead Poisoning Prevention 
convened a workgroup of recognized experts to review the existing evidence for adverse effects of past and 
current maternal lead exposure on maternal health and fertility and on the developing fetus, infant, and child 
in prenatal and postnatal states and to propose evidence-based strategies for intervention. 
These Guidelines for the Identification and Management of Lead Exposure in Pregnant and Lactating Women are 
based on scientific data and practical considerations regarding preventing lead exposure during pregnancy, 
assessment and blood lead testing during pregnancy, medical and environmental management to reduce 
fetal exposure, breastfeeding, and follow up of infants and children exposed to lead in utero. 
The guidelines also outline a research agenda that will provide crucial information for future efforts to prevent 
and treat lead exposure during pregnancy and lactation. Further research is needed for a better understand­
ing of lead’s effect on pregnancy outcomes and infant development; lead kinetics across the placenta and in 
breast milk and their relationship to long-term health effects; genetic susceptibility to damage from lead; as 
well as the pharmacokinetics, effectiveness, and safety of chelating agents in the pregnant woman. Research 
is also needed to address important clinical and public health needs including validation of risk question­
naires for pregnant women, optimal timing of blood lead testing, and effective strategies for identification and 
treatment of pica in pregnant women. 
I wish to thank the members of the Advisory Committee on Childhood Lead Poisoning Prevention, mem­
bers of the Lead in Pregnancy Workgroup, and consultants who developed this document and acknowledge 
their contribution to the health of the nation’s children. This document was voted on and approved with one 
abstention at the October 21-22, 2009, meeting of the Advisory Committee on Childhood Lead Poisoning Pre­
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Despite improvements in environmental policies and significant reductions in U.S. average blood lead levels, 
lead exposure remains a concern for pregnant and lactating women, particularly among certain population 
subgroups at increased risk for exposure. 
Recent National Health and Nutrition Examination Survey (NHANES) estimates suggest that almost 1% of 
women of childbearing age (15-44 years) have blood lead levels greater than or equal to 5 µg/dL (Centers for 
Disease Control and Prevention 2008, unpublished data). As documented in these guidelines, there is good 
evidence that maternal lead exposure during pregnancy can cause fetal lead exposure and can adversely af­
fect both maternal and child health across a wide range of maternal exposure levels. 
However, guidance for clinicians regarding screening and managing pregnant and lactating women exposed 
to lead has not kept pace with the scientific evidence. There are currently no national recommendations by 
any medical or nursing professional association that covers lead risk assessment and management during 
pregnancy and lactation. Currently, New York State, New York City, and Minnesota are the only jurisdictions 
that have issued lead screening guidelines and follow-up requirements for pregnant women by physicians or 
other providers of medical care. The lack of national recommendations about testing pregnant women and 
managing those identified with lead exposure above background levels has created confusion in the clini­
cal and public health sectors. In response to this need, the Centers for Disease Control and Prevention (CDC) 
Advisory Committee on Childhood Lead Poisoning Prevention (ACCLPP) convened the Lead and Pregnancy 
Work Group to review the existing evidence for adverse effects of past and current maternal lead exposure on 
maternal health and fertility and on the developing fetus, infant, and child in prenatal and postnatal states. 
This document presents ACCLPP’s summary of the evidence to date from human studies, conclusions, and 
CDC recommendations regarding 
•	 prevention of lead exposure for pregnant and lactating women, 
•	 risk assessment and blood lead testing of pregnant women, 
•	 medical and environmental management, 
•	 breastfeeding, and 
•	 follow up of infants and children of mothers with blood lead levels exceeding national norms. 
In instances where there is an absence of clear and convincing evidence, recommendations are based on the 
combined clinical, practical, and research experience of ACCLPP and work group members. This document 
also identifies research, policy, and health education needs to inform policy and improve care of pregnant and 
lactating women with lead exposure above background levels. The guidelines do not address all women of 
childbearing age, nor does it address male reproductive health issues associated with lead exposure. 
The evidence that prenatal lead exposure impairs children’s neurodevelopment, placing them at increased 
risk for developmental delay, reduced IQ, and behavioral problems, is convincing. The research also suggests, 
but is inconclusive, that fetal lead exposure at levels found in the United States results in low birth weight 
or adverse health conditions in adults who were exposed to lead in utero, among others. Further research is 
needed for a better understanding of several biomedical issues, including pregnancy outcomes and infant 
development associated with maternal lead exposure during pregnancy, lead kinetics across the placenta and 
in breast milk and their relationship to long-term health effects, genetic susceptibility to damage from lead, 
pharmacokinetics and effectiveness of chelating agents in the pregnant woman, among others. Research is 
also needed to address important clinical and public health needs, like validation of risk questionnaires for 
pregnant women, optimal timing of blood lead testing during pregnancy, and effective strategies for identifi­
cation and treatment of pica in pregnant women. 
iii 
iv 
This document provides guidance based on current knowledge regarding blood lead testing and follow-up 
care for pregnant and lactating women with lead exposure above background levels. Because there is no 
apparent threshold below which adverse effects of lead do not occur, CDC has not identified an allowable 
exposure level, level of concern, or any other bright line intended to connote a safe or unsafe level of exposure 
for either mother or fetus. Instead, CDC is applying public health principles of prevention in recommending 
follow-up blood lead testing and interventions when prudent. These guidelines recommend follow-up activi­
ties and interventions beginning at blood lead levels (BLLs) ≥5 µg/dL in pregnant women. Unlike the BLL level 
of concern of 10 µg/dL for children, which is a communitywide action level, a BLL of 5 µg/dL in pregnant wom­
en serves a different purpose: it flags the occurrence of prior or ongoing lead exposure above background 
levels, which may not otherwise be recognized. The vulnerability of a developing fetus to adverse effects and 
the possibility of preventing additional exposures postnatally justify intervention for pregnant women show­
ing evidence of lead exposure above background levels. 
CDC does not recommend blood lead testing of all pregnant women in the United States. State or local public 
health departments should identify populations at increased risk for lead exposure and provide community-
specific risk factors to guide clinicians in determining the need for population-based blood lead testing. Rou­
tine blood lead testing of pregnant women is recommended in clinical settings that serve populations with 
specific risk factors for lead exposure. Health care providers serving lower risk communities should consider 
the possibility of lead exposure in individual pregnant women by evaluating risk factors for exposure as part 
of a comprehensive occupational, environmental, and lifestyle health risk assessment of the pregnant woman, 
and perform blood lead testing if a single risk factor is identified. Assessment for lead exposure, based on risk 
factor questionnaires or blood lead testing, should take place at the earliest contact with the pregnant patient. 
For all patients, but especially those with known lead exposures, health care providers should provide guid­
ance regarding sources of lead and help identify potential sources of lead in the patient’s environment. Risk 
factors for lead exposure above background levels in pregnant women differ from those described in young 
children. Important risk factors for lead exposure in pregnant women include recent immigration, pica prac­
tices, occupational exposure, nutritional status, culturally specific practices such as the use of traditional 
remedies or imported cosmetics, and the use of traditional lead-glazed pottery for cooking and storing food. 
Lead-based paint is less likely to be an important exposure source for pregnant women than it is for children, 
except during renovation or remodeling in older homes. Pregnant women with blood lead concentrations of 
10 µg/dL or higher should be removed from occupational lead exposure. 
Follow-up testing; increased patient education; and environmental, nutritional, and behavioral interven­
tions are indicated for all pregnant women with blood lead levels greater than or equal to 5 µg/dL in order to 
prevent undue exposure to the fetus and newborns. Since lead exposure at these levels affects only approxi­
mately 1% of U.S. women of childbearing age, the recommendations in this guidance document should not 
significantly impact many individuals or clinical practices. 
The essential activity in management of pregnant women with blood lead levels ≥5 µg/dL is removal of the 
lead source, disruption of the route of exposure, or avoidance of the lead-containing substance or activity. 
Source identification beyond obtaining a thorough environmental and occupational history should be con­
ducted for BLLs ≥15 µg/dL in collaboration with the local health department, which will conduct an environ­
mental investigation of the home environment in most jurisdictions and an investigation of the work environ­
ment (in some jurisdictions). Women who engage in pica behavior, regardless of the substance consumed, 
may benefit from nutritional counseling. Pregnant and lactating women with a current or past BLL ≥5 µg/dL 
should be assessed for the adequacy of their diet and provided with prenatal vitamins and nutritional advice 
emphasizing adequate calcium and iron intake. Chelation therapy during pregnancy or early infancy may 
be warranted in certain circumstances where the maternal or neonatal blood lead exceeds ≥45 µg/dL and in 
consultation with an expert in lead poisoning. Insufficient data exist regarding the advisability of chelation for 
pregnant women with BLL <45 µg/dL. CDC recognizes the important benefits of breastfeeding for both the 
mother and child and considered the adverse health and developmental effects associated with lead exposure 
compared to those associated with not breastfeeding. The adverse developmental effects of ≥5 µg/dL in infant 
blood lead level was of greater concern than the risks of not breastfeeding. Thus, CDC encourages mothers 
with blood lead levels <40 µg/dL to breastfeed, however, mothers with higher blood lead levels are encour­
aged to pump and discard their breast milk until their blood lead levels drop below 40 µg/dL. These recom­
mendations are made for the U.S. population and are not appropriate in countries where infant mortality from 
infectious diseases is high. Specific recommendations regarding appropriate follow-up blood lead testing of 
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ABLES: Adult Blood Lead Epidemiology and Surveillance program, a CDC-funded state-based program to 
 
 
















AI (adequate intake): a recommended average daily nutrient intake level, based on estimations of average 
 
 




alternative medicines: for these guidelines, alternative medicines are defined as nonstandard therapies 
 
 
not sanctioned in modern Western medicine; typically from other countries; and usually unregulated in the 
 
 
United States, including folk, traditional, botanic, herbal, alternative, and complementary therapies, medicines, 
 
 




anemia: a condition in which there is a reduction of the number or volume of red blood cells or of the total 
 
 












anticipatory guidance: practical information given to individuals to promote health before a certain mile­













apoptosis: a form of cell death in which a programmed sequence of events leads to the elimination of cells 
 
 








at-risk populations: populations with characteristics, behaviors, or lifestyles (including home, work, and hob­





ayurveda: one of India’s traditional systems of medicine, involving a holistic system of healing and natural 
 
 












biomarker (biological marker): a measure of exposure to lead, or other substance, that is measured in hu­





BLL (blood lead level): the concentration of lead in a sample of blood expressed in micrograms per deciliter 
 
 







breast milk lead: levels of lead in breast milk; the concentration of lead in a sample of maternal breast milk is 
usually expressed in micrograms per liter (µg/L). 
bone lead: long-lived stores of lead from past exposure that is accumulated in the body’s skeletal system; 
measured in micrograms (µg) of lead/gram bone mineral. 
bone mobilization or bone turnover: the process by which the body dissolves part of the bone in the skel­
eton in order to maintain or raise the levels of circulating calcium in the blood or for pathological reasons, such 
as immobilization, age-related osteoporosis, or hyperthyroidism. 
bone resorption: the break down and wearing away of bone tissue that results in the release of bone minerals 
into circulation. 
care coordination: the formal coordination of the care of a mother or infant with a BLL that exceeds a specific 
value and making available existing services as needed to the mother-infant pair. 
case management: the follow-up care of a pregnant/lactating woman with a blood lead level ≥5 µg/dL, and 
her newborn infant, if necessary. Case management includes a) client identification and outreach, b) individual 
assessment and diagnosis, c) service planning and resource identification, d) linkage of clients to needed 
services, e) service implementation and coordination, f ) monitoring of service delivery, g) advocacy, and h) 
evaluation. 
casein: the main protein found in milk and other dairy products. 
CDC (Centers for Disease Control and Prevention): part of the U.S. Department of Health and 
Human Services. 
chelation therapy: the use of a chelating agent (chemical compounds that bind to metals) to remove toxic 
metals, such as lead, from the body. 
chronic: being long-lasting and recurrent. 
CI (confidence interval): an interval estimate that defines and upper and lower limit with an associated prob­
ability. 
clearance standards: maximum allowable lead dust levels (established by the U.S. Department of Housing 
and Urban Development and the U.S. Environmental Protection Agency) on floors and interior window sills 
after a residence has undergone lead hazard control work. 
CLPPP (Childhood Lead Poisoning Prevention Program): CDC-funded state or local program to prevent 
childhood lead poisoning. 
conception: union of the sperm and the egg which marks the onset of pregnancy (also “fertilization”). 
confirmatory test: a venous blood lead test performed after a previous capillary, filter paper, or venous blood 
lead test to verify the results before interventions occur. 
congenital anomaly: a structural or functional abnormality of the human body that develops before birth but 
is usually identified in the period just after birth or in early life. 
contraindication: a condition that makes a particular treatment or medical procedure inadvisable. 
creatinine: a chemical waste product generated from muscle processes that create and use energy in the hu­
man body; measured to determine if kidneys are functioning properly. 
 
 
cumulative: increasing by successive additions over a period of time. 
dyad: two individuals or units regarded as a pair, such as the mother-infant pair. 
DRI (dietary reference intake): a set of dietary reference values introduced in the 1990s with the primary goal 
of preventing nutrient deficiencies, but also reducing the risk for chronic diseases such as osteoporosis, cancer, 
and cardiovascular disease. 
EAR (estimated average requirement): nutrient intake levels expected to satisfy the needs of 50% of the 
people in a particular age group. 
encephalopathy: any diffuse disease of the brain that alters brain function or structure. Lead exposure is one 
of many possible causes of encephalopathy. Lead encephalopathy is a life-threatening emergency associated 
with high blood lead levels and often characterized by coma, seizures, ataxia, apathy, bizarre behavior, and 
poor physical condition. 
endogenous: developing or originating from within the body. 
endothelium: a thin layer of cells that line the body’s hollow organs including blood vessels. 
environmental investigation: an investigation of the residence (or other place where person spends signifi­
cant amounts of time) by trained personnel to identify lead hazards. 
exchange transfusion: simultaneous withdrawal of the recipient’s blood and transfusion with the donor’s 
blood. 
exogenous: developing or originating from outside the body. 
EPA (U .S . Environmental Protection Agency; U .S . EPA): federal agency charged with protecting human 
health and the environment by writing and enforcing regulations based on laws passed by Congress. 
FDA (U .S . Food and Drug Administration; U .S . FDA): federal agency responsible for assuring the safety, ef­
ficacy, and security of human and veterinary drugs, biological products, medical devices, the U.S. food supply, 
cosmetics, and products that emit radiation. 
fecundity: the potential reproductive capacity of an organism or population, as measured by the number of 
reproductive cells capable of reproducing (e.g., eggs and sperm). 
ferritin: the body’s major iron-carrying protein, which is measured to monitor iron status. 
fertility: the ability to conceive and have children through normal sexual activity. 
Fetal Origins of Adult Disease (or Barker) hypothesis: the suggestion that prenatal adverse nutritional 
or environmental conditions affect fetal development and have lifelong health and developmental 
consequences. 
fetus: the unborn human offspring from the end of the 8th week after conception (when the major structures 
have formed) until birth. 
first trimester (of pregnancy): time period extending from the first day of the last menstrual period through 
12 weeks of gestation. The first trimester is a critical window of fetal development that is important for the 
formation and development of organs and organ systems. 
follow-up test: a blood lead test used to monitor the status of a person with a previously blood test indicating 








gestational age: the age of a fetus or newborn, counting from the time of fertilization, usually measured in 
 
 
















HUD (U .S . Department of Housing and Urban Development): federal agency that develops and executes 
 
 








immigration: the one-way inward movement of individuals into a population or population area, usually to a 
 
 








IOM (Institute of Medicine): a nonprofit agency established in 1970 under the charter of the National Acad­

emy of Sciences that provides independent, objective, evidence-based advice to policymakers, health profes­
















iron deficiency: a disorder that occurs when there is not enough iron in the body, causing problems with red 
 
 











lactation: the period after childbirth when milk is produced and secreted from the mother’s breasts to provide 
 
 




lead-based paint: paint or other surface coating that contains lead equal to or exceeding 1.0 milligram per 
 
 
square centimeter or 0.5 percent by weight (5,000 parts per million), as defined by 302(c) of the Lead-Poison­





lead-based paint hazard: any condition that causes exposure to lead from lead-contaminated dust, lead-
 
 
contaminated soil, or lead-contaminated paint that is deteriorated or present in accessible surfaces, friction 
surfaces, or impact surfaces that would result in adverse human health effects as established by the appropri­
ate federal agency. 
lead-glazed ceramic pottery: ceramic ware or pottery manufactured mainly by artisans and small family 
businesses using a centuries-old tradition of low-temperature-fired lead glazes to vitrify the surface and color 
the objects, and often imported from Mexico and other countries. 
lead-safe: housing or building units with no lead-based paint hazards as determined by a lead risk assessment 
or by dust sampling at the conclusion of lead hazard control activities. 
lead-safe work practices: low-technology/best practices techniques, methods, and processes that minimize 
the amount of dust and debris created during the remodeling, renovation, rehabilitation, or repair of pre-1978 
housing that are used to control, contain, and clean up lead dust and deteriorated lead-based paint hazards in 
a manner that protects both the workers and the occupants of the unit. 
low birth weight: a baby that weighs less than 2,500 grams at birth. 
LPWG (Lead and Pregnancy Work Group): subgroup of the CDC Advisory Committee on Childhood Lead 
Poisoning Prevention. 
medical management: for this guidelines, medical management is the care provided by a health care pro­
vider to a pregnant/lactating woman or infant whose blood lead levels indicate exposure to lead above back­
ground levels. Medical management includes clinical evaluation for complications of lead exposure, family 
lead education and referrals, chelation therapy if appropriate, follow-up testing at appropriate intervals, and 
communication with local health department as necessary. 
µg/dL (micrograms per deciliter): a unit of measure for blood lead concentration. 
milk-to-plasma ratio: used to express the relative efficiency of passive transfer of a chemical from the blood 
into milk. 
neonate: a newborn infant, less than 1 month of age. 
neurodevelopment: normal growth and progression of the nervous system during the life of an organism, 
measurement of which usually incorporates aspects of intellectual and behavioral attainment. 
normotensive: blood pressure in the normal range for a healthy individual given their age. 
nutrient: substances that are vital to health and give us energy, growth, help repair body tissues, and regulate 
body functions. The two major nutrient groups are macronutrients (protein, carbohydrates, fat) and micronu­
trients (vitamins, minerals). 
nutrition: the way the human body takes in and uses foods. Substances or ingredients in food that are sources 
of nutrition are called nutrients. 
NHANES (National Health and Nutrition Examination Survey): a periodic assessment of the health and 
nutritional status of a representative sample of adults and children in the United States conducted by the CDC 
National Center for Health Statistics. 
NIOSH (National Institute for Occupational Safety and Health): the part of CDC responsible for conducting 
research and making recommendations for the prevention of work-related illnesses and injuries. 
OSHA (Occupational Safety and Health Administration): the main federal agency charged with promulga­
tion and enforcement of safety and health regulations. 
observational study: a type of study in which free-living individuals are observed and certain outcomes are 
measured with no attempt made to affect the outcome (for example, no treatment is given). 
organogenesis: the formation of organs within a developing fetus that occurs within the first trimester of 
pregnancy (prior to 16 weeks gestation). 
PCP (primary care provider): the health professional who oversees a patient’s care, usually a physician, nurse 
practitioner, or physician’s assistant. 
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placenta: a temporary organ joining the mother and fetus; it is attached to the wall of the uterus (womb) to 
 
 




















ppb (parts per billion): Represents the concentration of something in water or soil. One ppb represents one 
 
 




ppm (parts per million): Represent the concentration of something in water or soil. One ppm represents one 
 
 




preeclampsia: a condition in pregnancy characterized by a sharp rise in blood pressure, protein in the moth­

er’s urine, and swelling of the hands and feet; this condition has negative consequences for both the mother 
 
 




pregnancy: the period from conception to birth when a woman carries a developing fetus (baby) in her uterus 
 
 




pre- (or post-) menopause: before (or after) the end of a woman’s reproductive years; regular menstrual peri­













primary prevention: preventing a problem before it occurs. Primary prevention of lead poisoning eliminates 
 
 




















RCT (randomized [placebo-controlled] clinical trial): a study in which participants are assigned by chance 
 
 




RD (registered dietician): a certified professional with the combined education and experience to conduct 
 
 




RDA (recommended dietary allowance): used from 1941 until 1989 to evaluate food choices that would 
 
 











renovation: construction and/or home or building improvement measures (e.g., window replacement, weath­
erization, remodeling, repairing). 
risk factor questionnaire: a set of questions designed to elicit responses from an individual that can identify 
their characteristics that can increase that person’s chances of, in these guidelines, being exposed to lead from 
various sources. 
screening (blood lead screening): for lead poisoning, a laboratory test for lead that is performed on the 
blood of an asymptomatic person to determine if that person has evidence of lead exposure above back­
ground levels. 
secondary prevention: responding to a problem after it has been detected. Secondary prevention of lead 
poisoning involves identifying persons with confirmed lead exposure and eliminating or reducing additional 
lead exposure. 
spontaneous abortion (or miscarriage): the loss of a fetus before the 20th week of pregnancy. 
Tanner scale or Tanner stage: used to define physical measurements of a child’s development based on ex­
ternal primary and secondary sex characteristics, such as the size of the breasts or genitalia and development 
of pubic hair. 
targeted screening: blood lead testing of some, but not all, individuals in a population or group designated 
as being at increased risk for lead exposure. 
threshold: an established dose or level below which an effect does not occur. 
TTDI (maximum total tolerable daily intake): a term used by the FDA to caution against excessive intake of 
nutrients that can be harmful in large amounts. 
toxicokinetics: the fate and transport of chemicals in the human body. 
traditional medicines: see alternative medicines. 
umbilical cord: the tubal structure (consisting of two arteries and one vein) that connects the fetus (baby) to 
the placenta, supplying blood, oxygen and nutrients to the baby during pregnancy. 
universal screening: the blood lead testing of all persons in a population or group, such as pregnant women 
or city residents. 
U .S . PHSTF (U .S . Preventive Health Services Task Force): An independent panel of experts in primary care 
and prevention that systematically reviews the evidence of effectiveness and develops recommendations for 
clinical preventive services. 
WIC: Special Supplemental Nutrition Program for Women, Infants, and Children. 
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•	 Lead exposure remains a public health problem for certain groups of women of childbear
ing age and for the developing fetus and nursing infant. Prenatal lead exposure has known 
influences on maternal health and infant birth and neurodevelopmental outcomes. 
•	 Bone lead stores are mobilized in pregnancy and lactation for women with prior lead 
exposure, which is a concern since lead released into maternal blood and breast milk can 
adversely affect the fetus or newborn. 
•	 Certain population subgroups of women at increased risk for exposure have been identi
fied and may be highly exposed, particularly the following: workers in certain occupations; 
foreign-born recent immigrants; and those practicing certain behaviors associated with 
lead exposure, such as pica or renovation of older homes. 
•	 Identifying pregnant women with a history of lead poisoning or who are currently exposed 
to lead above background levels and preventing additional lead exposure can help prevent 
adverse health outcomes in these children. 
­
­
Despite improvements in environmental policies and significant reductions in U.S. average population blood 
lead levels, lead exposure remains a concern for pregnant and lactating women among certain population 
subgroups at increased risk for exposure. There is increasing awareness that unintended exposures to environ­
mental contaminants, such as lead, adversely affect maternal and infant health, including the ability to be­
come pregnant, maintain a healthy pregnancy, and have a healthy baby. In the United States, women of child­
bearing age represent approximately 42% of the total population (American Community Survey 2004) and at 
any given time almost 9% are pregnant (Crocetti et al. 1990). In the 2003-2006 National Health and Nutrition 
Examination Survey (NHANES) survey, the 95th percentile for blood lead levels among women aged 15-49 was 
2.4 micrograms per deciliter (µg/dL). As Figure 1-1 indicates, blood lead levels among women aged 15-49 have 
dropped substantially since the 1976-1980 NHANES. Recent NHANES estimates suggest that almost 1% of 
women of childbearing age (15-49 years) have blood lead levels greater than or equal to 5 µg/dL (Centers for 
Disease Control and Prevention 2008, unpublished data). 
Lead exposure remains a public health problem for subpopulations of women of childbearing age and for the 
developing fetus and nursing infant for several important reasons. First, prenatal lead exposure has known 
influences on maternal health and infant birth and neurodevelopmental outcomes (Bellinger 2005). Research 
findings suggest that prenatal lead exposure can adversely affect maternal and child health across a wide 
range of maternal exposure levels. In addition, adverse effects of lead are being identified at lower levels of ex­
posure than previously recognized in both child and adult populations (Canfield et al. 2003; Jusko et al. 2008; 
Lanphear et al. 2005; Menke et al. 2006; Navas-Acien et al. 2007; Tellez-Rojo et al. 2006). 
Second, bone lead stores are mobilized during periods of increased bone turnover such as pregnancy and lac­
tation. Over 90% of lead in the adult human body is stored in bone (Barry 1975; Barry and Mossman 1970), and 
may result in redistribution of cumulative lead stores from bone into blood during periods of heightened bone 
turnover, such as pregnancy and lactation (Gulson et al. 2003; Roberts and Silbergeld 1995). Since bone lead 
stores persist for decades, women and their infants may be at risk for continued exposure long after exposure 
to external environmental sources has been terminated. 
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Finally, there is evidence that a significant number of pregnant women, and presumably their infants, are be­
ing exposed to lead in the United States today. It is clear that exposed subgroups do exist and some may be 
highly exposed, particularly recent immigrants (Graber et al. 2006; Klitzman et al. 2002); workers in specific 
high-risk occupations (Calvert and Roscoe 2007); and those practicing certain behaviors, such as pica (Hackley 
and Katz-Jacobson 2003; Shannon 2003), use of culturally-specific remedies and products (Centers for Disease 
Control and Prevention 2004; Saper et al. 2004, 2008), and renovating older homes (Marino et al. 1990; Jacobs 
et al. 2002). Women living near hazardous wastes site or active smelters (Garcia-Vargas et al. 2001) and resi­
dents in countries still using leaded gasoline (Albalak et al. 2003) may also be highly exposed. 
Although lead exposure remains an important potential risk to the fetus, until now, little emphasis has been 
placed on developing guidelines for prenatal health care providers and women of childbearing age. There are 
currently no national recommendations or guidelines by any obstetric, family practice, pediatric, or nursing 
groups that cover lead risk assessment and management during pregnancy and lactation. Currently, New York 
State, New York City, and Minnesota are the only jurisdictions known to have issued lead screening regulations 
and follow-up recommendations for pregnant women by physicians or other health care providers (Minnesota 
Department of Health 2004; New York City Department of Health and Mental Hygiene 2006) [see Appendix I]. 
Other states have considered implementation of similar regulations or guidelines, and federal legislation has 
also been proposed. However, scientific discussion in this area has been limited. 
Because no national recommendations exist, the Centers for Disease Control and Prevention (CDC) and local 
and state lead poisoning prevention programs have not been able to consistently respond to concerns from 
medical providers about when to test pregnant or lactating women for lead exposure and how to manage 
pregnant or lactating women who have been identified with lead exposure above background levels that 
have resulted from widespread ambient lead contamination and naturally occurring lead in the earth’s crust. In 
response to this need, the Lead and Pregnancy Work Group was convened in April 2004 by the CDC Advisory 
Committee on Childhood Lead Poisoning Prevention (ACCLPP) to review the existing evidence for adverse ef­
fects of past and current maternal lead exposure on maternal health and fertility and on the developing fetus, 
infant, and child, and to develop recommendations on blood lead testing and management for pregnant and 
lactating women with lead exposure above background levels. 
For the purposes of the review of existing scientific literature, the work group was divided into three sub­
groups: Prevalence, Risk, and Screening; Maternal, Pregnancy, and Child Outcomes; and Management, Treat­
ment, and Other Interventions. The subgroups were asked to review the literature, summarize findings, and 
address the issues outlined in Appendix II. These guidelines do not include findings from animal studies, 
except when there are limited human data and consistent findings confirmed from multiple animal studies. 
This document presents ACCLPP’s summary of the evidence, provides guidance for preventing and treat­
ing lead exposure in pregnant and lactating women, and identifies research, policy, and education needs to 
improve health outcomes and care provided to pregnant women and their infants. These guidelines do not 





Figure 1-1 . Distribution of Blood Lead Levels in U .S . Women of Childbearing Age (15-49 Years) 
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•	 For centuries, exposure to high concentrations of lead has been known to pose health 
hazards. Recent evidence suggests that chronic low-level lead exposure also has adverse 
health effects in both adults and children and no blood lead threshold level for these ef­
fects has been identified. 
•	 CDC has not identified an allowable exposure level, level of concern, or any other bright 
line intended to connote a safe or unsafe level of exposure for either mother or fetus. In­
stead, CDC is applying public health principles of prevention to intervene when prudent. 
•	 Epidemiologic and experimental evidence suggest that lead is a potent developmental 
toxicant, but many details regarding lead’s mechanism of action have not been deter­
mined. 
•	 Recent epidemiologic cohort studies suggest that prenatal lead exposure, even with 
maternal blood lead levels below 10 µg/dL, is inversely related to fetal growth and neu­
rodevelopment independent of the effects of postnatal exposure, though the exact 
mechanism(s) by which low-level lead exposure, whether incurred prenatally or postna­
tally, might adversely affect child development remains uncertain. 
•	 Lead may adversely impact sexual maturation in the developing female and may reduce 
fertility, but the scientific evidence is limited. 
•	 Lead exposure has been associated with increased risk for gestational hypertension, 
but the magnitude of the effect, the exposure level at which risk begins to increase, and 
whether risk is more associated with acute or cumulative exposure, remain uncertain. 
•	 Evidence is limited to support an association between blood lead levels from 10-30 µg/dL 
and spontaneous abortion. There are also few and inconsistent studies on the association 
between blood lead levels and preterm delivery. 
•	 The available data are inadequate to establish the presence or absence of an association 
between maternal lead exposure and major congenital anomalies in the fetus. 
INTRODUCTION 
For centuries, exposure to high concentrations of lead has been known to pose health hazards. High levels of 
exposure can result in delirium, seizures, stupor, coma, or even death. Other overt signs and symptoms may 
include hypertension, peripheral neuropathy, ataxia, tremor, headache, loss of appetite, weight loss, fatigue, 
muscle and joint aches, changes in behavior and concentration, gout, nephropathy, lead colic, and anemia. In 
general, symptoms tend to increase with increasing blood lead levels. A substantial body of recent epidemio­
logic and toxicologic research demonstrates that multiple health effects can occur at low to moderate blood 
lead levels previously without recognized harm. Health effects of chronic low-level exposure in adults include 
cognitive decline, hypertension and other cardiovascular effects, decrements in renal function, and adverse 
reproductive outcome (Agency for Toxic Substances and Disease Registry 2007). 
This chapter focuses on the effects of maternal lead exposure on reproductive health, maternal health, preg­
nancy outcome, infant growth, and child neurodevelopment. Although the studies described in this chapter 
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focus on maternal exposures, paternal influences may also influence reproductive outcomes. Issues related 
to male-mediated reproductive toxicity for lead have been reviewed elsewhere (Apostoli et al. 1998; Jensen 
et al. 2006). In these guidelines, the discussion of scientific literature focuses on findings in humans. However, 
there also exists an extensive body of literature on the health effects of lead in experimental animals, which, 
while not cited, generally supports the human data. The reader is referred to other sources (Agency for Toxic 
Substances and Disease Registry 2007; U.S. Environmental Protection Agency 2006) for recent reviews of the 
experimental animal data. 
An area of active study is the relationship between toxic exposures (such as lead) and fetal programming of 
growth and chronic disease. According to the Barker hypothesis (Barker 1990), now known more broadly as 
“fetal origins of adult disease,” poor development in utero—for example, low birth weight—increases the risk 
for obesity, hypertension, and cardiovascular disease during adulthood (Barker 1995; Khan et al. 2003). These 
epidemiologic findings highlight the importance of the intrauterine environment and are consistent with 
experimental evidence of long-term “programming” in early life. For example, because exposure to develop­
mental toxicants, including lead, is associated with low birth weight, lead exposure to the fetus may increase 
the risk for later cardiovascular disease. Evidence supporting the fetal origins hypothesis is mounting rapidly 
(Ingelfinger and Schnaper 2005). However, evidence of effects from in utero lead exposure on adult disease are 
currently too limited to provide conclusive information. 
IMPACT OF LEAD EXPOSURE ON SEXUAL MATURATION AND FERTILITY 
Few studies have examined possible lead-related effects on sexual maturation and fertility. Delay in puberty is 
an important yet understudied health outcome that may be associated with relatively low blood lead levels. 
Two studies have examined this outcome using cross-sectional data from the third NHANES (NHANES III). 
Selevan et al. (2003) analyzed blood lead and pubertal development by race in girls ages 8-18 years of age. 
Blood lead levels as low as 3 µg/dL were associated with 2 to 6 month delays in Tanner stage measurements 
(breast and pubic-hair development) and menarche in African-American and Mexican-American girls, while 
Non-Hispanic white girls experienced non-statistically significant delays in all pubertal measures. Wu et al. 
(2003) found that higher blood lead levels were significantly associated with delayed attainment of menarche 
and pubic hair development, but not breast development, even after adjustment for race/ethnicity, age, family 
size, residence, income, and body mass index. The cross-sectional design of NHANES III limits the ability to as­
sess the temporal relation between blood lead and markers of puberty. 
The studies on time-to-pregnancy associated with lead exposure have not been conclusive. One study of time­
to-pregnancy did not suggest adverse effects of lead on fecundity at maternal blood lead concentrations less 
than 29 µg/dL. However, above this level, an association with longer time-to-pregnancy was found, but this 
was based on eight subjects (Sallmen et al. 1995). In a study of environmental lead exposure and reproductive 
health in Mexico City, no association was observed between maternal blood lead levels (mean = 9 µg/dL) and 
time-to-pregnancy in the first year (Guerra-Tamayo et al. 2003). However, in the subset of women with blood 
lead levels above 10 µg/dL, the likelihood of not achieving pregnancy after one year was five times higher 
(95% confidence interval [CI] 1.9-19.1) compared to women with blood lead levels below 10 µg/dL. 
Summary of Evidence: Sexual Maturation and Fertility 
Although studies are limited, there is some suggestion that blood lead at relatively low levels may lead to 
alterations in onset of sexual maturation and reduced fertility. These findings underscore the importance of 
considering sensitive markers of human fecundity in relation to lead exposure and should be confirmed in 
studies that can address the methodologic limitations of previous research. 
IMPACT OF LEAD EXPOSURE ON MATERNAL HYPERTENSION DURING PREGNANCY 
There is some evidence that maternal physiologic parameters in pregnancy can be modulated by low levels of 
lead exposure (Tabacova et al. 1994; Takser et al. 2005; Tellez-Rojo et al. 2004). However, the definitive relation­
ship between lead exposure and maternal health outcomes in pregnancy is unclear. Lead is an established risk 
factor for hypertension in adults (Hertz-Picciotto and Croft 1993; Kosnett et al. 2007). Hypertension is one of 
the most common complications of pregnancy. There is substantial evidence that lead damages the vascular 
endothelium (Vaziri and Sica 2004) and that endothelial dysfunction is an important mediator of hypertension 
and preeclampsia in pregnancy (Karumanchi et al. 2005). 
The most widely used classification of high blood pressure in pregnancy is that of the National High Blood 
Pressure Education Program Working Group (2000). This classification distinguishes between new hyperten­
sion arising during the pregnancy after 20 weeks (gestational hypertension) and preexisting hypertension 
(chronic hypertension). 
It is important to differentiate between non-proteinuric hypertension and hypertension plus proteinuria 
(preeclampsia), as adverse clinical outcomes are more closely related to the latter. Severe hypertension usually 
defined as a systolic blood pressure of ≥180 mm Hg or diastolic blood pressure of ≥110 mm Hg, even in the 
absence of proteinuria, has been associated with adverse maternal and perinatal outcomes. 
Gestational Hypertension 
Hypertension in pregnancy is defined as a systolic blood pressure of 140 mm Hg or higher or diastolic pres­
sure of 90 mm Hg or higher that occurs after 20 weeks gestation in a woman with previously normal blood 
pressure. Increasing levels of lead in blood have been associated with gestational hypertension. Among 3,851 
women delivering at a Boston hospital from 1979-1981, incidence of pregnancy hypertension and elevated 
blood pressure at delivery increased significantly as blood lead increased (mean blood lead 6.9 ± 3.3 µg/dL). 
During delivery, lead levels correlated with both systolic (Pearson r = 0.081, p = 0.0001) and diastolic (r = 0.051, 
p = 0.002) blood pressure. Using a reference level of 0.7 µg/dL, the relative risk doubled when blood lead level 
approached 15. There was no association, however, between blood lead level and risk for preeclampsia in this 
study (Rabinowitz et al. 1987). 
Rothenberg et al. (1999a) found that blood lead was a statistically significant predictor of maternal blood 
pressure among 1,627 women immigrants (mean blood lead 2.3 µg/dL) but not among nonimmigrants (mean 
blood lead 1.9 µg/dL). 
In a cross-sectional analysis of third trimester primigravid women in Malta (N = 143), investigators compared 
normotensive women to those with gestational hypertension (Magri et al. 2003). Those with hypertension 
(mean blood lead 9.6 ± 6 µg/dL, N = 30) had significantly higher blood lead levels compared to normotensive 
controls (mean blood lead 5.8 ± 3 µg/dL, N = 93). A study of women with gestational age ranging from 30-41 
weeks in Tehran, Iran, was conducted to assess the relationship between blood lead levels and gestational 
hypertension (Vigeh et al. 2004). Postpartum blood lead levels were significantly higher among 55 cases with 
hypertension (mean 5.7 ± 2.0 µg/dL) in comparison to 55 age-matched normotensive controls (mean 4.8 ±1.9 
µg/dL). 
The prevalence of gestational hypertension has been shown to be increased even at blood lead levels less 
than 5 µg/dL. Sowers et al. (2002) studied a cohort of 705 women aged 12-34 years who presented for prenatal 
care at one of three clinics in New Jersey with with mean (standard error) blood lead level equal to 1.2 ± 0.03 
μg/dL and found maternal blood lead significantly associated with gestational hypertension. 
Associations have also been found between gestational hypertension and bone lead. Rothenberg et al. (2002) 
reported on a prospective cohort study of 1,006 women aged 16-44 years enrolled during their third trimester 
in south central Los Angeles. This study included postpartum measures of tibia and calcaneus bone lead in 
addition to maternal blood lead levels. They found that each 10 µg/g increase in calcaneus bone lead (range 
-30.6 to 49.9 μg/g) was associated with an almost two-fold increased risk for third-trimester hypertension, a 
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0.70-mm Hg increase in third-trimester systolic blood pressure, and a 0.54-mm Hg increase in third-trimester 
diastolic blood pressure. 
Preeclampsia 
Preeclampsia, a pregnancy-specific disorder associated with increased maternal and perinatal morbidity and 
mortality, is defined as a) systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg 
beginning after the 20th week of gestation and b) proteinuria ≥300 mg per 24 hours. Preeclampsia is usually 
associated with edema, hyperuricemia, and a fall in glomerular filtration rate. Blood lead levels have been as­
sociated with the risk for preeclampsia, although the evidence is less clear than for gestational hypertension. 
Dawson et al. (2000) observed significant differences between normotensive (N = 20) and hypertensive or pre­
eclamptic (N = 19) pregnancies with respect to red blood cell lead content. They found maternal blood pres­
sure to be directly proportional to RBC lead content; however, the selection criteria and study population in 
this small group at increased risk are not well-defined, so selection bias and confounding cannot be ruled out. 
In the 2004 study by Vigeh et al. noted above, there were no significant differences in blood lead concentra­
tions among hypertensive subjects with proteinuria (N = 30) and those without proteinuria (N = 25). In an­
other study by Vigeh et al. (2006), among 396 postpartum women in Tehran, 31 with preeclampsia had signifi­
cantly higher blood lead levels (mean 5.09 ± 2.01 µg/dL) compared to 365 normotensive controls (mean 4.82 ± 
2.22 µg/dL) and significantly higher umbilical cord blood lead levels (mean 4.30 ± 2.49 µg/dL compared to 3.5 
± 2.09 µg/dL) (Vigeh et al. 2006). A 13-fold increased risk for preeclampsia compared to normotensive controls 
(mean blood lead 3.52 ± 2.09 µg/dL) was observed for every log-unit increase (~3 µg/dL) in blood lead. The 
1987 study by Rabinowitz et al. of 3,851 women delivering in Boston found no association between blood lead 
level and risk for preeclampia (Rabinowitz et al. 1987). 
Summary of the Evidence: Effects on Maternal Hypertension 
Gestational hypertension and preeclampsia have been associated with adverse maternal and perinatal out­
comes. Lead exposure has been associated with increased risk for gestational hypertension but the magni­
tude of the effect, the exposure level at which risk begins to increase, and whether risk is most associated 
with acute or cumulative exposure, remain uncertain. It is unclear whether lead-induced increases in blood 
pressure during pregnancy lead to severe hypertension or preeclampsia. However, even mild gestational 
hypertension can be expected to lead to increased maternal and fetal monitoring, medical interventions, and 
additional health care costs. Also, causality is unclear since preexisting hypertension reduces renal function, 
which in turn could result in the retention of lead. 
IMPACT OF LEAD EXPOSURE ON PREGNANCY OUTCOMES 
Spontaneous Abortion 
There is consistent evidence that the risk for spontaneous abortion is increased by maternal exposure to high 
levels of lead. In her review of studies on the association between elevated blood lead levels and spontaneous 
abortion, Hertz-Picciotto (2000) includes a detailed summary of studies involving high blood lead levels, which 
come primarily from the literature on industrial exposures in Europe during the 19th century. Yet few studies 
have addressed the risk for spontaneous abortion at lower levels of exposure. Of those studies that have ad­
dressed this issue, most reports provide limited evidence to support an association between maternal blood 
lead levels of 0 to 30 µg/dL and increased risk for spontaneous abortion (Laudanski et al. 1991; Lindbohm et al. 
1992; McMichael et al. 1986; Murphy et al. 1990; Tabacova and Balabaeva 1993). However, the lack of evidence 
for an association at these low-to-moderate blood lead levels may be due to methodologic deficiencies in 
these studies, such as small sample sizes, lack of control for confounding, problems in case ascertainment, 
and/or limitations in exposure assessment (Hertz-Piccioto 2000). 
The strongest evidence to date is a prospective study of pregnant women in Mexico City, which addressed 
most of the deficiencies of the prior studies and demonstrated a statistically significant dose-response rela­
tionship between maternal blood lead levels (average 11.0 µg/dL) and risk for spontaneous abortion (Borja-
Aburto et al. 1999). Odds ratios for spontaneous abortion for the blood lead groups 5-9, 10-14, and >15 µg/ 
dL were 2.3, 5.4, and 12.2, respectively, in comparison to the reference group (<5 µg/dL) (p for trend = 0.03) 
with an estimated increased odds for spontaneous abortion of 1.8 (95% CI = 1.1–3.1) for every 5 µg/dL in­
crease in blood lead. In another study of pregnant women (N = 207) from Mexico City (mean BLL 6.2 μg/dL), 
a 0.1% increment in the maternal plasma-to-blood lead ratio was associated with a 12% greater incidence of 
reported history of spontaneous abortion (p = 0.02) (Lamadrid-Figueroa et al. 2007). On average, women with 
no spontaneous abortions had higher blood lead levels than women with one or more reported spontaneous 
abortions (6.5 vs. 5.8 µg/dL); however, with each additional abortion experienced, women had an 18% greater 
plasma-to-blood lead ratio on average (p < 0.01). Women with a larger plasma-to-whole blood lead ratio may 
be at higher risk for miscarriage due to a greater availability of lead in plasma, which more readily crosses the 
placental barrier. 
Preterm Delivery, Low Birth Weight, Length, and Head Circumference 
Andrews et al. (1994) reviewed the epidemiologic literature through the early 1990s on prenatal lead exposure 
in relation to gestational age and birth weight. These studies are somewhat contradictory, most likely due to 
methodologic differences in study design, sample size, and/or degree of control for confounding. The more 
recent and well-designed studies suggest that maternal lead exposure during pregnancy is inversely related to 
fetal growth, as reflected by duration of pregnancy and infant size. Irgens et al. (1998), using a registry-based 
approach, found that women occupationally exposed to lead were more likely to deliver a low birth weight 
infant than women not exposed to lead (odds ratio [OR] = 1.1, 95% CI = 0.98–1.29). A case-control study in 
Mexico City found cord blood lead to be higher in preterm infants (mean 9.8 µg/dL) compared to term infants 
(mean 8.4 µg/dL) (Torres-Sanchez et al. 1999). A birth cohort study, also conducted in Mexico City, found ma­
ternal bone lead burden to be inversely related to birth weight (Gonzalez-Cossio et al. 1997) and birth length 
and head circumference at birth (Hernandez-Avila et al. 2002). A study by Rothenberg et al. (1999) among 
Mexican-Americans found that over the 1–35 μg/dL range of maternal blood lead at 36 weeks of pregnancy, 
the estimated reduction in 6-month infant head circumference was 1.9 cm (95% CI = 0.9–3.0 cm). 
Congenital Anomalies 
Very few studies have examined maternal lead exposure and risk for congenital malformations and, with one 
exception, none included biologic measures of lead exposure. Needleman et al. (1984) conducted a record re­
view and reported an association between cord blood lead and minor congenital anomalies, but major anom­
alies did not show a similar association. In a case-control study, Bound et al. (1997) found an increased risk 
between living in an area with water lead levels greater than 10 µg/L (ppb) and delivering a child with a neural 
tube defect. Irgens et al. (1998) found, in a registry-based study, women occupationally exposed to lead were 
more likely to deliver an infant with a neural tube defect than women not exposed to lead (OR = 2.87, 95% CI = 
1.1–6.4). In a case-control study conducted within the Baltimore-Washington Infant Study (Jackson et al. 2004), 
an association was observed between maternal occupational lead exposure and total anomalous pulmonary 
venous return although this relationship was not statistically significant (OR = 1.57, 95% CI = 0.64–3.47). 
Summary of the Evidence: Pregnancy Outcomes 
Overall, increased risk for spontaneous abortion appears to be associated with blood lead levels ≥30 µg/dL. 
Limited evidence suggests that maternal blood lead levels less than 30 µg/dL could also increase the risk for 
spontaneous abortion, although these findings remain to be confirmed in further research. Maternal lead ex­
posure may increase the risk for preterm delivery and low birth weight, although data are limited and a blood 
lead level at which the risks begin to increase has not been determined. The available data are inadequate to 
establish the presence or absence of an association between maternal lead exposure and major congenital 




IMPACT OF LEAD EXPOSURE ON INFANT GROWTH AND NEURODEVELOPMENT 
Infant Growth 
Few studies have investigated the effects of prenatal lead exposure on infant growth. Two studies suggest an 
association between maternal lead exposure and decreased growth. In one study, maternal bone lead levels 
were negatively associated with infant weight at one month of age and with postnatal weight gain between 
birth and 1 month (Sanin et al. 2001). In another study, postnatal linear growth rate was negatively related 
to prenatal blood lead level, although only when infants’ postnatal lead exposure was elevated (Shukla et al. 
1989). Infants born to a mother with prenatal blood lead concentration greater than 7.7 µg/dL (the median 
level in the cohort) and whose blood lead increased 10 µg/dL between 3 and 15 months of age were about 
2 cm shorter at 15 months of age (p = 0.01). Greene and Ernhart (1991) also reported negative associations be­
tween prenatal lead level and birth weight, birth length, and head circumference, although none were statisti­
cally significant. Data on the association between prenatal lead exposure and infant growth is limted and thus 
inconclusive. 
Lead and Neurodevelopment 
Neurotoxic effects of lead are observed during episodes of acute lead poisoning in both children and adults. 
It remains unclear, however, whether prenatal or postnatal lead exposure is more detrimental to neurodevel­
opment. A number of chemicals, including lead, have been shown, in experimental animal models as well as 
in humans, to cause morphological changes in the developing nervous system (Costa et al. 2004). Given the in­
complete blood-brain barrier in the developing nervous system, children might be more susceptible to insults 
during the prenatal and early postnatal periods (Bearer 1995; Rodier 1995; Weiss and Landrigan 2000). 
Animal research indicates that the central nervous system is the organ system most vulnerable to develop­
mental chemical injury (Rodier 2004), with vulnerabilities that pertain to processes critical to neurodevel­
opment, such as the establishment of neuron numbers; migration of neurons; establishment of synaptic 
connections, neurotransmitter activity, receptor numbers; and deposition of myelin. Neurons begin forming 
even before the neural tube closes. Most cerebral neurons form during the second trimester of gestation and 
migrate to their adult location well before birth (Goldstein 1990). Neuronal connections, however, are sparse 
at birth compared to adulthood. During the first 24 months of life, synaptic density and cerebral metabolic 
rate increase dramatically and by age 3 years are two-fold greater than those in the adult. The proliferation of 
synapses (synaptogenesis) is critical for the formation of basic circuitry of the nervous system (Rodier 1995). 
Synaptic “pruning” during early childhood establishes the final number of neurons. 
Lead is known to interfere with synaptogenesis and, perhaps, with pruning (Goldstein 1992). It interferes with 
stimulated neurotransmitter release at synapses in the cholinergic, dopaminergic, noradrenergic, and GABer­
gic systems (Cory-Slechta 1997; Guilarte et al. 1994). It substitutes for calcium and zinc as a second messenger 
in ion-dependent events. These disturbances in neurotransmitter release would thus be expected to disrupt 
the normal organization of synaptic connections (Bressler and Goldstein 1991). 
The brain is protected from large molecular compounds in the blood by the blood-brain barrier, created by 
tight junctions between endothelial cells in cerebral blood vessels (Goldstein 1990). The development of this 
barrier function begins in utero and continues through the first year of life (Goldstein 1990). The brain is one of 
the target organs for lead and lead exposure in utero and the first year of life may dirupt the development of 
the blood-brain barrier. 
These lead-induced biochemical disturbances in the brain are accompanied by impaired performance on a 
wide variety of tests of learning and memory in a variety of animal models and no threshold for these impair­
ments has been identified (White et al. 2007). 
 
Epidemiologic Evidence for Neurodevelopmental Effects of Lead 
A large number of studies provide convincing evidence that prenatal lead exposure impairs children’s neu­
rodevelopment (Table 2-1). In most of the early prospective studies, many children had prenatal exposures 
exceeding 10 µg/dL. Several studies reported significant inverse associations with neurobehavior (Bellinger et 
al. 1987; Dietrich et al. 1987a,b; Ernhart et al. 1987; Shen et al. 1998; Wasserman et al. 2000). One study found 
that the early developmental delays were largely overcome if postnatal lead exposures were low in the pre­
school years, but appeared to be more persistent among children whose postnatal blood lead levels were also 
greater than 10 µg/dL (Bellinger et al. 1990). Other studies found that the effects of prenatal exposure were 
independent of changes in postnatal blood lead levels (e.g., Wasserman et al. 2000). These inverse associations 
persisted into adolescence and beyond, as maternal blood lead levels during pregnancy predicted teenage at­
tention and visuoconstruction abilities (Ris et al. 2004), teenage self-reported delinquent behaviors (Dietrich et 
al. 2001), and increased arrest rates between the ages of 19 and 24 (Wright et al. 2008). A relationship between 
prenatal blood lead levels and the onset of schizophrenia between the late teens and early 20s is also seen 
(Opler et al. 2004, 2008). Some studies, however, did not find evidence of prenatal lead effects (e.g., Baghurst 
et al. 1992; Bellinger et al. 1992; Cooney et al. 1989a, 1989b; Dietrich et al. 1990, 1993; Ernhart et al. 1989; 
McMichael et al. 1988). 
More-recent prospective studies have included children with lower prenatal exposures, and continue to detect 
inverse associations with neurodevelopment. Wasserman et al. (2000) found independent adverse effects of 
both prenatal and postnatal blood lead on IQ among Yugoslavian children age 3-7 years. Prenatal lead ex­
posure was associated with a deficit of 1.8 IQ points for every doubling of prenatal maternal blood lead after 
controlling for postnatal exposure and other covariates. In a study conducted in Mexico City, Gomaa et al. 
(2002) found that umbilical cord blood lead and maternal bone lead levels were independently associated 
with covariate-adjusted scores at 2 years of age on the Mental Development Index score of the Bayley Scales 
of Infant Development with no evidence of a threshold. Maternal blood lead level early in the second trimester 
and in the third trimester was a significant predictor for some measures of mental and psychomotor develop­
ment at age 2 years (Wigg et al. 1988). In another study in Mexico City, maternal plasma lead level in the first 
trimester was a particularly strong predictor of neurodevelopment at age 2 years (Hu et al. 2006). When this 
cohort was assessed at 24 months, inclusion of umbilical cord blood lead level in the model indicated that 
it was a significant predictor of psychomotor development even when analyses were restricted to children 
whose lead levels never exceeded 10 µg/dL (Tellez-Rojo et al. 2006). Schnaas et al. (2006) found that prenatal 
lead exposure around 28-36 weeks gestation (third trimester) was a stronger predictor of reduced intellec­
tual development at ages 6–10 years than second trimester (12-20 weeks) exposure, but that study did not 
measure prenatal exposure in the first trimester of pregnancy. Jedrychowski et al. (2008) found a higher risk 
of scoring in the high-risk group on the Fagan Test of Infant Intelligence at age 6 months when umbilical cord 
blood was higher. Low-level umbilical cord blood lead levels can also negatively impact responses to acute 
stress (Gump et al. 2008). 
In another study conducted in Mexico City, third trimester increases in maternal blood lead levels were associ­
ated with decreased ability of newborns to self-quiet and be consoled during the first 30 days of life (Rothen­
berg et al. 1989). In addition, greater prenatal and perinatal lead exposure was associated with altered brain­
stem auditory evoked responses (Rothenberg et al. 1994, 2000). 
Threshold Levels and Persistence of Effects 
No threshold has been found for the adverse effects of lead on neurodevelopment (Centers for Disease Con­
trol and Prevention 2004). Recent evidence, in fact, suggests that the dose-effect relationship might be supra-
linear, with steeper dose responses at levels below 10 µg/dL than above 10 µg/dL (Bellinger and Needleman 
2003; Canfield et al. 2003; Jusko et al. 2008; Kordas et al. 2006; Lanphear et al. 2000; Tellez-Rojo et al. 2006). In 
the largest study of this issue, Lanphear et al. (2005) pooled data on 1,333 children who participated in seven 
11 
12 
 international population-based longitudinal cohort studies and were followed from birth or infancy until 5­
10 years of age. Among children with a maximal blood lead level <7.5 µg/dL, the decline in full-scale IQ for a 
given increase in blood lead was significantly greater than the decline observed among children with a maxi­
mal level ≥7.5 µg/dL. Nonlinear relationships were also detected in the Yugoslavia (Wasserman et al. 2000) and 
Mexico City (Schnaas et al. 2006) studies which suggest that the effects of prenatal exposure may also be more 
pronounced at blood lead levels less than 10 µg/dL. 
Evidence from several of the prospective studies suggests that the adverse effects of early childhood lead 
exposure on neurodevelopment persist into the second decade of life (Bellinger et al. 1992; Fergusson et al. 
1997; Ris et al. 2004; Tong et al. 1996; Wasserman et al. 2000) and are unrelated to changes in later blood lead 
level (Burns et al. 1999; Tong et al. 1998;). Administration of the chelating agent succimer to children with 
blood lead levels of 20-44 µg/dL did not prevent or reverse neurodevelopmental toxicity (Dietrich et al. 2004; 
Rogan et al. 2001). 
Summary of the Evidence: Infant Growth and Neurodevelopment 
Data on the association between prenatal lead exposure and infant growth are limted and thus inconclusive. 
The findings of recent cohort studies offer suggest that prenatal lead exposure at maternal blood lead levels 
below 10 µg/dL is inversely related to neurobehavioral development independent from the effects of postna­
tal exposure. While the lead-associated differences in test score are small when viewed as a potential change 
in an individual child’s score, they acquire substantially greater importance when viewed as a shift in the mean 
score within a population (Bellinger 2004). The mechanism(s) by which low-level lead exposure, whether 
incurred prenatally or postnatally, might adversely affect neurobehavioral development remains uncertain, 
although experimental data support the involvement of many pathways. 
Because there is no apparent threshold below which adverse effects of lead do not occur, CDC has not identi­
fied an allowable exposure level, level of concern, or any other bright line intended to connote a safe or unsafe 
level of exposure for either mother or fetus. Instead, CDC is applying public health principles of prevention to 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































•	 No single test is available to establish total body lead burden; biological markers (bio
markers) must be used to estimate maternal lead body burden and to assess lead dose to 
the fetus or infant during pregnancy or breastfeeding. 
•	 Blood lead is the most well-validated and widely available measure of lead exposure. 
However, a single blood lead test may not reflect cumulative lead exposure and may not 
be sufficient to establish the full nature of the developmental risk to the fetus/infant. 
Repeat testing may be necessary. 
•	 Bone is a potential endogenous source of lead exposure and studies have demonstrated 
that some of the previously acquired maternal bone lead stores are mobilized during 
pregnancy and lactation. However, bone lead measurement is almost exclusively a re
search tool. 
•	 Lead readily crosses the placenta by passive diffusion and has been measured in the fetal 
brain as early as the end of the first trimester, so primary prevention of exposure is par
ticularly important to reduce risk. 
•	 Lead has been detected in the breast milk of women in population-based studies; how
ever, the availability of high-quality data to assess the risk for toxicity to the breastfeeding 
infant is limited. 
•	 Given the difficulty of accurately and precisely measuring trace amounts of lead in human 
breast milk, routine measurement of breast milk lead is not warranted for routine clinical 






The purpose of this chapter is to discuss biological markers (biomarkers) that have been proposed to assess 
lead body burden and to summarize our present understanding of the biokinetics of lead during pregnancy 
and lactation. There is no single test available to establish total body lead burden, since lead may be in all body 
fluids and tissues including bone. Biomarkers must be used to estimate lead body burden and to assess lead 
dose to the fetus during pregnancy and to the infant during lactation. Figure 3-1 shows the major lead expo­
sure pathways from mother to infant. 
BIOLOGICAL MARKERS OF LEAD EXPOSURE 
Certain biomarkers of lead dose to the fetus during pregnancy have been validated as measures of exposure. 
These include measurement of lead collected from maternal venous blood during pregnancy and umbilical 
cord blood at delivery, and measurement of lead in maternal bone using the noninvasive technique of K-x­
ray fluorescence (Hu and Hernandez-Avila 2002). Each of these biomarkers provides an independent level of 
information regarding fetal lead exposure; together, they are critical to understanding whether lead toxicity 
varies based on timing of exposure, cumulative versus acute dose, and partitioning of lead between red cells 
and plasma (Hu and Hernandez-Avila 2002; Tellez-Rojo et al. 2004). 
Variability in individual blood lead levels and limitations in the accuracy of measurement techniques includ­





assessment of blood lead levels, particularly when blood lead levels are low. Laboratory instruments intro­
duce measurement error, as do certain blood lead sampling methods (e.g., capillary samples may be prone to 
contamination due to lead dust on the skin surface). Venous blood lead tests produce the most reliable results. 
Capillary samples have a high level of sensitivity but lower specificity and may produce a higher number of 
false positives. 
Other biomarkers have been used or proposed, usually because of the relative ease and noninvasiveness of 
collection procedures. These include hair, nails, teeth, saliva, urine, feces, meconium, placenta, and sperm. 
However, the utility of these alternatives as biomarkers for internal dose has not been demonstrated. In ad­
dition to the absence of consistent, validated analytic methods and standard reference materials for these 
biomarkers, they would also have to overcome the challenge of external contamination (Barbosa et al. 2005). 
Whole Blood Lead
Blood lead has been the most commonly used and readily available biomarker of exposure to date with stan­
dard units of measurement in micrograms per deciliter (1 µg/dL = 0.0484 µmol/L). Following removal of the 
subject from environmental exposure, the decline in blood lead concentration occurs relatively rapidly at first; 
the initial half-life of lead in blood is about 35 days (Rabinowitz et al. 1976). This initial rapid drop is followed 
by a slow continuing decline over several months to years. In addition to lead from exogenous sources, blood 
lead represents the contribution of past environmental exposure being mobilized from endogenous bone 
stores. It is this reservoir of lead that determines the slow decline in blood lead after the first few weeks follow­
ing removal from exposure. 
Umbilical cord whole blood lead collected at delivery has been widely used as a measure of fetal exposure 
(Harville et al. 2005; Satin et al. 1991; Scanlon 1971; Rothenberg et al. 1996;). Lead readily crosses the placenta 
by passive diffusion (Goyer 1990; Silbergeld 1986) and fetal blood lead concentration is highly correlated with 
maternal blood lead concentration (Goyer 1990). 
However, a single blood lead test may not reflect cumulative lead exposure and may not be sufficient to 
establish the full nature of the developmental risk to the fetus/infant. Physiologic changes, such as decreasing 
hematocrit, saturation of red cell lead-binding capacity, and increased bone resorption or intestinal absorption 
of lead, may influence the interpretation of blood lead levels during pregnancy. In addition, it is well known 
from the experimental literature that the vulnerability of developing organ systems, including the brain, to en­
vironmental toxicants can vary widely over the course of pregnancy (Mendola 2002). Thus, it is plausible that 
lead exposure may be particularly neurotoxic during a specific trimester (Hu et al. 2006; Schnaas et al. 2006). 
Plasma Lead
The overwhelming majority of lead in blood is bound to erythrocytes (DeSilva 1981), but plasma is the blood 
compartment from which lead is available to cross cell membranes (Cavalleri et al. 1978). An understanding of 
how plasma lead concentration is related to whole blood lead concentration is important. Plasma lead con­
centrations in the range of 0.1%-5.0% of whole blood lead concentration have been reported (DeSilva 1981; 
Manton and Cook 1984; Ong et al. 1986). Although whole blood lead levels are highly correlated with plasma 
lead levels, lead levels in bone and other tissues (particularly trabecular bone) exert an additional independent 
influence on plasma lead levels (Hernandez-Avila et al. 1998). Recent data suggest that the plasma-to-whole 
blood lead ratio may vary quite widely among and within individuals (Hu 1998; Lamadrid-Figueroa et al. 2006), 
raising questions about the use of maternal whole blood lead as a proxy for plasma lead and fetal exposure 
(Chuang et al. 2001; Goyer 1990; Hu et al. 2006). 
However, the measurement of maternal plasma lead is not likely to become a clinically useful tool. The meth­
ods required to measure plasma lead accurately are laborious and require specialized equipment and ultra-
clean techniques (Smith et al. 1998). Moreover, recent data suggest that the gain in using measurements of 
plasma lead during pregnancy to predict fetal/infant outcomes is only modest (Hu et al. 2006). Consequently, 
 
 
this biomarker may be a useful research tool in efforts to understand and detect the health impacts of environ­
mental lead exposure, but cannot be recommended at this time as a clinical tool. 
Bone Lead
Bone is a dynamic reservoir for lead, in constant exchange with blood and soft tissue elements (Rabinowitz 
1991; Tsaih et al. 1999). Lead is incorporated into the hydroxyapatite crystalline structure of bone, much like 
calcium, and may also transfer into bone matrix exclusive of incorporation into hydroxyapatite (Marcus 1985). 
Because over 90% of lead in the adult human body is stored in bone (Barry 1975; Barry and Mossman 1970), 
there is the possibility of redistribution of cumulative lead stores from bone into blood during periods of 
heightened bone turnover, such as pregnancy and lactation (Roberts and Silbergeld 1995). Lead in bone has a 
half-life of years to decades and therefore reflects cumulative lead exposure (Hu et al. 1998). Measurement of 
lead in bone using a noninvasive, in vivo X-ray fluorescence (XRF) technique makes epidemiologic evaluation 
of the impact of retained body burden of lead possible (Hu 1998). 
The amount of lead in bone depends on the individual’s lead exposure history. Smith et al. (1996) determined 
that bone contributed 40%-70% of the lead in blood of environmentally exposed subjects who were undergo­
ing total hip or knee joint replacement, indicating that the skeleton can be an important endogenous source 
of lead exposure. By examining the lead isotopic ratio in a small number of pregnant women who were recent 
immigrants to Australia (and pregnant Australian controls), Gulson and his colleagues (1997) were able to 
show that the skeletal contribution to maternal blood lead increased during pregnancy and lactation. Lead 
in maternal diet and bone lead were the main contributors to circulating maternal blood lead levels (Gulson 
1998a). The relative contribution of bone lead to blood lead will vary depending on the exposure history of 
the individuals. 
The measurement of bone lead requires special equipment and trained operators and is used mainly in 
research settings. Therefore, it is unlikely that this method will have widespread clinical application. However, 
this biomarker is a useful tool in research efforts to understand and detect the health impacts of cumulative 
lead exposure. 
Breast Milk Lead
Detectable levels of lead in breast milk have been documented in population studies of community-dwelling 
women with no known source of occupational or elevated environmental lead exposure (Abadin et al. 1997; 
Anderson and Wolff 2000). Given the correlation of breast milk lead levels with maternal and infant blood lead 
levels (Ettinger et al. 2004a, 2004b), milk lead can be used as an indicator of both maternal and neonatal expo­
sures (Hallén et al. 1995). In studies of lead in human breast milk, concentrations have been observed ranging 
over three levels of magnitude, from <1 to greater than 100 µg/L (ppb) (Chatranon et al. 1978; Ettinger et al. 
2004a; Gulson et al. 1997; Larsson et al. 1981; Murthy and Rhea 1971; Namihira et al. 1993). These differences 
are partially attributable to true differences in population exposures across time and geographic location 
(Solomon and Weiss 2002). However, it is also likely that a variety of methodological factors affect the analytic 
variability and validity of the reported results. Breast milk lead levels from published studies with extremely 
high values should be reviewed with caution due to the high potential for environmental contamination dur­
ing sample collection, storage, and analysis. Documented sources of breast milk contamination include the 
use of lead acetate ointment (Knowles 1974), lead in nipple shields (Knowles 1974; Newman 1997), foil from 
alcohol wipes used in sample collection (Hu et al. 1996), and latex laboratory gloves (Friel et al. 1996). Pretreat­
ment of biological materials is also subject to unintentional addition of contaminants from chemical reagents, 
digestion devices, and atmospheric particles (Coni et al. 1990; Stacchini et al. 1989). 
Inaccuracies of the laboratory analytic methods, particularly poor analytic sensitivity at low concentrations, 
also affect measurement of trace lead in human milk. Measurement of lead in breast milk is complicated by 
the fat content of human milk, which changes during feeding and over the course of lactation (Sim and McNeil 






the problem of either further contamination or loss during the intensive dry ashing procedure frequently used 
to prepare milk samples for analysis. Precise and accurate analysis is challenging due to difficulty in identify­
ing a method that will digest samples with 100% efficiency (Ettinger et al. 2004a, 2004b). Gulson et al. (1998b) 
reviewed and compared the results of a number of studies of the relationship of breast milk lead to maternal 
blood lead published over the past 15 years, and concluded that the line of best fit through the data “that are 
considered to represent the realistic relationships between lead in maternal blood and breast milk” defines 
an array of slope of less than 3%. The implication is that those studies yielding ratios greater than 3% suffered 
from significant contamination. 
Given the difficulty of accurately and precisely measuring trace lead in human breast milk, routine measure­
ment of breast milk lead is not warranted for clinical application. It will only be practical in research settings or 
in certain extenuating circumstances, assuming that a qualified laboratory can be identified. 
BIOKINETICS OF LEAD DURING PREGNANCY 
Changes in Maternal Blood Lead Levels During Pregnancy
There are several case reports of elevated blood lead measurements in pregnancy (Mayer-Popken et al. 1986; 
Rothenberg et al. 1992; Ryu et al. 1978; Shannon 2003). Most cross-sectional studies investigating blood lead 
levels during pregnancy have shown a tendency for blood lead levels to decrease at least through the first half 
of pregnancy (Alexander and Delves 1981; Bonithon-Kopp et al. 1986; Gershanik et al. 1974). Baghurst (1987) 
found no difference in BLLs between different stages of pregnancy (weeks 14-20, weeks 30-36, and delivery). 
However, Farias et al. (1996) found BLLs were associated with gestational week of measurement, with levels 
declining after week 12. 
Rothenberg et al. (1994), attempting to model kinetics over the course of pregnancy, showed a significant 
drop in blood lead levels from weeks 12 to 20. However, from 20 weeks to delivery, an analysis for linear trend 
confirmed a significant increase in blood lead levels in the later part of pregnancy. Schell et al. (2000) also 
reported changes in hematocrit-corrected blood lead levels over the course of pregnancy. Blood lead levels 
declined between the first and second trimesters and increased over the remaining course of pregnancy 
through delivery. Hertz-Picciotto et al. (2000) followed 195 women over the course of pregnancy and also 
found a U-shaped pattern of maternal blood lead concentration across pregnancy. The late pregnancy increas­
es were steeper among women with low dietary calcium intake in both the younger and older age groups. 
Most recently, Lamadrid-Figueroa and colleagues (2006) found increased plasma lead levels for a given whole-
blood lead value as pregnancy progresses for whole-blood lead levels greater than approximately 11.0 µg/dL, 
but not for those less than 10.0 µg/dL. 
Transfer of Lead to the Fetus
That lead reaches human fetal tissues has been known for many years (Barltrop 1969; Kehoe et al. 1933; 
Thompsett and Anderson 1935). Barltrop (1969) collected serial fetal blood lead measurements from each 
trimester throughout pregnancy and found no recognizable pattern but was able to show that maternal blood 
lead concentration was highly correlated with umbilical cord lead, suggesting transplacental movement of 
lead to the fetus. In fact, lead readily crosses the placenta by passive diffusion (Goyer 1990; Silbergeld 1986) 
and lead has been measured in the fetal brain as early as the end of the first trimester (13 weeks) (Goyer 1990). 
Bone Lead as an Endogenous Source of Exposure
Two early studies implicated bone lead as an endogenous source of exposure during pregnancy. Thompson et 
al. (1985) documented a case of increased maternal and infant blood lead in a woman with a history of child­
hood lead poisoning, but no exposure during pregnancy or for 30 years prior. Manton (1985) reported a rise in 
his wife’s blood lead levels over the course of her pregnancy along with changes in the specific lead-isotopic 
ratios, indicating that contributions to her blood lead during pregnancy did not correspond to an external 
source. 
Recent studies have documented that bone lead stores are mobilized during pregnancy and lactation (Gul­
son et al. 1997; Hernandez-Avila et al. 1996; Hu et al. 1996; Rothenberg et al. 2000). By examining the lead 
isotopic ratio in a small number of pregnant women who were recent immigrants to Australia (and pregnant 
Australian controls), Gulson and colleagues (1997) were able to show that the skeletal contribution to blood 
lead increased over pregnancy. Rothenberg et al. (2000) followed over 300 Hispanic-American women with 
serial blood lead levels over the course of pregnancy and found that whole blood lead concentrations were 
significantly influenced by bone lead. Markowitz and Shen (2001) reported a case of declining bone lead 
concentration in conjunction with an increase in blood lead levels over the course of pregnancy and the early 
postpartum period. Riess and Halm (2007) described a case report suggesting that bone sources at high levels 
can lead to an increase in BLL. 
Animal studies support the human data. Using stable lead isotopes in monkeys, researchers found that a 
29%-56% decrease in bone lead mobilization in the first trimester was followed by an increase in the second 
and third trimesters (Franklin et al. 1997). The increases were up to 44% over baseline levels. Further analysis of 
maternal bone and fetal bone and tissues revealed that from 7%-39% of lead in the fetal skeleton originated 
from maternal bone. 
BIOKINETICS OF LEAD DURING LACTATION 
Maternal bone turnover increases during lactation (Sowers et al. 2002), which has raised the concern that 
maternal blood lead concentrations might increase significantly during lactation. It has been estimated that 
up to 5% or more of bone mass is mobilized during lactation (Hayslip et al. 1989; Sowers 1996); therefore, the 
possibility exists for redistribution of cumulative lead stores from bone into plasma, thus returning lead to the 
maternal circulation. 
Gulson et al. (1998a) found that mobilization of lead from bone continued after pregnancy into the postpar­
tum period for up to 6 months during lactation and occurred at levels higher than during pregnancy. They 
concluded that the major sources of lead in breast milk were maternal bone and diet. Manton et al. (2003) 
observed sustained elevations of from 1 to 4 µg/dL in maternal blood lead concentration during the first 6 to 8 
months of lactation, after the expected normal postpartum reduction in plasma volume, in 6 nursing mothers 
with prepregnancy blood lead concentrations of less than 2 µg/dL. These elevations were followed by gradual 
declines over the next year in the two women who continued to breastfeed to 18 months postpartum. Isotope 
ratio analysis suggested that the additional lead originated from maternal bone. 
Osterloh and Kelly (1999) found no relationship between decreasing vertebral or femoral neck bone densites 
and the changes in maternal blood lead concentration at intervals over 6 months of lactation in 58 mainly 
poor Hispanic mothers with low mean blood lead concentrations of 2.35 µg/dL at enrollment in the study 
(32 to 38 weeks of gestation). However, at higher blood concentrations, Téllez-Rojo et al. (2002) observed an 
incremental increase of 1.4 µg/dL in blood lead concentration in women who were breastfeeding exclusively 
relative to women who had stopped lactation. These women had blood lead concentrations up to 23.4 µg/dL 
at delivery and were followed through 7 months postpartum. Bonithon-Kopp et al. (1986) found that women 
over 30 had significantly higher levels of breast milk lead than women between 20 and 30 years of age. Since 
bone accumulates lead with age, it is possible that the higher breast milk lead levels in the older women were 
associated with higher bone lead levels. Maternal bone lead levels have since been shown to be positively as­
sociated with breast milk lead concentrations (Ettinger et al. 2004a, 2006). 
PREDICTORS OF UMBILICAL CORD BLOOD LEAD LEVELS 
Umbilical cord blood lead has been widely used as a measure of fetal exposure (Rabinowitz et al. 1984; 
Rothenberg et al. 1996; Scanlon 1971). Numerous studies suggest that maternal blood lead and umbilical cord 
lead levels, measured concurrently at delivery, are highly correlated (Baghurst et al. 1991; Graziano et al. 1990; 
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Harville et al. 2005; Rothenberg et al. 1996), suggesting a near-perfect linear relationship. Most data indicate 
that umbilical cord lead is approximately 0.85 of maternal blood lead at parturition (Carbonne et al. 1998; Goy­
er 1990; Graziano et al. 1990). Thus, fetal-infant lead level, as measured in umbilical cord blood, is often lower 
than the maternal blood lead at delivery. However, some studies have shown umbilical cord lead to be higher 
than maternal blood lead levels at delivery and investigated the determinants for such differences (Harville et 
al. 2005; Rothenberg et al. 1996). 
Rothenberg et al. (1996) studied Mexican women of low-to-middle socioeconomic status from 12 weeks of 
pregnancy to delivery to determine factors that explain the relationship between cord and maternal blood 
lead. They found from 245 paired maternal-cord blood lead samples that mothers with occasional alcohol use 
during pregnancy, high milk intake, and more spontaneous abortions delivered babies with lower cord blood 
lead and that maternal age, use of lead-glazed pottery, and canned foods was associated with increased cord 
blood lead. They found cord blood lead levels were higher than maternal blood lead levels at delivery in 33% 
of the cases, predominantly influenced by older maternal age and lower milk consumption. The authors sug­
gested that the measurable influence of maternal blood lead on delivery cord blood lead is limited to the four 
to eight weeks prior to delivery. Also, many factors suspected of influencing bone lead also influenced cord 
blood lead, some of them independently of their effect on maternal delivery blood lead. 
Harville et al. (2005) studied factors influencing the difference between maternal and cord blood lead levels to 
determine why some infants receive higher exposures relative to their mother’s body burden than do others. 
They found that higher maternal blood pressure and alcohol consumption were associated with higher cord 
lead relative to the lead of the mother. Higher maternal hemoglobin and presence of the sickle cell trait were 
associated with lower cord blood lead in comparison to mother’s blood lead, suggesting that iron status may 
be an important factor in the maternal-fetal transfer of lead across the placenta. 
Chuang et al. (2001) modeled the interrelations of lead levels in bone, venous blood, and umbilical cord blood 
with exogenous lead exposure through maternal plasma lead in peripartum women. An interquartile range 
increase in either patella (trabecular) or tibia (cortical) bone lead was associated with an increase in cord 
blood lead by about 1 µg/dL. An increase of 0.1 µg/m3 in air lead was associated with an increase in the mean 
level of fetal cord blood lead by 0.67 µg/dL. With 1 additional day of lead-glazed ceramic use per week in the 
peripartum period, the mean cord blood lead level increased by 0.27 µg/dL. The models suggested that the 
contributions from endogenous (bone) and exogenous (environmental) sources were relatively equal, and 
that maternal plasma lead varies independently from maternal whole blood lead. 
 









































•	 Risk factors for lead exposure in pregnant women differ from those described for young 
children. 
•	 Common risk factors for pregnant women include recent immigration status, practicing 
pica, occupational exposure, use of alternative remedies or cosmetics, use of traditional 
lead glazed pottery, and nutritional status. 
•	 Pica during pregnancy appears to occur more frequently in sections of the South and in 
immigrant communities where this behavior is a culturally acceptable practice. 
•	 Lead-based paint is less likely to be an important exposure source for pregnant women 
than it is for children, except during renovation or remodeling of homes built before 1978. 
•	 Sources of lead exposure in the United States vary by population subgroup and geogra
phy; therefore, public health agencies should be consulted for community-specific risk 
data. 
•	 Fetal exposure to lead through maternal bone lead mobilization is possible for women 
with significant prior lead exposure; however, most women with blood lead levels typical 
in the United States are unlikely to contribute substantial burdens to their infants. 
­
INTRODUCTION 
This chapter discusses the distribution of blood lead levels in women of childbearing age, risk factors relevant 
to this population, and sources of lead exposure. Information on the distribution of blood lead levels in preg­
nant women in the United States is derived from cross-sectional surveys, case reports, and epidemiological 
studies. From the direct, albeit limited, information on the distribution of blood lead levels in pregnant wom­
en, along with the available complementary information on blood lead levels in women of childbearing age 
and in occupational settings, it is evident that the risk factors for lead exposure in pregnant women differ from 
those described in young children. Health care providers and public health departments need to understand 
the risk factors specific to pregnant women in order to identify sources of lead in pregnant women, provide 
patient education and counseling, and intervene to prevent or reduce exposures. 
For pregnant women, recent immigration and practicing pica are major risk factors for blood lead levels ≥5 µg/ 
dL. Occupational lead exposure and nutritional status are also important risk factors warranting assessment. 
Certain culturally specific practices, such as the use of alternative remedies or imported cosmetics and the use 
of traditional lead glazed pottery for cooking and storing food, are important risk factors for lead exposure in 
pregnant women (Centers for Disease Control and Prevention 2004; Saper et al. 2004, 2008). Some popula­
tion groups, such as immigrants, are more likely to be at risk for exposure from these sources. Shannon (2003) 
identified seven severely lead poisoned women who were exposed to sources of lead including ingestion of 
soil, pottery, or paint chips; household renovations; and use of herbal remedies. Lead-based paint is less likely 
to be an important exposure source for pregnant women than it is for children, except during renovation or 








Additionally, recent evidence has shown that bone resorption increases during pregnancy in all women (see 
Chapter 3). Although not an issue for most women with blood lead levels typical in the United States, fetal 
exposure to lead through maternal bone lead mobilization may be a concern for women with significant lead 
exposure earlier in life, either in the United States or in their countries of origin. 
EPIDEMIOLOGY OF BLOOD LEAD LEVELS IN U .S . WOMEN 
Distribution of Blood Lead Levels Among U .S . Women of Childbearing Age 
Lee et al. (2005) studied determinants of blood lead in U.S. women of childbearing age using data from 
NHANES III (1988-1994). The geometric mean blood lead level among women aged 20-49 years (N = 4,393) 
was 1.78 µg/dL (range 0.7-31.1). Approximately 30%, 6%, and <1% of the women had blood lead levels 
≥2.5 µg/dL, ≥5 µg/dL, and ≥10 µg/dL, respectively. A number of factors were associated with higher blood 
lead levels including higher maternal age, Black or Hispanic race/ethnicity, living in the Northeast region or 
in urban areas, lower educational level, poverty, lower hematocrit, alcohol use, cigarette smoking, and higher 
serum protoporphyrin level. Number of live births, breastfeeding history, year house was built, and type of 
drinking water were not significantly associated with differences in blood lead. Subjects in the first phase of 
the survey (1988-1991) had significantly higher weighted mean blood lead levels (2.0 µg/dL) than those in the 
second phase 1991-1994 (1.6 µg/dL), suggesting a decreasing trend in population average blood lead levels 
over time (p<0.01). 
NHANES data from 1999-2002 showed an even lower geometric mean blood lead level of 1.2 µg/dL among 
women age 20-59 (Centers for Disease Control and Prevention 2005). Mean blood lead levels were significantly 
higher in Blacks (1.4 µg/dL) and intermediate in Mexican Americans (1.3 µg/dL). The percentage of women 
15-49 years old with blood lead levels ≥10 µg/dL is 0.3% and ≥5 µg/dL is 0.9% (Centers for Disease Control and 
Prevention 2008, unpublished data). 
McKelvey et al. (2007) studied blood lead among New York City adults using data from the 2004 New York City 
Health and Nutrition Examination Survey (NYC HANES). Further analyses performed by the authors (unpub­
lished) specific to women 20-49 years of age (N = 755) found that the geometric mean blood lead level was 
1.30 µg/dL (range 0.33-27.3). Approximately 10.5%, 1.4%, and 0.2% of the women had blood lead levels 
≥2.5 µg/dL, ≥5 µg/dL, and ≥10 µg/dL, respectively. Blood lead was positively associated with: age; non-Hispan­
ic Black, White, or Asian race/ethnicity, compared to Hispanic; foreign birth; and former and current smoking. 
Blood lead was inversely proportional to educational level. After multivariable adjustment, Asian race/ethnic­
ity was the strongest predictor of blood lead level. In a separate study focused solely on immigrant mothers 
who gave birth in New York City in 2003, Graber et al. (2006) found that mean blood lead levels decreased with 
age by 0.032 µg/dL per year (see Case Study 4-1). 
Reported Occupational Exposures Among U .S . Women of Childbearing Age 
CDC’s state-based Adult Blood Lead Epidemiology and Surveillance (ABLES) program tracks laboratory-report­
ed BLLs in adults (age 16 years and older) from 37 states who have been tested through workplace monitoring 
programs or on the basis of clinical suspicion of lead exposure above background levels. The lowest reportable 
BLL varies by state and some states only report elevated results, not all test results. In the 10 states that report­
ed BLLs of any level in 2004, information was reported on 10,527 women of childbearing age (16-44 years). 
Among these women, 13% (1,370) had BLLs ≥5 µg/dL; 4.5% (476) had BLLs ≥10 µg/dL, and fewer than 1% (86) 
had BLLs ≥25 µg/dL. Of the women with BLLs ≥5 µg/dL, 32.3% reported occupational exposures; of those em­
ployed, the majority were in the manufacturing sector. Because testing practices vary by employer and clini­
cian, reporting practices vary by state, and all lead exposed women may not be tested, these data should not 
be used to estimate population-based rates of specific blood lead levels in the general population of women 
(Centers for Disease Control and Prevention 2007). 
 
 
RISK FACTORS FOR LEAD EXPOSURE IN U .S . WOMEN OF CHILDBEARING AGE 
Recent immigration to the United States and pica behavior are risk factors that have been shown to be associ­
ated with lead exposure above background levels in pregnant women, although they are actually behaviors 
that serve as proxies for other sources of lead. Women with a friend or relative identified with lead exposure 
above background levels are also more likely to have increased blood lead levels (Handley et al. 2007). In addi­
tion, the unique physiology of pregnancy and lactation has been shown to result in increased bone turnover 
and, thus, higher maternal BLLs. Nutrition may play a role in the extent to which lead is absorbed and the 
extent of bone turnover. An understanding of these factors is useful in assessing the sources of lead exposures 
in pregnant women and in developing interventions to prevent and/or interrupt lead exposure. Figure 4-1 
presents common risk factors for lead exposure by pregnant women in the United States. 
Recent Immigration to the United States 
A number of studies have identified immigrant status as a primary risk factor for lead poisoning in women and 
young children in the United States (Klitzman et al. 2002; Tehranifar et al. 2008). Immigrant status is a risk fac­
tor for blood lead levels much higher than concurrent blood lead levels in U.S. women of childbearing age in 
at least three ways. First, women from countries where relatively high lead exposure is endemic may carry high 
cumulative body burdens of lead. (Appendices III and V provide information about lead sources and culturally 
specific products associated with specific countries or regions.) Brown et al. (2000) investigated determinants 
of bone and blood lead concentrations in women in Mexico City during the early postpartum period and 
found that maternal age and time spent living in Mexico City, an area with high ambient lead contamina­
tion, were strong predictors of bone lead levels. Second, immigrants may transport lead-containing products, 
cultural practices, and behaviors with them from their countries of origin. Third, some recent immigrants may 
live in poor conditions that increase their risk for exposure to lead-based paint and other lead hazards from 
renovation and repair. In addition, since immigrant women may face cultural, linguistic, economic, and legal 
barriers to early prenatal care, these risk factors may be compounded by delays in identification and manage­
ment of lead poisoning. 
Data on 75 pregnant women identified with blood lead levels ≥15 µg/dL were provided in the Annual Report 
2006 for Preventing Lead Poisoning in New York City. Of these 75 women, 99% were foreign born (68% were 
from Mexico) and 73% reported using imported products during pregnancy, including foods, spices, herbal 
medicines, pottery, and cosmetics. None of the women were exposed to lead at work. 
Klitzman et al. (2002) reported on thirty-three pregnant women in New York City with blood lead levels of 
20 µg/dL or higher identified from 1996-1999 by the New York City Department of Health and Mental Hygiene 
blood lead surveillance program. Ninety percent of individuals were foreign born, the majority being from 
Mexico (57%), with a median time in the United States of 6 years (range 1 month to 20 years). Two-thirds of the 
women had levels between 20 and 29 µg/dL and possible sources of exposure were identified in 97% of these 
cases. Overall, thirteen (39%) reported pica behavior; 7 (21%) reported using imported pottery for cooking; 
and 8 (24%) reported consuming imported spices, tea, and/or food. Other sources identified included vitamins 
and supplements, lead-based paint hazards, and previous history of exposure to lead. 
Graber et al. (2006) conducted a retrospective record review of pregnant women seeking prenatal care from 
January 2003 to June 2005 at an inner-city women’s health center serving a largely immigrant population in 
Elmhurst Hospital, Queens, New York City. Of the 4,814 women seeking care, 91% were foreign born and 9% 
were U.S. born. These data from an inner-city medical clinic suggest that prenatal lead exposure dispropor­
tionately occurs during the pregnancies of immigrant women from certain countries and occurs at a preva­
lence high enough to warrant universal blood lead testing (see Case Study 4-1). 
Handley et al. (2007) studied 214 women in 2002-2003 who were enrolled in health department clinics in 
Monterey, California, for their prenatal care. The study population was 95% Latina and 87% were born in 
Mexico. Sixty-six of the women were born in Oaxaca, Mexico. The prevalence of blood lead levels ≥10 µg/dL 
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in the study population was 12%, much higher than concurrent blood lead levels in the U.S. population in 
general. Women with blood lead levels ≥10 µg/dL were more likely to be born in Oaxaca (96%), more likely to 
eat foods imported from Mexico (84%), and more likely to report having a friend or relative with “lead in their 
blood” (28%). This study identified home-prepared grasshoppers (chapulines) sent from Oaxaca as a source of 
lead exposure. 
Case Study 4-1. Prenatal Lead Exposure in New York City Immigrant   
Communities: The Elmhurst Queens Experience 
Of the 124,345 babies born in New York City in 2003, 52% were to mothers who were born out
side of the United States (New York Vital Statistics). Since many of the sources of lead for pregnant 
women are related to cultural practices, past exposures, and certain occupations, the prevalence of 
elevated blood lead levels among pregnant women in New York City is likely to be higher than U.S. 
averages. A retrospective record review of pregnant women seeking prenatal care at an inner-city 
women’s health center was conducted in order to describe the epidemiology of blood lead levels 
among pregnant women in an inner-city, primarily immigrant population. Computerized registra
tion and laboratory data for pregnant women seeking prenatal care from January 2003 to June 
2005 at the Women’s Health Center at Elmhurst Hospital, Queens, New York, were reviewed. 
Distribution of Age and Blood Lead Levels (BLLs) for U .S .- and Foreign-Born Pregnant  
Women in Elmhurst, Queens, NY (January 2003-June 2005) 
­
­
U.S. Born Foreign Born All Women 
N (%) 446 (9.3) 4,368 (90.7) 4,814 
Age (years) 23.7 28.3 27.8 
Age Range 14-43 13-52 13-52 
Mean BLL (µg/dL) 1.2 2.4 2.3 
BLL Range 0-17 0–31 0-31 
% with BLL ≥10 µg/dL 0.2 1.2 1.1 
% with BLL ≥5 µg/dL 1.6 11.5 10.6 
Note: All difference between the two groups were statistically significant (p<0.001) 
One hundred countries of origin were represented in the sample. Pregnant women who were born 
outside of the United States were 8.2 times (95% CI = 3.8 to 17.3) more likely to have a BLL ≥5 µg/ 
dL. Those women with the highest mean BLLs and percent with BLLs ≥5 µg/dL were from Bangla
desh (4.39 µg/dL, 36.6%), Mexico (3.23 µg/dL, 20.9%) and Pakistan (2.86 µg/dL, 17.6%). 
Women from countries where leaded gasoline is still in use had higher mean BLLs (3.42 µg/dL) 
and percent of women with BLLs ≥5 µg/dL (24.6%) in comparison to women from countries where 
leaded gasoline is no longer in use (1.42 µg/dL, 1.9%). Mean BLL decreased with age by 0.032 µg/ 
dL per year (p< 0.001). Mean BLL increased by 0.14 µg/dL (p<0.05) from 2003 to 2005 as did the 
percent of women with BLLs ≥10 µg/dL. BLLs did not vary by time  
of year. 
From Graber N, Gabinskaya T, Forman J, Gertner M. 2006. Prenatal lead exposure in New York City 
Immigrant communities [poster]. In: Pediatric Academic Societies (PAS) 2006 Annual Meeting, April 
29-May 3, 2006, San Francisco. 
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Pica 
Although formal pica definitions vary, the behavior common to all definitions of pica is a pattern of deliberate 
ingestion of nonfood items. Some definitions focus solely on the eating behavior (e.g., Medline defines pica 
as “a pattern of eating non-food materials (such as dirt or paper)” (Medline Plus 2009). Western medicine has 
viewed pica as aberrant and unhealthy behavior, an eating disorder, or a psychiatric diagnosis. For example, 
the American Psychiatric Association defines pica as the “compulsive eating or appetite for nonnutritive 
substances, either non-food items (e.g., clay, soil) or some food ingredients (e.g., starch, ice), which persists for 
more than one month” (American Psychiatric Association 1994). However, respected non-Western community 
institutions have historically accepted pica as a way to improve health. Pica has been practiced by people 
worldwide for medicinal, religious, and cultural reasons since antiquity (Abrahams and Parsons 1996; Hunter 
and de Kleine 1984). The Greeks and Romans used clay to treat various medical conditions. Certain Catholic 
sects in Central America have sold clay tablets inscribed with Christian scenes for centuries. These clay tablets, 
known as tierra santa, which are blessed before sale and believed to have health-giving properties, are avail­
able throughout Mexico and Central America. Clay tablets are also produced and sold throughout many parts 
of Africa and are eaten—generally not for religious or health-related purposes, but for their taste and texture. 
While pica appears to be relatively rare in the United States, it is a common practice in many parts of the world, 
particularly in Africa, Asia, and Central America. Prevalence rates have been reported to be as high as 50% to 
74% in parts of Africa (Nchito et al. 2004; Sule and Madugu 2001), and 23% to 44% in Latin America (Lopez et 
al. 2004). In the United States, pica appears to occur more frequently in sections of the South and in immigrant 
communities where this behavior is a culturally acceptable practice. Prevalence studies of pica in U.S. subpop­
ulations have found 34% in Mexican-born women living in California (Simpson et al. 2000), and 14% (Smulian 
et al. 1995) to 38% (Corbett et al. 2003) in low-income rural African-American women. 
In some studies, women felt that not giving in to pica cravings could harm their fetus and lead to miscarriage, 
illness, or an unhappy baby (Simpson et al. 2000). Since pica is viewed negatively by the Western medical com­
munity (American Psychiatric Association 1994), individuals who engage in pica may be reluctant to disclose 
that they consume nonfood items if asked directly about the practice. A review of 13 studies published be­
tween 1950 and 1987 (Horner et al. 1991) estimated that the risk for pica increases if pica is practiced by other 
family members and is increased six-fold if the woman had a prepregnancy history of pica. Other factors that 
may influence whether women are comfortable disclosing pica use include being able to converse in their 
native language, being able to discuss the practice in private, and being questioned about the practice in an 
accepting manner by someone from their own community (Simpson et al. 2000). 
Materials ingested as pica can be benign or potentially harmful and include ice, paper, dirt, clay, starch, ashes, 
and small stones as well as substances contaminated with lead or other toxic substances. Pica behavior has 
been associated with anemia and other nutritional deficiencies in cross-sectional studies, although pica has 
not been confirmed to be caused by nutritional deficiencies; pica has been associated rarely with more serious 
side effects, such as gastrointestinal blockages (Edwards et al. 1994; Geissler et al. 1998). Cases of lead poison­
ing have also been reported if the substances consumed are contaminated with lead. Most commonly these 
substances have been reported to be lead-contaminated soil and pottery [see Appendix III for a description of 
commonly ingested substances with pica]. 
In a case study of one Hispanic pregnant woman in California, Hamilton et al. (2001) found blood lead levels 
of 119.4 µg/dL in the woman and 113.6 µg/dL in the cord blood at delivery. The woman practiced a form of 
pica in which she broke a lead-glazed clay pot from Mexico into small pieces and ate several pieces daily. The 
researchers found that this practice was apparently not uncommon in Mexican women. Shannon (2003) re­
viewed seven cases of severely lead-poisoned women (BLLs ≥45 µg/dL) over a 3-year period and identified an 
additional eight cases from the medical literature. He found that severe lead poisoning in these mainly Hispan­
ic women occurred most often because of ingestion of lead-contaminated clay, soil, and pottery. Presenting 
features were mostly subtle, consisting of only malaise and anemia. 
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Mobilization of Endogenous Bone Lead in Pregnancy 
Although, the majority of U.S. women of childbearing age are unlikely to have bone lead stores large enough 
to result in large elevations in maternal blood lead concentrations, at least one recent case report suggested 
that bone sources at high levels can lead to an increase in BLL (Riess and Halm 2007). There also is evidence 
that with closely spaced multiple pregnancies, maternal blood lead levels in subsequent pregnancies are 
lower and the increases in maternal blood lead occurring during late pregnancy and lactation are lower rela­
tive to those in the first pregnancy (Manton et al. 2003; Rothenberg et al. 1994). This observation is consonant 
with observations from the lead industry in the nineteenth and early twentieth century (Legge 1901; Legge 
and Goadby 1912; Paul 1860), which held that if a lead-poisoned woman had a child, her symptoms would be 
assuaged. This limited evidence suggests that the greatest concern about lead exposure may be during the 
first pregnancy, although this observation is probably meaningful only at very high lead levels. 
Dietary and Lifestyle Factors 
Nutritional status may make women more susceptible to lead exposures. Adequate dietary intake of certain 
key nutrients (calcium; iron; zinc; vitamins C, D, and E) is known to decrease lead absorption (Mahaffey 1990). 
Iron deficiency anemia is associated with elevated blood lead levels and may increase lead absorption and 
also has an additional independent negative impact on fetal development. Calcium deficiency may increase 
bone turnover since maternal bone is a major source of calcium for the developing fetus and nursing infant. 
Chapter 7 provides a fuller discussion of nutritional issues. Both alcohol use and cigarette smoking have also 
been associated with higher lead levels and should be avoided during pregnancy and lactation. 
SOURCES OF LEAD EXPOSURE 
While various sources of lead exposure in pregnant women in the United States have been identified, these 
sources vary according to population subgroup and geography. Thus, assessment and reduction of sources 
must be specific to the community. The sources discussed below are those that have been identified in previ­
ous research and should be used as a guide for clinical and public health interventions. Figure 4-2 summarizes 
general advice for pregnant women to avoid lead exposure, although additional advice may be warranted due 
to specific local risk factors. 
Occupational Sources 
Lead is used in more than 100 industries [see Appendix IV for a list of major lead-using industries]. Occupa­
tions in which workers may be directly exposed to lead at significant levels include construction; smelting; 
auto repair; work on firing ranges; painting; manufacturing of ceramics, electrical components, batteries, wire 
and cable, plastics, pottery, and stained glass; battery and scrap metal recycling; mining; and all types of fer­
rous and nonferrous metals production. In addition, women and children may be exposed to lead through 
the inadvertent carriage of lead dust from the workplace on workers’ clothing, shoes, or bodies, also known as 
take-home exposure. Lead dust carried from work settles on surfaces in the vehicle and home, where it can be 
ingested or inhaled by young children with normal mouthing behavior and by household members handling 
workers’ clothing (Hipkins et al. 2004). The National Institute for Occupational Safety and Health documented 
cases of take-home lead exposure in a 1995 Report to Congress in response to the Workers’ Family Protection 
Act (National Institute for Occupational Safety and Health 1995). 
While BLLs in occupationally exposed individuals have fallen dramatically since lead industry standards were 
revised in 1978 (Anderson and Islam 2006), occupational exposures are still a source of lead exposure in wom­
en (Centers for Disease Control and Prevention 2007). According to reports from the ABLES Program, a total of 
442 (32.3%) of the 1,370 females with BLLs >5 µg/dL had occupational exposures (Centers for Disease Control 
and Prevention 2007). ABLES data from the New York State Department of Health indicate that 46% (62 of 
135) of women of childbearing age with moderate BLLs (10-25 µg/dL) reported occupational exposure as the 
primary source of lead exposure (Fletcher et al. 1999). Automobile battery manufacturing and lead battery re­
covery industries pose the highest risks although workers in the construction trades can also have significant 
exposures to lead (Centers for Disease Control and Prevention 2007; Fletcher et al. 1999). Laborers and painters 
have been found to have higher BLLs than other construction trade groups such as plumbers and electricians 
(Reynold et al. 1999). Construction work that is associated with higher BLLs includes bridge renovation; resi­
dential remodeling; and activities such as welding, cutting, and rivet busting (Reynold et al. 1999). 
The Occupational Safety and Health Administration (OSHA) has lead standards for general industry (29 CFR 
1910.1025) (Occupational Safety and Health Administration 1984) and construction (29 CFR 1926.62) (Oc­
cupational Safety and Health Administration 1993). Currently, under the OSHA standards, a worker must be 
included in a lead medical surveillance program if he/she is exposed to airborne lead levels of 30 µg/m3 or 
higher (8-hour time-weighted average) for more than 30 days per year. Partly to diminish the risk that a lead 
worker takes lead home on his clothing or body (take-home exposure), the lead standards contain provisions 
requiring access to showers, work clothes, and changing rooms at the workplace. Some workers potentially 
exposed to high levels of lead may not receive adequate medical surveillance because their work does not 
result in air lead levels that trigger the required surveillance. Additionally, certain occupations are exempt from 
the workplace protections established by OSHA. Exempted workers include some public employees and the 
self-employed. Self employed workers might include those in cottage industries such as battery reclamation, 
automobile/radiator repair, pottery and ceramics, and stained glass. These job categories may not be moni­
tored for lead exposures. In some cases, the home itself may function as a cottage industry workplace, increas­
ing the potential for lead exposure to all family members. Undocumented immigrant workers are a particularly 
vulnerable group in that their access to lead exposure monitoring and protective measures may be limited.
 Occupational exposure to lead also remains a problem in developing countries where industries are less likely 
to be regulated and little environmental monitoring is done. Studies have documented the impact of cot­
tage industries on lead exposure in international settings, including: backyard battery repair and recycling of 
batteries (Matte et al. 1989) and radiators (Dykeman et al. 2002) and the production of low-temperature fired 
lead-glazed ceramics (Fernandez et al. 1997; Hibbert et al. 1999) and tiles (Vahter et al. 1997). 
Lead-glazed Ceramic Pottery 
Of all the culturally specific practices and products that may put pregnant women at risk for lead exposure, 
the use of traditional lead-glazed ceramic pottery for cooking and storing food is perhaps the most well-docu­
mented in the literature (Hernandez-Avila et al. 1991, 1996; Romieu et al. 1994). Lead-glazed ceramics produc­
tion is a mostly home-based or cottage industry in Mexico where lead monoxide (greta; 93% lead by weight) is 
used to make a glaze that is often set in low-temperature (<1,000 degrees), wood-fired kilns. Pottery produced 
in this manner can leach large amounts of lead into food and beverages being cooked, served, or stored. This 
traditional pottery is used throughout the country across all levels of socioeconomic status. Acute high-dose 
exposures from foods and beverage contaminated by traditional Mexican pottery have been reported (Matte 
et al. 1994) and long-term use of lead-glazed ceramics may result in chronic low-to-moderate lead poisoning 
and elevated body burden of lead (Hernandez-Avila et al. 1991). Cases of lead poisoning have been reported 
after the consumption of crushed lead-glazed pottery, mainly among Hispanic women (Shannon 2003). 
Herbal and Alternative Remedies 
Lead has been found in some alternative medicines and therapeutic herbs traditionally used by East Indian, 
Indian, Middle Eastern, West Asian, and Hispanic cultures (Garvey et al. 2001; Saper et al. 2004, 2008). These 
alternative medicines can contain herbs, minerals, metals, or animal products. Lead and other heavy metals 
are put into certain folk medicines intentionally because these metals are thought to be useful in treating 
some ailments. They have also been reported to be added to increase the weight of the product for substanc­
es sold by weight. Sometimes lead unintentionally gets into the folk medicine during grinding, coloring, or 
other methods of preparation. Lead has been found in powders and tablets given for arthritis, infertility, upset 




Most of the published literature relating herbal therapies and alternative medicines to elevated BLLs has been 
in case reports of children or adults (Ernst 2002; Lynch and Braithwaite 2005), not specifically in women of 
childbearing age or pregnant or lactating women. Many of the alternative therapies used were self-adminis­
tered, rather than recommended by a traditional healer or health care provider. In a case study of one 45-year 
old Korean man who drank Chinese herbal tea for medicinal purposes, Markowitz et al. (1994) found a blood 
lead level of 76 µg/dL. The lead exposure was found to be hai ge fen (clamshell powder), one of 36 ingredients 
in the tea, which had become contaminated with lead. In another report, Cheng et al. (1998) described that 
six of eight children found to be taking herbal medicines had BLLs >10 µg/dL. Use of greta was described in 
a 2-year-old boy identified with a blood lead level of 83 µg/dL in a CDC report (1993). A review of 1991-1992 
California data yielded 40 cases with BLLs >20 µg/dL where children had received ethnic remedies. Over 80% 
of these children had Hispanic surnames (Centers for Disease Control and Prevention 1993). Tait et al. (2002) 
reported on a 24 year-old woman from India who immigrated to Australia and delivered a child there with a 
neonatal BLL that was the highest recorded for a surviving infant in the country (cord BLL was 158.3 µg/dL). An 
exposure assessment revealed the mother’s long-term ingestion of lead-contaminated herbal tablets as the 
source. 
Use of herbal and alternative remedies is not confined to immigrant communities and reported use is substan­
tial among the general population, as documented in several studies. Eisenberg found in a 1990 national U.S. 
survey that 34% of English-speaking adults >18 years of age reported use of at least one unconventional ther­
apy (Eisenberg et al. 1993). Only 10% reported receiving these alternative therapies from a traditional healer or 
health care provider and 72% did not tell their medical doctor that they used unconventional therapy. Highest 
use was in non-Black individuals between the ages of 25 to 49 with relatively higher education and income. A 
follow-up survey conducted in 1997 found that use had increased to 42% (Eisenberg et al. 1998). More than 
60% did not tell their medical doctors that they used alternative therapies. A 2001 New York City study found 
that 47% of women used medicinal therapies (Factor-Litvak et al. 2001). In a questionnaire survey of herbal 
medicine use among 734 women who had recently or were about to give birth in Massachusetts, Hepner et al. 
(2002) found that 7.1% reported the use of herbal remedies mostly on the advice of their health care provider. 
Although the rates of reported use of herbal and alternative remedies vary, symptomatic cases of lead poison­
ing have been reported from these sources. 
  
 
Case Study 4-2. Lead Poisoning Associated with Ayurvedic Medications, 
California (2003) 
Lead poisoning can occur from use of alternative or folk remedies. Ayurveda is a traditional form 
of medicine practiced in India and other South Asian countries. Ayurvedic medications can con­
tain herbs, minerals, metals, or animal products and are made in standardized and nonstandard­
ized formulations. 
A woman aged 31 years visited an emergency department with nausea, vomiting, and lower 
abdominal pain 2 weeks after a spontaneous abortion. One week later, she was hospitalized for 
severe, persistent microcytic anemia with prominent basophilic stippling that was not improving 
with iron supplementation. A heavy metals screen revealed a BLL of 112 µg/dL; a repeat BLL 
10 days later was 71 µg/dL, before initiation of oral chelation therapy. A zinc protoporphyrin mea­
surement performed at that time was >400 µg/dL. Her husband’s BLL was 6 µg/dL. No residen­
tial or occupational lead sources were identified, but the woman reported taking nine different 
ayurvedic medications prescribed by a practitioner in India for fertility during a 2-month period, 
including one pill four times daily. She discontinued the medications after an abnormal fetal ultra­
sound 1 month before her initial BLL. Analysis of her medications revealed 73,900 ppm lead in the 
pill taken four times daily and 21, 65, and 285 ppm lead in three other remedies. Her BLL was 22 
µg/dL when she was tested 9.5 months after the initial BLL testing. 
From Centers for Disease Control and Prevention. 2004. Lead poisoning associated with ayurvedic 
medications—five states, 2000-2003. MMWR Morb Mortal Wkly Rep 53;582-4. 
Imported Cosmetics 
Kohl, also known as ‘al kohl’ or ‘surma’, is a gray or black eye cosmetic applied to the conjunctival margins of 
the eyes that can contain up to 83% lead. It is used in the Middle East, India, Pakistan, and some parts of Africa 
for medicinal and cosmetic reasons (Parry and Eaton 1991). It is believed to strengthen and protect the eyes 
against disease. These cosmetics have been associated with elevated lead levels in children (Mojdehi and 
Gurtner 1996; Sprinkle 1995) and may also be used by women of childbearing age (Moghraby et al. 1989), es­
pecially those who are recent immigrants to the United States. [See Appendix V For a detailed list of alternative 
medicines, herbs, and cosmetics that may contain lead.] 
Foods and Other Consumer Products 
Lead can enter the food chain from contaminated soil or water, deposition from the air, or contact with food 
containers and processing. In the United States, dietary intakes of lead have been reduced due to: the removal 
of lead from gasoline; the elimination of lead-soldered cans and lead-based printing ink on candy wrappers 
and bread bags; and changes to agricultural practices, such as banning of lead-arsenate pesticides (Bolger 
et al. 1991, 1996). The U.S. Food and Drug Administration (FDA) maximum total tolerable daily intake (TTDI) 
of lead is 6 µg/day for children under 6 years of age, 25 µg/day for pregnant women, and 75 µg/day for other 
adults (Bolger et al. 1996; Carrington et al. 1996; U.S. Food and Drug Administration 1993). These values were 
established when dietary intake levels were higher than current estimates. Several scientists have suggested 
that this standard be revised and made more rigorous, which would lower the TTDI for children to 1 µg/day 
(Carrington et al. 1996; Ross, et al. 2000). Nonetheless, results from the Total Diet Study (sometimes called the 
market basket study)—an ongoing assessment by FDA that determines levels of various contaminants and 
nutrients in foods—indicate that current levels of lead in the U.S. food supply are quite low (available at http:// 
www.cfsan.fda.gov/~comm/tds-toc.html). The estimated daily dietary intake in the United States is currently 




On occasion, imported foods and food products brought to the United States have been identified with 
elevated levels of lead. For instance, Lozeena is an orange powder used to color rice and meat that contains 
7.8%-8.9% lead (U.S. Centers for Disease Control and Prevention 1998). FDA has issued warnings about tama­
rind candy lollipops (labeled Dulmex brand “Bolirindo”) imported from Mexico due to high levels of lead that 
may be associated with the product, especially in the wrapper (U.S. Food and Drug Administration 1993, 
2001). Analysis of these wrappers, which children may chew on or lick, showed between 21,000 to 22,000 
parts per million (ppm) of lead while the lollipop sticks contained more than 400 ppm of lead, and the candy 
itself contained approximately 0.2 ppm of lead. Recently, the FDA revised the recommended maximum lead 
level for lead in candy to 0.1 ppm (U.S. Food and Drug Administration 2006). Traditional food products that 
are contaminated with lead may be brought into the U.S. through unregulated routes (Handley et al. 2007). 
Chapulines (grasshoppers) from Mexico, for example, have been found to contain high levels of lead and have 
been the subject of a health alert by the California Department of Health Services (California Department 
of Health Services 2003). “Natural” calcium supplements derived from animal bone may contain lead (Ross 
et al. 2000; Scelfo and Flegal 2000). Waterfowl may ingest lead shot, become contaminated, and possibly be 
consumed by unsuspecting hunters and their families (Levesque et al. 2003). In addition, regular ingestion of 
game meat harvested with lead ammunition may be be a source of lead exposure (Kosnett 2009). 
Lead in Drinking Water 
Control measures taken during the last two decades, including actions taken under the requirements of the 
1986 and 1996 amendments to the Safe Drinking Water Act and the Environmental Protection Agency’s (EPA) 
Lead and Copper Rule (U.S. Environmental Protection Agency 1991, 1997a), have greatly reduced exposures to 
lead in tap water. Even so, lead still can be found in some metal water taps, interior water pipes, or pipes con­
necting a house to the main water pipe in the street (Centers for Disease Control and Prevention 2004b). Lead 
found in tap water usually comes from the corrosion of older fixtures or from the solder that connects pipes. 
When water sits in leaded pipes for several hours, lead can leach into the water supply. Most studies show that 
consumption of lead-contaminated water alone would not be likely to elevate blood lead levels in most adults 
to a level that is toxicologically significant, even exposure to water with a lead content close to the EPA action 
level for lead of 15 parts per billion (ppb) (U.S. Environmental Protection Agency 1991). Risk will vary, however, 
depending upon the individual, the circumstances, and the amount of water consumed. For example, infants 
who drink formula prepared with lead-contaminated water may be at higher risk because of the large volume 
of water they consume relative to their body size and the higher percentage of lead they absorb (Baum and 
Shannon 1997). [See related discussion on lead in reconstituted infant formula, Chapter 9.] Officials in com­
munities that are considering changes in water additives or that have implemented such changes in water dis­
infection should assess whether these changes might result in increased lead in residential tap water (Centers 
for Disease Control and Prevention 2004b; Miranda 2007). EPA has asked all state health and environmental 
officials to monitor lead in drinking water at schools and day care centers. 
Lead Paint: Home Repair, Renovation, and Remodeling Activities 
Lead-based paint was commonly used in homes built before 1950, and was not banned from sale for resi­
dential use in the United States until 1978. Recent studies estimate that more than 38 million U.S. homes still 
contain some lead-based paint, with two-thirds of the houses built before 1960 containing lead-based paint 
hazards (Jacobs et al. 2002). Lead-based paint hazards were concentrated in homes with incomes less than 
$30,000 (35% vs. 19% in homes with incomes >$30,000) and in the Northeast and Midwest where the preva­
lence was twice as high as in the South and West. 
Lead in paint and house dust are the most common sources of exposure in U.S. children (Lanphear et al. 1998). 
Among adults, however, exposure to lead-based paint and construction-related lead hazards occurs mainly 
during home repair, renovation, and remodeling activities conducted by the residents themselves or due to 
improper work practices of tradesmen and contractors (Centers for Disease Control and Prevention 2009; 
Feldman 1978; Fischbein et al. 1981; Jacobs 1998; Jacobs et al. 2003; Marino et al. 1990; Reis­
man et al. 2002; U.S. Department of Housing and Urban Development 1995). 
Two basic circumstances increase the risk for an adult’s exposure to lead-based paint: if 
paint has deteriorated, and when paint has been disturbed during remodeling or renova­
tion. Paint deterioration can be caused by moisture problems, poor maintenance, or other 
problems. The paint on moveable building components (friction and impact surfaces such 
as windows and doors) pose higher risks because routine opening/closing can damage 
the paint on their surfaces over time and lead-based paint was used on these components 
historically. Property owners should take precautions when repainting surfaces with dete­
riorated paint or performing any remodeling or renovation work that disturbs painted sur­
faces (such as scraping off paint or tearing out walls) (U.S. Environmental Protection Agency 
1997b). 
The U.S. government defines lead-based paint hazards as not only encompassing lead-
based paint, but also dangerous levels of lead in settled dust and bare soil. Testing for 
lead-based paint hazards can be done either by obtaining dust wipe samples from the floor 
and window sills or by using a portable x-ray fluorescence analyzer (XRF) to document the 
presence of lead in paint. EPA’s 2001 hazard standard (40 CFR 745) set the benchmark for 
floor dust lead level at 40 µg/ft2 and 250 µg/ft2 for interior window sills. 
Lead-contaminated Soil 
Soil may contain lead from deteriorating, exterior lead-based paint or other sources such 
as deposition from years of leaded gasoline use or industrial emissions. Lead-contaminated 
soil can be tracked into the home and mixed with household dust, which may also contain 
lead from interior paint sources. In the United States, lead-contaminated soil is defined as a 
hazard if there is 400 ppm of lead in bare soil in children’s play areas or an average of 1,200 
ppm for bare soil in the rest of the yard (U.S. EPA 2001). Poisoning from lead-contaminated 
soil is most common among young children who play on the floor and commonly mouth 
objects, but has also been reported to occur in women who consume lead-contaminated 
soil. For example, cases of lead poisoning have been reported after the consumption of 
lead-contaminated soil (Case Study 4-3). Exposure to lead from food grown in lead contami­
nated soil in urban gardens has also been noted (Finster et al. 2004). 
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  Case Study 4-3. A Case of Lead Poisoning from Soil Ingestion 
During Pregnancy 
S.N. is a 33-year-old woman who was pregnant four times with three living children. She was 
born in Jamaica, West Indies, and immigrated to the United States during her most recent preg­
nancy. Her obstetric history included three prior uncomplicated full-term vaginal deliveries. 
She registered for prenatal care at 19 weeks’ gestation with no significant historical problems. 
On questioning, she revealed a history of pica, eating soil from near her house. Her initial tests 
included a blood lead level of 26 µg/dL, free erythrocyte protoporphyrin 48 (normal < 35 µg/ 
dL), Hgb 9.5 g/dL, and Ferritin 4.9 ng/dL. She was counseled to stop the pica behavior and re­
ferred for genetic and nutritional counseling and to a special lead clinic. Her repeat blood lead 
level at 23 weeks’ gestation was 13 µg/dL. Environmental lead tests of the water were negative. 
Soil tests were negative, except for areas around the garage door of her house. The patient had 
no knowledge of lead levels or lead testing during her other pregnancies in Jamaica. She was 
admitted for induction of labor at 38 weeks’ gestation due to preeclampsia. She had a normal 
spontaneous vaginal delivery of a girl, 3,395 grams. Apgar scores were 9 at 1 minute and 9 at 5 
minutes. She was discharged on day 3 and followed postpartum as her blood pressure gradu­
ally decreased to normal levels. Her postpartum blood lead level was 13 µg/dL and free eryth­
rocyte protoporphyrin 60. S.N. decided to breastfeed and bottle-feed. At 6 weeks, the baby was 
noted to have a blood lead level of 20 µg/dL. 
From: Hackley B, Katz-Jacobson A. 2003. Lead poisoning in pregnancy: a case study with impli­
cations for midwives. J Midwifery Womens Health 48(1):30-8. 
Point Sources of Lead 
Point sources of lead exposure include active mining and smelting operations, lead contamination at former 
mining and smelting sites, and industrial emissions, such as those from battery-manufacturing and recycling 
activities, particularly in international settings where environmental regulations and monitoring programs 
may not be in place. Studies have documented the impact of lead mining and smelting activities, both in the 
United States and elsewhere (Baghurst et al. 1987; Benin et al. 1999; Graziano et al. 1990), and women who live 
near active or former lead mines and smelters may be exposed to high levels of lead contamination. 
Leaded Gasoline 
Recognition of the toxic effects of lead has prompted interventions that have resulted in reductions in lead 
exposure in many countries. In the United States, standards to phase out leaded gasoline use were first imple­
mented in 1973 (U.S. Environmental Protection Agency 1973). In 1995, leaded fuel accounted for only 0.6 % of 
total gasoline sales in the United States and, in 1996, the Clean Air Act banned the sale of leaded fuel for use in 
on-road vehicles (U.S. Environmental Protection Agency 1996). A worldwide initiative to phase-out lead in gas­
oline has already stimulated important reductions in ambient air lead levels and population blood lead levels 
in some countries (Cortez-Lugo et al. 2003; Romieu et al. 1992). A complete phase-out of leaded gasoline was 
completed throughout the Latin American and Caribbean region by 2005 (Burke 2004; Walsh 2007). However, 
in some parts of Africa, Asia, and the Middle East, leaded gasoline is still common (Partnership for Clean Fuels 
and Vehicles 2007). The impact of leaded fuel is more important in urban settings, given their higher vehicular 
density. 
Hobbies and Recreational Activities 
Hobbies and recreational activities that may cause exposure to lead include, but are not 
limited to creating stained glass; enameling copper; casting bronze; making pottery with 
certain leaded glazes and paints; casting ammunition, fishing weights, or lead figurines; jew­
elry making and electronics (with lead solder); glassblowing with leaded glass; print-making; 
refinishing old furniture; distilling liquor; hunting; and target shooting. 
47 
48 
Table 4-1. Risk Factors for Lead Exposure in Pregnant and   
Lactating Women 
 Recent immigration from or residency in areas where ambient lead contamination 
is high . Women from countries where leaded gasoline is still being used (or was recently 
phased out) or where industrial emissions are not well controlled. 
 Living near a point source of lead, such as lead mines, smelters, or battery recycling 
plants (even if the establishment is closed). 
 Working with lead or living with someone who does . Women who work in or who have 
family members who work in lead-industry (take-home exposures). 
 Using lead-glazed ceramic pottery . Women who cook, store, or serve food in lead-glazed 
ceramic pottery made in a traditional process and usually imported by individuals outside 
the normal commercial channels. 
 Eating nonfood substances (pica) . Women who eat or mouth nonfood items that may be 
contaminated with lead (such as soil or lead-glazed ceramic pottery). 
 Using alternative or complementary medicines, herbs, or therapies . Women who use 
imported home remedies or certain traditional herbs that may be contaminated with lead. 
 Using imported cosmetics or certain food products . Women who use imported cosmet
ics, such as kohl or surma, or certain imported foods or spices that may be contaminated 
with lead. 
 Engaging in certain high-risk hobbies or recreational activities . Women who engage 
in high-risk activities or have family members who do. 
 Renovating or remodeling older homes without lead hazard controls in place . Wom
en who have been disturbing lead paint and/or creating lead dust or spending time in 
such a home environment. 
 Consumption of lead-contaminated drinking water . Women whose homes have leaded 
pipes or source lines with lead. 
 Having a history of previous lead exposure or evidence of elevated body burden of 
lead . Women who may have high body burdens of lead from past exposures, particularly 
those who are deficient in certain key nutrients (calcium, iron). 
 Living with someone identified with an elevated lead level . Women who may have ex




Table 4-2. Key Recommendations to Prevent or Reduce Lead   
Exposure in Pregnant and Lactating Women 
 Never eat or mouth nonfood items, such as clay, soil, pottery, or paint chips, because they 
may be contaminated with lead (see Appendix III). 
 Avoid jobs or hobbies that may involve lead exposure, and take precautions to avoid take-
home lead dust if a household member works with lead. Such work includes construction 
or home renovation/repair in pre-1978 homes, and lead battery manufacturing or recycling. 
[See Appendix IV] 
 Avoid using imported lead-glazed ceramic pottery produced in cottage industries (de
scribed elsewhere in this chapter) and pewter or brass containers or utensils to cook, serve, 
or store food. 
 Avoid using leaded crystal to serve or store beverages. 
 Do not use dishes that are chipped or cracked. 
 Stay away from repair, repainting, renovation, and remodeling work being done in homes 
built before 1978 in order to avoid possible exposure to lead-conaiminated dust from old 
lead-based paint. Avoid exposure to deteriorated lead-based paint in older homes. 
 Avoid alternative cosmetics, food additives, and medicines imported from overseas that 
may contain lead, such as azarcon, kohl, kajal, surma, and many others listed in Appendix V. 
 Use caution when consuming candies, spices, and other foods that have been brought into 
the country by travelers from abroad, especially if they appear to be noncommercial prod
ucts of unknown safety. 
 Eat a balanced diet with adequate intakes of iron and calcium, and avoid the use of ciga










Key Recommendations for Initial Blood Lead Testing 
•	 Blood lead testing of all pregnant women in the United States is not recommended. 
•	 State or local public health departments should identify populations at increased risk 
for lead exposure and provide guidance about community-specific risk factors to assist 
clinicians in determining the need for blood lead testing for identified populations or for 
individuals at risk. 
•	 Routine blood lead testing of pregnant women is recommended in clinical settings that 
serve populations with identified risk factors for lead exposure. 
•	 In clinical settings where routine blood lead testing of pregnant women is not indicated 
on the basis of community-specific risk factors, health care providers should consider the 
possibility of lead exposure in individual pregnant women by evaluating risk factors for 
exposure as part of a comprehensive occupational, environmental, and lifestyle health risk 
assessment of the pregnant woman [see Table 4-1]. Blood lead testing should be per
formed if a single risk factor is identified at any point during pregnancy. 
•	 When indicated, blood lead testing should take place at the earliest contact with the 
patient, ideally pre-conceptionally or at the first prenatal visit, and be conducted using 
venous blood lead tests only. 
•	 Both maternal and infant blood lead level test results, along with relevant environmental 
findings, should be incorporated into both the mother’s and the infant’s medical records 
in a timely fashion. Even though such records are likely to be maintained separately, these 
data are necessary for proper medical management of mother and infant. 
Key Recommendations for Follow-up Blood Lead Testing 
•	 A toxicological threshold for adverse health effects has not been identified. Thus, follow-
up blood lead testing is recommended for pregnant women with BLL ≥5 µg/dL and their 
newborn infants to inform environmental and clinical decision-making. 
•	 Pregnant women with confirmed BLLs ≥45 µg/dL should be considered as high-risk preg






This chapter describes considerations for initial and follow-up blood lead testing during pregnancy and early 
infancy. It provides information for providers, public health agencies, and communities to guide the approach 
to the testing and follow up of blood lead levels where lead exposure above background levels is either 
known or thought to be a concern or where there is no information on the epidemiology of blood lead lev­
els among the target groups (pregnant women and infants less than 6 months of age). The tables outlining 
frequency of follow-up blood lead testing of newborns [Table 5-1] and infants [Table 5-2] exposed in utero fill a 
gap left by the CDC recommendation for the follow-up testing of lead-exposed children, which begins at age 6 




The strategy described in this chapter for secondary prevention of lead toxicity through testing and identifi­
cation of lead-exposed pregnant women is focused on the individual. However, a primary prevention strat­
egy of community-focused reduction of lead sources is crucial to prevent the adverse consequences of lead 
exposure. Secondary prevention strategies, such as testing and follow up of lead exposure above background 
levels in individual women, do not adequately prevent exposure or the resultant adverse health outcomes. An 
understanding of the community characteristics, ethnicity, cultural practices, local industry and common oc­
cupations, and alternative medicine use practices will assist in identifying groups of women at risk for lead ex­
posure. This strategy may be successful in primary prevention of exposure to the developing fetus and infant if 
it guides health education and outreach activities in high-risk communities. 
IDENTIFICATION OF PREGNANT WOMEN WITH ELEVATED BLOOD LEAD LEVELS 
Screening for Elevated Blood Lead Levels 
The purpose of screening pregnant women is to identify women exposed to lead who can reasonably be 
expected to benefit from the knowledge of their lead exposures above background levels and subsequent 
actions to prevent additional lead exposure or adverse effects to themselves or their fetuses. In this report, 
screening refers to a laboratory test that is performed on a blood sample from an asymptomatic person to 
determine if that person has evidence of lead exposure above background levels. One goal of identifying 
pregnant women at risk is to prevent the potential adverse health outcomes for mother and infant associated 
with lead exposure during pregnancy. As described in Chapter 2, evidence suggests that no threshold exists 
for the impacts of lead on maternal health or on the birth, growth, and neurodevelopmental outcomes of the 
offspring. NHANES data on the blood lead levels of U.S. women of childbearing age indicate that a BLL 
≥5 µg/dL is higher than the 98th percentile (or 3 standard deviations) for this population (Centers for Disease 
Control and Prevention 2009, unpublished data). Thus, a BLL ≥5 µg/dL indicates that a pregnant woman has 
been exposed to lead well above the U.S. average exposure. 
The U.S. Preventive Services Task Force (USPSTF) recently completed a review of the evidence for lead screen­
ing in pregnancy. USPSTF found no studies examining the effectiveness of screening or interventions on 
improving health outcomes in asymptomatic pregnant women, and a lack of availability of evidence for inter­
ventions to reduce blood lead levels in this population. The potential harms of screening cited include false-
positive test results, anxiety, inconvenience, work or school absenteeism, and financial costs associated with 
repeated testing (Rischitelli et al. 2006; U.S. Preventive Services Task Force 2006). However, the USPSTF review 
did not assess the health impact on subpopulations exposed to lead prenatally or during breastfeeding or the 
benefits of screening only such subgroups. 
CDC has determined that there is evidence for health effects in asymptomatic pregnant women at the popula­
tion level and that a threshold for these effects has not been established. However, there is currently a lack of 
evidence of improved outcomes from interventions provided to pregnant women with a BLL ≥5 µg/dL since 
no studies on this point exist. Therefore, the traditional model for medical decision-making of a case defini­
tion linked directly to a proven clinical treatment is not useful in this context. Until such research data are 
available, and given the convincing evidence of neurodevelopmental effects of lead in the prenatal period, 
CDC recommends a precautionary approach, noting that a BLL ≥5 µg/dL in a pregnant woman indicates that 
she has or has recently had exposure to lead well above that for most women of child bearing age in the U.S. 
population. Since there are still many potential lead sources that a pregnant woman can encounter, a blood 
lead test is a simple and inexpensive way to identify pregnant women with lead exposures above background 
levels, so that lead sources can be identified and further exposure can be prevented in the best interests of the 
mother and child. In addition, source identification and remediation activities may benefit other household 
and community members, depending upon the source in question, as well as the mother and fetus/infant in 
subsequent pregnancies. Finally, in contrast to abstract and generalized anticipatory guidance, blood lead test 
results above background levels are also concrete and actionable data points that may help focus attention by 
an expectant woman on the challenge of identifying and reducing lead exposure. 
Blood Lead Testing in the General Population and High-risk Subgroups 
Universal blood lead testing of all pregnant women in the United States is not warranted (Rischitelli et al. 2006; 
U.S. Preventive Services Task Force 2006) considering the current estimated prevalence of elevated blood 
lead levels is less than 1% of women of childbearing age (Centers for Disease Control and Prevention 2009, 
unpublished data). However, routine blood lead testing may be warranted in specific U.S. subpopulations at 
increased risk for lead exposure due to local, community-specific factors, such as environmental sources of 
lead or the demographics of the population. In addition, individual characteristics and behaviors put certain 
populations of women of childbearing age at increased risk for lead exposure relative to that of the general 
population. 
The presence of risk factors in a subpopulation of pregnant women, for example in a particular clinic popula­
tion, is an indication for routine blood lead testing among all pregnant women in this subpopulation. [See 
Case Studies 4-1 and 4-2 for examples from Elmhurst, New York, and California, respectively.] State or local 
public health departments should provide clinicians with information on community-specific risk factors ap­
propriate for use in determining the need for routine blood lead testing, including data describing the dis­
tribution of blood lead levels in the community and local knowledge of immigration patterns and ethnicity, 
common occupations, alternative medicine use, cultural practices, local industries, and idiosyncratic sources. 
Routine testing should continue in subpopulations known to be at increased risk until the specific risk factors 
within that population are better understood and more targeted methods for identifying women at increased 
risk can be employed. 
The presence of a large industry in a community, such as a battery recycling plant or a lead smelter, is also 
indication for blood lead testing of the local pregnant population. A list of occupations with the potential for 
lead exposure can be found in Appendix IV. When the prevalence of lead exposure above background levels 
is known to be high in certain communities, it may benefit the providers to develop a centralized blood lead 
testing program at a local hospital, clinic, or community center. 
Individual Risk Factor Assessments 
Blood lead testing of individual pregnant women based on individual risk factors may be warranted even 
when blood lead testing of population subgroups is not warranted. Identification of women who may be at 
increased risk for lead exposure consists of a comprehensive occupational, environmental, and lifestyle history 
to assess individual risk. However, validated risk factor questionnaires do not currently exist to predict who 
would benefit from blood lead testing. Local variation in lead exposure patterns makes national development 
of such a tool impractical. Instead, development (or adaptation) and validation of a risk factor questionnaire 
should occur at the local level, under the leadership of local public health authorities, after local risk factors for 
lead poisoning in pregnancy have been ascertained. 
In general, when risk factor questionnaires are used, a positive answer to any question should prompt the 
measurement of the patient’s blood lead level. The New York City Department of Health and Mental Hygiene 
developed a short tool consisting of five questions (New York City Department of Health and Mental Hygiene 
2006) [see Figure 5-1]. The Minnesota Department of Health recommends a seven-question tool (Minnesota 
Department of Health 2007) [see Figure 5-2]. At the time of publication of this document, these risk factor 
questionnaires have not yet been validated. Nevertheless, such questionnaires do have an inherent education­
al value, as they stimulate dialogue between the health-care provider and patient and create an opportunity 
to educate families about lead hazards. 
Assessments of other risk factor questionnaires primarily for children have been conducted, including one that 
was adapted for use with pregnant women. Stefanak et al. (1996) assessed the accuracy of the CDC childhood 
lead poisoning risk questionnaire (Centers for Disease Control and Prevention 1991) for administration as a 
screening tool to 314 pregnant women. In this study, which included both rural and urban areas, questions 
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associated with elevated blood lead in pregnant women included the following: home built before 1960 with 
chipping or peeling paint, current smoker, and consumption of more than nine servings of canned food per 
week. Women who answered “yes” to any one of those questions were five times more likely to have an el­
evated blood lead level (BLL ≥10 µg/dL) (p<0.001). The authors calculated the sensitivity and negative predic­
tive value of the CDC questionnaire to be 75.7% and 93.1%, respectively, in this population, suggesting a high 
confidence that a negative response would classify a respondent correctly. However, the positive predictive 
value was only 46%, suggesting less confidence in a positive response to correctly classify individuals. When a 
full 19-question survey was administered, the sensitivity and negative predictive value increased to 89.2% and 
96.4%, respectively. The performance difference between the questionnaires is most likely because the CDC 
childhood lead poisoning risk factor questionnaire developed for children does not target the major sources 
of lead exposure in pregnant women. 
Clinical Indicators for Blood Lead Testing 
Clinical indications for measuring a blood lead level include the presence of a risk factor for exposure, physi­
cal signs or symptoms, or the presence of a household member with known lead exposure above background 
levels. Most individuals with measurable lead exposure above background levels are asymptomatic. When 
symptoms or physical findings of lead poisoning are present, they are often difficult to differentiate as they 
are generally nonspecific and quite common. These include constipation, abdominal pain, anemia, headache, 
fatigue, myalgias and arthralgias, anorexia, sleep disturbance, difficulty concentrating, and hypertension, 
among others. Blood lead levels should be measured when these symptoms are present and the suspicion of a 
source of lead exists. Blood lead levels should also be measured in the work-up of acutely ill pregnant women 
presenting with severe abdominal colic, seizure, or coma, and considered in the differential diagnosis of con­
sistent constitutional symptoms (e.g., persistent headache, myalgias, fatigue, etc.) and anemia. 
Timing of Blood Lead Testing During Pregnancy 
Identifying maternal lead exposure prior to conception or early in the pregnancy potentially offers the most 
benefit to the developing fetus. Unfortunately, lead poisoning is frequently identified late in pregnancy. 
Klitzman et al. (2002) reports that the median gestational age at diagnosis was 25.4 weeks (range 6 to 39), 
while Shannon (2003) reports that lead poisoning was discovered in the third trimester in 12 of 15 (86%) 
subjects after the women presented with subtle but characteristic findings of severe lead poisoning, including 
malaise, anemia, or basophilic stippling on blood smear. Early blood lead testing may not always identify lead 
poisoned women sooner in cases where the exposure is first occurring during pregnancy, such as pregnancy-
related pica behavior. In these cases, the measurement of a BLL preconception or early in the first trimester 
may precede the patient’s exposure. Earlier testing, however, does have the benefit of early identification in 
pregnant women with chronic, ongoing, or historical cumulative exposures (Hu 1991; Hu and Hernandez-Avila 
2002; Hu et al. 1996). Therefore, it is recommended that blood lead testing of women at increased risk take 
place at the earliest contact with the patient, ideally preconceptionally or at the first prenatal visit. 
Methods to Collect Blood Samples for Testing 
Although blood lead levels can be measured from both capillary and venous samples, the preferred method 
for adults is a venous blood sample in a vacuum tube. Venous samples are more reliable than capillary blood 
lead levels, which can be inaccurate due to environmental contamination or dilution of the specimen from 
finger squeezing. Capillary samples can be used if strict protocols are employed to reduce the risk for contami­
nation; however, even if obtained under these conditions, a capillary BLL ≥5 µg/dL requires confirmation with 
a venous blood lead test. 
Methods to Analyze Lead Levels in Blood 
Blood lead levels from venous samples should be analyzed by a certified laboratory using one of the ap­
proved methods such as: inductively coupled plasma mass spectroscopy (ICP-MS), graphite-furnace atomic 
 
absorption spectrophotometry (GFAAS), or anodic-stripping voltammetry (ASV). Specimen tubes for collection 
should be lead-free and laboratories should be consulted about the preferred specimen tube and collection 
procedures. For details about laboratory analytic procedures see Analytical Procedures for the Determination of 
Lead in Blood and Urine, Approved Guideline (Parsons et al. 2001); available at http://www.clsi.org/source/
orders/free/c40-a.pdf 22. 
Using a centralized laboratory ensures the accuracy of testing and enables better compliance with local 
reporting requirements. Clinical Laboratory Improvement Act (CLIA) certification of laboratories and participa­
tion in national proficiency testing programs helps assure that the methods employed for blood lead testing 
are accurate and precise to within a specified range of BLLs. Regardless of the method employed, CLIA-man­
dated proficiency testing programs require accuracy to within the range of +/- 4 µg/dL (or +/- 10%). The limits 
of detection, accuracy, and precision of BLL determination will vary with the type of method used and among 
laboratories using the same method. Of the three commonly used methods, ICP-MS and GFAAS have limits of 
detection of about 0.3-1.0 µg/dL with values reported to two significant figures. ASV has a detection limit of 
1-3 µg/dL and is less precise usually reporting values as whole numbers, but is adequate for BLL testing above 
the limit of detection. For medical interpretation and decisions on management, BLLs can be rounded to a 
whole number. 
Measurement of the BLL of patients at risk for lead exposure can also be done at the point-of-care using a por­
table blood lead analyzer (Pineau et al. 2002; Shannon and Rifai 1997). Although this method offers the benefit 
of an immediate result and intervention, point-of-care measurements for pregnant women should be limited 
to situations where sending specimens to a centralized, certified laboratory is not feasible due to logistics, lack 
of refrigeration, or cost limitations. Any blood lead measurement ≥5 µg/dL obtained by this method should be 
confirmed by a certified laboratory with a venous blood lead test (as noted in the point-of-care’s instrument 
use guidance). 
Interpretation of Blood Lead Test Results 
Analytical variability must be considered when interpreting blood lead results. Changes in successive blood 
lead measurements on an individual can be considered significant only if the net difference of results exceeds 
the analytic variance of the method. The degree of analytical variability between laboratories that employ 
different analytic methods usually exceeds that within a single laboratory. Therefore, a single laboratory using 
one analytical method should be used to best compare multiple blood lead results from an individual or a 
population (Centers for Disease Control and Prevention 2005). As a practical matter, ACCLPP therefore recom­
mends that trends in blood lead levels for an individual should not be considered clinically significant until the 
magnitude of the change is ≥5 µg/dL (Binns et al. 2007). 
As described above, a BLL ≥5 µg/dL indicates that a pregnant woman has been exposed to lead well above 
the average U.S. exposure. Separate scientific studies indicate that adverse effects at BLLs ≥5 µg/dL are likely 
in pregnant women and likely to increase with increasing blood lead levels. Therefore, additional actions on 
the part of health care providers and public health are indicated for pregnant women with BLLs ≥5 µg/dL and 
their infants (see Table 6-1). 
As described in Chapter 6, occupationally exposed women should be referred to an occupational physician or 
center treating occupationally exposed adults. Steps to minimize lead exposure should be undertaken if the 
BLL is ≥5 µg/dL, and medical removal from workplace exposure should be undertaken if the BLL is ≥10 µg/dL. 
Transmission of Blood Lead Test Results 
Health care providers have two important responsibilities with respect to sharing laboratory reports of blood 
lead levels. First, blood lead levels of both mother and child should be transmitted and entered into both the 
mother’s and the infant’s medical records in a timely fashion. For instance, the infant’s initial and sequential 
55 
56 
BLLs should be in the mother’s chart, and vice versa, as these data should inform decisions about additional 
blood lead testing, breastfeeding, and environmental interventions, among other actions. In addition, infor­
mation about identified lead exposure sources can be clinically useful and should be shared. 
In jurisdictions where reporting of BLLs is not done by laboratories, health care providers should also notify 
the Lead Poisoning Prevention Program of the local or state health department of confirmed BLLs ≥10 µg/dL 
in a pregnant woman to ensure that health department data are complete and that women receive appropri­
ate services from public health. The report should include complete demographic information on the patient, 
the health care provider’s name and phone number, and the method of sample collection (venous or capil­
lary). 
FOLLOW-UP TESTING IN THE PREGNANT WOMAN 
Once a blood lead level ≥5 µg/dL has been identified, an important component in the management of lead-
exposed individuals is follow-up blood lead testing to assess trends. After the source of exposure has been 
identified and removed, it is expected that the BLL will decline. However, there is no clear formula to estimate 
the expected rate of decline of BLLs in exposed women or their offspring. Several factors play a role, including 
duration of the exposure, presence of physiological stressors affecting bone turnover rates, nutritional status, 
and medical and environmental interventions. 
Follow-up blood lead testing is indicated for pregnant women with a BLL ≥5 µg/dL according to the sched­
ules in Table 5-3. At higher BLLs, a follow-up confirmatory BLL might be indicated earlier than on the schedule 
provided. Even a single BLL ≥5 µg/dL should prompt the asking of certain risk related questions as soon as 
possible. Depending on the answers, it may be important to take immediate action. For example, if a pregnant 
woman from India has a BLL of 10 µg/dL and is taking ayurvedic supplements, she should be advised to im­
mediately stop taking the supplements instead of waiting weeks for another BLL. 
When the patient’s BLL does not fall after several months, the various factors that may impact the rate of 
decline (i.e., duration of exposure, psychological stressors, nutritional status, and medical and environmental 
interventions) should be reconsidered. In some cases, further environmental investigation may be needed. A 
continuing increase in the measured venous BLL during the follow-up period may indicate continuing or pos­
sibly increased exposure to lead and indicates a need for further environmental investigation. Potential causes 
of rising BLLs in pregnant women include the failure to address the source of the lead or inappropriate man­
agement of the lead source; continued use of lead-contaminated products such as spices, foods, cosmetic, 
folk remedies or lead-glazed ceramics that were not revealed during the initial investigation; and increases in 
mobilization of bone lead stores from past, high-dose exposures. Additionally, prevention of exposure to lead 
from occupational sources may not be adequate to maintain a BLL below the level of concern. (See Chapter 
6 for medical management guidelines for occupationally exposed women.) Measurement of follow-up BLLs 
is the main method for determining how urgently additional intervention is needed and whether blood lead 
levels are declining once interventions, such as removal from the source of exposure, have taken place. 
As described in Chapter 3, blood lead levels in pregnancy generally follow a U-shaped curve over the course of 
pregnancy, with peak blood lead level appearing to be at or near delivery. Assuming unchanging lead intake, 
the combination of hemodilution, increased weight of organs, and enhanced metabolic activity may account 
for much of the observed decrease in whole blood lead between 12 and 20 weeks gestation. Accelerated 
absorption of dietary lead, decreased elimination of lead from the body, and release of bone lead, perhaps 
following the calcium conservation strategies of late pregnancy, may all operate to yield the observed pattern 
of lead during pregnancy. Bone resorption dynamics change throughout pregnancy, and the implications for 
follow-up testing are two-fold. Pregnant women who have an initial blood lead level that is ≥5 µg/dL in the 
first trimester may have a lower BLL on repeat testing during the second trimester, regardless of interventions. 
This blood lead level may increase prior to delivery and may, in fact, be higher than the initial level. Addition­
ally, the measured BLL of pregnant women in the second and late first trimesters may be an underestimation 
of the actual body lead burden. However, the magnitude of this change is uncertain and it is unclear whether 
the change is clinically significant for determining whether a follow-up BLL <5 µg/dL measured in the first or 
second trimester should be repeated again at or near delivery. In addition, a single blood lead level cannot be 
used to establish a woman’s risk during her entire pregnancy. 
FOLLOW-UP TESTING IN THE NEWBORNS AND INFANTS <6 MONTHS OF AGE 
Maternal and umbilical cord lead levels at delivery are, in most cases, highly correlated. However, in a woman 
with a known BLL ≥5 µg/dL during pregnancy, umbilical cord or neonatal lead levels should be measured 
to establish a baseline for clinical management. Follow-up blood lead testing is indicated for neonates and 
infants with a BLL ≥5 µg/dL according to the schedules in Tables 5-1 and 5-2. After the child is 6 months of age, 
recommendations from Managing Elevated Blood Lead Levels Among Young Children: Recommendations from 
the Advisory Committee on Childhood Lead Poisoning Prevention (Centers for Disease Control and Prevention 
2002) should be followed. 
Potential causes of rising BLLs in newborns and infants under the age of 6 months include environmental 
sources of lead exposure, such as environmental contamination from lead dust and lead in the diet. Not 
enough is known about the kinetics of lead in the prenatally exposed newborn to make reliable projections 
about the rate of change of infant BLLs after birth. 
FOLLOW-UP TESTING IN THE LACTATING MOTHER AND NURSING INFANT 
Postpartum maternal blood lead levels are expected to increase during the first month after delivery (Os­
terloh and Kelly 1999; Rothenberg et al. 2000). This increase is thought to be due partially to postpartum 
hemoconcentration due to fluid loss and is also greater in lactating women than in women who bottle-feed 
their infants, suggesting that lactation stimulates the release of lead from bone (Tellez-Rojo et al., 2002) and 
that bone lead mobilization may actually be higher during lactation than in pregnancy (Gulson et al., 1998). 
These findings illustrate the importance of understanding that an increase in maternal blood lead level after 
delivery may not necessarily be associated with a new source of exogenous exposure and may, in fact, result 
from endogenous release of cumulative bone lead stores. However, it is difficult to draw a conclusion from the 
scientific literature about the magnitude of the change warranting concern. [See Chapter 9 for information on 
breastfeeding and Table 9-1 for information on follow-up of blood lead levels during lactation.] 
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Table 5-1 . Follow-up of Initial Blood Lead Testing of the Neonate (<1 Month of Age) 
 Initial Venous
 Blood Lead
Levela (BLL;  
µg/dL) 
Perform follow-up test(s)b 
<5 According to local lead screening guidelines for children. 
5-24 Within 1 month (at first newborn visit).c 
25-44 Within 2 weeks. Consultation with a clinician experienced in the management of children d with BLLs in this range is strongly advised.
≥45 
Within 24 hours and then at frequent intervals depending on clinical interventions and trend 
in BLLs. Prompt consultation with a clinician experienced in the management of children with 
d BLLs in this range is strongly advised.
a
 
The initial blood lead level may be either from an umbilical cord sample at the time of delivery or an infant venous BLL. A venous 
blood sample is preferred over a capillary sample. Decisions to initiate or stop breastfeeding or initiate chelation therapy should be 
based on venous blood lead test results only. 
bIf infants are breastfeeding, also follow recommendations in Chapter 9. 
cAccording to pediatric health supervision guidelines (well-baby visit schedule) or as clinically indicated based on trends in blood 
lead levels. 
dThe higher the BLL on the initial test, the more urgent the need for confirmatory testing. 
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Table 5-2 . Schedule for Follow-up Blood Lead Testing in Infants <6 Months of Agea,b 
Venous blood lead 
level (BLL; µg/dL) 
Early follow up (first 2-4 tests after 
identification or until BLL begins to decline) 
Later follow up (after BLL begins 
to decline) 
<10 According to local lead screening guidelines for children 
According to local lead screening 
guidelines for children 
10-14 3 monthsc Within 6-9 months 
15-19 1-3 monthsc Within 3-6 months 
20-24 1-3 monthsc Within 1-3 months 
25-44 2 weeks-1 monthd Within 1 month 
≥45 Within 24 hoursd As directed by clinician managing chelation treatment 
Adapted from Centers for Disease Control and Prevention. 2002. Managing elevated blood lead levels among young children: 
recommendations from the Advisory Committee on Childhood Lead Poisoning Prevention. Atlanta: U.S. Department of Health and 
Human Services. 
aAfter 6 months of age, recommendations from Managing Elevated Blood Lead Levels Among Young Children: Recommendations 
from the Advisory Committee on Childhood Lead Poisoning Prevention (Centers for Disease Control and Prevention 2002) should be 
followed. 
bIf infants are breastfeeding, also follow recommendations in Chapter 9. 
cSome case managers or primary care providers may choose to repeat blood lead tests on all new patients within a month to ensure 
that their BLL levels are not rising more quickly than anticipated. Seasonal variation of BLLs exists and may be more apparent in colder 
climate areas. Greater exposure in the summer months may necessitate more frequent follow ups. 
dConsultation with a clinician experienced in the management of children with BLLs in this range is strongly advised. 
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 Venousa Blood Lead
Level (BLL; µg/dL) Perform follow-up test(s)
b 
<5 None (no follow-up testing is indicated). 
5-14 Within 1 month. Obtain a maternal BLLc or cord BLL at delivery. 
15-24 Within 1 month and then every 2-3 months. Obtain a maternal BLL
c or cord BLL at delivery.  
More-frequent testing may be indicated based on risk factor history. 
25-44 Within 1-4 weeks and then every month. Obtain a maternal BLLc or cord BLL at delivery. 
≥45 
Within 24 hours and then at frequent intervals depending on clinical interventions and trend 
in BLLs. Consultation with a clinician experienced in the management of pregnant women 
with BLLs in this range is strongly advised. Obtain a maternal BLL or cord BLL at delivery. 
Table 5-3 . Frequency of Maternal Blood Lead Follow-up Testing During Pregnancy 
aVenous blood sample is recommended for maternal blood lead testing.
 
bThe higher the BLL on the screening test, the more urgent the need for confirmatory testing.
 









Figure 5-1 . New York City Department of Health and Mental Hygiene: Recommended Lead 
Risk Assessment Questions for Pregnant Women 
Health-care providers should use a blood lead test to screen pregnant women if they answer 
“yes” to any of the following questions: 
1.		 Were you born, or have you spent any time, outside of the United States?
In NYC, approximately 95% of identified lead-poisoned pregnant women are foreign born. 
Countries of birth in descending order of frequency include Mexico, India, Bangladesh, Russia, 
Pakistan, Ecuador, Haiti, Jamaica, Morocco, Dominican Republic, Guatemala, Guyana, El Salva­
dor, Gambia, Ghana, Honduras, Israel, Ivory Coast, Korea, Nepal, Sierra Leone, and Trinidad. 
2.		 During the past 12 months, did you use any imported health remedies, spices, foods, 
ceramics, or cosmetics? 
3.		 At any time during your pregnancy, did you eat, chew on, or mouth nonfood items such as 
clay, crushed pottery, soil, or paint chips? 
4.		 In the last 12 months, has there been any renovation or repair work in your home or 
apartment building? 
5.		 Have you ever had a job or hobby that involved possible lead exposure, such as home 










Figure 5-2 . Minnesota Department of Health: Recommended Lead Risk Assessment 
Questions for Pregnant Women 
Health-care providers should use a blood lead test to screen pregnant women if they answer 
“yes” or “don’t know” to any of the following questions, or if they have moved to Minnesota 
from a major metropolitan area or another country within the last 12 months: 
1.		 Do you or others in your household have an occupation that involves lead exposure? 
2.		 Sometimes pregnant women have the urge to eat things that are not food, such as clay, 
soil, plaster, or paint chips. Do you ever eat any of these things—even accidentally? 
3.		 Do you live in a house built before 1978 with ongoing renovations that generate a lot of 
dust (for example, sanding and scraping)? 
4.		 To your knowledge, has your home been tested for lead in the water and if so, were you 
told that the level was high? 
5.		 Do you use any traditional folk remedies or cosmetics that are not sold in a regular drug 
store or are homemade? 
6.		 Do you or others in your household have any hobbies or activities likely to cause 
lead exposure? 
7.		 Do you use non-commercially prepared pottery or leaded crystal? 
    
 
CHAPTER 6. MANAGEMENT OF PREGNANT AND LACTATING WOMEN 
EXPOSED TO LEAD 
Key Recommendations for Health Care Providers for the Management of Pregnant and 
Lactating Women with Blood Lead Levels ≥5 µg/dL 
For women with prenatal blood lead levels ≥5 µg/dL, 
•	 Attempt to determine source(s) of lead exposure and counsel patients on avoiding fur
ther exposure, including identification and assessment of pica behavior (see Chapter 4). 
•	 Assess nutritional adequacy and counsel on eating a balanced diet with adequate in
takes of iron and calcium (see Chapter 7). 
•	 Perform confirmatory and follow-up blood lead testing according to the recommended 
schedules (see Chapter 5 [and Chapter 9 if breastfeeding]). 
•	 For occupationally exposed women, review the proper use of personal protective equip
ment and consider contacting the employer to encourage reducing exposure. 
•	 Encourage breastfeeding consistent with the provisos in Chapter 9. 
For women with prenatal blood lead levels of 10-14 µg/dL, ALL OF THE ABOVE, PLUS: 
•	 Notify Lead Poisoning Prevention Program of local health department if BLLs ≥10 µg/dL 
are not reported by laboratory. 
•	 Refer occupationally exposed women to occupational medicine specialists and remove 
from workplace lead exposure. 
For women with prenatal blood lead levels of 15-44 µg/dL, ALL OF THE ABOVE, PLUS: 
•	 Support environmental risk assessment by the corresponding local or state health de
partment with subsequent source reduction and case management. 
For women with prenatal blood lead levels ≥45 µg/dL, ALL OF THE ABOVE, PLUS: 
•	 Treat as high-risk pregnancy and consult with an expert in lead poisoning on chelation 
and other treatment decisions (see Chapter 8). 
Note: Women of childbearing age with BLLs ≥5 µg/dL who are not currently pregnant or 







This chapter summarizes actions to be undertaken by health care providers, in coordination with local and 
state health departments, in providing clinical and environmental services to pregnant and lactating women 
with BLLs ≥5 µg/dL. Both the health department and health care provider have roles to play in keeping preg­
nant and lactating women and their offspring safe from further lead exposure. The chapter also describes how 
public health case management can work to coordinate actions between health departments and health care 





This report recommends follow-up activities and interventions beginning at BLLs ≥5 µg/dL in pregnant 
women; Table 6-1 presents specific CDC recommendations for medical and public health actions according to 
blood lead levels of the pregnant/lactating woman receiving intervention. Because the prevalence of BLLs
≥5 µg/dL, and especially ≥15 µg/dL, is low in the United States, the frequency of follow-up testing recom­
mended herein should not be an undue burden on the health care system. Although the BLL at which par­
ticular elements of case management will be initiated is variable by jurisdiction, education and follow-up BLL 
monitoring should be available for any pregnant woman who has a confirmed BLL ≥5 µg/dL. More intense 
management, including home environmental and source investigation, should be available to any pregnant 
woman with a BLL ≥15 µg/dL. 
Unlike the blood lead level of concern of 10 µg/dL for children, which is a communitywide action level, a BLL 
of 5 µg/dL in pregnant women serves a different purpose: it flags the occurrence of prior (or ongoing) lead ex­
posure above background levels, which may not otherwise be recognized. Given the vulnerability of a devel­
oping fetus to adverse effects and the possibility of preventing additional exposures, and despite the lack of 
proven interventions linked to improved outcomes, CDC feels it is prudent to initiate prevention and screen­
ing activities for pregnant women showing any evidence of lead exposure above background levels. And, 
as noted earlier, in contrast to abstract and generalized anticipatory guidance, blood lead test results above 
background levels are also concrete and actionable data points that may help focus attention by an expectant 
woman on the challenge of identifying and reducing lead exposure. 
This chapter describes the role of clinicians in medical management of pregnant and lactating women with 
BLLs ≥5 µg/dL, including both clinical interventions, with reference to detailed chapters, and environmental 
counseling to reduce lead exposures. This chapter also reviews the role of public health agencies in pro­
viding environmental investigations and case management. These essential activities complement those 
provided by health care providers to ensure that pregnant women receive the full spectrum of appropriate 
services to identify and reduce exposures to lead. 
MEDICAL MANAGEMENT: ROLE OF THE HEALTH CARE PROVIDER 
Medical management of pregnant women with BLL ≥5 µg/dL consists of two parallel tracks: environmental 
management and clinical services. The mainstay of management for pregnant women with blood lead levels 
≥5 µg/dL is removal of the source, disruption of the route of exposure, or avoidance of the lead containing 
substance or activity. Recommendations for reducing lead exposure are presented below. 
Recommended clinical care is described throughout this report in the chapters presenting the research base 
on blood lead testing, nutrition, chelation, breastfeeding, and other issues. For the convenience of readers, a 
brief overview of important aspects of clinical care to accompany environmental risk reduction is provided in 
Box 6-1. Each topic presented is discussed in detail in separate chapters, as noted. 
Reducing lead exposure can be a complex challenge, which does not always lend itself to straightforward 
interventions. Lead exposure can occur in the home, community, or workplace, so identifying specific sources 
of lead and exposure pathway(s) for an individual is essential to reducing exposure for a particular woman. 
Any or all of the following strategies may need to be applied depending on a woman’s residence, lifestyle, or 
occupation. This section describes the essential actions recommended for health care providers to assess lead 
exposure and counsel on its reduction. 
Source identification beyond obtaining a thorough environmental and occupational history should be con­
ducted in collaboration with the local health department when BLLs are ≥15 µg/dL. During this process, local 
or state health departments will visit the home to conduct in-person interviews and collect samples that allow 
for more-thorough understanding of the risk factors and lead sources and pathways of exposure. In some 
jurisdictions, an investigation of the workplace may take place as well. This information should be shared with 
the health care providers for both the mother and infant. Health care providers can assist in the investigation 
by providing information to health departments on suspected sources that are identified during the care of 
the patient. In identifying the source or risk factors, testing of all family and household members of the patient 
for blood lead levels will reveal whether the source is common to everyone or unique to the patient. 
Evaluate Occupational Exposure and Make Appropriate Notifications 
While blood lead levels in occupationally exposed individuals have fallen dramatically since lead industry 
standards were revised in 1978 (Anderson and Islam 2006), occupational exposures are still a source of lead ex­
posure in women (Centers for Disease Control and Prevention 2007; Fletcher et al. 1999). Public health depart­
ments and health care providers should evaluate occupation as a possible source of lead exposure in pregnant 
or lactating women with BLLs ≥5 µg/dL and, if occupational exposure exists, refer these women to an occupa­
tional physician or occupational medicine center that treats occupationally exposed adults. Appendix IV lists 
major lead-using industries. 
Under current OSHA standards, workplace protections to reduce lead exposure include medical surveillance, 
periodic air monitoring, and provision of change and shower facilities to reduce take-home exposure. Medical 
removal is required by OSHA only when blood lead concentrations exceed 50 µg/dL (for construction) or 60 
µg/dL (for general industry). BLLs of 40 µg/dL trigger a medical evaluation. However, the OSHA standards are 
out of date and are inadequate for protecting the health of lead-exposed workers, especially pregnant women 
and their offspring. Adverse health effects have been associated with much lower blood lead levels currently 
set as benchmarks for OSHA enforcement. 
New evidence has emerged over the last 20 years showing that both cumulative as well as acute lead ex­
posures pose significant health risks (Kosnett et al. 2007). As discussed in Chapter 2 of this document, lead 
exposure during pregnancy has been associated with an increased risk for spontaneous abortion and adverse 
effects on fetal growth and neurodevelopment. In response to current research findings, recent recommenda­
tions by Kosnett et al. (2007) and by the Association of Occupational and Environmental Clinics (2007) call for 
setting the general lead industry blood lead level of concern to 10 µg/dL; for occupationally exposed women 
who are or may become pregnant, the goal is to maintain a BLL <5 µg/dL. 
From a clinical perspective, it is important to note that the OSHA Medical Surveillance Guidelines included 
as Appendix C to the 1977 Lead Standard (www.osha.gov/pls/oshaweb/owadisp.show_document?p_ 
table=STANDARDS&p_id=10033) explicitly states: 
“Recommendations [regarding medical removal protection] may be more stringent than the specific 
provisions of the standard. The examining physician, therefore, is given broad flexibility to tailor special 
protective procedures to the needs of individual employees. This flexibility extends to the evaluation 
and management of pregnant workers and male and female workers who are planning to raise chil­
dren. Based on the history, physical examination, and laboratory studies, the physician might recom­
mend special protective measures or medical removal for an employee who is pregnant or who is plan­
ning to conceive a child when, in the physician’s judgment, continued exposure to lead at the current 
job would pose a significant risk.” 
The appendix goes on to state: “The adverse effects of lead on reproduction are being actively researched and 
OSHA encourages the physician to remain abreast of recent developments in the area to best advise pregnant 
workers or workers planning to conceive children.” 
Since substantial research developments have occurred since the 1970s when the OSHA standards were 
developed, occupationally exposed women who are or may become pregnant should be removed from lead 
exposure if their blood lead level is ≥10 µg/dL. If the blood lead level is in the range of 5 to 9 µg/dL, the health 
care provider should ask about potential sources of lead exposure on the job and review appropriate use of 










order to keep exposure as low as possible and to prevent take-home exposures for other household members. 
Specifically, patients should be advised to 
•	 Wear a respirator and keep it clean. 







•	 Wash hands and face before eating and drinking. Never eat or drink in the work area. 
•	 Normal handwashing and cleaning of eating surfaces may not remove all surface lead, ‘lead visualization’ 
wipes are available can help determine if lead has been removed to an adequate degree. 
•	 When possible, wash or shower and change clothes and shoes before leaving work. Keep all work items 
away from family areas in the home, and wash and dry work clothes separately from other laundry. 
Where feasible, the occupational medicine provider should consider contacting the woman’s employer with 
recommended best practices to monitor and reduce lead exposure in their workplace. An example of such 
a letter is provided in Appendix XIV. Appendix XV contains the California Department of Public Health Work­
place Hazard Alert. Prior to issuing such a letter, the healthcare provider should discuss the contents with the 
affected employee, and obtain her authorization. Although the letter in Appendix XIV refers to the medical 
removal protection provisions of the OSHA lead standards, the provider and the employee should be aware 
that some patients (e.g., employees of government agencies, mines, railroads and airlines) may work for a busi­
ness that does not necessarily fall under OSHA jurisdiction. For these employees, the reference to the OSHA 
standard should be omitted and the employee should give explicit consent for release of medical information 
to her employer. 
Identify and Discourage Pica Behavior 
As discussed in Chapter 4, the behavior common to all definitions of pica is a pattern of deliberate ingestion 
of nonfood items, which can cause lead exposure if the substances consumed are contaminated with lead. 
All pregnant women, but especially those with blood lead levels ≥5 µg/dL, should be counseled to never eat 
nonfood items that may contain lead, such as clay, soil, pottery, or paint chips. Appendix III lists commonly 
reported pica substances. 
Once pica is identified, the specific behavior must be characterized in order to determine how best to inter­
vene. Clinicians are encouraged to follow a standardized history outline to obtain a more complete picture of 
pica behavior for an individual woman. Table 6-2 provides suggested factors to assess and characterize pica 
behavior, including such issues as the reason(s) for the behavior (if known) and the substance(s) being con­
sumed. Only a few studies are available that evaluate the effectiveness of interventions designed to reduce 
or eliminate pica behavior. Most of these studies evaluated the impact of interventions on pica behavior in 
developmentally delayed individuals or those with obsessive-compulsive disorders (Goh et al., 1999; McAdam, 
et al. 2004; Piazza et al. 1998). Other studies have attempted to reduce pica behavior by providing vitamin 
supplements and improving the quality of the diet. While this approach appears to be effective in some case 
reports (Bugle and Rubin 1993; Pace and Toyer 2000), a randomized, double blind, placebo-controlled, two-by­
two factorial study found that micronutrient supplementation did not affect geophagy (eating earth) in 220 
school-aged children in Zambia (Nchito et al. 2004). They concluded that the results supported the premise 
that geophagy is a learned activity and that nutritional deficiencies associated with geophagy are more likely 
to be a result, not a cause, of this practice. No intervention studies were found that included pregnant women. 
Therefore, until further research is available that can guide clinical practice, interventions should promote 
alternative, healthier strategies in response to the patient’s apparent reasons for pica. The approach depends 
upon eliciting accurate information from the patient about the behavior. In the clinical setting, it may be use­
ful to ask women specifically about the discomforts of pregnancy and the techniques being used to minimize 
them. Pica has been commonly reported to be used in pregnancy to help relieve abdominal pain, diarrhea, 
and nausea; to assuage cravings and to improve appetite; and to impart a sense of well-being. Obstetrical pro­
viders also should inquire about cravings. Ice pica is particularly common and is often accompanied by pica as­
sociated with less benign substances. Inquiring first about general cravings in pregnancy, then about specific 
cravings for ice, and finally cravings for other less-commonly ingested nonfood items may be more likely to 
uncover pica behavior. Follow-up questions inquiring about the ingestion of other substances commonly used 
by members of a woman’s community may also help elicit a history of pica. 
If the substance is consumed due to cravings, then substitution with a similar, but uncontaminated, substance 
could be suggested. If a woman is experiencing stomach upset, nausea, or lack of appetite, more appropriate 
interventions should be followed. Current recommendations of the American College of Obstetricians and 
Gynecologists (ACOG) for the effective management of nausea and vomiting in pregnancy include vitamin 
B6 supplementation, use of antiemetic medications, and nonpharmacological approaches such as use of 
“sea-bands” which use pressure points on the wrist to suppress nausea. These interventions can reduce the 
discomfort associated with nausea and vomiting of pregnancy by 70% (American College of Obstetricians and 
Gynecologists 2004). When associated with a psychiatric disorder, appropriate referrals for counseling and 
behavior modification are warranted. 
Descriptive studies have found associations between nutritional deficiencies and pica. Several studies report­
ed lower serum ferritin levels (Edwards et al. 1994; Geissler et al. 1998), lower hemoglobin or hematocrit levels 
(Corbett et al. 2003; Edwards et al. 1994; Geissler et al. 1998; Rainville 1998), or higher rates of anemia (Ket­
taneh et al. 2005) in those who engage in pica, while others have found no health effects associated with pica 
(Smulian et al. 1995). Therefore, women who engage in pica behavior, regardless of the substance consumed, 
require nutritional counseling. 
Counsel Women About Avoiding Sources of Lead Exposure 
Avoid alternative products that may contain lead and stay informed of new risks 
As discussed in Chapter 4, certain products have been found to be contaminated with lead. Some products 
have been associated clearly with lead poisoning cases and women should be counseled to avoid these 
products. These include alternative cosmetics, food additives, and medicines imported from overseas that 
may contain lead, such as azarcon, kohl, kajal, surma, and many others listed in Appendix V. Pregnant women 
should be informed that herbal medicines and alternative remedies imported personally or ordered from 
other countries by mail or online are not subject to FDA premarket approval and therefore their safety cannot 
be assured, even if the product is professionally packaged and labeled. Pregnant women should be cautioned 
against consuming candies, spices, and other foods that have been brought into the country from travelers 
abroad, especially if they appear to be noncommercial products, since their safety is unknown. 
Obstetrical providers should advise pregnant women not to expose their fetuses to the risks of herbal medi­
cines and supplements (Marcus and Snodgrass 2005). Herbal medicines and supplements are often regarded 
as safe by the public and some health care providers, but there is no scientific basis for that belief. In addition, 
certain herbal medicines and supplements are known to be contaminated with lead and, therefore, should 
be avoided. There are no rigorous scientific studies of the safety of herbal medicines and supplements dur­
ing pregnancy, and the Teratology Society has stated that it should not be assumed that they are safe for the 
embryo or fetus (Friedman 2000). 
The literature also contains numerous reports of excessive lead intake associated with the use of lead-glazed 
ceramic pottery produced by artisans or small manufacturers overseas. As noted earlier, pregnant women 
should be warned that lead leaches out of these products if they are used for food preparation or storage, es­
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pecially if used to store acidic liquids such as wine or juice. Leaded crystal glassware is another potential lead 
source, but one that has not been linked with lead poisoning cases. 
On occasion, products available through domestic channels of commerce are found to cause lead exposures 
to consumers. Recent exposures of concern reported by the media have included jewelry, toys, and other 
products. In some cases, federal agencies have authority to issue recalls of contaminated products, but some­
times they can only issue warnings. For instance, dietary supplements sold in the United States are not subject 
to FDA premarket approval, but FDA has authority to act if products are adulterated (e.g., lead contaminated) 
or misbranded. In either instance, consumer education is essential to avoiding these exposures. Consumers 
and health care providers can monitor FDA and CPSC recalls and CDC alerts in order to be apprised of newly 
recognized products of concern. Local health departments can also communicate this information to com­
munities and medical providers. Pregnant women should be given an updated list of products found to be 
contaminated with lead at their prenatal visits. [For more information, see Chapter 4 and American Academy 
of Pediatrics (2005); Binns et al. (2007);Centers for Disease Control and Prevention (2002)]. The Consumer Prod­
uct Safety Improvement Act (CPSIA), which took effect in February 2009, lowered the allowable lead content of 
consumer products intended for children 12 and younger, setting the standard at 600 ppm of lead in any ac­
cessible part. Beginning in August 2009, the allowable concentration declined to 300 ppm, and in August 2011 
it will decline to 100 ppm. Starting in 2010, manufacturers must test their products and certify that they meet 
CPSIA standards. In the meantime, products exceeding the new standard remain prohibited and are subject to 
recall. 
Avoid using lead-contaminated drinking water 
Lead found in drinking water is usually due to corrosion that causes lead to leach out of plumbing pipes. The 
Safe Drinking Water Act (1991) prohibited the sale of lead-containing pipe for residential use (U.S. Environ­
mental Protection Agency 1991). Homes built before 1986 are more likely to have lead in pipes, fittings, solder, 
fixtures, or faucets. Therefore, owners of older homes may want to test their water for lead. Certain attributes 
of the water, such as its temperature and pH, as well as the presence of additives, can all affect lead levels. 
Families with private wells as a water source will need to test their water to determine if lead contamination is 
a problem, as this is not regulated by EPA. 
The EPA’s community action level for lead in tap water is 15 ppb. If test results exceed this level, public water 
systems must comply with public education requirements, as well as conduct additional testing. Such public 
water systems may also be required to conduct source water treatment and/or lead service line replacement. 
Reducing lead levels in water may also require replacing internal plumbing such as pipes or fixtures or both. 
Until the source(s) of lead is removed, homeowners should employ several strategies to minimize their expo­
sure to lead in tap water. Flushing the system for several minutes after nonuse discards water that has been 
standing in the system and is more likely to contain lead. All tap water used for consumption—whether for 
drinking, cooking, or particularly for preparation of infant formula—should be flushed before use. Use of bot­
tled or filtered water are other alternatives, although not all filtration systems remove lead and not all bottled 
water is guaranteed to be lead-free. For detailed instructions for flushing water, along with testing information 
and federal regulations, see the EPA Lead in Drinking Water Web page (http://www.epa.gov/safewater/lead/ 
index.html). 
Avoid exposure to lead hazards in housing (paint, dust, soil) 
As noted in Chapter 4, lead-based paint hazards are a major source of exposure for young children. In con­
trast, the research literature suggests that pregnant women are more likely to be exposed to lead-based paint 
hazards associated with renovations in older homes. Nevertheless, pregnant women should be educated 
about the potential risks associated with lead-based paint in older housing for several important reasons. First, 
pregnant women should understand the importance of using lead-safe work practices in older homes during 
repair, renovation, repainting, or remodeling work. Failing to minimize and contain dust generated by any ac­
tivity that disturbs paint can increase or create exposure risk. Dangerous paint removal and repair techniques 
that generate lead dust or fumes such as dry scraping, sanding, burning of paint with a torch, or using a high-
temperature heat gun should be avoided—and may be illegal in some jurisdictions or in federally subsidized 
housing. Without appropriate education, there is a risk that families (or renovation workers) will inadvertently 
create or worsen lead-based paint hazards as they work diligently to prepare the baby’s room or make other 
home improvements, thereby exposing the pregnant woman and fetus to lead during the pregnancy or after­
ward when the baby comes home. 
Federal law requires that property owners disclose known lead-based paint and lead hazards to prospec­
tive buyers and renters of older homes and that remodeling contractors give lead information to residents 
before renovating homes built before 1978. A new EPA regulation (promulgated April 2008; effective April 
2010) requires lead-safe work practices during renovation/repainting projects, and includes strict controls 
on disturbance of lead paint by a contractor performing renovation in a residence where a pregnant woman 
resides (see http://www.epa.gov/lead/pubs/renovation.htm). Pregnant women and their families should be 
encouraged to inquire whether painters or other contractors scheduled to perform work in their homes have 
received training in lead-safe work practices. 
Families should also understand the importance of maintaining painted surfaces in older homes. While intact 
lead-based paint poses little risk, peeling paint or other signs of paint deterioration in a pre-1978 home can 
result in lead exposure hazards. If there is peeling paint (or any other indication of a problem) in the home of a 
family that is expecting or has young children, and lead-based paint is suspected to be present, the homeown­
er or tenant should contact the local health department for advice on options such as testing and remediation. 
Appropriate remediation strategies vary according to the location and condition of the lead-based paint and 
the extent of the contamination. Interventions can include a range of activities such as professional cleaning; 
thorough repair or replacement of components (e.g., entire windows, window sashes, trim/molding, or door 
jambs), paint stabilization, complete repainting, or complete paint removal. All of these interventions have 
been found to significantly reduce lead dust levels for at least 3 years postintervention, with the more inten­
sive treatments found to be associated with greater post-intervention reductions (Dixon et al. 2005). In cases 
where heavy soil contamination has occurred, the soil may need to be removed. However, when less con­
tamination is present, techniques such as planting with ground covers or installing gravel pathways, drip line 
boxes, or raised planting beds and play areas may be sufficient (Binns et al. 2004; Dixon et al. 2006). 
After interventions have been completed in the home, the home should not be reoccupied until it has passed 
lead dust clearance testing, indicating that the home has been adequately cleaned and that invisible lead dust 
has not been left behind. Numerous resources are available for the general public. For more information, see 
Chapter 11, Resources and Referral Information. 
Minimize lead exposure from point sources 
Women who live close to active lead mines, smelters, or battery recycling plants should take precautions to 
avoid exposure to lead via inhalation exposures or ingestion of hazardous waste (e.g., mine tailings, acid mine 
drainage) through contamination of the home environment from industrial lead dust or fumes. 
Avoid hobbies and recreational activities that may involve lead exposure 
Numerous recreational activities can result in exposure to lead. These activities include crafts (print making, 
stained glass, ceramics), outdoor sports (hunting and fishing), and liquor distillation, among others. [See Ap­
pendix IV for a detailed list.] Since women may not know that these activities carry a risk for lead exposure, 
consumer education is critical. General safety procedures such as performing these activities in well-ventilated 
spaces, frequent hand washing, and the use of jacketed ammunition at shooting ranges, can all minimize the 
risk of lead exposures from recreational activities. Under some circumstances, consumption of game meat 
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(e.g., venison, wild fowl) harvested with lead ammunition may pose a risk for excess lead exposure (Kosnett 
2009). Health care facilities providing care to pregnant women should provide informational brochures to 
pregnant women on the risks associated with these activities. 
ENVIRONMENTAL AND CASE MANAGEMENT: ROLE OF PUBLIC HEALTH AGENCIES 
This section describes the essential role of public health agencies in assuring appropriate services for preg­
nant women needing intervention for lead exposure above background levels. Such public health services are 
recommended at various blood lead levels to complement ongoing medical management being provided by 
the woman’s health care provider (see Table 6-1). Specifically, public health agencies ensure that lead hazards 
in the home environment are assessed and remediated. Public health agencies also provide case management 
services to ensure that all appropriate services are provided. Public health agencies can also provide guidance 
about reimbursement issues regarding environmental investigation or case management and make referrals 
to private providers, such as lead risk assessors, if necessary. 
Environmental Investigation and Management 
As previously noted, the critical element in the prevention of lead exposure is the control or elimination of 
all sources of lead, which must include the home environment to be effective. The goal of environmental 
management is to ensure a lead-safe home for mothers and babies. To this end, it is recommended that an 
investigation of the home environment, which is variously called an environmental investigation, exposure 
assessment, or risk assessment, be conducted for all women and newborn infants with BLLs of ≥15 µg/dL in 
order to identify potential sources of lead and pathways of exposure and to identify appropriate activities to 
reduce or prevent further lead exposure. This investigation and subsequent control activities should be carried 
out by the local or state health department, or under its supervision, as part of case management activities for 
pregnant and lactating women identified with blood lead levels ≥15 µg/dL. 
The investigation should include questions about potential lead exposure pathways, a visual inspection of the 
home and other relevant environments, and testing of specific media for the presence of lead (such as water, 
household dust, soil, paint chips, foods, ethnic remedies, spices, ceramic ware, or other suspected sources of 
lead), as indicated. Examples of environmental management protocols for pregnant women are found in Ap­
pendix VIII (New York City Department of Health [NYC DOH] Pregnancy Risk Assessment Form), which is used 
for all women with prenatal BLLs of ≥15 µg/dL); Appendix IX (Minnesota DOH Assessment Interview Form); 
and Appendix X (Minnesota DOH Lead-Based Paint Risk Assessment Form), which is used for both pregnant 
women and for children with elevated blood lead levels). An example of an environmental management pro­
tocol for infants of mothers with elevated prenatal blood lead levels who do not have elevated BLLs is found in 
Appendix XI (NYC DOH Primary Prevention Information Form). An example of a protocol for environmental risk 
assessment for case management of young infants and children with blood lead levels of 15 µg/dL or higher is 
provided in Appendix XII (NYC DOH Child Risk Assessment Form). 
At a minimum, environmental management should include isolating the expectant mother from known expo­
sure sources, by workplace removal for occupational exposures and through temporary relocation until hazard 
remediation has been completed and clearance achieved for lead-based paint hazards in the home. Local and 
state health departments may also utilize information and resources provided by the Centers for Disease Con­
trol and Prevention’s National Center for Environmental Health (NCEH) and other agencies and organizations 
[see Chapter 11 for resources and referral information] to provide the most current and updated case manage­
ment services to their constituents (Centers for Disease Control and Prevention 2002). 
Case Management 
This section is intended to facilitate the management of pregnant and lactating women and newborn infants 
with lead exposure above background levels by providing information and guidance to health department 








Case management of pregnant women with lead exposure involves coordinating, providing, and overseeing 
the services required to reduce their BLLs to prevent harm to the developing fetus. It is based on the efforts of 
an organized team that includes the pregnant woman and newborn infant’s health care providers. A hallmark 
of effective case management is ongoing communication with the health care and other service providers and 
a cooperative approach to solving any problems that may arise during efforts to decrease the mother-infant 
pair’s BLLs and eliminate lead hazards in the their environment. 
CDC recommends that public health agencies provide case management services for pregnant women with 
blood lead levels ≥15 µg/dL (See Table 6-1). These services are adapted from the current model of case man­
agement adopted by CDC for young children, which has eight components: a) client identification and out­
reach, b) individual assessment and diagnosis, c) service planning and resource identification, d) the linking of 
clients to needed services, e) service implementation and coordination, f ) the monitoring of service delivery, 
g) advocacy, and h) evaluation (Centers for Disease Control and Prevention 2002). Typical case management 
activities could include the following, depending upon the patient’s needs and local resources: 
•	 Assess factors that may impact the woman’s BLL (including sources of lead, nutritional status, access to 
services, family interaction, and understanding). 
•	 Visit the woman’s residence and other sites where the woman spends significant amounts of time, such 
as a job site, to conduct a visual investigation of the site and identify sources of environmental lead 
exposure. Such visits may be made by a case manager and/or by certified environmental investigators or 
risk assessors. 
•	 Develop a written plan for intervention. 
•	 Oversee the activities of the case management team. 
•	 Coordinate implementation of the plan, including collaboration with the primary health care provider(s) 
and other specialists. 
•	 Evaluate compliance with the plan and the success of the plan. 
•	 Ensure that a woman receives services in a timely fashion consistent with guidance. 
Another variable, the duration of management, will depend on when the blood lead level ≥5 µg/dL is identi­
fied—during the prenatal period, at birth, or while the mother-infant pair is nursing. The interventions recom­
mended in this report are for the secondary prevention of adverse health effects from lead exposure; that is, 
to prevent further lead exposure and to reduce BLLs in pregnant women who have been identified as having 
lead exposure. However, the ultimate goal is primary prevention of any lead exposure of the developing fetus 
or newborn infant. Of course, primary prevention is also indicated for women of reproductive age who may 
become pregnant, not only those who are already pregnant. The importance of primary prevention should not 
be overlooked, since the behavioral and cognitive effects of lead exposure in young children may be irrevers­
ible. 
Practices and resources for case management of lead exposure vary markedly among states, cities, and juris­
dictions. (In some communities, case management is called care coordination.) The sources of exposure and 
prevalence of blood lead levels above background levels among pregnant and lactating women and newborn 
infants also vary by geographic location and community-specific risk factors and may not be readily identifi­
able. Therefore, users of these guidelines may need to modify them to meet the needs unique to their specific 






Box 6-1: Medical Management of Pregnant Women With BLL ≥5 µg/dL 
This box provides clinicians with a concise reference on general considerations in medical man­
agement of their patients with confirmed lead exposure above background levels. Readers are 
encouraged to refer to the relevant chapters for additional information. 
Counseling patients on identifying and avoiding lead sources (Chapter 4) 
For all patients, but especially those with known lead exposures, health care providers should 
provide guidance regarding sources of lead and help identify potential sources of lead in patients’ 
environments. Public health agencies may have additional information on community-specific 
risk factors based on geographic location, occupation, or ethnic background. If not completed 
prior to determination of initial blood lead level, providers should take a complete occupational 
and environmental history, including questions that may identify the presence of risk factors for 
lead exposure. 
Identification and counseling regarding pica behavior (Chapters 4 and 6) 
Many studies agree that pica behavior is likely to be underreported. Identifying pica in a clinical 
setting may best be accomplished by treating it as a sensitive issue: proceeding from general to 
more-specific questions and from less-intrusive to more-intrusive questions. A recommended 
approach is to ask women specifically about techniques being used to minimize the discom­
forts of pregnancy and about cravings, inquiring first about general cravings in pregnancy, then 
about specific cravings for ice, and finally cravings for other less commonly ingested nonfood 
items. Follow-up questions inquiring about the ingestion of other substances commonly used by 
members of a woman’s community may also help elicit a history of pica. If a substance is con­
sumed due to cravings, then substitution with a similar, but uncontaminated, substance could be 
suggested. When associated with a psychiatric disorder, appropriate referrals for counseling and 
behavior modification are warranted. Women who engage in pica behavior, regardless of the sub­
stance consumed, may benefit from nutritional counseling due to the documented associations 
between nutritional deficiencies and pica. 
Nutritional assessment and referrals (Chapter 7) 
Pregnant and lactating women with a current or past BLL ≥5 µg/dL should be assessed for the 
adequacy of their diet and provided with prenatal vitamins and nutritional advice emphasizing 
calcium and iron intake. A balanced diet with a dietary calcium intake of 2,000 milligrams daily 
should be maintained, either through diet or by supplementation or by a combination of both. 
Additionally, iron status should be evaluated and supplementation provided in order to correct 
and prevent any iron deficiency. Women with anemia (defined in pregnancy as a hemoglobin 
level <11 g/dL in the first trimester and third trimester and <10.5 g/dL in the second trimester), 
requires higher dosing (Institute of Medicine 1990). Generally, pregnant women with iron defi­
ciency anemia should be prescribed 60 to 120 mg of iron daily in divided doses. Dosage can be 
reduced to 30 mg daily once anemia is corrected. Women receiving supplemental iron or calcium 
should be encouraged to split the dose, taking no more than 500 mg of calcium or 60 mg of iron 
at one time, as only small amounts of these nutrients can be absorbed at any one time. Obstetri­
cal providers should advise pregnant women not to expose their fetuses to the risks of herbal 
medicines, since there is no evidence of their safety and some are known to be lead-
contaminated. 
 
Interpretation and follow-up of blood lead tests (Chapter 5) 
Pregnant women identified with blood lead levels ≥5 µg/dL should be tested per Table 5-3. Follow-up 
blood lead testing should be performed according to schedules provided in Table 5-1 for newborns and 
Table 5-2 for infants under 6 months of age. Adjust the frequency of follow-up tests according to the 
chronicity of exposure; risk factors for continued, repeat, or future exposure; and types of clinical inter­
ventions. Occupationally exposed women should be referred to an occupational physician or center 
treating occupationally exposed adults and removed from the workplace lead exposure at BLL ≥10 µg/ 
dL. If not reported directly by the clinical laboratory, the health care provider should notify the Lead Poi­
soning Prevention Program of the local or state health department of BLLs ≥10 µg/dL. Communication 
with the local or state health department and the pediatric health care provider is crucial in ensuring ap­
propriate follow-up care and developmental monitoring and referrals. Pregnant women identified with 
blood lead levels ≥5 µg/dL should be tested at the time of birth to establish a baseline to guide postnatal 
care for mother and child, and followed up according to the testing schedule in Table 9-1. If past expo­
sure to lead was higher than for most people, maternal blood lead levels may increase slightly during 
lactation due to the liberation of lead from bone stores. 
Assisting with identification of lead sources in the environment (Chapters 4 and 6) 
The essential activity in management of pregnant women with blood lead levels ≥5 µg/dL is removal 
of the lead source, disruption of the route of exposure, or avoidance of the lead-containing substance 
or activity. Source identification beyond obtaining a thorough environmental and occupational history 
should be conducted in collaboration with the local health department when BLLs ≥15 µg/dL, which 
will conduct an environmental investigation of the home environment in most jurisdictions. This process 
usually includes in-home interviews and collection of environmental samples to confirm lead sources 
and pathways of exposure. Health care providers can assist by providing information to health depart­
ments on suspected sources identified during patient care. Findings should be shared with the health 
care providers of the mother and infant. 
Chelation therapy (Chapter 8) 
In consultation with a lead poisoning expert, pregnant women with confirmed BLLs ≥45 µg/dL may be 
considered for chelation therapy and should be considered as high risk pregnancies. Immediate removal 
from the lead source is still the first priority. In some cases, women may need hospitalization. Reserving 
the use of chelating agents for later in pregnancy is consistent with the general concern about the use of 
unusual drugs during the period of organogenesis (National Research Council, 2000). However, BLLs 
≥70 µg/dL may result in significant maternal toxicity and chelation therapy should be considered, re­
gardless of trimester, in consultation with experts in lead poisoning and high-risk pregnancies. Chelation 
therapy should also be considered in neonates and infants less than 6 months of age for a confirmed BLL 
≥45 µg/dL. 
Counseling on breastfeeding (Chapter 9) 
Initiation of breastfeeding should be encouraged for mothers with BLLs <40 µg/dL. At maternal blood 
lead levels between 20-39 µg/dL, breastfeeding should be intiated accompanied by sequential infant 
BLLs to monitor trends. A woman with a confirmed BLL ≥40 µg/dL should not initiate breastfeeding. She 
should be advised to pump and discard her breast milk until her blood lead has declined to <40 µg/dL. 
Breastfeeding should continue for all infants with BLLs <5 µg/dL or trending downward. For breastfed 
infants whose blood lead levels are rising or failing to decline by 5 µg/dL or more, environmental and 
other sources of lead exposure should be evaluated. If no external source is identified, and maternal BLLs 
>20 µg/dL and infant BLLs ≥5 µg/dL, then breast milk should be suspected as the source, and temporary 
interruption of breastfeeding until maternal blood lead levels decline should be considered. 
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BLL Health Care Providers Public Health Providers 
  Collect all blood lead test results 
<5 
  Provide anticipatory guidance routinely and health 
education materials to all pregnant and lactating 
women 
  Develop and disseminate guidelines and health 
education materials to providers 
  Provide community-specific risk factors and 
population-based blood lead testing guidance 
to clinicians 
Above actions plus 
  Attempt to determine source(s) of lead exposure 
and counsel patients on strategies to reduce 
exposure 
5-9 
  For occupationally exposed women, review 
proper use of personal protective equipment and 
consider contacting the employer 
As above 
  Assess nutritional adequacy 
  Confirmatory and follow-up testing (see Table 5-3) 
Above actions plus 
10-14 
  Notify lead poisoning prevention program of local 
health department if not reported by laboratory 
  Refer occupationally exposed women to 
occupational medicine specialists 
  For occupationally exposed women, recommend 
removal from exposure 
Above actions plus 
  Send out health education materials to patient 
  For occupationally exposed women, remove 
from exposure 
15–44a 
Above actions plus 
  Assist local health department with complete 
exposure source assessment 
Above actions plus 
  Perform or refer for environmental investigation, 
source reduction/lead hazard control, case 
management 
≥45b 
Above actions plus 
  Treat as high-risk pregnancy 
  Consider chelation (inpatient) (see Chapter 8) in 
consultation with lead poisoning expert 
Above actions plus 
  Facilitate consultation with an identified lead 
poisoning expert experienced in managing 
chelation in pregnant women 
Table 6-1 . Recommended Actions by Blood Lead Level in Pregnancy 
aEnvironmental interventions to control lead exposures at blood lead levels below those in this chart support the goal of lead-safe 
housing for all children and are appropriate in jurisdictions with resources available to provide such services. 
bBlood lead levels ≥70 µg/dL may result in significant maternal toxicity; therefore, chelation should be considered regardless of 
trimester of pregnancy and in consultation with an identified lead poisoning expert (see Chapter 8 for more details). 
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Topic Reason Why Information Is Important Specific Questions to Ask 
Demographics Context, identify populations at risk Age, race, ethnicity, country, and region of origin 
What substance(s) consumed? 
Substance(s) 
consumed 
Determine if substance(s) are harmful and 
if extent of use likely to pose health risks, 
identify source of pica substance(s) for public 
health interventions if needed 
Dose consumed (amount and frequency)?  
 
Substance consumed throughout pregnancy?  
 
Where obtained? 
(Be as specific as possible in case a sample needs 
to be obtained for testing for contamination) 
Reason for use 
Useful in being able to elicit a pica history 
in women of similar background or 
experiencing similar symptoms, helpful 
in developing an appropriate plan to help 
individual woman stop the intake of harmful 
substances 
Reason(s) for use: treatment for specific symptom, 
general health, or spiritual or emotional well­
being 
Age at onset? 
Pica behavior 
Understanding of the persistence of the 
behavior and a clue to how difficult it will be 
to eradicate 
Use affected by hormonal changes (menses, 
pregnancy, lactation) or stress? 
Substitution if usual pica substance not available? 




Improve the understanding of how pica 
behavior affects pregnancy outcomes 
Current pregnancy: gestational age at delivery, 
birth weight of child, preeclampsia, gestational 
diabetes 
Previous pregnancy history: spontaneous 





Information will be useful in identifying 
communities at risk and in planning public 
health interventions if needed 
Who else consumes substance in community 
(family, neighbors)? 
What quality(ies) about the substance is/are 
important? 
What problems are thought to be associated with 
its use? 
Table 6-2 . Suggested Factors to Assess and Characterize Pica Behavior 
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Key Points for Nutrition and Lead 
•	 The human body’s nutritional status affects the absorption, deposition, and excretion of lead 
and may also affect lead toxicity. 
•	 Lead exposure can also modify the body’s ability to utilize nutrients. 
•	 Avoidance of lead exposure remains the primary preventive strategy for reducing adverse 
health effects. However, the existence of nutrient-lead interactions suggests that optimiz
ing nutritional status during pregnancy and lactation may assist in preventing the adverse 
consequences of lead exposure. 
General Nutritional Recommendations for Pregnant and Lactating Women 
•	 All pregnant and lactating women should eat a balanced diet in order to maintain adequate 
amounts of vitamins, nutrients, and minerals. 
•	 All pregnant and lactating women should be evaluated for iron status and be provided with 
supplementation in order to correct iron deficiency. 
•	 All pregnant and lactating women should be evaluated for the adequacy of their diets and 
be provided with appropriate nutritional advice and prenatal vitamins. 
•	 Women in need of assistance should be referred to programs, such as WIC or the Supplemen
tal Nutrition Assistance Program (SNAP) (formerly food stamps). 
•	 All pregnant and lactating women should avoid the use of alcohol, cigarettes, herbal medi
cines, and any other substance that may adversely affect the developing fetus or infant. 
Recommendations for Pregnant and Lactating Women with Blood Lead Levels ≥5 µg/dL 
•	 In pregnant and lactating women with BLLs ≥5 µg/dL or with a history of lead exposure, a 
dietary calcium intake of 2,000 milligrams daily should be maintained, either through diet or 




OVERVIEW OF THE RELATION BETWEEN NUTRITION AND LEAD 
Pregnancy and the first 2 years of life are exceptionally important intervals with respect to adequate maternal 
and child nutrition (Horton 2008). Pregnancy and lactation are also critically important periods from a toxico­
logical perspective because of the special significance of the potential for adverse effects of toxic exposures 
on early human development. If inadequate nutritional status increases susceptibility to the toxic effects of 
lead, lifelong adverse effects are more likely. In addition, lead exposure can interfere with the metabolism of 
nutrients—an especially important consideration when nutritional status is marginal. This chapter provides an 
overview of the information on dietary intake and lead levels in pregnant women. These data are limited. Any 
beneficial effects of dietary supplementation must be demonstrated in well-designed (randomized, placebo-
controlled) clinical trials. However, given the importance of basic nutrition in normal pregnancy and lactation, 
this chapter provides practical recommendations based on the limited suggestive data available for primary 
and secondary prevention of lead exposure. Recommended dietary intakes (dietary reference intakes [DRIs]— 
formerly called RDAs) are from the Institute of Medicine, Food and Nutrition Board, unless specifically noted 
otherwise, and are provided for reference as Appendix XIII (Institute of Medicine 1997, 2001). 
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Decades of laboratory and clinical investigation have confirmed that the body’s nutritional condition affects 
lead absorption, deposition, metabolism, and excretion (for reviews see Ahamed and Siddiqui 2007; Bogden 
et al. 2001; Mahaffey 1980, 1985; Mahaffey et al. 1992; Ros and Mwanri 2003). The physiological mechanisms 
that are the basis for nutrition/lead interactions are multiple and include nutrients: binding lead in the gut, 
competing with lead for absorption, altering intestinal cell avidity for lead, or altering affinity of target tissues 
for lead (Ballew and Bowman 2001). Lead can modify the metabolism of nutrients (Pounds, 1991; Sauk and 
Somerman 1991). For example, changes in iron metabolism and changes in the formation of the metaboli­
cally active forms of vitamin D occur with lead exposure. As understanding of cellular biology has advanced, 
the mechanisms through which nutritional status (at least for the divalent cations, calcium and iron) alter the 
metabolic response to lead are becoming clarified (Godwin 2001). 
Avoidance of lead exposure remains the primary preventive strategy for reducing adverse effects of lead ex­
posure. However, the existence of nutrient-lead interactions suggests that optimizing nutritional status during 
pregnancy and lactation may reduce the adverse consequences once lead exposure has occurred. Although 
the lead-nutrient interaction data are limited and somewhat inconsistent, ensuring adequate intakes of min­
erals such as calcium; iron; selenium; and zinc, and vitamins C, D, and E is a strategy that is generally health 
promoting, is associated with few risks, and may confer additional benefits to lead-exposed pregnant and 
lactating women. 
Whether there are benefits for lead poisoned pregnant and lactating women resulting from ingestion of 
dietary supplements in excess of nutritional requirements is not clear and super-supplementation is not 
recommended. Differences in response between marginally adequate and super-nutritional status may be 
physiological. For example, the physiological mechanisms that foster adaptation to low dietary intakes (e.g., in­
creased production of binding proteins in the gastrointestinal tract that can transport lead, as well as calcium 
or iron) may differ significantly from those that occur when nutrient intakes are higher than required. Dietary 
supplementation with nutrients at levels higher than those required by nonexposed women may constitute 
a secondary prevention effort aimed at reducing circulating levels of lead in the mother and at reducing lead 
exposure to the developing fetus and nursing infant. 
Studies of the effects of nutrition and blood lead levels are complicated by a number of different factors. A 
general problem is that variability in the nutritional status of subjects can impact whether there is a response 
to changes in the nutrient level. For example, iron absorption is increased when the body is deficient in iron, 
but when the body is iron-replete absorption of additional iron is inhibited (Finch 1994). These same mecha­
nisms also influence the percent of lead that is absorbed. Specific problems related to observational studies 
are discussed below. 
OBSERVATIONAL STUDIES OF ASSOCIATIONS BETWEEN BLOOD LEAD AND MATERNAL DIET 
The majority of the research on the influence of nutrition on lead status during pregnancy and lactation has 
been observational. Such studies can only determine the associations between nutritional status and lead poi­
soning, not whether these associations are causal. Observational studes are further complicated because the 
intercorrelations between nutrients in the diet limit the identification of the effects of specific dietary compo­
nents Observational studies on the association of maternal diet and lead have shown varying results. 
In an observational study of maternal diet during pregnancy, higher intakes of calcium, iron, and vitamin D 
were associated with lower neonatal blood lead levels (Schell et al. 2003). Before treatment, more than 50% of 
the mothers had dietary intakes below the recommended dietary allowances for zinc, calcium, iron, vitamin 
D, and kilocalories. Maternal and neonatal blood lead levels were correlated and all of the neonatal blood lead 
levels were low (geometric mean = 1.58 µg/dL). 
West (1994) investigated the relationship between prenatal vitamin supplement use and maternal blood 
lead levels and pregnancy outcomes in 349 African American women. Supplement users had significantly 
lower blood lead levels than those who did not use supplements (p = 0.0001). This study did not describe the 
content of the supplements consumed or provide adherence data, but levels of calcium and vitamins C and 
E were confirmed by blood analysis and were higher among the reported supplement-users, suggesting that 
the self-reports were accurate. 
Among postpartum women in Mexico City, lower levels of bone lead were associated with higher intakes of 
calcium, vitamin D, phosphorus, magnesium iron, zinc, and vitamin C, though these relationships showed 
inconsistent trends (Ettinger et al. 2004). Gulson et al. (2006) measured daily intakes of the micronutrients 
calcium, magnesium, sodium, potassium, barium, strontium, phosphorus, zinc, iron, and copper from 6-day 
duplicate diets (2-13 collections per individual) and blood lead concentrations in a small number of mother-
child pairs (total of 21 pregnant and 15 nonpregnant subjects in one cohort, nine pregnant subjects in a 
second cohort, and one group of ten 6- to 11-year-old-children) to evaluate the association of dietary intakes 
of selected micronutrients and blood lead. They found no statistically significant relationship between blood 
lead concentration and intake of specific micronutrients (Gulson et al. 2006). 
ROLE OF SPECIFIC NUTRIENTS WITH RESPECT TO LEAD 
Calcium 
Association of dietary calcium intake and lead 
Increased lead absorption and tissue retention among overtly calcium-deficient experimental animals have 
been confirmed in multiple species. As shown in experimental animal studies reported in the 1970s, a diet 
clearly deficient in only calcium when fed to rats for several months produced much higher tissue stores of 
lead than occurred in animals fed comparable amounts of lead plus a calcium-adequate diet (Mahaffey et al. 
1973; Mahaffey-Six and Goyer 1972). Unusually high deposition of lead in nonosseous tissues (including the 
kidneys) occurred in contrast with less dramatic elevations of bone lead (Mahaffey et al. 1973). This differ­
ence likely reflects impaired bone formation and deposition of lead into bones of the high-lead, low-calcium 
animals (Mahaffey et al. 1973). The increased absorption and retention of lead by calcium-deficient animals 
has been confirmed in other species (among others, see information for dogs (Hamir et al. 1982; Stowe and 
Vandevelde 1979) and horses (Willoughby et al. 1972). Generally, the major calcium effects on lead absorption 
and distribution occur when dietary calcium is deficient (Hertz-Picciotto et al. 2000). Little influence of calcium 
on lead metabolism is observed by increasing calcium intake above required levels in animal studies, i.e., the 
equivalent of super supplementation (e.g., Barton et al. 1978; Mahaffey et al. 1973). 
Confirmation of the impact of low dietary calcium intakes has also been found among human subjects who 
were also shown to have increased lead absorption when their diets were low in calcium (Heard and Cham­
berlain 1982). Several cross-sectional studies of calcium intake and blood lead levels in women of childbearing 
age and pregnant women have shown an inverse relationship between calcium-rich foods or calcium intake 
and blood lead levels. Lacasana-Navarro et al (1996) observed a statistically significant association among 
women of reproductive age between increased calcium intake and reduced risk of blood lead levels >10 µg/ 
dL. Farias et al. (1996) showed that consumption of foods providing calcium (corn tortillas and milk products) 
was associated with reduced blood lead levels. Researchers also observed a statistically significant trend 
among women of reproductive age between decreased risk of elevated blood lead levels (>10 µg/dL) with 
increasing calcium intake (Lacasana-Navarro et al. 1996). Higher milk intake during pregnancy has also been 
associated with lower maternal and umbilical cord lead levels in postpartum women in Mexico (Hernandez-
Avila et al. 1997). 
Dietary calcium supplementation and lead levels 
During pregnancy and lactation, lead accumulated in the maternal skeleton is released (Gulson et al. 1999; 
Manton et al. 2003; Osterloh and Kelly 1999), with greater mobilization of lead during lactation than during 





tion of skeletal mineral. Observations of the variability in release of skeletal lead reinforced the suggestion that 
low calcium intake may contribute to mobilization of skeletal lead during pregnancy (Gulson et al. 1999). Use 
of calcium supplements to meet fetal demand for calcium and thereby reduce maternal bone mobilization has 
been described. Results from Gulson et al. (2004) indicated that calcium supplements were ineffective in mini­
mizing the mobilization of lead from the skeleton during lactation; however, this small observational study 
lacked a control group and was not designed to properly account for other potential confounding factors. 
Calcium supplementation (1,200 mg at bedtime) during the third trimester of pregnancy has been shown, in 
a randomized crossover trial design, to reduce maternal bone resorption by 14% on average in comparison 
to placebo (Janakiraman et al. 2003), suggesting that calcium supplements may reduce maternal bone lead 
mobilization during the third trimester of pregnancy. 
Two large randomized clinical trials have been conducted to assess whether calcium supplements reduce 
blood lead levels during pregnancy and lactation. In a randomized, double-blind, placebo-control trial of 
calcium supplementation during lactation, Hernandez-Avila et al. (2003) showed that 1,200-mg daily dietary 
supplementation with calcium carbonate among lactating women reduced maternal BLLs 15%-20% over the 
course of lactation. Compared with women who received the placebo, those who took supplements had a 
modest decrease in their blood lead levels of -0.12 µg/dL at 3 months (95% CI = -0.71 to 0.46 µg/dL) and 
-0.22 µg/dL at 6 months (95% CI = -0.77 to 0.34 µg/dL). The effect was more apparent among women who 
were most compliant with supplement use and had patella bone lead >5 µg/g bone (-1.16 µg/dL; 95% CI = 
-0.23 to -2.08). During the second and third trimesters of pregnancy, calcium supplementation (1,200 mg) 
was associated with an average reduction of 19% in blood lead concentration in relation to placebo (p<0.001) 
(Ettinger et al. 2009). In another randomized control trial, calcium supplementation (1,200 mg) was associated 
with modest reductions in blood lead when administered during pregnancy. These effects were strongest 
in the most-compliant women, including those who: consumed >75% pills (-24%, p<0.001); or had baseline 
blood lead greater than 5 µg/dL (-17%, p<0.01); or reported use of lead-glazed ceramics and high bone lead 
(-31%, p<0.01). In the subset of most-compliant women with high patella bone lead (>5 µg/g) and reported 
use of lead-glazed ceramics, the reduction in blood lead of 31% corresponds to an average reduction of 
1.95 µg/dL (95% CI = -0.78 to -2.87). Bone resorption was also reduced by 13% in the supplement group com­
pared with the placebo group (p = 0.002) (Tellez-Rojo et al. 2006). Calcium supplementation was also associat­
ed with 5%-10% lower breast milk lead levels among these women over the course of lactation (Ettinger et al. 
2006), suggesting that calcium supplementation may also be an intervention strategy to reduce lead in breast 
milk from both current and previously accumulated sources. Such data support the role of calcium supple­
mentation in decreasing bone resorption, which can release bone lead stores. Calcium supplementation may 
also decrease intestinal absorption of lead. 
Overall, calcium supplementation has been associated with modest reductions in blood lead levels both when 
administered during pregnancy and lactation. Suppression of bone resorption appears to be the most likely 
mechanism, although reduced absorption of lead from the gastrointestinal tract may also contribute to this 
change. It has been suggested that high levels of calcium are needed to supply the nutritional needs of the 
developing fetus (Johnson 2001). 
Calcium status in U.S. women 
Calcium requirements during pregnancy and lactation have been investigated extensively. The increased 
fetal/infant demand for calcium is met by increasing maternal gastrointestinal absorption, decreasing renal 
excretion, and increasing bone mineral mobilization (Kovacs and Kronenberg 1997). Physiological adaptations 
(including endocrine responses) are part of why there is no simple relationship between dietary calcium intake 
and calcium availability to mother, fetus, or infant (Prentice 2000a). In general, however, Americans do not 
meet dietary recommendations for calcium (Ma et al. 2007), with ethnic minorities and socially disadvantaged 
groups more likely not meeting dietary calcium recommendations (Affenito et al. 2007). The recommended 
intakes for calcium are 1,300 mg for pregnant and lactating women 18 years and younger and 1,000 mg for 
pregnant and lactating women 19 years of age and older. 
Estimated calcium intake during pregnancy in the United States varies substantially. Based on data from 
1999-2000 NHANES, average calcium consumption for women of childbearing age was between 820 and 
940 grams from both diet and supplements. Earlier data from NHANES II showed that for white women in the 
18-through-39 year age group mean calcium intake from food was 642 mg/day, contrasted with 467 mg/day 
among black, non-Hispanic women (Looker et al. 1993). African Americans in all age groups have been shown 
to consume fewer mean servings of total dairy, milk, cheese, and yogurt than non-African-Americans and have 
lower calcium intakes (Fulgoni et al. 2007; Weinberg et al. 2004). Meeting dietary recommendations for calci­
um on a dairy-free diet is difficult (Gao et al. 2006), but can be made easier through the use of calcium-fortified 
foods such as citrus juices (Gao et al. 2006) and consumption of ready-to-eat cereals, which facilitate milk in­
take (Song et al. 2006). In contrast to several of the studies cited above, the assessment by Harville et al. (2004) 
evaluated total oral calcium intake including both food and antacids. Although median oral calcium intake 
exceeded 1,200 mg/day, more than 10% of the youngest women consumed <600 mg calcium/day. Within the 
overall group, 10% of African-American women and 6% of white women reported being either lactose intoler­
ant or allergic to milk. However, there was no difference in calcium intake (both approximately 1,200 mg/day) 
for women reporting lactose intolerance and not being intolerant. It should be noted that in this particular 
study, many of the women were enrolled in the Women, Infants, and Children (WIC) program which supplies 
milk and cheese. In this study racial differences in calcium intake were not significant. 
Calcium requirements are increased substantially during pregnancy and lactation to meet the demands of 
the developing fetus and nursing infant (Prentice 2000b). Approximately 25 to 30 grams of calcium are trans­
ferred to the fetus during pregnancy, with the majority of this transfer occurring during the third trimester 
(Institute of Medicine 1990). The major physiological adaptation of the mother to meet this increased calcium 
requirement is increased efficiency in intestinal absorption of calcium. Decreased renal excretion of calcium 
and increased bone mineral mobilization are other maternal mechanisms used to meet the needs of the fetus. 
The Institute of Medicine (IOM) currently recommends 1,000 mg calcium per day for pregnant and lactating 
women 19-50 years (and 1,300 mg per day for pregnant and lactating women <19 years) (Institute of Medicine 
1997). Optimal calcium intake may be achieved through diet, calcium-fortified foods, calcium supplements, or 
various combinations of these. 
NIH has articulated several challenges to optimate calcium intake (National Institutes of Health 1994). High 
oxalate and phytate in a limited number of foods can reduce the availability of calcium in these foods. Other 
factors, such as drugs (glucocorticoids), can decrease calcium absorption. There are also genetic factors that 
may significantly influence many aspects of calcium metabolism. Vitamin D metabolites enhance calcium 
absorption. Sources of vitamin D, besides supplements, include sunlight, vitamin D-fortified liquid dairy prod­
ucts, cod liver oil, and fatty fish. Calcium and vitamin D need not be taken together to be effective. Excessive 
doses of vitamin D may introduce risks such as hypercalciuria and hypercalcemia and should be avoided. In 
addition, high levels of calcium intake have several potential adverse effects but there are adaptive mecha­
nisms that protect from calcium intoxication at calcium intakes less than approximately 4 g/day. Even at intake 
levels less than 4 g/day, people may be more susceptible to developing hypercalcemia or hypercalciuria and 
high blood calcium levels may produce renal damage. There is also some concern that increased calcium in­
take might interfere with absorption of other nutrients, such as iron, or medications. Ingestion of some forms 
of calcium supplements or milk may reduce iron absorption by as much as 50%. However, calcium formations 
that contain citrate and ascorbic acid enhance iron absorption. 
There are two randomized placebo-controlled trials that aimed to decrease lead exposure to fetus and nursing 
infant by providing 1,200 milligrams of daily calcium supplementation to maternal diet during pregnancy (Et­
tinger et al. 2008) and lactation (Hernandez-Avila et al. 2003). Both studies found that, on average, women in 
the calcium supplement group had 20% lower maternal blood lead levels than the placebo group at the end 
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of follow up, suggesting decreased potential for exposure to the fetus and nursing infant. These studies were 
carried out in Mexico City, Mexico where the estimated average dietary calcium intake was about 800 mil­
ligrams per day, similar to estimates in the United States. NHANES data on dietary intake of selected minerals 
in 1999-2000 indicate that for women aged 20-39, the average dietary intake of calcium is 797 mg (Ervin et al. 
2004). In pregnant women with exposure to lead, high calcium intake (2,000 mg/day) may diminish pregnan­
cy-induced increases in blood lead levels by decreasing intestinal absorption of lead or by decreasing mater­
nal bone resorption (mobilization), thereby reducing exposures to the fetus (Johnson 2001). Thus, the amount 
of calcium supplement should be adjusted by combining estimated average dietary intake and supplementa­
tion in order to achieve the recommended calcium intake of 2,000 mg per day. Care should be taken as some 
calcium supplements, particularly those derived from natural sources (bonemeal, dolomite, or oyster shell), 
have been found to contain high levels of lead (Bourgoin et al. 1993; Ross et al. 2000; Scelfo and Flegal 2000). 
Summary 
In summary, calcium supplementation in pregnant women with elevated blood lead levels may be beneficial 
in reducing blood lead levels. For pregnant and lactating women with BLLs ≥5 µg/dL or a history of lead expo­
sure above background levels, a dietary calcium intake of 2,000 mg daily should be maintained either through 
diet or in combination with supplements. 
Iron 
Association of dietary iron intake and iron status with lead levels 
Both low iron status and elevated lead exposure impair hematopoiesis and intellectual development during 
gestation and infancy (Black et al. 2008). Exposure to lead and reduced iron status result in greater impairment 
than the lead-associated impairment in heme biosynthesis alone (Kwong et al. 2004; Mahaffey-Six and Goyer 
1973). Such findings were confirmed in humans, as well as experimental animals (Barton et al., 1978; Mahaffey 
1983). 
Iron absorption is highly regulated physiologically and iron absorption is reduced when iron stores are en­
larged (Finch 1994). Overall, variation of iron stores in a normal range do not increase lead absorption, but iron 
deficiency raises the level of divalent metal transporter proteins which carry lead as well as iron (Morgan and 
Oates 2002). The ability to control iron absorption through regulation of the molecular mechanisms of iron 
absorption appears during late infancy (Leong et al. 2003). 
Iron deficiency is associated with increases in absorption and deposition of lead (Barton et al. 1978). Several 
cross-sectional studies in children showed an inverse relationship between iron status and blood lead (Brad­
man et al. 2003; Choi and Kim 2003; Hammad et al. 1996). Consistent with pediatric studies, cross-sectional 
studies of lead-exposed adults have found that lower serum iron and dietary intake, as well as increased rates 
of iron deficiency anemia, were associated with higher blood lead levels and better iron status was associated 
with lower blood lead levels (Baghurst et al. 1987; Graziano et al. 1990; Kim et al. 2003). These studies have 
generally used dietary intake or laboratory tests (e.g., serum iron or ferritin) to determine iron status. 
There are few studies that have investigated the association between iron intake or iron status and blood lead 
levels. These studies do not provide consistent findings. Schell et al. (2003) studied the effect of maternal diet 
during pregnancy on neonatal blood lead levels. Among the nutrients studied, iron had the largest impact 
on newborn lead levels: a two standard-deviation decrease in maternal iron intake (from 30.2 to 11.8 mg/day) 
was associated with a 0.51 µg/dL increase in newborn lead (29% of the mean newborn lead level of 1.72 µg/ 
dL). More than 50% of mothers in this study had intakes below the recommended dietary allowance for iron in 
pregnancy. However, data from a nationally representative population survey that included reproductive-aged 
women (N = 4,394 women aged 20-49 years) found a positive association between dietary iron intake and 
blood lead levels (Lee et al. 2005). 
Dietary iron supplementation and lead 
Studies of the association between iron status and blood lead levels found that children with iron-deficiency 
had higher blood lead levels than iron-replete children (Markowitz et al. 1990; Wright et al. 1999, 2003). Con­
sequently, many experts recommend that iron supplementation be prescribed only to iron-deficient children, 
irrespective of lead exposure, and do not recommend universal iron supplementation for the prevention or 
treatment of lead poisoning in children (Wright et al. 1999). 
Iron supplementation has been shown to prevent lead-induced disruption of the blood-brain barrier during 
rat development (Wang et al. 2007a). The supplemental iron protected the blood brain barrier from changes 
in permeability caused by lead (Wang et al. 2007a) and was also protective against lead-induced apoptosis 
(Wang et al. 2007b). A prospective study of the effects of prenatal lead exposure on child development was 
carried out in Yugoslavia with outcomes assessed at age 4 years (Wasserman et al. 1994). Because 34% of the 
cohort was iron deficient (hemoglobin concentrations <10.5 g/dL at age 2 years and serum ferritin concentra­
tions <12 ng/dL), iron supplements were provided when children were 18 to 38 months of age. Treatment of 
iron deficiency improved the hematological profile. Low-iron status and elevated lead exposure both affect 
infants’ intellectual development. Lead exposure was associated with cumulative losses in cognitive function 
during the preschool years. Deficits attributable to iron-deficiency anemia at age 2 (Wasserman et al. 1992) ap­
pear to have been reversed by age 4 in response to iron supplementation. 
Effectiveness and strategies for iron supplementation during pregnancy have been evaluated, indicating that 
the efficacy of the supplement intervention is dependent on the following: composition of the diet; presence 
of a condition, such as pregnancy, that would alter iron absorption or loss; composition of the supplement; se­
verity of the iron deficiency at baseline; and the duration of the intervention (Beard 2000). There have been no 
supplementation trials addressing the effects of iron on lead levels in pregnancy and the research data are too 
scanty to determine the relationship between maternal iron intake and maternal or neonatal blood lead levels. 
However, given that iron deficiency is common among pregnant women (Kraemer and Zimmermann 2007), 
until further data are available, all women should be evaluated for the adequacy of their iron status and intake 
and be provided with appropriate nutritional advice and supplements if deficiencies exist. 
Iron status in U.S. women 
Pregnancy is the most at-risk period for developing iron-deficiency anemia (American College of Obstetrics 
and Gynecology 2008; Beard 2000). The current recommended intakes for iron are 27 mg in pregnant women 
and 10 mg in lactating women (Institute of Medicine 2001). While there is some uncertainty regarding the 
most useful indicators of iron status during pregnancy, cell indices (including mean cell volume, percent 
hypochromic red blood cells, percent reticulocytes, and cellular hemoglobin in reticulocytes) have been rec­
ommended as indicators of iron status (Ervasti et al. 2007), but their usefulness in diagnosing iron deficiency 
longitudinally needs to be confirmed. 
Based on NHANES III data, 9% to 11% of adolescent girls and women of childbearing age were iron deficient 
[defined as having an abnormal value for at least two of three laboratory tests for iron status that included 
erythrocyte protoporphyrin, transferrin saturation, or serum ferritin] (Looker et al. 1997). Iron-deficiency ane­
mia was found in 5% of women, which corresponds to an estimated 3.3 million U.S. women. Iron deficiency 
was more common among women who were from minority, low-income, and multiparous groups (Looker et 
al. 1997, 1999). Among women ages 19 through 50 years who participated in NHANES during the years 1988 
through 1994, 72 ± 4% of pregnant women and 60 ± 4% of lactating women (Cogswell et al. 2003) were iron 
deficient. Use of supplements containing iron was associated with a significant reduction in the prevalence 
of iron deficiency among women ages 19-through-50 years, but the study lacked statistical power to make 
this assessment for pregnant and lactating women (Cogswell et al. 2003). Low-income women and minor­




Supplemental Nutrition Program for Women, Infants, and Children in 12 U.S. states indicated that the preva­
lence of post-partum anemia was 27%, reaching 48% among non-Hispanic black women (Bodnar et al. 2001). 
Using NHANES III data, Bodnar et al. (2001) estimated that, among women with a poverty index ratio >130%, 
postpartum women (up to 12 months postpartum) had the highest rates of iron deficiency of between 12% 
and 13%. Mexican-American females have a higher prevalence of iron-deficiency anemia than did non-Hispan­
ic white females (Frith-Terhune et al. 2000). 
Summary 
Studies of the effect of iron supplementation in lead poisoned women are not available. Thus, iron supplemen­
tation in pregnant and lactating women should be consistent with those given for pregnancy and lactation. 
No additional iron supplementation is recommended for women with elevated BLLs. However, the iron status 
of all pregnant women should be evaluated and supplementation should be provided to correct any deficien­
cy. 
Zinc 
Deficiencies of other trace elements, such as zinc, may increase both lead absorption and lead toxicity (Cerk­
lewski and Forbes 1976). Although of substantial importance worldwide (Black et al. 2008), zinc deficiency is 
not common in the United States (Hotz et al. 2003). Suboptimal zinc status may be caused by lack of zinc in 
the diet, but more likely is caused by inhibition of zinc absorption by factors such as other trace metals (e.g. 
iron, copper, lead, cadmium) (Lonnerdal 2000). Serum zinc concentration is influenced by multiple covariables 
and declines during pregnancy, presumably reflecting hemodilution that occurs during pregnancy (Hotz et al. 
2003). In general, dietary protein is associated with increased zinc absorption and the U.S. population gener­
ally receives sufficient protein from dietary sources. Hence, zinc deficiency is not considered of major impor­
tance in altering susceptibility to lead toxicity in the U.S. population. 
Ascorbic Acid (Vitamin C) 
Another category of nutrient-lead interactions involve nutrients noted for their antioxidant properties (e.g., 
ascorbic acid [vitamin C], vitamin E, selenium, thiamine). Antioxidants are involved in the prevention of cellular 
damage that occurs from free radicals (atoms or groups of atoms that can be formed when oxygen interacts 
with certain molecules). The role of the antioxidant nutrients in altering the outcomes of lead exposure is not 
well established. Supplementation with vitamin C and other antioxidants (such as vitamin E and selenium) 
may prevent lead-induced oxidative damage due to lead exposure and bolster the body’s antioxidant defense 
system. Unfortunately, the research conducted to date is insufficient in either quality or quantity to evaluate 
many of these hypotheses. 
In addition to its antioxidant properties, vitamin C has been suggested as acting as a natural chelating agent 
that enhances the urinary elimination of lead from the body (Simon and Hudes 1999). Two large cross-section­
al studies in adults have found associations between blood lead levels and dietary intake or serum levels of 
vitamin C (Lee et al. 2005; Simon and Hudes 1999). In an analysis of nutritional data provided by over 15,000 
adult participants in NHANES III, Simon and Hudes (1999) found that adults in the highest two serum vitamin 
C tertiles had a 65% to 68% lower prevalence of elevated blood lead levels compared to adults in the lowest 
tertile (p = 0.03). In another analysis of NHANES III data, Lee et al. (2005) described the relationship between 
serum vitamin C and blood lead levels in over 4,000 reproductive-aged women (20-49 years). Women with 
high serum vitamin C levels had a 2.5 lower odds of having blood lead levels in the highest decile (>4 µg/dL). 
Among postpartum women in Mexico City, higher intakes of vitamin C were associated with lower levels of 
breast milk lead (Ettinger et al. 2004). 
Studies with human subjects have also found that supplementation with vitamin C reduced lead levels 
(Dawson et al. 1999). One study randomly assigned nonoccupationally exposed male smokers into three 
treatment groups (placebo N = 25, Vitamin C 200 mg daily N = 25, and vitamin C 1,000 mg daily N = 25). 
Baseline blood lead levels were low and similar to that reported by other studies of the general population. 
Supplementation with 1,000 mg of vitamin C (but not 200 mg) reduced blood lead levels by 81% (Dawson et 
al. 1999). However, according to a literature review by Hsu and Guo (2002), the benefit of vitamin C supple­
mentation seems to be found most consistently in studies with subjects with lower lead levels. Human and 
animal studies with higher blood lead levels in general tend to show minimal to no improvement with vitamin 
C supplementation. 
Determining the dose of vitamin C needed to lower blood lead levels is unclear in that dose-response was not 
typically observed in these studies. Blood lead levels were lowered only in those studies which the vitamin C 
intake exceeded nutritionally recommended intakes. The safety of exceeding these levels is unclear. In sum­
mary, the research to date suggests that vitamin C may lower blood lead levels. However, further research is 
needed to confirm these conclusions, since the studies conducted to date have relatively small numbers of 
subjects and do not include pregnant or lactating women. 
Vitamin D 
A final category of nutritional interactions with lead is interference by lead with formation of metabolites of 
the nutrient. The primary example of this is the severe compromise found in formation of the metabolites of 
vitamin D (i.e., the endocrine function of vitamin D) as lead exposure increases (Mahaffey et al. 1983; Rosen et 
al. 1980; Smith et al. 1981). Lead is well established as inhibiting the renal synthesis of 1,25-dihydroxyvitamin 
D in rats (Smith et al. 1981), chicks (Fullmer 1995), and young children (Rosen et al. 1980). As the body burden 
of lead increases (exposures associated with children’s blood across blood lead concentrations of 12 to 120 µg/ 
dL), there is a linear decline in 1,25-dihydroxyvitamin D (Mahaffey et al. 1983). To date, this interaction has not 
been evaluated among pregnant or lactating women. 
Important sources of vitamin D are from synthesis of vitamin D through sunlight activation of pro-vitamin D 
present in skin and dietary intake (Holick 2007). Many factors influence the efficiency of cutaneous produc­
tion of vitamin D. In winter months, ultraviolet B rays, needed to promote cutaneous vitamin D production, are 
absent at latitudes above 35° N (i.e., north of Memphis, Tennessee). Dark-skinned individuals require exposures 
about 5-10 times as long as light-skinned individuals to achieve similar levels of cutaneous vitamin D produc­
tion. (Holick 2004). Even in summer months, sun exposures outside the peak sun hours of 10:00 AM to 3:00 PM 
have limited impact on cutaneous vitamin D synthesis (Holick 2003). Application of sunscreen blocks produc­
tion of vitamin D (Holick 2007). Higher prepregnancy body mass index is associated with lower vitamin D 
status (Bodnar 2007a). Additionally, women who wear concealing clothing or are house-bound may have low 
vitamin D. Clinicians should therefore be aware of the potential for multiple risk factors for inadequate vitamin 
D status among certain recent immigrants who may not receive adequate exposure to sunlight. 
Vitamin D status in U.S. women 
The recommended adequate intake of vitamin D in both pregnant and lactating women is 200 IU. However, 
only about half of U.S. women ages 19-50 years get this amount of vitamin D daily from diet or supplement 
sources (Moore et al. 2004). The lowest mean dietary intakes of vitamin D in the U.S. population (based on data 
from food consumption patterns identified in the NHANES III and multiple years of the Continuing Survey of 
Food Intakes by Individuals [http://www.ars.usda.gov/Services/docs.htm?docid=14392]) were among teenage 
girls and women (Moore et al. 2004). The American Academy of Pediatrics (AAP) recommends that all children 
and adolescents receiving <400 IU/day from foods receive a supplement of 400 IU vitamin D daily (Wagner 
et al. 2008). In adults, daily supplementation with 400 IU vitamin D increases 25(OH)D by 7.0 nmol/L (Heaney 
2003). Supplementation of a pregnant woman with 400 IU vitamin D, as in prenatal vitamins, has little effect 





Inadequate vitamin D status is common among women in the United States (Bodnar et al. 2007a,b; Hollis 
2005; Hollis and Wagner 2004; Looker et al. 2008; Specker 2004; Specker et al. 1994). There is no universal con­
sensus on adequate levels of 25-hydroxyvitamin D, but 75-80 nmol/L (Calvo and Whiting 2006) is a common 
benchmark. The AAP recommends that pregnant women maintain a 25(OH)D level of ³80 nmol/L (32 ng/mL) 
(Wagner et al. 2008). 
Based on NHANES 2000-2004 data, lower-than-optimal serum 25-hydroxyvitamin D levels were frequent 
(Looker et al. 2008); 49.1% of non-Hispanic white pregnant women, 76.4% of Mexican-American pregnant 
women, and 92.2% of non-Hispanic black pregnant women had serum 25-hydroxyvitamin D <75 nmol/L and 
8.5%, 74.6%, and 41.6%, respectively, had serum 25-hydroxyvitamin D <50 nmol/L (Looker et al. 2008). Among 
a sample of pregnant women residing in northern United States, 25(OH) vitamin D levels were considered 
≤ 80 nmol/L in 83.3% of black women and 47.1% of white women; more than 90% of these women used pre­
natal vitamins (Bodnar et al. 2007b). 
Summary 
Because data on the association of lead and Vitamin D are limited, no specific recommendation is made for 
supplementation of vitamin D in lead poisoned pregnant or lactating women. Adequate levels of vitamin D 
should be maintained. 
NUTRITIONAL ASSESSMENT AND REFERRALS 
All pregnant women should be assessed for the adequacy of their diets and be provided with appropriate 
nutritional advice and prenatal vitamins. This should be reinforced and maintained throughout pregnancy and 
lactation. General nutritional guidance is readily available; for example, see Dunlop et al. (2008) and Gardiner 
et al. (2008). Nutritional assessment of pregnant and lactating women with blood lead levels ≥5 µg/dL should 
be, at a minimum, consistent with anticipatory guidance, evaluation, and nutritional recommendations for all 
pregnant and lactating women. However, in pregnant and lactating women with a current or past BLL ≥5 µg/ 
dL, certain nutritional recommendations should particularly be reinforced. Calcium and iron are of particular 
focus here for reasons that are related to how calcium and iron influence blood lead levels and pregnancy out­
comes. A balanced diet with a dietary calcium intake of 2,000 milligrams daily should be maintained through 
diet, supplementation, or a combination of both. Additionally, iron status should be evaluated and supple­
mentation provided in order to correct and prevent any iron deficiency. Anemia is the most easily identifiable 
indicator of functional iron deficiency. The Institute of Medicine (IOM) recommends starting iron supplemen­
tation after 12 weeks of pregnancy with the lowest dose needed. Women with anemia (defined in pregnancy 
as a hemoglobin level less than 11 g/dL in the first trimester and third trimester, and less than 10.5 g/dL in the 
second trimester), require higher dosing (Institute of Medicine 1990). Generally, pregnant women with iron 
deficiency anemia should be prescribed 60 to 120 mg of iron daily in divided doses. Dosage can be reduced to 
30 mg daily once anemia is corrected. Women receiving supplemental iron or calcium should be encouraged 
to split the dose, taking no more than 500 mg of calcium or 60 mg of iron at one time, as only small amounts 
of these nutrients can be absorbed at any one time. 
Referrals and Resources 
Practitioners who interact with pregnant or lactating women should routinely screen for the presence of nutri­
ent deficiencies like iron deficiency. Although comprehensive assessment of dietary adequacy is not routinely 
conducted in medical office visits, all pregnant and lactating women should be screened for the adequacy of 
their diets. If the presence of dietary inadequacy is suspected, women should be provided appropriate nutri­
tional advice and should be referred to resources designed to improve knowledge and/or access. Appendix 
XIII contains nutritional reference information, including dietary reference intakes: recommended vitamin and 
elements intakes for individuals, tolerable upper intake levels, food sources for key nutrients, dietary 
assessment tools, and other background information. Resources that might be useful for referrals or interac­
tions with patients are summarized in this section. 
Registered dietitian 
A registered dietitian (RD) is a health professional who has received specialty training in food and nutrition. 
Using various dietary assessment tools, an RD can conduct a thorough assessment of an individual’s dietary 
intake and can identify dietary inadequacies. Local RDs can be located by contacting local health care facilities, 
such as hospitals or health centers, or by using the Find A Nutrition Professional link of the American Dietetic 
Association Web site (http://www.eatright.org). 
WIC 
The Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) is a federal grant pro­
gram that provides nutritious foods, nutrition education, and referrals to low-income (at or below 185% of 
the U.S. poverty income guidelines) pregnant and lactating women (in addition to infants and children) who 
are at nutritional risk. The two major types of nutrition risk recognized for WIC eligibility are medically based 
risks—such as anemia, underweight, overweight, history of pregnancy complications, or poor pregnancy out­
comes—and dietary risks—such as failure to meet the dietary guidelines or inappropriate nutrition practices. 
In most WIC state agencies, WIC participants receive checks or vouchers to purchase specific foods each 
month that are designed to supplement their diets. The foods provided are high in one or more of the follow­
ing nutrients: protein, calcium, iron, and vitamins A and C. These are the nutrients frequently lacking in the 
diets of the program’s target population. Detailed information about WIC including eligibility criteria, contact 
information, and instructions for applying can be found on the WIC Web site (http://www.fns.usda.gov/wic/). 
Supplemental Nutrition Assistance Program (formerly the Food Stamp Program) 
The Supplemental Nutrition Assistance Program (SNAP) is a federal program that provides low-income house­
holds with subsidies they can use like cash at most grocery stores. The assistance can be used to buy breads 
and cereals; fruits and vegetables; protein foods like meat, fish, and poultry; and dairy products. For additional 
information, call 1-800-221-5689 or visit the SNAP Web site (http://www.fns.usda.gov/snap/). 
MyPyramid 
The USDA Center for Nutrition Policy and Promotion launched the MyPyramid for Pregnancy and Breastfeed­
ing Web site in May 2008 (http://www.mypyramid.gov/mypyramidmoms/). This Web site allows pregnant 
and lactating women to create a personalized MyPyramid Plan for Moms that shows what and how much to 
eat from each food group during each trimester of pregnancy and each stage of breastfeeding. The site also 
provides additional information on nutritional needs during pregnancy and breastfeeding, weight gain during 









Key Recommendations for Chelation Therapy 
•	 Chelation therapy should be considered for pregnant women with confirmed blood lead 
levels ≥45 µg/dL on a case-by-case basis, in consultation with an expert in lead poisoning. 
•	 Pregnant women with confirmed BLLs ≥45 µg/dL should be considered as having high-risk 
pregnancies and managed in consultation with an expert in high-risk pregnancy. 
•	 Pregnant women with life-threatening lead encephalopathy should be chelated regardless 
of trimester. 
•	 Insufficient data exist regarding the advisability of chelation for pregnant women with BLLs 
<45 µg/dL. 
•	 Infants (0-6 months of age) with a confirmed BLL of ≥45 µg/dL should be considered as can
didates for chelation in consultation with an expert in pediatric lead chelation therapy. 
•	 Before considering chelation therapy for a pregnant woman (or infant), blood lead levels 
should be repeated and confirmed using an additional venous blood lead sample collected 
within 24 hours. 
•	 Chelation therapy must occur in a lead-safe environment; therefore, prior to initiating chela




There is a potential role for chelation therapy to treat pregnant woman and newborns, and, in some cases, 
chelation may be life-saving. However, the scientific evidence to support its use is very limited, and chelation 
during pregnancy and in the early postpartum period should be initiated only in consultation with an expert 
in treatment for lead poisoning. 
OVERVIEW OF CHELATION 
Chelation therapy utilzes the chemical characterstics of a chelating agent to remove lead from participation 
in biological reactions in the body, by binding the agent with the metal (lead) to form a chelate. A chelate is 
defined as a “complex formation involving a metal ion and two or more polar groupings of a single molecule” 
(Stedman’s 2008). Notice that this definition does not indicate the fate of the chelated metal. Possibilities 
include excretion of the chelate, persistence in the tissue where the bonding occurred, or redistribution to 
other tissues. Ideally, the drug should effectively increase lead excretion, be easily administered, be affordable, 
and be safe. The consequences of lead removal should be to halt further toxicity and to reverse previous lead 
effects (Markowitz 2000). 
DRUGS AVAILABLE IN THE UNITED STATES 
There are four drugs (CaNa2EDTA, DMSA, BAL, PCA) in use for lead chelation in the United States (Table 8-1) 
and others are in use elsewhere. None of these drugs specifically bind only lead and, thus, some loss of essen­
tial elements also occurs. The toxicity profiles of these drugs differ. Two of the drugs are administered orally 
(DMSA, PCA) and two must be given parenterally (BAL im only; CaNa2EDTA im or iv). The latter two require 
expert nursing care and are always used in the hospital. The former two are used in both inpatient and outpa­
tient settings. All of these drugs increase lead excretion, primarily through the kidneys (Aposhian 1982; Gra­
ziano et al. 1999). There may also be tissue redistribution during or as a consequence of chelation. 
89 
90 
The introduction of chelating agents for the treatment of severe lead poisoning (blood lead ≥70 µg/dL) was 
associated with a marked decline in lead-related mortality in children, from 30% to <1% (Chisolm 1968). 
Chelation treatment at lower blood lead levels, where mortality is not a major concern, is associated with a fall 
in blood lead levels and an improvement in biochemical markers of lead toxicity, such as erythrocyte proto­
porphyrin (EP) levels and delta-aminolevulinic acid dehydratase (ALAD) activity (Graziano et al. 1991; Piomelli 
1996). Depending on the amount of lead in the body prior to chelation, the effect of treatment on blood lead 
is generally temporary, with levels increasing within 2 weeks after the conclusion of a course of treatment in 
many patients. The effect on the biochemical markers of toxicity is disparate. ALAD activity declines as blood 
lead rebounds, whereas EP levels tend to fall if no further lead absorption occurs, despite the rebound in 
blood lead. All of the drugs increase the excretion of essential metals, but to differing degrees. DMSA appears 
to be the most specific for binding heavy metals such as lead and mercury. The excessive loss of essential met­
als has been postulated to account for the observed teratogenicity associated with all of the agents tested in 
animal studies. 
Utility of These Drugs in Other Populations 
Candidates for chelation therapy differ by age group. Previous CDC guidelines (1991) established a blood lead 
level of ≥45 µg/dL as the indication for treatment of children regardless of symptoms. At these levels, gastro­
intestinal symptoms may occur in a a large number of children; biochemical toxicity is demonstrable in the 
majority of children (elevated EP level, decreased ALAD activity); and, subclinically, cognitive scores are likely 
lower. Additionally, and of importance, such children are very likely to excrete large amounts of lead in re­
sponse to chelation treatment—much greater amounts than they would spontaneously excrete over periods 
of time comparable to a course of chelation. However, the amount excreted is only a small fraction of the total 
lead in the body. Though symptoms and biochemical markers of toxicity may improve post chelation, there is 
no documentation of cognitive improvements in nonencephalopathic children. For blood lead levels of <45 
µg/dL, chelation treatment can also lower blood lead levels and improve biochemical markers of toxicity tem­
porarily. However, there is no evidence that lead excretion is substantially increased for the majority of chil­
dren. A randomized placebo-controlled trial of succimer for children with initial BLLs of 20–44 µg/dL also failed 
to demonstrate any difference in mean cognitive scores when tested 2 years later (Rogan et al. 2001). There are 
no published guidelines identifying a specific blood lead level as requiring chelation therapy in adults nor is 
there a universal protocol for which agents to use, dose, or duration of treatment. 
CONCERNS ABOUT CHELATION THERAPY DURING PREGNANCY 
Consideration of chelation therapy during pregnancy requires identification of the targeted beneficiary and 
estimation of the anticipated benefits and risks. Limited availability of research findings on comparable pa­
tients means that extrapolation from data on other types of patients are necessary to make treatment deci­
sions. Since the correlation between maternal and newborn blood lead levels is high as measured by cord 
and maternal blood lead levels determined at delivery, maternal blood lead level can be used as a proxy for 
the fetus’ blood lead level. Therefore, if the known risks and benefits of chelation treatment for lead poisoned 
children are extrapolated to fetuses, then a blood lead level ≥45 µg/dL in the mother’s blood would trigger 
chelation treatment of the fetus in situations where the fetus is the intended beneficiary of the treatment. If 
the intended beneficiary of chelation therapy is the pregnant woman, then there is insufficient clinical data to 
guide decisions about treatment by blood lead level in the absence of symptoms. 
No chelation-attributable toxicities have been reported in the existing published case reports. However, 
very limited information is available to understand any potential short- or long-term effects. Use of chelat­
ing agents should therefore only be considered in consultation with experts in lead poisoning and high risk 
pregnancies. 
CLINICAL EVIDENCE IN PREGNANCY AND IN THE NEWBORN 
The literature search identified only case reports of chelation therapy during pregnancy (see Table 8-2) and 
early postpartum (see Table 8-3). In general, maternal blood lead levels decline after a course of chelation and 
neonatal blood lead levels at birth were also lower than peak maternal levels during the pregnancy. However, 
very limited information is available to determine if any long term benefit is derived from in utero treatment 
or whether adverse effects occur from chelation. In the few case reports, babies did not appear to have gross 
developmental delays. 
The women in the case reports were selected for chelation therapy based on their blood lead levels with the 
lowest pretreatment level reported as 44 µg/dL, although in that case a prior blood lead of 62 µg/dL was 
observed. All women appeared to have been treated during the second half of pregnancy. All but one of 
the women were treated with varying amounts and for varying durations with CaNa2EDTA. A single patient 
also received BAL in addition to CaNa2EDTA. A single case reported the exclusive use of DMSA. In all cases, 
CaNa2EDTA therapy was associated with a decline in maternal blood lead levels. There was no change in 
maternal blood lead after the one case of treatment with DMSA (18-day course). However, she was treated as 
outpatient without apparent oversight for either compliance or ongoing lead exposure. In all but one case a 
healthy newborn was delivered. The exception occurred in a case where maternal blood lead pretreatment 
was 104 µg/dL. The woman received CaNa2EDTA and BAL. The 1.6 kg infant was born prematurely after an­
tepartum hemorrhage 36 hours into treatment. This baby was later noted to have developmental delay and 
hearing deficit. No consistent pattern in cord blood lead levels was apparent in the few cases where they were 
reported. The interval between chelation and delivery also varied from months to minutes. Cord blood lead 
levels were higher than maternal blood lead in the case treated with DMSA and in that of the sick premature 
infant described. In the other cases cord blood lead levels were lower than maternal prechelation levels. In sev­
eral reports, chelation treatment was not initiated until shortly before or soon after delivery and was directed 
toward the newborns. Various drugs at full dosages have been used singly or in combination: CaNa2EDTA 
alone, CaNa2EDTA and BAL, CaNa2EDTA and DMSA, and DMSA alone. In general, chelation therapy was well 
tolerated by the infants. 
Exchange transfusion has been used, in combination with chelation therapy, to successfully lower blood lead 
levels in neonates (Hamilton et al. 2001; Mycyk and Leikin 2004). In one case report, after a single-volume 
exchange transfusion, the infant with a cord blood lead level of 100 µg/dL was chelated on day 2 with a 
combination of BAL and CaNa2EDTA for 5 days, at the end of which the blood lead was 37 µg/dL (Mycyk and 
Leikin 2004). Chelation was continued for 19 days with DMSA, at the end of which the infant’s blood lead was 
38 µg/dL. Both the exchange and chelation treatments were described as “well tolerated.” Of particular inter­
est in this case is that maternal blood lead at preconception was 117 µg/dL and declined to 72 µg/dL by the 
third trimester. The mother was not chelated during her pregnancy. The baby was delivered at 40 weeks with a 
blood lead level of 100 µg/dL, weighed 3.7 kg, and achieved normal developmental milestones at 1 month of 
age. Another case report (Hamilton et al. 2001) describes a double-volume exchange transfusion plus 5 days 
intravenous CaNa2EDTA where the infant blood lead of 114 µg/dL fell to 12.8 µg/dL immediately following the 
exchange transfusion. Caution is advised, however, as Bearer et al. (2000, 2003) report on blood transfusions in 
newborn premature infants as an unexpected source of lead exposure. The relative benefits/risks of chelation 
versus exchange transfusion have not been investigated. 
SUMMARY AND RECOMMENDATIONS REGARDING CHELATION THERAPY 
While chelation may be beneficial especially in protecting the mother with very elevated blood lead levels, 
given the lack of controlled studies and the paucity of even published case reports or series, chelation therapy 
should be undertaken only with advice from experts in this field. Such decision making should weigh the lack 
of definitive evidence of safety for the fetus (especially in the first trimester) against the extensive safety profile 
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and experience with these drugs in children and adults. Recommendations for chelation therapy prenatally 
and postnatally are presented below: 
Prenatal Chelation of the Mother 
BLLs ≥70 µg/dL may result in significant maternal toxicity and chelation therapy should be considered, regard­
less of trimester, in consultation with an expert in the management of lead poisoning, high-risk pregnancies, 
and neonatology. Lead poisoning may be life threatening at levels greater than 100 µg/dL, though many cases 
have been described where patients with such levels were asymptomatic. Encephalopathic pregnant women 
should be chelated regardless of trimester. 
Pregnant women with confirmed BLLs ≥45 µg/dL (repeated on at least two venous blood samples collected 
within 24 hours) may be considered for chelation therapy and should be managed in conjunction with experts 
in high-risk pregnancy and lead poisoning. Immediate removal from the lead source is still the first prior­
ity and, in some cases, pregnant women may require hospitalization. When chelation is being considered, it 
should be performed in an inpatient setting only with close monitoring of the patient and in consultation with 
a physician with expertise in the field of lead chelation therapy. Data regarding the reproductive risk associ­
ated with chelation during pregnancy are sparse. Most case reports of infant outcomes report on the use of 
chelating agents after the first trimester (see Table 8-2). Reserving the use of chelating agents for later in preg­
nancy is consistent with the general concern about the use of unusual drugs during the period of organogen­
esis (National Research Council, 2000). However, severe maternal lead intoxication, such as encephalopathy, 
will warrant chelation regardless of the stage of pregnancy. (Contact the CDC Healthy Homes and Lead Poison­
ing Prevention branch [http://www.cdc.gov/nceh/lead] or the American College of Medical Toxicology [http:// 
www.acmt.net] for a list of experts). 
Neonatal Chelation of the Infant 
Chelation should be considered in neonates and infants less than 6 months of age for a confirmed BLL ≥45 µg/ 
dL in consultation with a pediatric expert in lead chelation therapy. The limited data published suggest that 
toxicities for 0- to 6-month-olds are no different than those of 6- to 12-month-olds. Chelation treatment must 
occur in an environment free of lead hazards; therefore, prior to initiating chelation therapy, the patient should 
be removed from further lead exposure. Very limited data are available on the use of exchange transfusion as 
an alternative in this age group. 
Chelating Agents 
Three of the four available chelating agents (CaNa2EDTA, BAL, DMSA) have been used during pregnancy and 
may be considered. Data for penicillamine used in pregnancy are unavailable. (This drug is FDA-approved for 
use in children, but its use in pregnancy is not approved.) The most experience, little as it is, has been with 
CaNa2EDTA. This drug may be used intravenously at regular doses for 5 days. [Important Note: Calcium edetate 
(CaNa2EDTA) must not be confused with edetate disodium (Na2EDTA). From 2003 to 2005, three individuals— 
including two children—died of cardiac arrest caused by hypocalcemia during chelation therapy, as a result of 
inadvertent treatment with edetate disodium (Na2EDTA) (Brown et al. 2006).] 
Name  Synonym(s) Chemical Name  Number of Reported Cases
a 
Used in Pregnancy 
 Calcium Edetateb 
Calcium disodium versenate, 
versenate, edetate disodium 












 BALd Dimercaprol, British anti-Lewisite, BAL in Oil (BAL) 
2,3-dimercapto-L
propanol 1 
D-penicillamine Penicillamine, PCA, cuprimine (D-pen) 3-mercapto-D-valine 0 
Table 8-1 . Chelating Agents Used to Treat Lead Poisoning 
aSee Tables 8-2 and 8-3 for details of the case reports 
 
bNever use edetate disodium (Na2EDTA) alone without calcium (Brown et al. 2006) 
 
cSuccimer did not lower BLL after 1 course of treatment (Horowitz et al. 2001) 
 






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 CHAPTER 9. BREASTFEEDING


Key Considerations for Breastfeeding 
•	 Human breast milk is specific to the needs of the infant and is the most complete and ideal 
source for infant nourishment in the first year of life. 
Key Recommendations for Initiation of Breastfeeding 
•	 Measurement of levels of lead in breast milk is not recommended. 
•	 Mothers with BLLs <40 µg/dL should breastfeed. 
•	 Mothers with confirmed BLLs ≥40 µg/dL should begin breastfeeding when their blood 
lead levels drop below 40 µg/dL. Until then, they should pump and discard their breast 
milk. 
•	 These reccomendations are not appropriate in countries where infant mortality from infec
tious diseases is high (World Health Organization Collaborative Study Team on the Role of 
Breastfeeding on the Prevention of Infant Mortality 2000). 
Key Recommendations for Continuation of Breastfeeding 
•	 Breastfeeding should continue for all infants with BLLs below 5 µg/dL. 
•	 Infants born to mothers with BLL ≥5 µg/dL can continue to breastfeed unless there are 
indications that the breast milk is contributing to elevating BLLs. These infants should have 
blood lead tests at birth and be followed according to the schedule in Chapter 5. 
•	 For infants whose blood lead levels are rising or failing to decline by 5 µg/dL or more, 
environmental and other sources of lead exposure should be evaluated. If no external 
source is identified, and maternal BLLs are >20 µg/dL and infant BLL ≥5 µg/dL, then breast 
milk should be suspected as the source, and temporary interruption of breastfeeding until 
maternal blood lead levels decline should be considered. 
Key Recommendations for Use of Reconstituted Infant Formula 
•	 Infant formula requiring reconstitution should be made only with water from the cold 
water tap. Flush the tap for at least 3 minutes before use and then heat the water or use 
bottled or filtered tap water known to be free of lead. 
­
Breastfeeding is an optimal infant feeding practice compared with other infant feeding practices which carry 
risks. With regard to short-term risks, lack of breastfeeding is associated with increases in common childhood 
infections, such as diarrhea (Chien and Howie 2001) and ear infections (Ip et al. 2007), with potentially serious 
complications such as meningitis, dehydration, and hearing impairment. Lack of breastfeeding also increases 
the risk for some relatively rare but severe infections and diseases, such as severe lower respiratory infections 
(Bachrach et al. 2003; Ip et al. 2007), leukemia (Ip et al. 2007; Kwan et al. 2004), and—especially important for 
preterm infants—necrotizing enterocolitis (Ip et al. 2007). The risk of hospitalization for lower respiratory tract 
disease in the first year of life is more than 250% higher among babies who are formula fed compared with 
those who were exclusively breastfed at least 4 months (Bachrach et al. 2003). Furthermore, the risk for Sudden 
Infant Death Syndrome is 56% higher among formula-fed versus breastfed infants (Ip et al. 2007). The Agency 
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for Healthcare Research and Quality (2007) report also concludes that formula feeding has long-term health 
effects related to increased risks for certain chronic diseases and conditions, such as type 2 diabetes (Owen 
2006) and childhood obesity (Arenz et al. 2004), both of which have increased among U.S. children over time. 
Decisions made with regard to breastfeeding by a mother whose blood lead levels exceed background lev­
els should be based on scientific evidence suggesting undue risk for the child. Scientific observations have 
consistently shown that biologically significant elevations in milk lead concentration do not occur in lactating 
women at the blood lead concentrations typical of women with long-term residence in developed countries. 
Only a small number of American women will meet the crieteria to defer breastfeeding, though more will 
be subject to additional follow up out of an abundance of caution. Transfer of lead can occur from maternal 
plasma to breast milk in roughly the same concentrations. This chapter describes recommendations for breast-
feeding by women with blood lead levels above background levels and summarizes the scientific evidence 
supporting these recommendations. 
INTRODUCTION 
The overall goal in counseling a woman whether or not to breastfeed is to provide the best possible nutrition­
al and nurturing environment for the infant. Any decision either not to initiate or to discontinue breastfeed­
ing must be made only after careful consideration of all the factors involved. The basis of the initial decision-
making process should include a thorough discussion between the mother and her health care provider of the 
factors to be considered. This discussion should ideally take place before the baby is born. Many factors have 
an impact on whether or not a woman with a blood lead level ≥5 µg/dL chooses to breastfeed her child. Many 
of these factors are poorly quantified and others are not readily quantifiable. Thus, a detailed and balanced 
discussion is essential. 
THE IMPORTANCE OF BREASTFEEDING 
Due to the unique nutritional characteristics of human milk, breastfeeding is understood to be the optimal 
mode of nutrient delivery to term infants. The U.S. Department of Health and Human Services’ Blueprint for Ac­
tion on Breastfeeding (U.S. Department of Health and Human Services 2000) emphasizes the value of breast-
feeding, as does AAP (American Academy of Pediatrics 2005). Human breast milk is specific to the needs of 
the human infant. It provides the ideal nutrients for human growth and development in the first year of life, in 
a form that is readily transferred into the infant’s bloodstream. Human milk also protects the breastfed infant 
against certain common infections and reduces the incidence of certain chronic diseases as well as symptoms 
of allergy (U.S. Department of Health and Human Services 2000). Women who breastfeed experience less post­
partum bleeding, earlier return to prepregnancy weight and a reduced risk for ovarian cancer and premeno­
pausal breast cancer (U.S. Department of Health and Human Services 2000). Breastfeeding also provides the 
added benefit of the mother-child bonding that takes place during nursing sessions. 
The decision to breastfeed in the presence of a possible contraindication should be made on an individual 
basis, considering the risk of the complication to the infant and mother versus the tremendous benefits of 
breastfeeding (Lawrence 1997; Lawrence and Lawrence 2005). 
The current AAP statement on breastfeeding does not address the issue of breastfeeding by mothers with lead 
exposure above background levels (American Academy of Pediatrics 2005). An earlier statement specifically 
addressing the transfer of toxic environmental agents through breast milk and the risk of infant exposure to 
environmental toxicants by this route suggests that before advising against breastfeeding, the practitioner 
should weigh the benefits of breastfeeding against the risks of not receiving human milk (American Academy 
of Pediatrics 2001). 
Specifically with regard to lead, a technical information bulletin published by the Health Resources and Ser­
vices Administration in 1997 held that breastfeeding is not contraindicated unless the concentration of lead in 
 
maternal blood exceeds 40 µg/dL (Lawrence 1997). This recommendation was one small section of a larger re­
view of the evidence then available on breastfeeding benefits and contraindications. It has not been updated 
since publication. 
LEAD IN BREAST MILK 
Since maternal blood is the medium from which lead is transferred to breast milk and ultimately to the nurs­
ing infant, the relationship of lead in maternal blood to lead in breast milk is of key importance. Early studies 
supported the belief that milk lead levels were one-tenth to one-fifth the levels of lead in maternal whole 
blood (for a review, see Abadin et al. 1997). These high values were due in part to contamination and analyti­
cal inaccuracies in the laboratory measurement of lead in breast milk. (See Chapter 3 for discussion of issues 
associated with laboratory analysis of lead in human milk.) 
Recent carefully conducted studies of lead in breast milk consistently show breast milk lead to maternal blood 
lead ratios of approximately 3% or less; that is, a milk lead concentration of 3 µg/dL (or 30 µg/L) would be as­
sociated with a maternal blood lead concentration of 100 µg/dL, or a milk lead concentration of 0.3 µg/dL (3 
µg/L) would be associated with a maternal blood lead concentration of 10 µg/dL. Gulson et al. (1998) found 
that the breast milk lead to blood lead ratio was less than 3% in 15 adult female immigrants to Australia with 
blood lead concentrations up to 34 µg/dL. Li et al. (2000) evaluated 119 nonoccupationally exposed women in 
Shanghai, reporting a mean maternal blood lead concentration of 14.3 µg/dL and a mean milk lead to blood 
lead ratio of 3.9%. Counter et al. (2004) reported ratios of milk lead concentration to maternal blood lead 
concentration in 13 nursing mothers from Ecuadorian Andean villages. The ratios ranged from 0.4% to 3.3% in 
12 of the subjects, appearing to increase with increasing blood lead level. The thirteenth subject, with a blood 
lead concentration of 27.4 µg/dL, had a milk lead to blood lead ratio of 7.5%. Ettinger et al. (2004a) showed 
that breast milk lead was significantly correlated with maternal blood lead at one month postpartum in 
310 lactating women in Mexico City. The ratio of the geometric mean milk lead concentration to the geometric 
mean maternal blood lead concentration was 0.013, or 1.3%, and the highest observed blood lead concentra­
tion was 29.9 µg/dL. 
There is limited evidence that with closely spaced multiple pregnancies, baseline maternal blood lead concen­
trations are lower and the increases in maternal blood lead concentrations occurring during late pregnancy 
and lactation are reduced relative to those in the first pregnancy (Manton et al. 2003; Rothenberg et al. 1994). 
However, for most women in the United States, more than 98% of whom have blood lead levels <5 µg/dL, this 
has no practical implications. 
INFANT LEAD EXPOSURE FROM BREAST MILK 
Limited experimental observations suggest that breast milk lead has a relatively small impact on infant blood 
lead. It is generally agreed that biologically significant elevations in milk lead concentration do not occur in 
lactating women at the blood lead concentrations typical of women with long-term residence in developed 
countries (Gulson et al. 2003; Manton et al. 2003; Sowers et al. 2002). Other sources of lead also contribute 
to the nursing infant’s blood lead level. Manton et al. (2000) concluded from lead isotope analyses that the 
principal source of lead exposure in very young children, irrespective of whether they are breast- or bottle-fed, 
is hand-to-mouth activity. However, the relative importance of early hand-to-mouth activity depends on the 
child’s environment. Neonatal bone turnover is another potential source of lead in infant blood (Gulson et al. 
2001) that should be factored into expectations about infant blood lead levels. Bone turnover is very high in 
the newborn because both bone accretion and bone loss during reshaping of the growing bone are high. The 
rapid turnover of bone lead is reflected in a short blood lead half-life in very young children compared to older 






Although levels of lead in breast milk are generally low, they can influence infant blood lead levels over and 
above the influence of maternal blood to which the infant was exposed in utero. In a large-scale study of 
breast milk and infant blood lead levels, milk lead was found to account for 10% of the variance in 6-month 
blood lead and there was a linear dose–response relationship between breast milk lead and infant blood lead 
at age 6 months (Rabinowitz et al. 1985). In another study, breast milk lead accounted for 12% of the variance 
of infant blood lead levels at 1 month of age and levels of breast milk lead were significantly correlated with 
infant blood lead (Ettinger et al. 2004b). 
It is possible to estimate milk lead concentrations associated with various maternal blood lead concentrations. 
As discussed above, the most probable value of the maternal milk lead to blood lead ratio is substantially less 
than 3%. Table 9-2 illustrates calculated milk lead concentrations at various maternal blood lead concentra­
tions assuming breast milk lead concentration to be 3% of maternal blood lead concentration. Employing a 
tenfold larger percentage, this calculation might be thought of as providing an upper limit on the milk lead 
associated with a given maternal blood lead. It partly offsets the effect of binding of lead to milk casein at very 
low concentrations. 
From the breast milk lead, that portion of the nursing infant’s blood lead originating from maternal milk can 
be estimated. Ettinger et al. (2004b) reported that an increase of about 2 µg/L in breast milk lead was associ­
ated with a 0.82 µg/dL increase in the blood lead of breast-fed infants at 1 month of age, adjusting for cord 
blood lead, infant weight change, and reported breastfeeding status. Calculated based on this observed rela­
tionship, the increase in infant blood lead concentration associated with different maternal blood lead con­
centrations can be estimated (Table 9-3). Based on this calculation, the predicted contribution of breast milk 
lead to infant blood lead at 1 month of age would be about 3.7 µg/dL at a maternal blood lead concentration 
of 30 µg/dL, 2.5 µg/dL at a maternal blood lead concentration of 20 µg/dL, or 0.25-0.5 µg/dL at maternal blood 
lead concentrations of 2-4 µg/dL. This calculation is based on a data set whose values did not exceed 
30 µg/dL. Its application outside this range represents an extrapolation and becomes progressively less certain 
as maternal blood lead increases above 30 µg/dL. These calculations are supported by observational data only 
in infants about 1 month old, but they do not suggest undue concern for lead exposure of nursing infants at 
maternal blood lead and breast milk lead concentrations typical of those found in the United States. 
Evidence also suggests that the breast milk lead to maternal blood lead ratio may increase in a nonlinear 
fashion when maternal blood lead concentrations exceed about 40 µg/dL. This hypothesis is supported both 
by observational data on women with very high breast milk lead concentrations (Li et al. 2000; Namihara et al. 
1993) and by studies on the components of the blood (e.g., plasma) and breast milk as they relate to mater­
nal lead exposure (Hernandez-Avila et al. 1998; Manton and Cook 1984; Manton et al. 2001; O’Flaherty 1993; 
Schutz et al. 1996). A finding that breast milk contains proportionally more maternal lead at higher blood 
lead levels suggests possible risk associated with breastfeeding at maternal blood lead levels above 40 µg/dL. 
Epidemiological evidence is not entirely consistent about the extent to which maternal blood lead concentra­
tions increase during lactation (Ettinger et al. 2006; Manton et al. 2003; Tellez-Rojo et al. 2002). 
The breastfeeding recommendations developed herein are intended for women living in the United States. In­
sufficient data are available to guide clinical decisions regarding women with extremely high breast milk lead 
concentrations or in women living or working in lead-polluted areas outside the United States. Some evidence 
suggests different rates of transfer of lead into breast milk for maternal blood lead concentrations less than 
and greater than about 40 μg/dL (Li et al. 2000), but available human data are insufficient to make reliable 
estimates. 
RECOMMENDATIONS FOR BREASTFEEDING 
On the basis of the health and developmental benefits to infants of breastfeeding and consideration of the 
available research on the contribution of breast milk lead to infant blood lead, CDC has developed clinical 
 
guidance for breastfeeding by women exposed to lead. Initial criteria for breastfeeding are maternal blood 
lead levels, but ongoing monitoring of infant blood lead levels (described in Chapter 5) provides the addi­
tional feedback loop needed for clinical decision making about continuing breastfeeding. Specifically, a rise in 
infant BLL of 5 µg/dL or more is regarded as clinically significant and affects breastfeeding recommendations. 
Testing recommendations for women with BLL ≥5 µg/dL identified during pregnancy or at delivery are pre­
sented in Table 9-1 and for infants in Tables 5-1 and 5-2. Measurement of breast milk lead is not recommended 
given current laboratory methods and the availability of maternal blood lead as a proxy. 
An important practical challenge to clinicians in implementing these recommendations is ensuring that the 
recommended laboratory and other findings are entered into both the mother’s and the infant’s medical 
records in a timely fashion, as noted in Chapter 5. For instance, the mother’s initial and sequential blood lead 
levels should be in the infant’s chart. Without this data, clinicians lack the information needed to provide ap­
propriate and real-time guidance about breastfeeding. 
Initiating Breastfeeding 
Initiation of breastfeeding should be encouraged for all mothers with blood lead levels <40 µg/dL, with follow-
up recommendations varying by blood lead levels. Initial maternal BLLs <20 µg/dL are unlikely to be associ­
ated with a detectable increase in infant blood lead, even using a ratio of breast milk to maternal blood ten 
times the most likely value, as in the above calculations. In women with BLLs between 5-19 µg/dL, an initial 
infant blood lead level is warranted to establish a baseline. 
At maternal blood lead levels between 20-39 µg/dL, data do not exist to weigh accurately the risks of lead 
exposure from breast milk against the benefits of breastfeeding. Thus, a prudent course of action is for these 
women to initiate breastfeeding accompanied by sequential mother and infant blood lead levels to moni­
tor trends, so that adjustments can be made if indicated. Mothers with BLL between 20-39 µg/dL should be 
retested 2 weeks postpartum and then at 1- to 3-month intervals, depending on the direction and magnitude 
of trend in infant blood lead levels (Table 9-1). 
CDC considered the adverse health and developmental effects associated with lead exposure compared to 
those associated with not breastfeeding and, based on the available information, determined that at maternal 
blood lead levels ≥40 µg/dL the adverse developmental effects of ≥5 µg/dL increase in an infant’s blood lead 
level was of greater concern than the risks of not breastfeeding until maternal blood lead level dropped 
<40 µg/dL. Mothers with blood lead levels ≥40 µg/dL should not initiate breastfeeding immediately. They 
should be advised to pump and discard their breast milk until their blood lead levels drop below 40 µg/dL. In 
such cases, infants’ blood lead levels should be monitored after the initiation of breastfeeding. This recommen­
dation reaffirms the prevailing guidance about deferring breastfeeding at maternal BLL ≥40 µg/dL. 
Continuing Breastfeeding 
All infants born to mothers with BLL ≥5 µg/dL should have blood lead tests at birth and be followed according 
to the schedule in Chapter 5. Breastfeeding should continue for all infants with BLLs below 5 µg/dL or trending 
downward. 
For breastfed infants whose blood lead levels are rising or failing to decline by 5 µg/dL or more, environmental 
and other sources of lead exposure should be evaluated. If no external source is identified, and maternal BLLs 
are >20 µg/dL and infant BLL ≥5 µg/dL, then breast milk should be suspected as the source, and temporary 
interruption of breastfeeding until maternal blood lead levels decline should be considered. There are insuffi­
cient data to estimate how many mother-child pairs would meet these criteria, but anecdotal evidence sug­




Follow-up testing of women with BLL ≥5 µg/dL identified during pregnancy or at delivery should follow the 
schedule outline in Table 9-1. This should include women with known risk factors that are not controlled, re­
gardless of the BLL of the women or their infants. 
Lead in Infant Formula 
Since breast milk may not be provided exclusively, for an extended period of time, or even at all, many infants 
are likely to be nourished, at least in part, by commercially available infant formula. Therefore, it is important to 
characterize the contribution of non-breast milk sources to total potential lead exposure from dietary intake in 
infants and young children. 
Over the past several decades, the FDA and other federal agencies have worked to reduce dietary and other 
lead exposures of the general population, and in particular of vulnerable subpopulations such as infants, 
children, and pregnant women (Bolger et al. 1996). Lead-lined and lead-soldered cans are no longer used 
for commercial infant formula produced in the United States, and the most recent Total Diet Study confirms 
that currently marketed milk-based ready-to-feed infant formulas in the United States contain no appreciable 
amounts of lead. Only one sample (in the high-iron category) of 88 samples of high- and low-iron infant 
formula contained any measurable lead (trace lead detected in 1 sample = 0.007 mg/kg) (U.S. Food and Drug 
Administration 2007). 
To the extent that lead can be found in infant formula, the relative bioavailability of such lead may be less 
than that of lead in breast milk. For example, it has been documented that iron is more readily absorbed from 
breast milk than from infant formula (Lonnerdal 1985). Rabinowitz et al. (1985) found breast milk to be the 
strongest correlate of 6-month blood lead levels while formula lead correlated poorly with infant blood lead 
levels. However, Gulson et al. (1998) showed that the contribution of formula to infant blood lead varied from 
24% to 68% in exclusively formula-fed infants. They later estimated average daily intake of lead at age 
6 months for infants in their Australian study group fed exclusively by breast milk to be 0.73 µg (subjects = 17; 
observations = 78), and for infants fed exclusively by infant formula to be 1.8 µg (subjects = 11; observations = 
42) (Gulson et al. 2001). Ettinger et al. (2004b) also found that infants fed exclusively with breast milk had lower 
blood lead levels than those fed partially with breast milk, suggesting that formula or other dietary sources 
may contribute more lead to infant diets than breast milk does. In that study, an interquartile range increase in 
breast milk lead (~2 ppb) increased infant blood lead by 25%, or approximately 1 µg/dL. 
There are published reports of lead entering formula through lead in tap water used to prepare infant for­
mula (Shannon and Graef 1989) or the use of leaded storage containers (Shannon 1998). For instance, in a 
convenience sample of home-prepared reconstituted infant formula collected in a pediatrics department in 
metropolitan Boston, two of forty samples were found to have lead concentrations above 15 µg/L (Baum and 
Shannon 1997), which is the EPA lead action level for water. It is recommended that infant formula requiring 
reconstitution be made only with bottled or filtered tap water, or with cold water after flushing the tap for 
at least 3 minutes before use. Water authorities, in conjunction with state and local public health authorities, 
should consider issuing recommendations for the use of tap water in preparing infant formula based on lead 









Table 9-1 . Frequency of Maternal Blood Lead Follow-up Testing During Lactationa to Assess Risk for 
Infant Lead Exposureb from Maternal Breast Milk 
Initialc Venousd Blood Perform follow-up blood lead test(s) Lead Level (BLL; µg/dL) 
Every 3 months, per guidelines for adult blood lead testing (Appendix VI), unless infant 5-19 e blood lead levels are rising or fail to decline.
2 weeks postpartum and then at 1- to 3-month intervals depending on direction/ 20-39 magnitude of trend in infant BLLs. 
Within 24 hours postpartum and then at frequent intervals depending on clinical 
interventions and trend in BLLs. 
≥40 
Consultation with a clinician experienced in the management of lead poisoning is 
advised. 





























Breast Milk Lead 
Concentration, 
µg/Lb 
Infant Lead Intake from 
Breast Milk at Age 9 
Months, µg/dayc 
Infant Lead Intake 
from Breast Milk 
at Age 12 Months, 
µg/dayd 
1 0.03 0.3 0.3 0.27 
2 0.06 0.6 0.6 0.54 
3 0.09 0.9 0.9 0.81 
4 0.12 1.2 1.2 1.1 
5 0.15 1.5 1.5 1.4 
8 0.24 2.4 2.4 2.2 
10 0.3 3 3 2.7 
20 0.6 6 6 5.4 
30 0.9 9 9 8.1 
40 1.2 12 12 11.0 
aCalculated as 3% of maternal blood lead concentration. 
 
bNumerically equal to maternal plasma lead concentration, but expressed per liter rather than per deciliter. 
 
cAssuming the upper ingestion limit of 1,000 mL milk per day at these ages (U.S. Environmental Protection Agency 1997). 
 
dAssuming the upper ingestion limit of 900 mL milk per day at this age (U.S. Environmental Protection Agency 1997). 
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Table 9-2 . Estimated Daily Intake of Lead from Breast Milk at Different Maternal Blood Lead Concentrations 
Maternal Blood Lead  
Concentration, µg/dL 
Estimated Breast Milk Lead 
Concentration, µg/Lc 
Estimated Associated Increase in Infant 
Blood Lead at Age 1 Month, µg/dLd 
1 0.3 0.12 
2 0.6 0.25 
3 0.9 0.37 
4 1.2 0.49 
5 1.5 0.62 
8 2.4 0.98 
10 3 1.2 
20 6 2.5 
30 9 3.7 
40e 12 4.9 
Table 9-3 . Estimateda Increase in Infant Blood Lead Concentrationb Associated with Different Maternal 
Blood Lead Concentrations at 1 Month Postpartum 
aThis estimation integrates absorption, distribution, and excretion. 
bThese values are estimations based ICP-MS laboratory analysis and increments of less than 2 µg/dLwould not necessarily be 
 
 








dCalculated based on the observation that a 2 µg/L increase in breast milk lead is associated with an increase of 0.82 µg/dL in the blood 
 
 


















CHAPTER 10. RESEARCH, POLICY, AND HEALTH EDUCATION RECOMMENDATIONS 
INTRODUCTION 
The clinical and public health recommendations presented throughout these guidelines are based on current 
research findings where available; however, research has not been published to provide definitive guidance 
on all issues of interest. On other topics, the research base is clear, but existing policy is not consistent with 
research findings. For some topics, existing training and continuing education mechanisms are not working 
to deliver key findings to health professionals in critical fields, like obstetrics, pediatrics, family practice, and 
nursing. Together, these gaps in research, policy, and health education create an infrastructure that fails to 
reinforce optimal clinical and public health practice. This chapter presents specific research, policy, and health 
education needs identified by CDC to improve current service delivery and to inform development of future 




Long-term prospective studies of the effect of lead exposure during fetal development and disease risks 
later in life 
Given the immaturity of the blood-brain barrier in the developing nervous system, children might be more 
susceptible to morphologic changes in the nervous system during the prenatal and early postnatal periods. 
Further research is needed on 
•	 Lead kinetics across the placenta and in breast milk, and their relationship to development and disease 
risk across the lifespan for children exposed to lead in utero or as nurslings. 
•	 Specific health outcomes of interest, other than neurodevelopmental effects, such as pregnancy out­

come and cardiovascular disease in adulthood following in utero exposure. 
 

Follow-up studies of pregnancy outcomes and infant development in women with a history of lead expo­
sure above background levels during pregnancy 
Research is needed to better characterize health outcomes for mothers and infants associated with maternal 
lead exposure during pregnancy—at low elevations of blood lead typical for the U.S. population of women of 
childbearing age, as well as in more heavily exposed subgroups. Research is needed on 
•	 Specific health outcomes of interest, including pregnancy-related hypertension, low birth weight, and 
preterm birth. 





•	 Epidemiology of lead exposure during pregnancy and health outcomes. 
•	 Experimental investigation of the biological mechanisms. 
Genetic susceptibility to adverse effects of lead exposure (gene-environment interactions) 
Some studies have suggested that specific genes may render certain individuals more vulnerable to the ad­









•	 Characterize whether and how the bioaccumulation and toxicokinetics of lead are associated with 
 
 




•	 Investigate other potential gene-environment interactions. 
Value of maternal biomarkers to predict later infant and childhood blood lead levels 
While research has shown that maternal blood lead level is closely associated with infant/cord blood lead level 
at birth, the kinetics of lead in the newborn exposed in utero are not well understood. In addition, it is not clear 
whether tissue stores built up during gestation may be a significant source of lead as children age. Studies 
are needed to determine whether maternal biomarkers (maternal or umbilical blood lead levels) are useful to 
predict postnatal blood lead levels throughout infancy and childhood. 
Biokinetics of lead in breastmilk 
More information is needed on the biokinetics and cumulative dose of lead to the breastfeeding infant at vari­
ous maternal flood lead levels. Research is needed to determine how breast milk lead levels change over the 
course of lactation, and whether there are factors in breast milk or maternal diet that would enhance or retard 
the absorption of lead from breast milk by the infant. 
Biokinetics of lead with nutritional supplementation or super-supplementation during pregnancy 
•	 Large randomized clinical trials are needed to determine if nutritional supplements, diet modification, 
or a combination of diet and supplements may be a means of secondary prevention of exposure to lead 
during pregnancy. 
•	 Research is needed to determine whether the impact of nutritional factors differs for women prepreg­
nancy, during pregnancy, or during lactation, or depending on the woman’s lead burden or prior chela­
tion therapy. Extrapolation from animal studies may be necessary. 
Pharmacokinetics and effectiveness of chelating agents during pregnancy and lactation 
Minimal clinical data are available to inform decisions regarding the use of chelating agents in pregnant 
women, such as data on toxicity, treatment regimen, and timing of treatment. Studies are needed on 
•	 The effects of prenatal chelation on mothers and infants and on lead kinetics across the placenta; how­
ever, since this type of research is often not possible in humans due to ethical concerns about research 
on human subjects, extrapolation from animal studies may be necessary. 
•	 The effectiveness of chelation therapy on mitigation of adverse health outcomes other than neurodevel­
opment. 
Use of educational and developmental support and intellectual stimulation to improve academic/life per­
formance of children exposed to lead in utero 
Current research shows that lead exposure is associated with lifelong health and developmental effects in 
humans; however, questions have been raised from animal studies and clinical experience about whether and 
the extent to which certain cognitive effects can be mitigated by educational interventions during childhood. 
Long-term follow-up studies of children exposed to lead in utero are needed to evaluate whether specific 
educational or developmental interventions can improve cognitive outcomes. To be useful, such studies must 




Identification and development of new therapeutic agents or mechanisms to remove lead from breast milk 
and bone or tissue storage sites in women of childbearing age. 
Since bone lead stores persist for decades, women and their infants may be at risk for exposure long after 
environmental sources have been abated. At present, no interventions are available to remove lead from 
breast milk or from bone or tissue storage sites in women of childbearing age. Identification and development 
of prepregnancy interventions that decrease bone lead stores, or render them less mobilizable, may prove 
beneficial. 
Health Services Research 
Develop estimates for the number and distribution of pregnant women in the United States who should 
have blood lead tests, and the costs and benefits associated with testing and follow-up care 
Limited data are available on the numbers of pregnant women who meet the criteria for blood lead testing 
recommended in these guidelines. Research is needed to 
•	 Estimate the number of pregnant women in the US who should be tested for lead exposure, the costs for 
such testing, and the costs for recommended follow-up care. This research should include an assessment 
of the ability of high-risk women to access blood lead testing and follow-up services, including environ­
mental intervention, as well as determine who bears the burden of these costs. 
•	 Estimate the societal benefits expected to be derived from testing and treating pregnant women for 
lead exposure as recommended herein. 
Develop guidance for validation of risk questionnaires for pregnant women in specific clinical settings and 
subpopulations 
Only a few communities have developed risk questionnaires to inform decisions about blood lead testing of 
pregnant women; however, these guidelines recommends their use. Practical methods for adapting and vali­
dating risk questionnaires at the local level should be developed and disseminated by CDC and state and local 
health departments. Such guidance would allow local health agencies and health care providers to develop 
reliable risk questionnaires that are responsive to local conditions. 
Optimal timing for blood lead testing during pregnancy 
Identification of lead-exposed pregnant women potentially offers the most benefit to women and their in­
fants; however, there are no studies that identify when in pregnancy blood lead testing should be done. Given 
the curvilinear trajectory of blood lead levels over the course of pregnancy, blood lead testing done in differ­
ent trimesters may either over- or underestimate the woman’s true lead exposure. 
Characterize risk factors for pica and clinical strategies to identify pica in pregnant and lactating women 
While pica behavior is relatively uncommon in the general population, pica is observed in some populations 
of pregnant women in the United States, particularly those who have recently immigrated. Research is needed 
on how clinicians can more effectively identify pica, particularly those factors (age, race, country of origin, 
nutritional or health status, etc.) that may predispose a woman to pica. 
Effectiveness of interventions to reduce pica among pregnant women 
Only a few studies are available that evaluate the effectiveness of interventions designed to reduce or elimi­










behavior modification strategies for specific types of pica. Given the frequency of pica among some immigrant 
populations, culturally specific interventions should be a priority for investigation. 
HEALTH POLICY NEEDS 
Stronger Occupational Standards for Lead Exposure, Especially for Pregnant Women 
Current OSHA policy requires medical evaluations at blood lead levels of 40 µg/dL, and removal from the 
workplace when blood lead levels exceed 50 µg/dL (for construction) or 60 µg/dL (for general industry). Some 
industries where workers may be exposed to high levels of lead are not protected by OSHA. Current occupa­
tional standards were developed over 30 years ago and have not been updated to reflect research findings 
that lead exposure during pregnancy is associated with adverse effects on fetal growth and neurodevelop­
ment, maternal health, and an increased risk for spontaneous abortion. Updated standards consistent with the 
current knowledge about the health effects of lead exposure are needed to provide clear guidance to industry, 
policy makers, and workers, as well as because medical judgments may be influenced by existing regulations. 
•	 The Occupational Safety and Health Administration Standard for lead exposure should be updated to 
require that occupationally exposed women who are pregnant be removed from lead exposure if their 
blood lead level is 10 µg/dL or higher. 
•	 If the blood lead level is in the range of 5 to 9 µg/dL, efforts should be made to identify and reduce lead 
exposure on the job and review appropriate use of personal protective equipment. 
•	 All lead-exposed workers who have the potential to be exposed by lead ingestion, even in the absence 
of documented elevations in air lead levels, should be under medical surveillance. 
•	 Lead exposure should be regulated in categories of workers currently not covered by the OSHA stan­
dard. 
Regulation of Alternative Medicines and Dietary Supplements to Ensure Product Safety and Accuracy in 
Labeling and Marketing 
National policy is needed to establish regulatory mechanisms to control the safety and quality of alternative 
medicines and dietary supplements sold commercially in the United States. 
•	 Health claims for alternative medicines and dietary supplements should meet the same rigorous criteria 
as claims by drugs used to prevent or treat disease. 
•	 Regulatory standards for the content, labeling, and marketing of such products should be established 
and enforced. 
•	 The Federal Trade Commission, in cooperation with FDA, should ensure that advertising for dietary 
 
 




Regulatory Authority to Require Lead Safety in Dwellings Occupied by Pregnant Women and Resources 
to Control Lead Hazards in These Units 
State and local health or housing agencies should have the statutory authority to require and enforce lead 
paint hazard abatement in rental housing where pregnant women reside, to allow parents to bring their ba­
bies home to safe housing. Such statutes should also have provisions to protect pregnant tenants from retalia­
tory eviction by property owners unwilling to comply. Jurisdictions should also have public resources available 
to control lead hazards in those units where private resources are unattainable. [See Chapter 11 for informa­
tion on lead safety resources.] 
 
Mandatory Reporting of All Adult Blood Lead Levels 
Public health agencies need to be informed of blood lead testing results on adults in order to identify and 
investigate new community exposure sources, monitor epidemiological trends, and assure appropriate inter­
ventions for identified cases, including environmental inspection and case management services. Laboratories 
should be required to report all blood lead level test results on adults to the health department, preferably in 
standard electronic form. Such reporting could enable health departments to identify pregnant women with 
lead exposure above background levels for priority interventions. 
Reimbursement for Blood Lead Testing and Follow-Up Care for Uninsured Pregnant and Lactating Wom­
en and Their Infants 
Blood lead testing and follow up services (including case management, nutritional interventions, chelation 
therapy, and environmental investigation) are essential to appropriate medical management of pregnant and 
lactating women with lead exposure above background levels. However, a lack of insurance can be prohibitive 
to proper care for many women. In addition, such services may not be covered by insurance for documented 
immigrants during their first 5 years of residence in the United States or at all for undocumented immigrants. 
The State Children’s Health Insurance Program allows the use of federal funds for prenatal services to women 
regardless of immigration status in order to ensure the health of the fetus. States should use these funds for 
services necessary to reduce or treat lead exposure above background levels during the woman’s pregnancy 
and lactation. 
Sharing of Clinical Data Via Electronic Health Records
Proper medical management of pregnant or lactating women with lead exposure above background levels 
and their infants requires that the medical records of both mother and child contain relevant data related to 
lead. For example, the infant’s chart should contain information about the mother’s blood lead level at birth 
and about identified environmental sources. Likewise, the mother’s chart should contain information about 
the infant’s blood lead level. However, such records are likely to be maintained by diferrent health care provid­
ers and complicated by differing records systems, the possibility of different maternal/child surnames, etc. The 
adoption of electronic medical records would permit an automated linkage of the two charts to ensure that 
appropriate data can be transmitted to the other chart. 
HEALTH EDUCATION NEEDS 
Continuing Medical Education on Lead and Pregnancy 
Continuing Medical Education (CME) training on lead and pregnancy is needed to familiarize health care 
providers with this current research base and clinical recommendations. CDC, in consultation and cooperation 
with medical specialty associations (e.g., ACOG, AAP, American Academy of Family Physicians), nursing asso­
ciations (e.g., American Nurses’ Association, American College of Nurse Midwives), and environmental health 
associations should develop a training course module on lead and pregnancy or alternatively incorporate 
a discussion of lead exposure and pregnancy into preexisting educational materials, such as the Agency for 
Toxic Substances and Disease Registry’s Case Studies in Environmental Medicine, which can be taken for con­
tinuing education credit. The training should include information on evaluating risk factors for lead exposure 
as part of an occupational, environmental, and lifestyle health risk assessment. 
Environmental Health Requirement in Basic Practitioner’s Curriculum 
Pediatric medical and nursing education currently lacks sufficient environmental health content neces­
sary to prepare pediatric health care professionals to prevent, recognize, manage, and treat environmental 
exposure related disease including lead exposure during pregnancy. Thus, educational opportunities for 
physicians, nurses, environmental engineers, and other practitioners during their training are needed. Such 




mental Health Specialty Units (PEHSUs) and CDC’s provider education series are appropriate vehicles for these 
courses. CDC and the PEHSUs should coordinate publications and educational offerings with ACOG, AAP, the 
American Academy of Family Physicians, and the American College of Nurse Midwives. 
Preconceptional Counseling on Lead Exposure for Adults of Childbearing Age 
Primary and reproductive health care providers should provide counseling to patients of childbearing age 
about the effects of lead on fertility, pregnancy, and infant outcomes. They should educate their patients 
about possible lead exposure sources and how to reduce exposure in advance of conception. Such counseling 
should include referrals to appropriate sources for further assistance in assessing and reducing environmental 
or occupational lead expsosures. CDC should collaborate with the national professional health organizations, 
such as the American College of Obstetricians and Gynecologists, American Medical Association, and The 
American Academy of Family Physicians, and nonprofit organizations, such as the March of Dimes, to develop 
and disseminate educational materials to convey these messages. 
Expand Resources for National Centralized Data Collection and Management Facility 
A comprehensive online system is needed to improve dissemination of data on various sources of lead to 
medical and public health providers and the community. Such a system would provide real-time product iden­
tification information to alert providers and the communities at risk for exposure. It would also allow agencies 
that are testing products (e.g., CPSC, FDA, State of California) to enter information on tainted products into one 
easily accessible database. 
Evaluate the Effectiveness of Currently Available Personal Protective Equipment 
The capacity of available personal protective equipment to keep BLLs below 5 µg/dL is an area of needed 
research. Such studies should also inform the creation of more sophisticated equipment that can ensure that 



























CHAPTER 11. RESOURCES AND REFERRAL INFORMATION 
Contact information is provided here for key information sources for topics covered in this report. While not an 
exhaustive list, these resources provide a useful starting point for readers interested in updates, publications, 
referrals, or additional information. 
For information on lead poisoning prevention, including screening, case management, and referrals to 
state and local lead poisoning prevention programs: 























; Current statement on children, including literature review on low-level health effects in children 
; Current recommendations for case management of children with elevated blood lead levels 
; Reports on lead sources and epidemiology 
; Links to state and local lead poisoning prevention programs 
; Links to information about recalls of consumer products with lead (or see http://www.cpsc.gov or http:// 
www.fda.gov) 
For information on occupational and environmental health resources, expert contacts, and clinic 
locations nationwide: 














































































































For information on nutritional support for eligible women and infants, including state 
contact information: 











For information about lead-safe housing, including lead-based paint, renovation, and repainting: 
U.S. EPA brochure titled Reducing Lead Hazards When Remodeling Your Home, available at http://www. 
epa.gov/lead/pubs/rrpamph.pdf 
U.S. Department of Housing and Urban Development publication titled Lead Paint Safety Field Guide, 
available at http://www.hud.gov/offices/lead/library/lead/LeadGuide_Eng.pdf 















For information on lead and drinking water: 
Data on local drinking water 
http://www.epa.gov/safewater/dwinfo/index.html 
























For general information about lead poisoning (for consumers or professionals): 















Office of Healthy Homes and Lead Hazard Control












Office of Pollution Prevention and Toxics
U.S. Environmental Protection Agency
http://www.epa.gov/lead/ 
U.S. Consumer Product Safety Commission – product recalls and safety alerts
http://www.cpsc.gov/ 
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Existing State Legislation Related to Lead and Pregnant Women 
SCREENING LAW(S): 
New York Public Health Law §1370-a(2) 
Summary: Requires dept to promulgate and enforce regulations for screening children and 
pregnant women for lead poisoning, and for follow-up treatment for those with positive
results. 
New York Public Health Law §1370-c 
Summary: Authorizes dept to establish screening intervals and methods, which shall be
followed by every physician or other provider of medical care to children or pregnant
women. 
Connecticut Gen. Stat. §19a-111 
The commissioner shall establish, in conjunction with recognized professional medical 
groups, guidelines consistent with the CDC for assessment of the risk of lead poisoning, 
screening for lead poisoning and treatment and follow-up care of individuals including 
children with lead poisoning, women who are pregnant and women who are planning 
pregnancy. 
RISK REDUCTION LAW(S): 
Maryland Code §6-801- 6-852; Article 48A §734-737; Real Property § 8-208.2 
Comply with specific Risk Reduction standards when notified of certain conditions such as
chipping paint or the presence in the unit of a child or pregnant woman with an elevated
blood lead level of 15 µg/dl or higher. 
Minnesota Statute §144.9504 
Lead risk assessment. (a) An assessing agency shall conduct a lead risk assessment of a
residence according to the venous blood lead level and time frame set forth in clauses (1) to
(4) for purposes of secondary prevention: within ten working days of a pregnant female in 
the residence being identified to the agency as having a venous blood lead level equal to or
greater than ten micrograms of lead per deciliter of whole blood.
Subd. 5. Lead orders. (a) An assessing agency, after conducting a lead risk assessment, 
shall order a property owner to perform lead hazard reduction on all lead sources that
exceed a standard adopted according to section 144.9508.
EDUCATION LAW(S): 
Michigan Comp. Laws §333.5473a(2-3)
Summary: Requires department to establish and conduct educational programs to educate
homeowners and remodelers of lead-safe practices and methods of lead-hazard reduction 
activities; (4): requires department to recommend appropriate maintenance practices for 
owners of residential property and day care facilities designed to prevent lead poisoning in
children 6 years or younger and pregnant women. 
PROPOSED LEGISLATION (NOT ENACTED): 
California – Requires the Department to make available to all health care providers that
administer perinatal care services informational materials on lead and require providers to 
make this information available to pregnant women. 
New York – Bill aimed at eliminating lead hazards in housing which is or will be occupied by
pregnant women or children 7 years of age or less. 
Ohio - Requires the Director to produce an educational audio-video recording on lead
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Charge Questions to the Lead and Pregnancy Work Group 
Subgroup 1. Prevalence, Risk and Screening
This group was asked to review literature including but not limited to: 
• Distribution of BLLs and other measures of lead body burden in: 
− women of childbearing-age 
− pregnant women at various gestational ages 
− lactating women
− newborns
• Risk factors/sources for elevated blood lead levels in pregnant and lactating
women and the newborns 
• Relationship between: 
− maternal blood/bone lead levels and newborn blood lead levels
− pregnancy BLLs and postpartum BLLs? 
Based on subgroup findings, address the following questions: 
• When should pregnant women be screened for lead poisoning and when
should screening occur?  Are there questions that can predict which woman
should be screened? 
• What culturally sensitive interventions should be recommended to reduce 
exposure to potential sources?
Subgroup 2. Maternal, Pregnancy and Child Outcomes
This group was asked to review literature including but not limited to: 
• Impact of elevated blood lead levels on: 
− fertility (spontaneous abortion, stillbirth) 
− maternal health (pregnancy induced hypertension) 
− pregnancy outcomes (preterm delivery, gestational age, birth weight,
birth length, head circumference) 
− neurodevelopment outcomes due to prenatal exposure 
− behavioral outcomes due to prenatal exposure 
Based on subgroup findings, address the following questions: 
• When blood lead levels are elevated, what guidance should medical providers
be providing to:
− women of child-bearing age regarding delaying of pregnancy? 
− pregnant women about potential outcomes? 
Subgroup 3. Management, Treatment and Other Interventions 
This group was asked to review literature including but not limited to: 
• Breast milk exposure including: 
− Amount transmitted to baby 
− Benefits vs. hazards of breast feeding when blood lead levels are elevated 
• Effectiveness of nutritional supplementation during pregnancy and lactation 
• Indications/Contraindications/Adverse effects of chelation on: 
− pregnant woman, fetus, and newborns
Based on subgroup findings, address the following questions:
• What is the follow-up testing schedule at various blood lead levels for
pregnant and lactating women and for the newborns? 
• At what blood lead level, if any, should women be advised against
breastfeeding?  
• What nutrition counseling or nutritional supplements should be
recommended?
• What chelating agents should be employed?
• What interventions should be provided by public health agencies at
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Commonly-ingested Substances in Pregnancy-related Pica, Reasons for Use, and
Country/Race-Ethnicity of Origin 
Substance/Name Reason Used (If








































Corn Starch Nausea/GI upset US African-Americans 
(South) 
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List of Occupations and Hobbies that Involve Lead Exposure 
Lead Related Occupations and Industries 
Ammunition/explosives production 
Automotive repair shops 
Battery manufacturing and recycling 
Brass, bronze, copper or lead foundries 
Bridge, tunnel and elevated highway/subway construction 
Cable/wire stripping, splicing or production 
Ceramic manufacturing 
Firing range work 
Glass recycling, stained glass and glass manufacturing 
Home renovation/restoration 
Lead Abatement 
Lead production or smelting 
Machining or grinding lead alloys 
Manufacturing and installation of plumbing components 
Manufacturing of industrial machinery and equipment 
Metal scrap yards and other recycling operations 
Motor vehicle parts and accessories 
Occupations using firearms 
Plastics manufacturing 
Pottery making 
Production and use of chemical preparations 
Rubber manufacturing 
Sandblasting, sanding, scraping, burning or disturbing lead paint 
Use of lead based paints 
Welding or torch-cutting painted metal 
Hobbies and Activities That May Cause Lead Exposure 
Making stained glass and painting on stained glass 
Copper Enameling 
Bronze Casting 
Making pottery and ceramic ware with lead glazes and paints 
Casting ammunition, fishing weights or lead figurines 
Collecting, painting or playing games with lead figurines 
Jewelry making with lead solder 
Electronics with lead solder 
Furniture refinishing 
Glassblowing with leaded glass 
Print making and other fine arts 
Liquor distillation 
Hunting and target shooting 
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Alternative Cosmetics, Food Additives, and Medicines that Contain Lead 
Exposure Source Description/Exposure Pathway 
Albayalde or albayaidle Used by mainly by Mexicans and Central Americans to treat
vomiting, colic, apathy and lethargy. 
Al Kohl (Middle East,
India, Pakistan, some
parts of Africa) 
A gray or black eye cosmetic applied to the conjunctival margins of
the eyes for medicinal and cosmetic reasons. Can contain up to 
83% lead. It is believed to strengthen and protect the eyes against
disease and may be used as an umbilical stump remedy. 
Also known as simply as kohl. 
Al Murrah Used as a remedy for colic, stomach aches and diarrhea in Saudi
Arabia. 
Anzroot A remedy from the Middle East used to treat gastroenteritis. 
Azarcon Also known as alarcon, coral, luiga, maria luisa, or rueda. 
Bright orange powder used to treat “empacho” (an illness believed 
to be caused by something stuck in the gastrointestinal tract,
resulting in diarrhea and vomiting). Azarcon is 95% lead. 
Ayurvedic medicine
(Tibet) 
Traditional medicines that may contain lead. Some examples
include: guglu, sundari kalp, jambrulin 
Ba-Baw-San or Ba-Bow-
Sen (China) 
Herbal medicine used to detoxify “fetal poisoning” and treat colic
pain or to pacify young children. 
Bali goli A round, flat black bean which is dissolved in “gripe water” and
used within Asian Indian cultures for stomach ache. 
Bint Al Zahab (Iran) Rock ground into a powder and mixed with honey and butter given





A yellow lead oxide used by local jewelers and as a home remedy 
for diarrhea, colic, constipation and general neonatal uses. 
Bokhoor (Kuwait) A traditional practice of burning wood and lead sulfide to produce
pleasant fumes to calm infants. 
Cebagin Used in the Middle East as a teething powder. 
Chuifong tokuwan A pill imported from Hong Kong used to treat a wide variety of
ailments. 
Cordyceps Used in China as a treatment for hypertension, diabetes and
bleeding. 
Deshi Dewa A fertility pill used in Asia and India. 
Farouk A teething powder from Saudi Arabia. 
Ghasard Brown powder used in Asian Indian cultures as a tonic to aid in
digestion. 
Greta (Mexico) Yellow powder used to treat “empacho” (see azarcon); can be
obtained through pottery suppliers, as it is also used as a glaze for
low-fired ceramics. Greta is 97% lead. 
Hai Ge Fen (Concha
cyclinae sinensis) 
A Chinese herbal remedy derived from crushed clam shells. 
Henna Used as a hair dye and for temporary tattoos in the Middle East
and India - may contain lead. 
169 
Guidelines for the Identification & Management of Pregnant Women with Elevated Lead Levels   
   
 










Jin Bu Huan (China) An herbal medicine used to relieve pain. 
Kandu A red powder from Asia and India used to treat stomach ache. 
Koo Sar Red pills from China used to treat menstrual cramps. 
Kushta Used for diseases of the heart, brain, liver, and stomach and as an
aphrodisiac and tonic in India and Pakistan. 
Litargirio A yellow or peach-colored powder used as a deodorant, a foot
fungicide and a treatment for burns and wound healing particularly
by people from the Dominican Republic. 
Lozeena An orange powder used to color rice and meat that contains 7.8%­
8.9% lead. 
Pay-loo-ah (Vietnam) A red powder given to children to cure fever or rash. 
Po Ying Tan (China) An herbal medicine used to treat minor ailments in children. 
Santrinj (Saudi Arabia) An amorphous red powder containing 98% lead oxide used 
principally as a primer for paint for metallic surfaces, but also as a
home remedy for "gum boils" and "teething." 
Surma (India) Black powder used as an eye cosmetic and as teething powder or 
umbilical stump remedy. 
Tibetan herbal vitamin Used to strengthen the brain. 
Traditional Saudi 
medicine 
Orange powder prescribed by a traditional medicine practitioner
for teething; also has an antidiarrheal effect. 
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Recommendations for Medical Management of Adult Lead Exposure 
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Research conducted in recent years has increased public health concern about the toxicity of lead 
at low dose and has supported a reappraisal of the levels of lead exposure that may be safely toler­
ated in the workplace. In this article, which appears as part of a mini-monograph on adult lead 
exposure, we summarize a body of published literature that establishes the potential for hyperten­
sion, effects on renal function, cognitive dysfunction, and adverse female reproductive outcome in 
adults with whole-blood lead concentrations < 40 µg/dL. Based on this literature, and our collec­
tive experience in evaluating lead-exposed adults, we recommend that individuals be removed 
from occupational lead exposure if a single blood lead concentration exceeds 30 µg/dL or if two 
successive blood lead concentrations measured over a 4-week interval are ≥ 20 µg/dL. Removal of 
individuals from lead exposure should be considered to avoid long-term risk to health if exposure 
control measures over an extended period do not decrease blood lead concentrations to < 10 µg/dL 
or if selected medical conditions exist that would increase the risk of continued exposure. 
Recommended medical surveillance for all lead-exposed workers should include quarterly blood 
lead measurements for individuals with blood lead concentrations between 10 and 19 µg/dL, and 
semiannual blood lead measurements when sustained blood lead concentrations are < 10 µg/dL. It 
is advisable for pregnant women to avoid occupational or avocational lead exposure that would 
result in blood lead concentrations > 5 µg/dL. Chelation may have an adjunctive role in the med­
ical management of highly exposed adults with symptomatic lead intoxication but is not recom­
mended for asymptomatic individuals with low blood lead concentrations. Key words: adult lead 
exposure, blood lead, chelation, medical management, medical surveillance, pregnancy. Environ 
Health Perspect 115:463–471 (2007). doi:10.1289/ehp.9784 available via http://dx.doi.org/ 
[Online 22 December 2006] 
As a likely consequence of its capacity to 
interfere with biochemical events present in 
cells throughout the body, inorganic lead 
exerts a wide spectrum of multisystemic 
adverse effects. These health impacts range 
from subtle, subclinical changes in function 
to symptomatic, life-threatening intoxication. 
In recent years, research conducted on lead-
exposed adults has increased public health 
concern over the toxicity of lead at low dose. 
These findings support a reappraisal of the 
levels of lead exposure, sustained for either 
short or extended periods of time, that may 
be safely tolerated in the workplace. In this 
article we offer health-based recommenda­
tions on the management of lead-exposed 
adults aimed at primary and secondary pre­
vention of lead-associated health problems. 
As noted in the introduction to this mini-
monograph (Schwartz and Hu 2007) the 
authors of this article are an independent sub­
group of an expert panel (8 of 13 members) 
originally convened by the Association of 
Occupational and Environmental Clinics 
(www.aoec.org) to address these management 
issues. In deriving the recommendations in 
this article, we took note of a body of litera­
ture that establishes the potential for adverse 
health effects at blood lead concentrations or 
exposure levels permissible under current 
workplace regulations established in the 
1970s by the U.S. Occupational Safety and 
Health Administration (OSHA). These regu­
lations generally require removal from lead 
exposure when whole-blood lead concentra­
tions exceed 50 or 60 µg/dL. These values are 
considerably above blood lead concentrations 
of the general population of the United 
States, which had a geometric mean of 
12.8 µg/dL in the late 1970s (National 
Center for Health Statistics 1984), and a 
recent value of 1.45 µg/dL [U.S. Centers for 
Disease Control and Prevention (CDC) 
2005]. 
In setting forth our perspective on the rec­
ommended medical management of adult lead 
exposure, the narrative of this article focuses 
on four categories of health effects—hyperten­
sion, decrement in renal function, cognitive 
dysfunction, and adverse reproductive 
outcome—that have been the subject of much 
recent research. The discussion of these end 
points highlights those studies, that by virtue 
of their design and scope, were particularly 
influential in establishing the authors’ con­
cerns regarding the potential for adverse 
health effects at low to moderate levels of lead 
exposure in adults. Collectively, these effects 
support the preventive medical management 
strategies that are recommended in the tables. 
A review of the extensive literature on the 
health effects of lead is beyond the scope of 
this article, but the reader is referred to 
reviews on the cardiovascular and cognitive 
impacts of lead on adults that appear else­
where in this mini-monograph (Navas-Acien 
et al. 2007; Shih et al. 2007), as well as a 
review on recent lead literature prepared by 
the U.S. Environmental Protection Agency 
(EPA) for its Air Quality Criteria for Lead 
(U.S. EPA 2006). 
Table 1 is a summary of the adverse 
health risks associated with different blood 
lead concentrations and presents correspond­
ing medical management recommendations 
that range from discussion of risks and 
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reduction of lead exposure at low levels to 
removal from lead exposure accompanied by 
probable chelation therapy at the highest lev­
els. The designation of risks as either “short­
term” or “long-term,” depending on whether 
the risks are associated with exposure lasting 
less than or more than 1 year, reflects a quali­
tative understanding of the duration of lead 
exposure that may be required to elicit cer­
tain adverse health effects of lead. For some 
of the long-term risks, such as hypertension, 
research employing noninvasive K-shell X-ray 
fluorescence measurement of lead in bone, a 
biomarker of long-term cumulative exposure, 
suggests that several years of sustained eleva­
tions in blood lead may be necessary for a 
significant risk to emerge. The use of 1 year 
as a cut-point in the table is not intended to 
represent a sharp division, in terms of cumu­
lative dose, between what might constitute a 
short-term versus a long-term risk nor does it 
imply that a significant long-term risk begins 
to exist as soon as 1 year is surpassed. Blood 
lead, a measure of the amount of lead circu­
lating in the tissues, reflects both recent 
exogenous exposure as well as endogenous 
redistribution of lead stored in bone. 
The categorization of risks in Table 1 by 
discrete intervals of blood lead concentration 
is a qualitative assessment. In clinical practice, 
substantial interindividual variability in the 
susceptibility to symptomatic adverse effects 
of lead is commonly observed. Factors that 
might influence the risk of lead toxicity in 
adults include preexisting disease affecting 
relevant target organs (e.g., hypertension, 
renal disease, or neurologic dysfunction), 
nutritional deficiencies that modify the 
absorption or distribution of lead (e.g., low 
dietary calcium or iron deficiency), advanced 
age, and genetic susceptibility. Although 
recent studies suggest that polymorphisms in 
specific genes may modify the toxicokinetics 
and renal effects of lead (Theppeang et al. 
2004; Weaver et al. 2006; Wu et al. 2003), 
research findings at present are insufficient to 
conclusively identify genotypes that confer 
increased risk. 
Table 1. Health-based management recommendations for lead-exposed adults. 
Blood lead level Short-term risks Long-term risks 
(µg/dL) (lead exposure < 1 year) (lead exposure ≥ 1 year) Management 
< 5 None documented None documented None indicated 
5–9 Possible spontaneous abortion Possible spontaneous abortion Discuss health risks 
Possible postnatal developmental delay Possible postnatal developmental delay Reduce lead exposure for women who are or may become pregnant 
Possible hypertension and kidney dysfunction 
10–19 Possible spontaneous abortion Possible spontaneous abortion As above for BLL 5–9 µg/dL, 
Possible postnatal developmental delay Reduced birth weight plus: 
Reduced birth weight Possible postnatal developmental delay Decrease lead exposure 
Hypertension and kidney dysfunction Increase biological monitoring 
Possible subclinical neurocognitive deficits Consider removal from lead exposure to avoid long-term risks if exposure 
control over an extended period does not decrease BLL < 10 µg/dL, or 
if medical condition present that increases risk with continued exposurea 
20–29 Possible spontaneous abortion Possible spontaneous abortion Remove from lead exposure if repeat BLL measured in 4 weeks 
Possible postnatal developmental delay Possible postnatal developmental delay remains ≥ 20 µg/dL 
Reduced birth weight Reduced birth weight 
Hypertension and kidney dysfunction 
Possible subclinical neurocognitive deficits 
30–39 Spontaneous abortion Spontaneous abortion Remove from lead exposure 
Possible postnatal developmental delay Reduced birth weight 
Reduced birth weight Possible postnatal developmental delay 
Hypertension and kidney dysfunction 
Possible neurocognitive deficits 
Possible nonspecific symptomsb 
40–79 Spontaneous abortion Spontaneous abortion Remove from lead exposure 
Reduced birth weight Reduced birth weight Refer for prompt medical evaluation 
Possible postnatal developmental delay 
Nonspecific symptomsb 
Possible postnatal developmental delay 
Nonspecific symptomsb 
Consider chelation therapy for BLL > 50 µg/dL with significant 
symptoms or signs of lead toxicity 
Neurocognitive deficits Hypertension 
Sperm abnormalities Kidney dysfunction/nephropathy 






≥ 80 Spontaneous abortion Spontaneous abortion Remove from lead exposure 
Reduced birth weight Reduced birth weight Refer for immediate/urgent medical evaluation 
Possible postnatal developmental delay 
Nonspecific symptomsb 
Possible postnatal developmental delay 
Nonspecific symptomsb 
Probable chelation therapy 
Neurocognitive deficits Hypertension 
Encephalopathy Nephropathy 
Sperm abnormalities Peripheral neuropathy 
Anemia Neurocognitive deficits 




BLL, blood lead level.


aMedical conditions that may increase the risk of continued exposure include chronic renal dysfunction (serum creatinine > 1.5 mg/dL for men and > 1.3 mg/dL for women, or protein­
 

uria), hypertension, neurologic disorders, and cognitive dysfunction. bNonspecific symptoms may include headache, fatigue, sleep disturbance, anorexia, constipation, arthralgia, myal­

gia, and decreased libido.





















Recommendations for medical management of adult lead 
Health Effects at Low Dose 
Hypertension. Animal investigations support 
a pressor effect of lead at low dose (Fine et al. 
1988; Gonick et al. 1997; Vaziri 2002). 
Epidemiologic investigations conducted in 
large general population samples (e.g., Harlan 
1988; Nash et al. 2003; Pocock et al. 1988; 
Schwartz 1988) suggest lead may elevate 
blood pressure in adults at blood lead concen­
trations < 20 µg/dL. In some human studies 
of the link between blood lead and blood 
pressure, the relationship appeared to be 
influenced by subjects’ sex or race (e.g., Den 
Hond et al. 2002; Staessen et al. 1996; 
Vupputuri et al. 2003). Three meta-analyses 
of studies examining the relationship between 
blood lead and blood pressure found rela­
tively consistent effects of blood lead on blood 
pressure. The studies showed statistically signif­
icant coefficients for a 2-fold increase in blood 
lead of 1.0 mmHg (Nawrot et al. 2002; 
Staessen et al. 1994) or 1.25 mmHg (Schwartz 
1995) for systolic blood pressure, and 
0.6 mmHg for diastolic blood pressure 
(Nawrot et al. 2002; Staessen et al. 1994). 
The study populations analyzed in these 
meta-analyses included many with blood lead 
concentrations < 20 µg/dL. 
Further support for the impact of low-
level lead exposure on blood pressure has 
emerged from studies employing K-shell 
X-ray fluorescence measurement of lead in 
bone, a biomarker of long-term cumulative 
lead exposure. In two major studies drawn 
from samples of the general population, bone 
lead concentration was a significant predictor 
of the risk of hypertension (Hu et al. 1996; 
Korrick et al. 1999). Findings from the study 
by Hu et al. (1996) illustrate the associated 
risk. In that general population sample of 
middle-aged to elderly men (n = 590), the 
average blood lead concentration was 
6.3 µg/dL. On the basis of the subjects’ ages 
(mean 67 ± 7.2 years), it may be expected 
that they lived most of their adult lives at a 
time when the blood lead concentration of 
the general population ranged from 10 to 
25 µg/dL (Hofreuter et al. 1961; Mahaffey 
et al. 1982; Minot 1938). Comparing the 
lowest with the highest quintile of bone lead 
among that cohort, a tibia bone lead incre­
ment of 29 µg/g was associated with a 1.5 
odds ratio (OR) for hypertension [95% confi­
dence interval (CI), 1.1–1.8]. Given the slope 
of 0.05 that has described the linear relation­
ship between tibia bone lead concentration 
and cumulative blood lead index in subjects 
with chronic lead exposure in many studies 
(Hu et al. 2007), this increment in bone lead 
is roughly equivalent to a cumulative blood 
lead index of 580 µg/dL • years (i.e., 29 ÷ 
0.05 = 580). Considered in the context of a 
40-year working lifetime, the risk of lead-
associated hypertension may be significantly 
reduced by preventive measures that lower 
chronic workplace blood lead concentrations 
from the 20s and 30s µg/dL range to 
< 10 µg/dL. For example, a change in average 
workplace blood lead concentration from 
25 to 10 µg/dL over a 40-year working life­
time would reduce a worker’s cumulative 
blood lead index by 600 µg/dL • years, slightly 
more than the 580 µg/dL • years cited above. 
Hypertension is a significant risk factor 
for cardiovascular and cerebrovascular mortal­
ity. As reviewed in an accompanying article in 
this mini-monograph (Navas-Acien et al. 
2007), studies conducted in general popula­
tion cohorts have consistently observed a pos­
itive association between lead exposure and 
cardiovascular disease. Because of their size 
and design, studies derived from the National 
Health and Nutrition Evaluation Surveys 
(NHANES) are particularly notable. A 
16-year longitudinal analysis of the general 
population cohort studied between 1976 and 
1980 as part of NHANES II found that 
blood lead concentrations of 20–29 µg/dL at 
baseline were associated with 39% increased 
mortality from circulatory system disease 
compared with subjects with blood lead 
< 10 µg/dL [relative risk (RR) 1.39; 95% CI, 
1.01–1.91] (Lustberg and Silbergeld 2002). 
Two studies recently examined the longi­
tudinal relationship between blood lead con­
centration and cardiovascular mortality 
among participants in NHANES III. In a 
12-year longitudinal study of participants in 
NHANES III, ≥ 40 years of age (n = 9,757), 
the subgroup with blood lead concentration 
≥ 10 µg/dL (median, 11.8) had a relative risk 
of cardiovascular mortality of 1.59 (95% CI, 
1.28–1.98) compared with subjects with 
blood lead < 5 µg/dL (Schober et al. 2006). 
In a 12-year longitudinal analysis of subjects 
≥ 17 years of age (n = 13,946), the relative 
risk for cardiovascular mortality was 1.53 
(95% CI, 1.21–1.94), comparing a blood 
lead of 4.92 µg/dL (80th percentile of the dis­
tribution) with a blood lead of 1.46 µg/dL 
(20th percentile of the distribution) (Menke 
et al. 2006). 
Renal effects. Renal injury that appears 
after acute high-dose lead exposure may 
include reversible deficits in proximal tubular 
reabsorption and prerenal azotemia induced 
by renal vasoconstriction and/or volume 
depletion (Coyle et al. 200; Wedeen et al. 
1979). In a minority of exposed individuals, 
years of chronic, high-dose lead exposure may 
result in chronic lead nephropathy, a slowly 
progressive interstitial fibrosis characterized 
by scant proteinuria (Lilis et al. 1968). 
Epidemiologic investigations of renal function 
in workers with lower levels of chronic lead 
exposure have yielded variable findings. For 
example, in a cohort of approximately 800 
current and former lead workers with mean 
blood lead of 32 ± 15 µg/dL, there was no 
significant linear relationship between blood 
lead concentration and two measures of renal 
function, serum creatinine and creatinine 
clearance (Weaver et al. 2003). There was an 
interaction between age and tibia lead concen­
tration, a biomarker of cumulative lead expo ­
sure, on these same biomarkers, resulting in a 
trend toward worse renal function with 
increasing bone lead in the oldest tercile of 
workers (> 46 years of age) but improved renal 
function with increasing bone lead in the 
youngest workers (≤ 36 years of age). The 
authors suggested that lead-induced hyperfil­
tration, a finding noted in other studies, might 
presage the eventual development of lead-
induced renal insufficiency. Both blood lead 
and tibia lead were correlated with increased 
urinary N-acetyl-β-D-glucosaminidase (NAG), 
a biomarker of early biological effect on the 
renal tubule, but in an analysis of a smaller 
subset of the lead workers (n = 190) that con­
trolled for the relatively low levels of urinary 
cadmium (1.1 ± 0.78 µg/g creatinine), only 
the relationship with tibia lead and NAG 
remained significant (Weaver et al. 2003). 
Among a cohort of 70 active lead workers 
with a median blood lead concentration of 
32 µg/dL (range, 5–47), there were modest 
correlations between blood lead and urinary 
β-2-microglobulin (r = 0.27; p = 0.02), and 
between cumulative blood lead index and 
NAG (r = 0.25; p = 0.04) (Gerhardsson et al. 
1992). 
Several studies conducted in general popu­
lation samples have reported an association 
between blood lead concentration and com­
mon biomarkers of renal function (serum 
creatinine and creatinine clearance). In a cross-
sectional investigation of a subcohort of mid­
dle-aged to elderly men enrolled in the 
Normative Aging Study (n = 744), there was a 
negative correlation between blood lead (mean, 
8.1 ± 3.9 µg/dL; range, < 4.0–26.0 µg/dL) and 
measured creatinine clearance, after natural 
log transformation of both variables and 
adjustment for other covariates (Payton et al. 
1994). Among an adult population that 
included subjects with environmental cad­
mium exposure [n = 965 men (geometric 
mean blood lead, 11.4 µg/dL; range, 
2.3–72.5 µg/dL); n = 1,016 women (geomet­
ric mean blood lead, 7.5 µg/dL; range, 
1.7–60.3 µg/dL)], log-transformed blood lead 
concentration was inversely correlated with 
measured creatinine clearance (Staessen et al. 
1992). In a population-based study of Swedish 
women 50–59 years of age (n = 820), low lev­
els of blood lead (mean 2.2 µg/dL; 5th–95th 
percentiles, 1.1–4.6 µg/dL) were inversely 
correlated with creatinine clearance and 
glomerular filtration rate, after adjusting for 
age, body mass index, urinary or blood cad­
mium, hypertension, diabetes, and regular use 
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of nonsteroidal anti-inflammatory drug 
(NSAID) medication (Akesson et al. 2005). 
Individuals with other risk factors for 
renal disease, notably hypertension and dia­
betes, may be more susceptible to an adverse 
impact of low-level lead exposure on renal 
function. Among adults participating in 
NHANES III (n = 15,211), blood lead was a 
risk factor for elevated serum creatinine 
(defined as ≥ 99th percentile of the analyte’s 
race and sex specific distributions, generally 
> 1.2–1.5 mg/dL) and “chronic kidney dis­
ease” (defined as an estimated glomerular fil­
tration rate < 60 mL/min) only among 
subjects with hypertension (n = 4813) 
(Muntner et al. 2003). Compared with 
hypertensives in the lowest quartile of blood 
lead (range, 0.7–2.4 µg/dL), hypertensive 
subjects in the next highest quartile of blood 
lead (range, 2.5–3.8 µg/dL) had a covariate 
adjusted OR for elevated serum creatinine of 
1.47 (95% CI, 1.03–2.10) and for chronic 
kidney disease of 1.44 (95% CI, 1.00–2.09). 
At the next highest quartile of blood lead 
(range, 3.9–5.9 µg/dL), the covariate-adjusted 
OR for elevated serum creatinine was 1.80 
(95% CI, 1.34–2.42), and for chronic kidney 
disease it was 1.85 (95% CI, 1.32–2.59). In a 
subcohort of middle-aged to elderly men par­
ticipating in the Normative Aging Study (n = 
427, blood lead 4.5 ± 2.5 µg/dL), multiple 
regression analysis revealed that log-trans­
formed blood lead was positively correlated 
with serum creatinine in hypertensive but not 
normotensive subjects (Tsaih et al. 2004). In 
a longitudinal study of this cohort over a 
mean of 6 years, an interaction between lead 
and diabetes yielded a positive association 
between baseline blood lead concentration 
and change in serum creatinine that was 
strongest in diabetic subjects (Tsaih et al. 
2004). An interaction with diabetes was also 
present in the association of tibial lead con­
centration with longitudinal change in serum 
creatinine (Tsaih et al. 2004). Although these 
general population studies are consistent with 
an adverse effect of lead exposure on renal 
function at notably low levels, the extent to 
which diminished renal function may itself 
result in increased body lead burden has not 
been fully elucidated. 
Cognitive dysfunction. A few studies 
examining relatively small numbers of work­
ers (n ≤ 100) with blood lead concentrations 
ranging approximately 20–40 µg/dL have 
associated lead exposure with subclinical 
decrements in selective domains of neurocog­
nitive function (Barth et al. 2002; Hänninen 
et al. 1998; Mantere et al. 1984; Stollery 
1996). Among a large cohort of current and 
former inorganic lead workers studied in 
Korea, a cross-sectional analysis (n = 803 
workers) (Schwartz et al. 2001) and a 3-year 
longitudinal analysis (n = 576 workers) 
(Schwartz et al. 2005) found that blood lead 
concentrations across the approximate range 
of 20–50 µg/dL were associated with subclini­
cal neurocognitive deficits. Among a small 
population of former lead workers (n = 48) 
and age-matched controls with similar blood 
lead concentrations (approximately 5 µg/dL 
in both groups; range, 1.6–14.5 µg/dL; mean 
age, 39.8 years), increases in current blood 
lead concentration within the entire study 
population were correlated with poorer per­
formance on several tests of neurocognitive 
function but on only one measure was cumu­
lative lead exposure (measured in the workers) 
associated with poorer performance (Winker 
et al. 2005). 
In the population-based sample of adults 
20–59 years of age participating in the 
NHANES III study (n = 4937), there was no 
relationship between blood lead concentra­
tion (geometric mean, 2.51 µg/dL) and 
covariate-adjusted performance on neu­
rocogntive function (Krieg et al. 2005). 
However, significant associations have 
emerged in some studies of older adults with 
slightly higher blood lead concentrations. In a 
rural subset of elderly women (mean age, 
71.1 ± 4.7 years; n = 325) with background, 
community lead exposure (geometric mean 
blood lead concentration, 4.8 µg/dL; range, 
1–21 µg/dL), certain measures of neuro­
psychologic function (Trailmaking part B and 
Digit Symbol test) were performed more 
poorly by women in the upper 15th per­
centile of blood lead (blood lead ≥ 8 µg/dL, 
n = 38; Muldoon et al. 1996). However, in 
the slightly younger subset of elderly women 
who resided in an urban area (mean age, 
69.4 ± 3.8 years; n = 205), no relationship 
between blood lead (geometric mean, 
5.4 µg/dL) and neuropsychologic perfor­
mance was discernible (Muldoon et al. 1996). 
In a general population sample of middle-
aged to elderly men (n = 141; mean age, 
66.8 ± 6.8 years) with a mean blood lead con­
centration of 5.5 ± 3.5 µg/dL examined as 
part of the Normative Aging Study, increased 
blood lead concentration was associated with 
poorer performance on neuropsychologic 
assessment of memory, verbal ability, and 
mental processing speed (Payton et al. 1998). 
In a larger subset of men (n = 736; mean age, 
68.2 ± 6.9 years) from the Normative Aging 
Study assessed with the Mini-Mental Status 
Examination (MMSE), the OR for having a 
test score associated with an increased risk of 
dementia was 3.4 (95% CI, 1.6–7.2) compar­
ing the mean blood lead of the highest quar­
tile (mean, 8.9 µg/dL) to that of the lowest 
quartile (mean, 2.5 µg/dL) (Wright et al. 
2003). There was a positive interaction 
between age and blood lead, which is consis­
tent with a lead-associated acceleration in age-
related neurodegeneration. 
As reviewed in an accompanying article in 
this mini-monograph (Shih et al. 2007), there 
is evidence that at low levels of lead exposure, 
biomarkers of cumulative lead exposure, such 
as lead in bone, may be associated with an 
adverse impact on neurocognitive function 
that is not reflected by measurement of 
lead in blood. Among subjects from the 
Normative Aging Study (n = 466; mean age, 
67.4 ± 6.6 years) examined for longitudinal 
change in MMSE score over an average of 
3.5 ± 1.1 years, higher patella bone lead con­
centrations, a biomarker of cumulative lead 
exposure, predicted a steeper decline in per­
formance (Weisskopf et al. 2004). By com­
parison, baseline blood lead concentration 
(median, 4 µg/dL; interquartile range = 3, 5) 
did not predict change in MMSE score. In a 
longitudinal analysis of performance on a bat­
tery of cognitive tests in a subset of the 
Normative Aging Study, bone lead measure­
ments were predictive of worsening perfor­
mance over time on tests of visuospatilal/ 
visuomotor ability (Weisskopf et al. 2007). In 
a cross-sectional analysis of 985 community 
dwelling residents 50–70 years of age, increas­
ing tibia bone lead concentrations were sig­
nificantly associated with decrements in 
cognitive function, whereas an impact of 
blood lead (mean, 3.46 ± 2.23 µg/dL) was 
not apparent (Shih et al. 2006). 
Reproductive outcome in women. Adverse 
effects on reproductive outcome constitute a 
special risk of lead exposure to women of 
reproductive age. A nested case–control study 
examined the association of blood lead con­
centration with spontaneous abortion in a 
cohort of 668 pregnant women seeking pre­
natal care in Mexico City (Borja-Aburto et al. 
1999). After matching for maternal age, edu­
cation, gestational age at study entry, and 
other covariates, the OR for spontaneous 
abortion before 21 weeks gestation was 1.13 
(95% CI, 1.01–1.30) for every 1 µg/dL 
increase in blood lead across the blood lead 
range of 1.4–29 µg/dL. Compared with the 
reference category of < 5 µg/dL of blood lead, 
women whose blood lead levels were 5–9, 
10–14, and > 15 µg/dL had ORs for sponta­
neous abortion of 2.3, 5.4, and 12.2, respec­
tively (test for trend, p = 0.03). Although 
several earlier studies failed to detect this sub­
stantial impact, they may have been subject 
to methodologic limitations not present in 
the Mexico City investigation (Hertz-
Picciotto 2000). 
Several studies have found that lead expo­
sure during pregnancy affects child physical 
development measured during the neonatal 
period and early childhood. In an extensively 
studied cohort of 272 full-term, parturient 
women from Mexico City with environmental 
lead exposure common to the region (mean 
maternal blood lead, 8.9 ± 4.1 µg/dL; mean 
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tibia bone lead, 9.8 ± 8.9 µg/g; range, 
12–38 µg/g), every increase of 10 µg/g in 
maternal tibia lead was associated with a 73-g 
(95% CI, 25–121) decrease in birth weight 
(Gonzalez-Cossio et al. 1997). The impact of 
tibia bone lead on birth weight was nonlinear 
and was most pronounced in mothers with the 
highest quartile of bone lead (> 15–38 µg/g) 
where the decrement relative to the lowest 
quartile was estimated to be 156 g. Primarily 
in the same cohort, a maternal patella lead 
concentration > 24.7 µg/g was associated with 
an OR of 2.35 (95% CI, 1.26–4.40) for a 
neonate with one category smaller head cir­
cumference at birth, assessed as a five-cate­
gory–ordered variable (Hernandez-Avila et al. 
2002). In a different Mexico City cohort, each 
doubling of maternal blood lead at 36 weeks 
of pregnancy (geometric mean, 8.1 µg/dL; 
25th–75th percentile, 5–12 µg/dL) was associ­
ated with a decrease of 0.37 cm (95% CI, 
0.57–0.17) in the head circumference of a 
6-month-old infant (Rothenberg et al. 
1999b). 
Prenatal lead exposure assessed by umbili­
cal cord blood lead concentration has been 
inconsistently associated with an adverse effect 
on neurobehavioral development in childhood. 
However, recent studies suggest that mobiliza­
tion of maternal bone lead during pregnancy 
may contribute to fetal lead exposure in ways 
that may be incompletely reflected by the sin­
gle measurement of umbilical cord whole-
blood lead (Chuang et al. 2001; Tellez-Rojo 
et al. 2004). In a prospective study conducted 
in Mexico City of 197 mother–infant pairs, a 
statistically significant adverse effect of umbili­
cal cord blood lead (mean, 6.7 ± 3.4 µg/dL; 
range, 1.2–21.6 µg/dL) was also accompanied 
by an independent adverse effect of maternal 
bone lead burden on the 24-month Mental 
Development Index (MDI) of the Bayley 
Scales of Infant Development, which 
decreased 1.6 points (95% CI, 0.2–3.0) for 
every 10-µg/g increase in maternal patellar 
lead (mean, 17.9 ± 15.2 µg/g; range, 
< 1–76.6 µg/g) (Gomaa et al. 2002). 
A prospective study that measured mater­
nal plasma lead and maternal whole-blood 
lead during pregnancy found that maternal 
plasma lead during the first trimester was the 
stronger predictor of infant mental develop­
ment at 24 months of age (Hu et al. 2006). 
In this cohort, first trimester maternal plasma 
lead was 0.016 ± 0.014 µg/dL and first 
trimester maternal whole-blood lead was 
7.07 ± 5.10 µg/dL (n = 119). Adjusting for 
covariates that included maternal age, mater­
nal IQ, child sex, childhood weight and 
height for age, and childhood whole-blood 
lead at 24 months, an increase of one SD in 
loge (natural log)–transformed plasma lead in 
the first trimester was associated with a 
3.5-point decrease in score on the 24-month 
MDI of the Bayley Scales of Infant 
Development. The corresponding impact of 
one SD increase in loge maternal whole 
blood during the first trimester was a 
2.4-point decrease in the 24-month MDI. 
The logarithmic relationship between mater­
nal plasma and blood lead concentrations 
and infant MDI indicated that the strongest 
effects occurred among mothers with the 
lowest plasma and blood lead concentrations. 
Two long-term prospective studies that 
conducted multiple measurements of mater­
nal blood lead during pregnancy and child­
hood have identified an adverse impact of 
low-level prenatal lead exposure on postnatal 
neurobehavioral development extending 
beyond infancy. Applying a repeated mea­
sures linear regression technique to analysis of 
age-appropriate IQ test data obtained in 390 
children 3–7 years of age, the Yugoslavia 
Prospective Lead Study found independent 
adverse effects of both prenatal and postnatal 
blood lead. After controlling for the pattern 
of change in postnatal blood lead and other 
covariates, IQ decreased 1.8 points (95% CI, 
1.0–2.6) for every doubling of prenatal blood 
lead, which was assessed as the average of 
maternal blood lead at midpregnancy and 
delivery (mean, 10.2 ± 14.4 µg/dL; n = 390) 
(Wasserman et al. 2000). The Mexico City 
Prospective Lead Study used generalized lin­
ear mixed models with random intercept and 
slope to assess the impact on IQ measured at 
6–10 years of age of blood lead measurements 
systematically obtained during weeks 12, 20, 
24, and 36 of pregnancy, at delivery, and at 
multiple points throughout childhood 
(Schnaas et al. 2006). Geometric mean blood 
lead during pregnancy was 8.0 µg/dL (range, 
1–33 µg/dL; n = 150); from 1 through 5 years 
it was 9.8 µg/dL (2.8–36.4 µg/dL), and from 
6 through 10 years it was 6.2 µg/dL (range, 
2.2–18.6 µg/dL). IQ at 6 to 10 years of age, 
assessed by the Wechsler Intelligence Scale for 
Children—Revised, decreased significantly 
only with increasing natural-log third-
trimester blood lead, controlling for other 
blood lead measurements and covariates. 
Every doubling of third trimester blood lead 
(geometric mean of maternal blood lead at 
weeks 28 and 36 = 7.8 µg/dL, 5th–95th per­
centile: range, 2.5–24.6 µg/dL) was associated 
with an IQ decrement of 2.7 points (95% CI, 
0.9–4.4). Notably, the nonlinear (i.e., log-lin­
ear) relationships detected in the Yugoslavia 
and Mexico City studies indicate that across a 
maternal blood lead range of 1–30 µg/dL, an 
increase in blood lead from 1 to 10 µg/dL will 
account for more than half the IQ decrement. 
Two independent cohorts have provided 
evidence that maternal lead burden during 
pregnancy may be associated with increased 
risk of pregnancy hypertension and/or ele­
vated blood pressure during pregnancy. In a 
retrospective study of 3,210 women during 
labor and delivery, increasing umbilical cord 
blood lead levels (mean, 6.9 ± 3.3 µg/dL; 
range, 0–35 µg/dL) were associated with 
increased systolic blood pressure during labor 
(1.0 mmHg for every doubling of blood lead) 
and increased odds of hypertension (not fur­
ther defined) recorded any time during preg ­
nancy (OR = 1.3; 95% CI, 1.1–1.5) for every 
doubling of blood lead (Rabinowitz et al. 
1987). A prospective study of third trimester 
blood lead (geometric mean, 2.3 ± 1.4 µg/dL; 
range, 0.5–36.5 µg/dL) in 1,188 predomi­
nantly Latina immigrants showed that, in the 
immigrants, every doubling in blood lead was 
associated with increased third-trimester sys­
tolic blood pressure (1.2 mmHg; 95% CI, 
0.5–1.9) and diastolic blood pressure 
(1.0 mmHg; 95% CI, 0.4–1.5) (Rothenberg 
et al. 1999a). A study of a subset of the same 
cohort (n = 637) without regard to immigra­
tion status found that every 10-µg/g increase 
in calcaneus (heel) bone lead increased the 
OR of third trimester pregnancy hypertension 
(systolic > 90 and/or diastolic > 140 mmHg) 
by 1.86 (95% CI, 1.04–3.32) (Rothenberg 
et al. 2002). 
Medical Surveillance for 
Lead-Exposed Workers 
The OSHA workplace standard for lead 
exposure in general industry (adopted in 
1978) and a corresponding standard for lead 
exposure in construction trades (adopted in 
1993) set forth medical surveillance require­
ments that include baseline and periodic 
medical examinations and laboratory testing. 
Details of the two standards, which establish 
distinct criteria for the implementation of 
surveillance, can be found on the OSHA 
website (OSHA 2002). Because of the con­
cern regarding adverse health effects of lead 
associated with the lower levels of exposure 
discussed in this article, we recommend a 
revised schedule of medical surveillance activ­
ities (Table 2). Unlike the OSHA medical 
surveillance requirements, which apply only 
to workers exposed to airborne lead levels 
≥ 30 µg/m3 as an 8-hr time-weighted aver­
age, the recommendations in Table 2 are 
intended to apply to all lead-exposed workers 
who have the potential to be exposed by lead 
ingestion, even in the absence of documented 
elevations in air lead levels (Sen et al. 2002). 
As shown in Table 2, the level of a worker’s 
current blood lead measurement, as well as 
possible changes in lead-related exposure, 
influences the recommended time interval for 
subsequent blood lead measurements. Blood 
lead measurements should be obtained from 
a clinical laboratory that has been designated 
by OSHA as meeting the specific proficiency 
requirements of the OSHA lead standards. 
OSHA maintains a list of these laboratories 
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on its website (OSHA 2005). Venous blood 
should be used for biological monitoring of 
adult lead exposures, except where prohibited 
by medical or other reasons. Routine meas­
urement of zinc protoporphyrin, a require­
ment of the OSHA lead standards, is not 
recommended in Table 2 because it is an 
insensitive biomarker of lead exposures in 
individuals with blood lead concentrations 
< 25 µg/dL (Parsons et al. 1991). 
The content of the baseline or preplace­
ment history and physical examination for 
lead-exposed workers should continue to fol­
low the comprehensive scope set forth in the 
OSHA lead standard for general industry. 
Measurement of serum creatinine will iden­
tify individuals with chronic renal dysfunc­
tion who may be subject to increased health 
risks from lead exposure. With the potential 
exception of an annual blood pressure meas­
urement and a brief questionnaire regarding 
the presence of medical conditions (such as 
renal insufficiency) that might increase the 
risk of adverse health effects of lead exposure, 
medical evaluations for lead-exposed workers 
should be unnecessary as long as blood lead 
concentrations are maintained < 20 µg/dL. 
Annual education of lead workers regarding 
the nature and control of lead hazards, and 
ongoing access to health counseling regarding 






As summarized earlier in this article, the recent 
findings concerning lead-related adverse repro­
ductive outcomes render it advisable for preg­
nant women to avoid occupational or 
avocational lead exposure that would result in 
blood lead concentrations > 5 µg/dL. Calcium 
supplementation during pregnancy may be 
especially important for women with past 
exposure to lead. Calcium decreases bone 
resorption during pregnancy (Janakiraman 
et al. 2003) and may minimize release of lead 
trial among Mexican women with mean 
blood lead concentrations of approximately 
9 µg/dL found that calcium supplementation 
during lactation may reduce the lead concen­
tration of breast milk by 5–10% (Ettinger 
et al. 2006). Breast feeding should be encour­
aged for almost all women (Ettinger et al. 
2004a; Sanin et al. 2001; Sinks and Jackson 
1999), with decisions concerning women 
with very high lead exposure addressed on an 
individual basis. 
Medical Treatment of Elevated 
Blood Lead Concentration and 
Overt Lead Intoxication 
Removal from all sources of hazardous lead 
exposure, whether occupational or nonoccu­
pational, constitutes the first and most funda­
mental step in the treatment of an individual 
with an elevated blood lead concentration. A 
careful history that inquires about a broad 
spectrum of potential lead sources is recom­
mended (Occupational Lead Poisoning 
Prevention Program 2006). Removal from 
occupational lead exposure will usually require 
transfer of the individual out of any environ­
ment or task that might be expected to raise 
the blood lead concentration of a person not 
using personal protective equipment above 
background levels (i.e., 5 µg/dL). If there has 
been a history of an affected individual bring­
ing lead-contaminated shoes, work clothes, or 
equipment home from the workplace, evalua­
tion of vehicles and the home environment for 
significant levels of lead-containing dust might 
be considered (Piacitelli et al. 1995). Although 
such “take-home” exposure might contribute 
to further lead exposure of the worker, it ordi­
narily poses more of a potential risk to young 
children and pregnant or nursing women who 
share the worker’s home environment 
(Hipkins et al. 2004; Roscoe et al. 1999). 
Medical treatment of individuals with 
overt lead intoxication involves decontamina­
tion, supportive care, and judicious use of 
chelating agents. Comprehensive discussion 
of such treatment is beyond the scope of this 
article but has been reviewed in recent med­
ical toxicology texts (Kosnett 2001, 2005). A 
variety of chelating agents has been demon­
strated to decrease blood lead concentrations 
and increase urinary lead excretion. A recent 
double-blind randomized clinical trial of oral 
chelation in young children with blood lead 
concentrations ranging from 22 to 44 µg/dL 
found that the drug succimer lowered blood 
concentrations transiently but did not 
improve cognitive function (Dietrich et al. 
2004; Rogan et al. 2001). Although anecdotal 
evidence suggests that chelation has been 
associated with improvement in symptoms 
and decreased mortality in patients with lead 
encephalopathy, controlled clinical trials 
demonstrating efficacy are lacking. Treatment 
recommendations are therefore mostly 
empiric, and decisions regarding the initiation 
of chelation therapy for lead intoxication have 
occasionally engendered controversy. 
In our experience, adults with blood lead 
concentrations ≥ 100 µg/dL almost always 
warrant chelation, as levels of this magnitude 
are often associated with significant symptoms 
and may be associated with an incipient risk of 
encephalopathy or seizures. Occasionally, 
patients with very high blood lead con­
centrations may have no overt symptoms. 
Patients with blood lead concentrations of 
80–99 µg/dL, with or without symptoms, can 
be considered for chelation treatment, as may 
some symptomatic individuals with blood 
lead concentrations of 50–79 µg/dL. These 
demarcations are imprecise, however, and 
decisions on chelation should be made on a 
case-by-case basis after consultation with an 
Table 2. Health-based medical surveillance recommendations for lead-exposed workers. 
Category of exposure		 Recommendations 
All lead-exposed workersa		 Baseline or preplacement medical history and physical examination, baseline from bone stores and subsequent fetal lead BLL, serum creatinine 
exposure (Gomaa et al. 2002). BLL (µg/dL)
Maternal body lead burden and external < 10 BLL every month for first 3 months of placement, or upon change in task to 
lead exposure influence the lead concentra­ higher exposure, then BLL every 6 months 
tion of breast milk (Ettinger et al. 2006; If BLL increases ≥ 5 µg/dL, evaluate exposure and protective measures. 
Gulson et al. 1998). The few studies that Increase monitoring if indicated 
See Table 1 for pregnancy concerns used ultraclean techniques and mass spec­ 10–19 As above for BLL < 10 µg/dL, plus:
trometry analyses report human breast milk BLL every 3 months 
concentrations ranging from 0.6 to 3% of Evaluate exposure, engineering controls, and work practices
maternal blood lead (Ettinger et al. 2004b; Consider removal (see Table 1) 

Gulson et al. 1998; Manton et al. 2000; Revert to BLL every 6 months after 3 BLLs < 10 µg/dL 

Sowers et al. 2002). Using 1% as a guide, it ≥ 20 Remove from exposure if repeat BLL measured in 4 weeks remains ≥ 20 µg/dL, 
or if first BLL ≥ 30 µg/dL (see Table 1) can be estimated that nursing mothers with a Monthly BLL testing 
blood lead concentration < 20 µg/dL will Consider return to lead work after 2 BLLs < 15 µg/dL a month apart, then 
have breast milk with a concentration monitor as above 
< 2 µg/L, a value that approximates the 
BLL, blood lead level. amount of lead in infant formula (Gulson aLead-exposed means handling or disturbing materials with a significant lead content in a manner that could reasonably 
et al. 2001). A recent randomized clinical be expected to cause potentially harmful exposure through inhalation or ingestion.
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experienced specialist in occupational medi­
cine or medical toxicology. 
Hair lead analysis or measurement of 
urine lead concentration seldom provide 
exposure information of clinical value beyond 
that provided by the history and the measure­
ment of blood lead concentration. Chelation 
initiated exclusively on the basis of hair or 
urine lead levels or chelation of asymptomatic 
individuals with low blood lead concentra­
tions is not recommended. 
Adults with overt lead intoxication will 
generally experience improvement in symp­
toms after removal from lead exposure and 
decline in blood lead concentration. This clini­
cal observation on improvement in overt 
symptoms finds some support from the rela­
tively limited number of studies that have 
examined the impact of naturally declining 
blood lead concentrations on cognitive func­
tion in occupationally exposed subjects 
(Chuang et al. 2005; Lindgren et al. 2003; 
Winker et al. 2006). Improvement or resolu­
tion of neurocognitive or neurobehavioral 
symptoms may sometimes lag the decline in 
blood lead concentration, possibly because of 
the relatively slower removal of lead from the 
central nervous system (Cremin et al. 1999; 
Goldstein et al. 1974). The pace of improve­
ment can be highly variable, and may range 
from weeks to a year or more depending on 
the magnitude of intoxication. Anecdotal expe­
rience and analogy to other forms of brain 
injury suggest a potential role for rehabilitative 
services (e.g., physical therapy, cognitive reha­
bilitation) in enhancing the prospect for recov­
ery, and in demonstrating the capacity for safe 
return to work. Short-term improvement in 
neurocognitive function associated with a 
decline in blood lead concentration does not 
obviate concern that long-term cumulative lead 
exposure may nonetheless have a deleterious 
effect on cognitive reserve, and may accelerate 
age-related decline in cognitive function 
(Schwartz et al. 2005; Weisskopf et al. 2004). 
Additional Management 
Considerations 
With appropriate engineering controls, safe 
work practices, and personal protective equip­
ment, workers without a previous history of 
substantial lead exposure should be able to 
work with lead in a manner that minimizes 
the potential for hazardous levels of exposure. 
For such workers, elevations in blood lead 
concentration that result from unforeseen 
transient increases in exposure will often 
decline promptly once the exposure is con­
trolled. However, in a worker with a long his­
tory of high exposure, redistribution of lead 
from a large internal skeletal burden may 
result in a prolonged elevation of blood lead 
concentration despite marked reductions in 
external lead dose. 
The recommendations for management of 
adult lead exposure contained in this article are 
derived from consideration of risks to health, 
and have not been the subject of a cost-benefit 
analysis examining economic feasibility or 
social impacts. Nonmedical, socioeconomic 
factors will likely influence how workers, 
employers, and clinicians respond to the rec­
ommendations. In particular, the blood lead 
concentrations for which some major interven­
tions, such as removal from lead exposure, are 
recommended are considerably lower than 
those explicitly specified in the current OSHA 
lead standards (OSHA 2002). The OSHA 
standards do require an employer to imple­
ment reductions in exposure recommended by 
a physician who determines an employee has a 
“detected medical condition” that places him 
or her at increased risk of “material impair­
ment to health.” This nonspecific provision 
could form the basis for implementation of 
protective workplace action at the lower blood 
concentrations recommended by the authors. 
Nonetheless, clinicians should inform patients 
that such recommendations may be contested 
by an employer or an insurer, and could poten­
tially jeopardize their job benefits or work 
Table 3. Recommended interpretive guidance for clinical laboratories reporting adult blood lead 
concentrations. 
Blood lead level 
(µg/dL) Management recommendations and requirementsa for adults 
< 5 No action needed 
5–9 Discuss health risks 
Reduce exposure for pregnancy 
10–19 Discuss health risks. Decrease exposure. Monitor BLL 161:283–293. 
Remove from exposure for pregnancy, certain medical conditions, long-term risks Den Hond E, Nawrot T, Staessen JA. 2002. The relations
20–29 Remove from exposure if repeat BLL in 4 weeks remains 20 µg/dL between blood pressure and blood lead in NHANES ≥ 
National Health and Nutritional Examination Surv30–79 Remove from exposure. Prompt medical evaluation and consultation advised for BLL > 40 µg/dL J Hum Hypertens 16:563–568. 
OSHA requirements may apply Dietrich KN, Ware JH, Salganik M, Radcliff J, Rogan 
Chelation not indicated unless BLL > 50 µg/dL with significant symptoms Rhoads GG, et al. 2004. Effect of chelation therapy on t
≥ 80 Urgent medical evaluation and consultation indicated neuropsychological and behavioral development of le
OSHA requirements may apply exposed children after school entry. Pediatrics 114:19–2
Chelation may be indicated if symptomatic and/or BLL ≥ 100 µg/dL Ettinger AS, Tellez-Rojo MM, Amarasiriwardena C, Peters
KE, Schwartz J, Aro A, et al. 2006. Influence of mater
BLL, blood lead level. Primary management of lead poisoning is source identification and removal from exposure. A single

 bone lead burden and calcium intake on levels of lead
BLL does not reflect cumulative body burden or predict long-term effects.

 breast milk over the course of lactation. Am J Epidem
aRefer to OSHA general industry and construction lead standards for occupational exposure.

 163:48–56. 
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status. Prudent case management that consid­
ers the worker’s perspective on their unique 
health risks and employment situation will 
usually be advisable. 
Interpretative Guidance for 
Clinical Laboratory Report 
Forms 
Clinical laboratories routinely offer brief 
interpretative guidance on the forms that 
report the result of blood lead concentrations. 
There is considerable variability among labo­
ratories regarding the content of such guid­
ance, and laboratories exercise their own 
discretion regarding the source and detail of 
the information they provide. Unlike the 
management guidance chart for childhood 
blood lead concentrations published by the 
CDC (2002), which is often reproduced by 
clinical laboratories, no corresponding CDC 
guidance exists for blood lead concentrations 
measured in adults. Notwithstanding the lim­
itations inherent in an abbreviated tabular 
format, Table 3 represents a guidance chart 
for adult blood lead measurements that is 
proposed for use by clinical laboratories. 
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Medical Management Guidelines for Lead-Exposed Adults
Revised 04/24/2007 
Summary: 
Overexposure to inorganic lead continues to be an important problem worldwide.  The
reduction of lead in the U.S. environment, largely accomplished through effective EPA 
regulatory efforts, has resulted in lowering the overall geometric mean whole blood lead level
(BLL) for the general population in the United States from approximately 13 µg/dL (0.63 
µmol/L) in the 1970s to less than 2 µg/dL (0.10 µmol/L) (CDC 2005; NCHS 1984). Lead 
exposure remains a significant public health and medical concern for thousands of children and 
adults exposed primarily through remaining lead-based paint in older housing stock as well as
to workplace exposures, although other sources occur. For children and adults, the role of 
environmental investigation, identification and reduction or elimination of sources of exposure 
remains of primary importance.  While the clinical care of lead-exposed children has been well 
established in the pediatric and public health communities, similar clinical recommendations 
for adults have not been widely available. 
The purpose of this document is to provide useful advice to clinicians caring for adult patients 
who have been exposed to lead, whether at work, at home, through hobbies, in the community, 
through consumer products, retained bullets, or other sources.  This document is derived, in 
part, from the input of an expert panel convened by the Association of Occupational and 
Environmental Clinics (AOEC).  However, three clinical scholars then considered the medical 
evidence submitted by the expert panel and incorporated many of the conclusions reached by 
this panel. This paper, therefore, reflects a general consensus of the clinical views of AOEC 
members, not necessarily the expert panel, particularly in areas where the expert panel had 
been unable to come to consensus.  The following points are emphasized: 
1) Medical care serves as an adjunct to public health and industrial hygiene exposure control.  
Clinicians who evaluate patients with potential lead exposure should have appropriate referral 
mechanisms in place for prevention of further exposure to lead.  Although one goal of health 
care is to remove the patient from exposure, the social consequences of potential disruption of 
housing or of income may be important and must be considered by the clinician. 
2) Current occupational standards are not sufficiently protective and should be strengthened.  
Although the federal Occupational Safety and Health Administration’s (OSHA) lead standards 
have provided guidance that has been beneficial for lead-exposed workers, these regulations
have not been substantially changed since the late 1970s and thus are primarily based on health 
effects studies that are well over three decades old.   There is an urgent need to revise them. 
3) The clinical guidelines presented here are appropriate for adults, recognizing that younger 
adults, particularly those in workplace settings, may share developmental risks that place them
closer to pediatric populations, and that maternal exposure, whether in the workplace or in the 
























4) Clinicians should feel free to contact any of the member AOEC clinics for additional
telephone advice, and are encouraged to refer patients when appropriate. 
Background 
Lead is used in over 100 industries.  Job activities known to involve the use or disturbance of 
lead include: handling of lead-containing powders, liquids, or pastes; production of dust or 
fumes by melting, burning, cutting, drilling, machining, sanding, scraping, grinding, polishing, 
etching, blasting, torching, or welding lead-containing solids; and dry sweeping of lead-
containing dust and debris. Adults also encounter lead in environmental settings and through 
activities such as home remodeling, particularly in homes built before 1978 that contain lead-
based paint, lead-contaminated consumer products, traditional remedies, moonshine whiskey, 
hobbies, such as melting lead sinkers or use of target ranges, from retained bullets, and through
other sources. 
Lead is not an essential element and serves no useful purpose in the body.  A substantial body 
of recent research demonstrates that multiple health effects can occur at levels once considered 
safe. The routes of exposure for inorganic lead are inhalation and ingestion.  Once absorbed, 
lead is found in all tissues, but eventually 90% or more of the body burden is accumulated (or 
redistributed) into bone with a biological half-life of years to decades.  Lead is excreted
primarily in the urine.  Lead does not remain in the bone permanently but is slowly released 
back into the blood. 
The “dose” or quantity of lead that a person receives will be determined by the concentration 
of lead in the air and/or the amount ingested as well as the duration of such exposure.  The 
BLL remains the predominant biological marker used in clinical assessment, workplace 
monitoring, public health surveillance, and regulatory decisions regarding removal from
exposure under the OSHA lead standards. 
Research tools capable of measuring cumulative lead exposure, such as the use of in-vivo K-
shell X-ray fluorescence (K-XRF) instruments for the rapid, non-invasive measurement of lead 
in bone, have expanded recent understanding of long-term consequences from lead exposure
on a population basis.  These studies have demonstrated adverse effects of lead exposure 
across populations, including on neurologic, reproductive and renal function and on blood 
pressure, that occur at extremely low levels of exposure and appear not to have a threshold. 
However, because inter-individual differences are greater than population differences at lower
lead levels, these effects are less important for clinical evaluation than they are for public
health policy. The preponderance of the evidence for adverse effects at levels of exposure far 
below those currently permitted by OSHA speaks forcefully for an immediate reduction in 
permissible exposure levels in the workplace and for enhanced public health attention to those
sources, including among self employed individuals, not currently subject to OSHA regulation.  
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Because lead interferes with biochemical processes occurring in cells throughout the body,
adverse effects occur in multiple organ systems.  The non-uniformity of symptoms that appear
in exposed individuals, as well as a growing body of epidemiologic studies, suggest that wide 
variation exists in individual susceptibility to lead poisoning.  Early overt symptoms in adults 
are often subtle and nonspecific, involving the nervous, gastrointestinal, or musculoskeletal 
systems.  High levels of exposure can result in delirium, seizures, stupor, coma, or lead colic.  
Other overt signs and symptoms include hypertension, peripheral neuropathy, ataxia, tremor, 
gout, nephropathy, and anemia. In general, symptoms increase with increasing BLLs.   
In addition to exposure that occurs from external sources, carefully performed lead isotope 
studies demonstrated that pregnancy and lactation are both associated with large increases in 
the release of lead from the maternal skeleton (Gulson et al. 2003).  High levels of lead in 
women’s bones at the time of childbirth corresponded to lower birth weight (Gonzalez-Cossio 
et al. 1997), lower weight gain from birth to one month of age (Sanin et al. 2001), and reduced 
head circumference and birth length (Hernandez-Avila et al. 2002).  
In males, abnormal sperm morphology and decreased sperm count have been observed at BLLs 
of approximately 40 µg/dL (1.93 µmol/L) or less (Telisman et al. 2000). In the absence of 
effects on sperm count or concentration, the impact of paternal lead exposure on reproductive 
outcome is uncertain. 
Recent research has examined several genetic polymorphisms that may influence lead uptake, 
distribution, and target organ toxicity.  However, at this point in time, research findings are 
insufficient to conclusively identify subpopulations that may have increased susceptibility to 
lead toxicity based on specific genotypes.  Other factors that might modify the risk of lead
toxicity include pre-existing disease affecting relevant target organs (such as diabetic 
nephropathy or borderline hypertension), nutritional deficiencies (particularly of dietary 
cations such as iron and calcium), ethnicity, and aging. 
CLINICAL ASSESSMENT OF LEAD EXPOSURE   
Taking a detailed medical and occupational/environmental history is a fundamental step in the
assessment of a person with lead exposure.  It is important to ask about exposure to lead in 
current and previous jobs (Table 1), protections used, biological and air monitoring data,
hygiene practices, knowledge and training, hobbies, traditional medications, moonshine use 
and other non-occupational sources (Table 2). A medical and reproductive history is essential 
in identifying individuals at increased risk of adverse health effects from lead exposure.  Table 
3 summarizes symptoms and target organ toxicity of lead at progressive BLLs. Physical exam
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Blood Lead Level and Zinc Protoporphyrin 
The BLL is the most convenient and readily interpretable of the available lead biomarkers. It is
mainly an estimate of recent external exposure to lead, but it is also in equilibrium with bone 
lead stores. The BLL alone is not a reliable indicator of prior or cumulative dose or total body
burden; nor can a single BLL be used to confirm or deny the presence of chronic health effects 
thought due to lead exposure. The “normal” or “reference range” BLL is less than 5 µg/dL 
(0.24 µmol/L) for more than 90% (CDC 2005) of the adult population.  When interpreting the 
BLL, key questions are whether the exposure has been 1) of short-term or long-term duration; 
2) recent or in the remote past; and 3) of high or low intensity.   
Erythrocyte protoporphyrin IX (EP), which can be measured as free EP (FEP) or zinc 
protoporphyrin (ZPP), is a measurement of biological effect and is an indirect reflection of lead 
exposure.  Lead affects the heme synthesis pathway.  Increases in EP or ZPP are not detectable 
until BLLs reach 20 to 25 µg/dL, (0.97-1.21 µmol/L) followed by an exponential rise relative 
to increasing BLLs. An increase in EP or ZPP usually lags behind an increase in BLL by two 
to six weeks. 
Periodic testing of BLL and ZPP, called biological monitoring, is required by the OSHA lead 
standards for workers exposed to significant levels of airborne lead.
Other Laboratory Tests 
Depending on the magnitude of lead exposure, a complete blood count, serum creatinine, blood 
urea nitrogen, and complete urinalysis may be indicated.  Evaluation of reproductive status 
may be pertinent for some lead-exposed adults.   
 It is important to check BLLs of family members, particularly children, of lead-exposed 
individuals.  Lead workers may unwittingly expose their families to lead dust brought home on 
clothes, shoes and in cars. 
Except for rare circumstances, there is little or no value in measuring lead in urine or hair. 
Because of the pharmacokinetics of lead clearance, urine lead changes more rapidly and may 
vary independently of BLL. Urine lead is less validated than BLL as a biomarker of external 
exposure, or as a predictor of health effects.  Lead in hair may be a reflection of external 
contamination rather than internal lead dose; laboratory analysis is not standardized. 
EXPOSURE INVESTIGATION 
The occupational and environmental exposure history is the first step in identifying the source 
of the lead exposure. Both because the cornerstone of intervention is source removal or 
reduction and because others may be at risk from exposure, the first step is to identify the
source. A list of US Environmental Protection Agency accredited laboratories is available at 
http://www.epa.gov/lead/nllaplist.pdf. Assistance, especially for non-occupational problems 
such as herbal remedies, candy, moonshine etc. is available from the local and/or state health


















The clinician, with the patient’s permission, should also contact the employer for further 
exposure information, such as air level monitoring, biologic monitoring and Material Safety 
Data Sheets (MSDSs). Work related exposure measurements should be readily available to the 
clinician.  The federal OSHA standards are available at 
http://www.osha.gov/SLTC/lead/standards.html. Small businesses can obtain information at
http://www.osha.gov/dcsp/smallbusiness/index.html 
HEATH-BASED MEDICAL MANAGEMENT
The single most important aspect of treating lead poisoning is removal from exposure, yet 
there may be important socioeconomic constraints for a given individual that limit this
approach. For this reason, the panel and the AOEC petition OSHA to update the requirements 
of the current lead standards and urge clinicians to engage public health and industrial hygiene 
professionals whenever lead exposure is suspected. 
Documented health risks and medical management recommendations are summarized in Table 
4. The table presents recommendations for a broad range of BLLs.  Although the BLL range is 
categorized in discrete steps, the outcomes will not neatly conform to these arbitrary divisions, 
and expectation of health effects in the BLL categories will also be influenced by cumulation 
of dose. For example, clinical peripheral neuropathy can be present at the high end of the BLL 
40 to 79 μg/dL (1.93-3.81 µmol/L) range, while it would not be expected to occur from lead 
exposure at the low end of the same range. The table is intended to assist clinicians in 
discussing the short-term and long-term health risks of lead exposure with their patients. 
There are other instances where removal from lead exposure is warranted that are consistent 
with the OSHA lead standards. In addition to specific “trigger” BLLs for medical removal 
protection (MRP), under the OSHA lead standards (e.g. BLL 50 µg/dL (2.41 µmol/L) or 
greater) the physician can remove an individual from lead work due to a medical condition 
which places the employee “at increased risk of material impairment to health from exposure 
to lead”, chronic renal dysfunction (serum creatinine > 1.5 mg/dL (133 µmol/L) for men, > 1.3 
mg/dL (115 µmol/L) for women, or proteinuria),  hypertension, neurological disorders, 
cognitive dysfunction, and pregnancy. 
Central nervous system effects may have a delayed onset and may sometimes persist well after 
the BLL has dropped below the BLLs at which the OSHA lead standards permit return to 
work. These persistent effects could negatively impact work performance and safety in certain 
jobs. Anecdotal evidence, and analogy to other neurotoxic injury, suggests that individuals 
who develop overt neurological signs and symptoms from lead exposure above that 
permissible under current OSHA regulations may benefit from rehabilitative measures (e.g., 
physical therapy, cognitive rehabilitation) that have been used effectively in patients with other 






















program may enhance the prospect for recovery, and may demonstrate the worker’s capacity to 
safely return to work. 1 
Medical Surveillance
Medical surveillance is an essential part of an employer’s lead safety program and includes
biological monitoring with periodic BLL testing, medical evaluation, and treatment if needed, 
and intervention to prevent or control identified exposure.  The BLL is the best available 
measure of total exposure from both inhalation and ingestion.  Biological monitoring provides 
feedback to the employer and worker about the efficacy of workplace controls, helps avoid 
surprises, and saves costs such as medical removal.
Currently, under the OSHA standards, a worker must be included in a lead medical
surveillance program if his/her airborne lead exposure is 30 µg/m3 (eight-hour time-weighted 
average) or higher for more than 30 days per year.  The panel believes that the trigger for 
medical surveillance should not rely solely on air monitoring results; instead, workers should 
be included in a medical surveillance program whenever they are handling or disturbing
materials with a significant lead content in a manner that could reasonably be expected to 
cause potentially harmful exposure through inhalation or ingestion.   
A medical surveillance program with increased frequency of BLL testing and early 
intervention for all lead-exposed workers is recommended to reduce health risks. The panel 
does not recommend routine ZPP testing as an early biomarker of lead toxicity; however, ZPP 
measurement is required by OSHA for certain levels of lead exposure.  New employees and 
those newly assigned to lead work should have a preplacement lead medical examination and 
BLL test, followed by periodic BLL testing, blood pressure measurement, and health status 
review. Monthly BLL testing is recommended for the first three months of employment for an 
initial assessment of the adequacy of exposure control measures. Subsequently, testing 
frequency can be reduced to every six months as long as BLLs remain below 10 µg/dL (0.48 
µmol/L). Any increase in BLL of 5 µg/dL (0.24 µmol/L) or greater should be addressed by re­
examining control measures in place to see where improvements should be made and by 
increasing BLL monitoring if needed.  If the task assignment changes to work with 
significantly higher exposures, the initial BLL testing schedule of monthly tests for the first 
three months at this task should be repeated.   
The above schedule for BLL testing may be inadequate for certain situations where the 
exposures are very high and/or highly variable.  In these situations, the BLL testing schedule 
should be tailored to address the special risks of different types of work and exposures.  For 
example, a construction worker may have very high, intermittent exposures in contrast to 
someone working in a battery plant or other general industry setting with significant exposures 
but less day-to-day variability. Employees assigned to tasks where exposures are extremely 










     










i.e., at least monthly. In general, it is a good idea to do BLL testing at peak exposures to assess 
controls and, specifically for the construction trades, to test pre-, mid-, and post-job. 
Because of the significant reduction of lead in the general environment, new workers enter lead 
jobs with very low BLLs while others who have worked with lead often have much higher 
BLLs and body burdens. With increased biological monitoring frequency to ensure that low 
BLLs are maintained, it is possible that some workers with lead-related health risks may be 
able to work safely in a lead-exposed environment.  All lead-exposed workers should receive 
education about the health effects of lead and prevention information from the clinician and the 
employer, and they should be provided necessary protections including protective clothing, 
clean eating areas, and hygiene measures such as wash-up facilities and/or showers to prevent 
both ingestion of lead and take-home exposures. 
Chelation Therapy 
Primary management for adult lead poisoning is identification of the lead source and cessation 
of exposure. In adults, chelation therapy generally should be reserved for individuals with high 
BLLs and/or significant symptoms or signs of toxicity.  There is no evidence-based guidance 
in this regard because of lack of appropriate studies.   
Based upon the clinical experience and judgment of panel members, the following general 
recommendations concerning chelation are offered: chelation therapy is recommended for 
adults with BLLs 100 µg/dL (4.83 µmol/L) or greater, can be strongly considered for BLLs 80 
to 99 µg/dL (3.86-4.78 µmol/L), and possibly considered for BLLs between 50 and 79 µg/dL 
(2.41-3.81 µmol/L) in the presence of lead-related symptoms.  BLLs greater than 100 µg/dL 
(4.83 µmol/L) almost always warrant chelation as they are usually associated with significant 
symptoms and may be associated with an incipient risk of encephalopathy or seizures. These 
are general recommendations and clinicians may vary appropriately from these 
recommendations depending upon circumstances.  Adults with a very high BLL (e.g., 90 
µg/dL (4.34 µmol/L)) may remain asymptomatic.  Oral chelation has largely supplanted
parenteral agents. Chelation therapy relies on enhancing renal excretion, and remobilization of 
lead from other body stores may occur. Guidance on administration of chelating agents is 
available in several publications (e.g. Kosnett 2004).  Clinicians unfamiliar with chelation 
protocols are encouraged to contact AOEC clinics (http://www.aoec.org/directory.htm or 1­
888-347-2632) or with other physicians experienced in treating adults with lead poisoning for 
additional advice prior to instituting treatment. 
On a population basis it is important to reduce fetal exposure to lead, and maternal lead levels
less than 5 µg/dL are optimal.  However, laboratory measures are not absolutely precise, and 
clinical judgment is needed in every patient encounter.  Chelation should be used during 
pregnancy ONLY to protect the life and health of the mother and ONLY if the potential benefit 
to the mother justifies the potential risk to the fetus.  This decision will need to be made on a 
case by case basis by the attending physician. Because of the increase in lead mobilized from
maternal bone during pregnancy, clinicians should be aware that maternal blood lead levels 






















exposure. Women with a history of long-term lead exposure or prior elevated BLL's should be 
monitored regularly during pregnancy for BLL elevation. If the occupational history or clinical
evaluation suggests elevated bone lead stores, clinicians may wish to counsel patients on 
delaying conception until the risk of mobilization of lead from bone depots has been reduced.   
Prophylactic chelation therapy of lead-exposed workers, to prevent elevated BLLs or to 
routinely lower BLLs to pre-designated concentrations believed to be “safe,” is prohibited by 
OSHA. Non-traditional uses of chelation therapy are not advised.  There is no established 
basis to initiate chelation based on results of hair analysis or, in most cases, urine lead levels 
nor for chelation of asymptomatic individuals with low blood lead concentrations.  Chelation 
should be used during pregnancy only if the potential benefit justifies the potential risk to the 
fetus. Breast feeding during chelation therapy is not recommended.  The effect of chelating 
agents on the fetus and newborn is unknown. 
Pregnancy and Breast Feeding Concerns 
Prevention of fetal and postnatal lead exposure of breastfed infants requires identification and 
control of sources of environmental and occupational lead exposures (both endogenous and 
exogenous) for pregnant and lactating women.  The CDC has established 10 µg/dL (0.48 
µmol/L) as a BLL of concern in children (CDC 2002). 
Because fetal blood contains approximately 80% of the blood lead concentration of the mother, 
and because of the risk of spontaneous abortion, the panel’s recommendation is that the
mother’s BLL should be kept below 5 µg/dL (0.24 µmol/L) from the time of conception 
through pregnancy. For women with a history of lead exposure, calcium supplementation 
during pregnancy may be especially important and may thus minimize release of lead from
bone stores and subsequent fetal lead exposure. 
In a recent prospective study, umbilical cord BLL and maternal bone lead measured shortly 
postpartum were independent risk factors for impaired mental development of the infants
assessed at 24 months of age, even after controlling for contemporaneous BLL (Gomaa et al.
2002). Long-term prospective studies suggest that the adverse neurodevelopmental effects of
prenatal lead exposure may not persist into adolescence if early postnatal exposure falls to 
background levels (Bellinger et al. 1990, 1992; Tong et al. 1996).  However, maternal BLL 
measured during pregnancy has been associated with alterations in brainstem auditory response 
at in the offspring at age five (Rothenberg et al. 2000), and in retinal response at age 10 
(Rothenberg et al. 2002b). 
Lead does not concentrate in breast milk because it does not bind to nor dissolve in fat; thus, 
levels of lead are generally higher in a mother’s blood than in her milk.  Lead in human breast
milk appears to be well-absorbed by breast fed infants.  Nevertheless, breast feeding should be 
encouraged in most situations since the benefits generally outweigh the negatives.  Decisions 

















If elevated maternal blood lead is suspected or demonstrated, the source(s) of lead exposure in 
the mother’s diet, home, and work environment should be identified and mitigated.  Also, the 
clinician should monitor infant BLLs during the early weeks of breast feeding.  Only upon 
detection and elimination of all other suspected lead sources without corresponding reduction 
of infant BLL should cessation of breast feeding be advised. 
Retained Bullet
Gunshot injuries to the head, face, and neck may be associated with swallowed bullets, 
fragments, or pellets, which result in a rapid increase in blood lead in the first days following 
injury. After detection of bullet fragments in the gut with X-rays, efforts to promote
gastrointestinal decontamination may result in a gradual reduction of blood lead over the 
following weeks. Retained bullets or fragments, particularly those in joint spaces, are risk 
factors for elevated BLL after injury.  Decisions to remove bullet fragments imbedded in tissue
should be made in consultation between the treating physician and the surgeon.  Individuals 
with retained bullets should receive baseline and periodic blood lead testing to monitor their 
lead status. Follow-up blood lead levels may not be needed if the bullets are in muscle tissue 
and physicians are sure the lead fragments have not migrated from muscle into tissues more 
likely to allow lead uptake. 
CONCLUSIONS 
AOEC offers these Guidelines as a resource for health care providers, public health 
professionals, employers, and others to utilize in providing medical management of lead-
exposed adults. In this document, the panel has summarized the current scientific evidence
concerning the non-carcinogenic adverse health effects in adults from exposure to inorganic 
lead. 
The toxic effects of lead can occur without overt symptoms.  A substantial body of recent 
research demonstrates a high probability that lead exposure at levels previously thought to be 
of little concern can result in an increased risk of adverse chronic health effects if the exposure
is maintained for many years, thereby resulting in a progressively larger cumulative dose.  
Such effects may include elevations in blood pressure and increased risk of hypertension, 
kidney disease, cognitive dysfunction and/or accelerated declines in cognitive function, and 
reproductive risks. 
Prevention of lead exposure should remain the primary goal of health care providers, public 
health professionals, and employers.  Biological monitoring, mainly by periodic measurement 
of blood lead levels (BLLs) for adults engaged in activity with potential exposure to lead, 
should be conducted routinely to assess the efficacy of primary prevention and to guide the 
clinician in determining whether exposure has become excessive.  Clinicians are encouraged to 
advise patients of the risks associated with any elevation of lead level and to advocate strongly 













Jobs and Industries with Potential Lead Exposure 
General Industry 
Lead production or smelting 
Brass, bronze, copper, or lead foundries 
Ammunition/explosives production
Scrap metal handling 
Firing ranges 
Machining or grinding lead alloys 
Manufacture of radiation shielding 




Battery manufacturing or recycling 
Automotive radiator repair 
Lead soldering 
Ceramic manufacturing 
Cable/wire stripping, splicing or production 
Rubber manufacturing 
Plastics manufacturing
Leaded glass manufacturing 
Paint/pigment manufacturing
Construction 
Renovation, repair or demolition of structures 
with lead paint 
Welding or torch-cutting painted metal 
Sandblasting, sanding, scraping, burning, or 
disturbing lead paint 
Use or disturbance of lead solder, sheeting, 
flashing, or old electrical conduit 
Plumbing, particularly in older buildings 
194 
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Non-occupational and Environmental Sources of Lead Exposure 
Remodeling or painting  pre-1978 housing Lead solder in stained-glass artwork 
Peeling paint Lead-soldered cans
Ethnic medicines or folk remedies (e.g., Lead-contaminated candies 
azarcon, greta, pay-loo-ah, kandu, some Backyard scrap metal recycling Ayurvedics) 
Moonshine (liquor from a homemade still)Pica (ingestion of lead-containing nonfood 
items, e.g., soil or ceramics, plaster, or paint Antique pewter plates, mugs, utensils, toys 
chips) Imported brass or bronze kettles, cookware 
Retained lead bullet or fragments  Lead-glazed tableware or cooking vessels 
Melting lead for fishing weights, bullets, or toys Leaded crystal tableware 
Imported vinyl miniblinds Mine tailings
Recreational target shooting Beauty products such as kohl eye make-up, 
Lead-contaminated drinking water supply certain hair dyes 
Using lead glazes for ceramics 
Painting/stripping cars, boats, bicycles 
195 
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Health Effects to Lead Exposed Adults by Blood Lead Level 
Blood Lead Level (μg/dL) (µmol/L)
5-9(0.24-0.43) 10-19(0.48-0.92) 20-39(0.97-1.88) 40-79(1.93-3.81) ≥ 80(≥ 3.86)
‣ Possible ‣ Possible ‣ Spontaneous ‣ Spontaneous ‣ Spontaneous 
adverse spontaneous abortion abortion abortion 
population abortion 
effects ‣ Reduced newborn ‣ Reduced ‣ Reduced 
suggested by ‣ Reduced newborn birth weight newborn birth newborn birth 
epidemiologic birth weight weight weight
al studies ‣ Possible blood 
‣ Possible blood pressure changes ‣ Non-specific ‣ Non-specific 
pressure changes symptoms symptoms
‣ Possible renal 
‣ Possible renal dysfunction ‣ CNS effects ‣ CNS effects 
dysfunction
‣ Possible non-specific ‣ Sperm effects ‣ Sperm effects 
symptoms  -lowered counts 
-Headache    -abnormal sperm ‣ Peripheral
-Fatigue Neuropathy
-Sleep disturbance ‣ Subclinical 
     -Anorexia peripheral ‣ Hypertension
     -Constipation neuropathy
-Diarrhea 
     -Arthralgia ‣ Possible 
‣ Anemia 
     -Myalgia 
-Decreased Libido 




‣ Possible anemia 




‣ Possible CNS effects damage ‣ Gout 
-Memory and 
attention deficits  ‣ Possible gout 
196 
TABLE 4 
Health Based Management Guidelines 
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Health Based Management Guidelines 
Blood Lead Level (μg/dL) (µmol/L)
5-9(0.24-0.43) 10-29(0.48-1.40) 30-79**(1.45-3.81)** ≥ 80(≥ 3.86)
‣ Lead education ‣ Consider clinical ‣ Lead education ‣ Immediate removal 
-Occupational assessment from lead exposure 
    -Environmental  -History: ‣ Clinical assessment 
-Reproductive         occupational      -History ‣ Refer for immediate/
environmental      -Exam, labs (BUN, Cr,  urgent medical
‣ Follow-up blood         medical CBC)  evaluation and 
lead levels (BLLs)     -Exam, labs -Identify risk factors     consideration  
-Identify risk factors -Family BLLs     of chelation therapy 
-Family BLLs 
‣ Exposure Assessment ‣ Clinical assessment 
‣ Exposure investigation 
-MSDSs ‣ Consultations as ‣ Lead education 
-Air testing appropriate
     -Workplace   
communication ‣ Lead Hazard 
‣ Exposure investigation 
‣ Consider consultations 
Reduction ‣ Consultations 
-Occupational Medicine 
     -Industrial Hygienist 
     -Public Health     
department 
‣ Removal from lead 
exposure** 
‣ Possible chelation for 
‣ Lead hazard reduction 
‣ Medical surveillance 
‣ Lead hazard reduction BLL>50 with signs or symptoms of  toxicity
‣ Consider removal from
lead exposure if 
warranted 
‣ Medical Surveillance 
-Follow-up BLLs 
-Follow-up clinical
‣ Lead education 
assessments 
**Note this is the 
‣ Follow-up BLLs recommendation by 
    (See Medical   AOEC. Consult the 
Surveillance OSHA Standard for the 






   
   
 
  
















These guidelines were adopted in May 2007 following approval by a three fourths 
majority of the AOEC member clinics.  This version of the guidelines supercedes the
prior version approved in December 2005.
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PREGNANCY RISK ASSESSMENT FORM
Instructions: Fill out the information on the first page using the Activity Report. The information on 
this page will be double-checked beginning on Page 2. 
Case Name:____________________________________________________________________ 
Last Middle First 
Expected Date of Confinement (EDC): ______________/_________/_______________ 
Month Day Year 
BLL at case assignment (µg/dL): __________ Test date: ______/______/_______ 
Report date: ______________/_________/_______________ DOB: ________/______/_______ 
Month Day Year Month Day Year 
Address 
Street: Apt#: 
   
City/Borough: State: Zip: 
 
Home telephone number (_______) ________ - ___________  
Work telephone number (_______) ________ - ___________                    Not provided 
Cell telephone number (_______) ________ - ___________                   Not provided 
Prior LPPP Pregnant Woman Case: No Yes 
Prior or Current LeadQuest Child Case: No Yes>> LI #________________________
(18 years or younger) 
Interview Language Information 
Instructions: In the office, the primary language of the pregnant woman should be determined. If 
necessary, an interpreter from the family, the LPPP office, or telephone interpreting services can be 
used to assist in gathering information. 
Please check off the language used by the pregnant woman during the interview and whether an 
interpreter was used: 
Interview language:
English Spanish  Russian Bengali Hindi Haitian-Creole Urdu 
Other:_____________________________ 
Interpreter Used:
No   Yes 
   If yes>> Type of interpreter used:  
 Family member       Friend  Telephone interpreting services 
    LPPP staff      Other:______________________ 
Staff member conducting interview:_________________________  1 
Interview Date: ____/____/________ Time Started: ___________                           
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A. CONTACT INFORMATION 
I would like to make sure the information we have in our records is correct. 
1. What is the exact spelling of your name?
Instructions: Ask for the spelling of the name.
  Confirmed Last Name
  Confirmed First Name 
  Confirmed Middle Name   NA 
2. What is your date of birth? __________/_____________/____________ 
Month Day Year 
3. Please confirm the address where you currently live. 
Instructions: Confirm the address from Page 1.  Check off the confirmed box if information is correct. 
Otherwise write in correct information. 
  Confirmed Street: Apt#:
  Confirmed City/Borough: State: Zip: 
3a. How long have you been living at this address?   
______ year(s) _____ month(s) _____ day(s) 
4. Please tell me your current home telephone number. 
Instructions: Confirm the home phone number from Page 1. Check off the confirmed box if 
information is correct. Otherwise write in correct information. 
  Confirmed Home telephone number: (________) _________ - ___________ 
4a. If you work, please tell me your work number: 
(______) ________ - __________ 
  NA 
4b. If you have a cell phone, please tell me your cell 
number: (______) ________ - __________ 
  NA 
4c. Which phone number is the best to reach you?   Home   Cell  Work 
4d. Which days of the week are the easiest to reach you?
 Mon   Tues  Wed   Thurs   Fri   Sat   Sun   Any day 





      
 










                    
 
             
 
                 
   
 
      
   
 
                    
 
                 
 













State: Zip:                         
 Documents shown Telephone number:  (______) ______ - ____________  No documents shown 
 
ID:___________________________
B. HOUSEHOLD INFORMATION 
Now I’d like to find out about the other people in your household because they may have been exposed to 
lead. 
5. How many children under age 18 live with you?  _____________ 
Instructions: If no child(ren), go to Section C. 
Please give me the name and date of birth of the child(ren). Let’s start with the youngest child. 
Instructions: Write in information. If more than 3 children, write on back of form. 
#1 #2 #3 
Full Name 






Date of Birth _______/_______/________ 
Mo Day Year 
_______/_______/________ 
Mo Day Year 
_______/_______/________ 
Mo Day Year 
Relationship to 
You 
Daughter / Son 
Other:_________________ 
Daughter / Son 
Other:__________________ 
Daughter / Son 
Other:__________________ 
BLL (µg/dL) ___________ ___________ ___________ 
Date of BLL _______/_______/________ 
Mo Day Year 
_______/_______/________ 
Mo Day Year 
_______/_______/________ 
Mo Day Year 
Instructions:  Provide education about blood lead testing for children. 
C. MEDICAL INFORMATION  
I need to write down contact information for your doctor and health insurance. If you have a card, letter 
or bill from the doctor or health insurance, I can copy down the information. 
Instructions: Ask to see card and write down information.  If no information shown, ask for spelling of
name and address. 
6. What is the contact information for your doctor? 
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ID:___________________________
7. Do you currently have any type of health insurance such as PCAP or Medicaid? 
  No >> go to Q. 8   Yes >>   Don’t know >> go to Q. 8
7a. If yes>> Instructions:  Ask to see insurance card and write down information. If no card provided, 
ask for any information available.
Plan Name
ID # 
Additional Information   Card shown 
 No card shown 
8. When was your first doctor or prenatal care 
visit during this pregnancy? ______/_______/________
Month Day Year 
  Don’t know 
8a. When is your next doctor or prenatal care 
appointment?   _______/_____/________
Month Day Year 
  Not scheduled/ 
                Don’t have one 
8b. How far along are you in your pregnancy 
right now? ________________(weeks)   Don’t know 
8c. What is your expected due date? 
  ______/_______/________
Month Day Year 
  Don’t know 
8d. Are you currently taking a prenatal vitamin with calcium? 
  No   Yes 
9. At which hospital do you plan to have your baby? 
Hospital Name:
City/Borough: State: 





      
 
 
                      
   
             
                                                         
  
                
   
 















             
ID:___________________________
10. In the past, were you ever told you had a high blood lead level or were you diagnosed with lead 
poisoning? 
  No >> go to Section D   Yes >>   Don’t know >> go to Section D
If yes >> 
10a. What was the blood lead level? ___________µg/dL   Don’t know 
10b. When was the blood test taken?    _______/_______/________
  Mo  Day    Year   Don’t know 
10c. In what city and state was the 
blood test performed? City: ____________ State:_______ Country:________________ 
10d. Were you pregnant at that time?   No   Yes 
D. DEMOGRAPHIC INFORMATION 
Now, I’d like to learn more about your background.
11. What is the highest grade or year of school you have completed? 
Instructions: Read out the categories. Do not read out Declined to answer.  
  Never attended school or only attended kindergarten 
  Some elementary or primary school 
  Completed elementary or primary school 
  Some high school 
  Completed high school/ high school graduate 
  Some college or technical school 
  College graduate 
  Declined to answer 
12. Which of the following groups best describes your race or ethnicity?  I’m going to first read out all 
the categories. You can tell me more than one category. 
Instructions: Read out all categories first.  Check as many as reported.  
  African American or Black 
  American Indian or Alaska Native 
  Asian 
  Hispanic or Latino 
  Native Hawaiian or Other Pacific Islander 
 White or Caucasian 
Instructions: Do not read aloud. 
  Other group not listed, Instructions: If mentioned, write in response. 
________________________________________ 


















              
    
  

















E. COUNTRY OF BIRTH/ FOREIGN TRAVEL  
Now I have a few questions about where you were born and any trips you may have taken outside of the 
US. This information can help us identify possible ways you may have been exposed to lead.  I am not 
interested in your immigration status. 






  Other country: ______________________________ 
  Declined to answer 
Instructions: If woman was born in Bangladesh, Ecuador, India, Mexico, or Pakistan show list at 
the end of the form (Appendix A). 






  Don’t know >> go to Q. 13b 
Instructions: For ALL women born outside of the US. 
13b. How long did you live there? ____ day(s) ____ month(s) ____ year(s) 
13c. When (what month and year) did you 
come to the US? 
Month: ____________ Year: _________
Instructions: For all women, including US-born women. 
For foreign-born women – read first part of sentence.  For US-born, start from 2nd line: 
14. Since leaving [birth country],
Have you ever spent any time outside of the US? This includes any traveling, visiting family or friends, or 
living in another country. 





      
 
 
 #1 #2 #3 
Country  
When did you stay there?  ____/_____ ___/______ ___/______ 
(start w/ most recent)            Mo/Year          Mo/Year          Mo/Year 
How long did you stay?   Less than 1 month  Less than 1 month  Less than 1 month 
 More than 1 month  More than 1 month  More than 1 month 
 Don’t know  Don’t know   Don’t know  
How often do you travel there?  1x a year  1x a year  1x a year 
 every 2 years  every  2 years  every 2 years 











14a. If yes >> Instructions: Write down all information about time spent outside of US. Ask for all 
visits. If more than 3 times, write below.  
F. IMPORTED REMEDIES, FOODS, SPICES, COSMETICS AND POTTERY 
Now I am going to ask you about some product(s) you may have used or come in contact with, such as 
medications and health remedies, foods and spices.  Some of these products may be made in other 
countries and may contain lead. They could be products or items: 
• sent by friends and family 
• brought back from trips you may have taken 
• bought in local stores 
• or given to you by friends or family 
I want to find out if you used any of these products during the past 12 months. 
Instructions: Ask woman to show you products in the kitchen and medicine cabinets. Take note of 
any product(s) that may contain lead. If Yes to Questions 15 – 18, ask to see product(s). See 
sampling guidelines. Complete Non-Dust Chain of Custody Form. 
15. [Imported Medicines] Have you used any imported…  
Sample 
Product No Yes >> Taken Comments/Observations 
(Yes/No) 
Medicines? (e.g. Products to help    
become pregnant or remedies for Yes / No 
stomach problems) 
Ayurvedics? (e.g. Remedies based on    Yes / No traditional Indian medical system) 
Vitamins?   Yes / No  
Powder or pills?   Yes / No  
Herbs?   Yes / No  
Teas?   Yes / No  










   










    
    
 
 
   
   
  
    
 
   
   
ID:___________________________
16. [Imported Cosmetics] Have you used any imported… 





Cosmetics? (e.g. Eye makeup, 
hair dye) Yes / No 
Deodorant? Yes / No 
Any other imported 
cosmetics?:____________ Yes / No 
17. [Imported Food] Have you eaten any imported… 





Spices? (e.g. Orange or red spices) Yes / No 
Foods? Yes / No 
Snacks or candies? (e.g. Candy 
spiced with chili or sold in clay
pots)
Yes / No 
Any other imported 
food?:__________________ Yes / No 
18. [Imported Pottery] Have you been served food in or eaten from imported, antique or painted… 





Clay pots? Yes / No 
Ceramic dishes, bowls, 
pitchers, or cups? Yes / No 
Any other imported 











          
 




    
    
  
 
   
   
    
 







           
          
ID:___________________________
G. NON-FOOD ITEMS 
Now I’d like to ask you about your eating habits during your pregnancy. Women often crave or have an 
urge to eat many different things when pregnant. Some women eat new foods when they are pregnant; 
some eat things that are recommended during pregnancy by family and friends; and some women also 
eat things that are not considered food. 
19. At any time during your pregnancy, have you eaten, chewed on or mouthed anything that is not food? 
Some examples are paint chips, soil, clay, crushed pottery or other items. 
  No >> go to Section H   Yes >> 
19a. If yes >> Instructions: Write in information in table. 
#1 #2 #3 
Item Name/Description 
Where did you get it? 
For how long have you been eating 
it? ______ wks/mo/yrs ______ wks/mo/yrs ______ wks/mo/yrs 
How often do/did you eat, on 
average? (daily, weekly, monthly) 
How much do you eat, on average? 
Why did you eat it? 
Sample Taken 
No / Yes No / Yes No / Yes 
Comments/Observations 
Instructions: See sampling guidelines and complete Non-Dust Chain of Custody Form. 
H. OCCUPATION AND HOBBIES 
Now I’d like to ask you about the jobs, hobbies or activities of people in the household. 
20. Are you currently working? 
  Yes >> 20a. Please describe the work you do. 
  No >> 20b. Have you worked in the past? 
  No 

























































































































Metal or car battery recycling;



















refinishing, jewelry making, stained 
glass, pottery, ceramics, glass 
blowing; making fishing weights, 





















      
 







    
 
 
   
                   








   
ID:___________________________
I. PAINT HAZARDS 
22. In the past 12 months, has there been water damage, deteriorated plaster or paint in this home? 
  No >> go to Q.23   Yes >>   Don’t know >> go to Q.23
22a. If yes >> Can you please show me and describe the damage? 
Location/Room 
Describe Damage 





23. In the past 12 months, has there been any renovation or repair work at your current address, at an 
address where you lived previously or another address where you have spent time? 
  No >> go to Q.24   Yes >>   Don’t know >> go to Q.24












24. Do you plan to stay at this current address after your baby is born? 







      
 
 
         
  
                               
              













J. ALTERNATE CONTACT 
Finally, I would like to ask for a contact person in case we cannot reach you.
25. Is there another person, like a family member or friend, who lives at a different address, whom we
could contact? 
  No >> go to Q. 26   Yes >> 
25a. What is this person’s relationship to you?
  Husband   Boyfriend  Mother   Father   Brother   Sister   Aunt 
  Uncle   Grandmother   Grandfather   Other: _______________________ 
25b. Please tell me his/her name and telephone number? 
Alternate contact’s last name 
Alternate contact’s first name 
Home number (_______) ________ -____________      Not provided 
Work number (_______) ________ -____________      Not provided
Cell number (_______) ________ -____________      Not provided
Instructions: Inform woman that she should notify alternate contact that we may contact him/her but 
only if we cannot get in touch with her. 
26. Is there anything else you would like to tell me?  
Instructions: Ask if there are any questions. 
  No   Yes >>_______________________________________________________
Time Ended: ______________ 
Visual Inspection
Now I need to look around your home for possible sources of lead exposure. I may need to take
some samples. The results of the tests will be provided to you as soon as they are available. 





      
 
 
             
    
      
         
         
   
    
    
     
   
 
 
     
     
ID:___________________________
SUMMARY 
Instructions: Check all those that apply. Then, ask if there are any questions. 
Potential Lead Exposure
Yes No 
    Emigrated from or traveled to a foreign country with significant lead contamination 
    Used imported health remedies, food or spices  
    Used imported pottery or cosmetics 
    Ate, chewed or mouthed non-food items
    Participated in an activity that may involve lead exposure 
    Present during repair work that disturbed paint 
Samples 
Yes No 
    Imported health remedy/food/spice sample taken
    Imported pottery or cosmetic sample taken
    Nonfood sample(s) taken 
Missing Information 
Yes No 
    Doctor’s contact information needed


















   
ID:___________________________
Counseling and Education
Follow up with your doctor 
 How often you will need a blood lead test is based on the results of your previous blood tests as well
as your risk for further exposure. 
 Discuss breastfeeding with your doctor. Breastfeeding is generally considered safe in most cases.   
Eat a healthy diet during pregnancy 
 It is important to eat foods with enough calcium, iron and vitamin C. 
 Talk to your doctor to make sure you are getting enough of these nutrients. Your doctor may suggest 
changes to your diet or may prescribe a supplement to help you get enough of these nutrients. 
Reduce your exposure to lead 
 Avoid using medicines, spices, foods or cosmetics from other countries. They are more likely to 
contain lead than products made in the United States.
 Avoid using clay pots and dishes from other countries to cook, store or serve food. Do not use 
pottery that is chipped or cracked. 
 Never eat non-food items such as clay, soil, pottery or paint chips. 
 Stay away from any repair work being done in your home. 
 Avoid jobs and hobbies that may involve contact with lead.  
Get other household members tested for lead 
 This is especially important for children younger than 6 years of age, children with developmental 
problems and pregnant women. 
 Older children and adults should be tested if they may have had contact with lead. 
For more information about lead poisoning 
 Speak with your doctor.
 You can contact me at 212-676-6379. 
 Call 311 and ask for the BAN-LEAD information line. 
 Go to www.nyc.gov/lead. 









   
   
    
   
   
   
   
  
       
    
  
   
  






   
  
  
     
   
   
    
   
     
   
    
    
  
     
 
 
   
ID:___________________________
APPENDIX A: Question 13a. 
Instructions: Please show this list to the woman and ask her to tell you/point to the area where she was born. 
Then return to Q.13a on page 6 and write in name of area. If the area is not on the list, please write in the area 
and ask for the spelling. 
Mexico 
  Aguascalientes   Guerrero   Quintana Roo 
  Baja California   Hidalgo   San Luis Potosí 
  Baja California Sur   Jalisco   Sinaloa
  Campeche  México   Sonora 
  Chiapas  Michoacán (de Ocampo)   Tabasco 
  Chihuahua  Morelos   Tamaulipas 
  Coahuila (de Zaragoza)   Nayarit   Tlaxcala 
  Colima   Nuevo Léon   Veracruz (-Llave) 
  Distrito Federal   Oaxaca   Yucatán
  Durango   Puebla   Zacatecas
  Guanajuato   Querétaro (de Arteaga)   Other (specify):_________________ 
Ecuador 
  Azuay   Los Ríos 
  Bolívar  Manabí 
  Cañar  Morona-Santiago 
  Carchi   Napo 
  Chimborazo   Orellana 
  Cotopaxi   Pastaza 
  El Oro   Pichincha 
  Esmeraldas   Sucumbíos 
  Galápagos   Tungurahua 
  Guayas   Zamora-Chinchipe 
  Imbabura   Other (specify):_________________
  Loja
Pakistan 
  Bahawalpur   Lahore   Sahiwal
  Faisalabad   Larkana   Sargodha 
  Gujranwala  Mardan   Shekhupura 
  Gujrat  Multan   Sialkot
  Hyderabad   Okara   Sukkur 
  Islamabad   Peshawar   Sahiwal
  Jhang Maghiana   Quetta   Sargodha 
  Karachi   Rahimyar Khan   Shekhupura 
  Kasur   Rawalpindi   Sialkot
  Sukkur 





      
   
  
   
  
   
  
   
  
  
    
    
  
  
   
 
    
  
 
   
   
    
   
    
   
    
   
   
   
   
   
   
   
   
  
    
    
    
    
    
  





  Bandarban   Narsingdi   Lalmonir Hat 
  Barguna   Jamalpur   Satkhira 
  Barisal   Gopalganj   Narail 
  Bhola   Kishorganj   Rajshahi 
  Brahmanbaria  Madaripur   Bogra 
  Chandpur   Netrakona   Naogaon 
  Chittagong   Rajbari   Nator
  Comilla   Narayanganj   Kurigram 
  Cox's Bazar   Shariatpur   Nawabganj 
  Dhaka   Sherpur   Nilphamari 
  Dhaka   Tangail   Pabna 
  Faridpur   Khulna   Sylhet 
  Feni   Kushtia   Habiganj 
  Gazipur  Magura  Maulvi Bazar 
  Jhalakhati   Khulna   Panchagarh 
  Khagrachari   Meherpur   Sunamganj 
  Lakshmipur  Manikganj   Dinajpur 
  Noakhali   Bagerhat   Rajshahi 
  Patuakhali   Chuadanga   Rangpur 
  Pirojpur   Jessore   Sirajganj 
  Rangamati  Munshiganj   Gaibanda 
 Mymensingh   Jaipur Hat 




  Assam  Mahārāshtra 
  Bihār  Manipur 
  Chandīgarh  Meghālaya
  Chhatisgarh  Mizorām 
  Dādra & Nagar Haveli   Nāgāland
  Damān & Diu   Orissa 
  Delhi   Pondicherry 
  Goa   Punjab 
  Gujarāt   Rājasthān 
  Haryāna   Sikkim
  Himāchal Pradesh   Tamil Nādu 
  Jammu & Kashmīr   Tripura 
  Jharkhand   Uttaranchal 
  Karnātaka   Uttar Pradesh 
  Kerala   West Bengal (Bangla) 
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RISK ASSESSMENT INTERVIEW FORM 
Date:_________________________ Case #: ________________________ 
Child’s Name:_______________________________ Date of Birth:__________________________ 
Parent’s Name(s):____________________________ Person interviewed:______________________________ 
Address: __________________________________________________________________________________ 
Phone # (include area code):____________________ 
1. Are there any other children under the age of six? Yes______ No______
Names: _________________________ ____________________________ 
Have they been tested for lead?  Yes_____ No_____ 
2. How long have you lived at this address?_____________ Own_______ Rent______ 
Year built:______________ 
If rented, landlord’s name, address and phone number:___________________________________________ 
If less than 12 months, list previous address for past 12 months:____________________________________ 
3. Has any renovation of the residence taken place within the past year? Any furniture renovation? Please specify: 
4. Does child spend several hours each week in another location such as a day care facility, grandparent’s home, 
     babysitter’s home, playgrounds, neighbor’s home, other neighborhood areas? If so, what are those addresses?: 
1. __________________________________________ Average time each week:_______hrs. 
2.__________________________________________ Average time each week:_______hrs. 
5. Occupations of adults in household:____________________________________________________________ 
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7. Are there areas of bare soil near the residence?  Yes ____ No ____ 
Is there a sand box or play area near a street or alley, or next to the house or garage?  Yes ______ No ________ 
8. Is car repair done at the residence? Where? _______________________________________________________ 
9. Note the condition of the surrounding neighborhood. Are there areas of potential lead exposure?
10. Where does the child play inside and outside the residence? __________________________________________ 
Where does the child like to hide? _______________________________________________________________ 
11. Has the child been given folk medicines such as: 
Greta (Hispanic) ____ Azarcon (Hispanic) ____  Surman (Asian) _____ Pay-loo-ah(Hmong) _____ 
12. Does the child have contact with or access to: 
pesticides4 __________ car batteries1 ______                                     bullets, gunshot or reloads8 ________ 
solder2 ______ painted, antique or foreign toys5 _____ pewter items9 _______ 
lead sinkers or other fishing  pool cue chalk6 _______ ceramic dishes or food 
supplies ______ colored newsprint7 _______ containers11 _______ 
stained glass3 ______ paint, varnish or supplies10_______
13. Does the child:
     suck the thumb ______  eat soil/mud pies _______ chew/suck on miniblinds _______ 
     put fingers in mouth _____  eat crayons ________ spend time at windows ________ 
eat paint chips ______ chew/suck on matches _______ chew/suck on windowsills or
 pick at paint ______ chew/suck on furniture ______  sashes _______ 
14. Where do parents think lead exposure is occurring? _______________________________________________ 
Foot Note: 
1. Car batteries are made of lead. 
2. Solder used for electrical or plumbing work may contain lead. 
3.  Leaded solder is typically used to hold the stained glass together at the seams. 
4. Some older pesticides may contain lead arsenate, usually in powder form. 
5. Antique toys or those produced in another country may have lead paint. 
6. Some brands of green pool cue chalk may contain lead. 
7. Colored newsprint, more likely glossy print, may be printed with ink containing lead. 
8. Bullets and shot used for reloading are made of lead and the dust from reloading may also be a hazard. 
9. Pewter contains lead.
10. Old paint and varnish may contain lead. 










































Lead-Based Paint Risk Assessment Report 




[RA signature on line (delete this)] 
[RISK ASSESSOR’S NAME], [LICENSE NUMBER (LR####)]




























LEAD RISK ASSESSMENT REPORT 
[ADDRESS]
[CITY, MINNESOTA, ZIP] 
Case: [CASE NUMBER] 
I. AUTHORITY 
Minnesota Statutes 144.9504, subdivision 2, sub-subdivision (a) requires the Minnesota 
Department of Health (MDH) to conduct a lead risk assessment on a property according to the 
venous blood lead level of a child or pregnant female residing at the property. 
II. BACKGROUND
(Pick one of the following paragraphs, delete the rest)
MDH conducted a lead risk assessment at the property located at [ADDRESS] in [CITY], 
Minnesota, on [DATE OF RISK ASSESSMENT]. The property was constructed in [YEAR] and 
is owned by [PROPERTY OWNER NAME, PROPERTY OWNER ADDRESS, PROPERTY
OWNER CITY, STATE, ZIP, PHONE NUMBER]. 
(If unable to determine the year of construction) 
MDH conducted a lead risk assessment at the property located at [ADDRESS] in [CITY], 
Minnesota, on [DATE OF RISK ASSESSMENT]. MDH was unable to determine the year of
construction. The property is owned by [PROPERTY OWNER NAME, PROPERTY OWNER 
ADDRESS, PROPERTY OWNER CITY, STATE, ZIP, PHONE NUMBER]. 
(If unable to determine the year of construction or the phone number of the property owner)
MDH conducted a lead risk assessment at the property located at [ADDRESS] in [CITY], 
Minnesota, on [DATE OF RISK ASSESSMENT]. MDH was unable to determine the year of
construction. The property is owned by [PROPERTY OWNER NAME, PROPERTY OWNER 
ADDRESS, PROPERTY OWNER CITY, STATE, ZIP. MDH was unable to determine the 
phone number of the property owner.] 
III. FINDINGS 





















(Use one of the following sentences: MDH did not observe any dust or debris in the property. OR 




The lead risk assessment was conducted with an x-ray fluorescence (XRF) analyzer, dust wipe 
sampling [and soil sampling]. MDH used a [BRAND AND MODEL] XRF (Serial #####) to 
analyze painted surfaces. The specific testing locations are located in Appendix A. Analytical
results from the XRF testing are located in Appendix B. Dust wipe samples [and soil samples] 
were collected and sent to [LAB NAME, LAB ADDRESS, LAB CITY, LAB STATE, LAB 
PHONE NUMBER, (EPA ID#)] for analysis. The analytical results of the dust wipe samples 
[and soil samples] are located in Appendix C. (If snow cover prevents soil sampling, delete soil 
sampling from the paragraph and add this sentence: Due to snow cover, soil sampling was 
unable to be completed at this time, but will be done as soon as conditions allow. An amended 
report will be issued with the soil sampling results.) 
V. DISCLOSURE REQUIREMENT 
Code of Federal Regulations, title 24, section 35.88, and title 40, section 745.107, requires that a
copy or a summary of the lead risk assessment report be provided to current lessees and future 
tenants if renting the property; or to the purchaser of the property at the time of sale of this 
property. 
VI. RECOMMENDATIONS 
The following table identifies the location, type and severity of lead hazards observed at the 
property. They are prioritized with the items at the top of the table having the most immediate
health impact while those near the bottom of the table will impact health to a lesser extent.
Lead Hazards 
Location Component Color Severity 
Child’s Bedroom All Windows Blue Poor 
Parent’s Bedroom Closet Door Brown Poor 
Living Room All Windows White Poor 
Kitchen Door Casing Green Poor 
Front Porch Floor Red Poor 
Front Porch Railing Red Poor 
Rear Porch Railing Red Poor 
Back Yard Bare Soil N/A Poor 
Parent’s Bedroom All Windows White Intact 
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Kitchen Window Sash by Sink White Intact 
Rear Porch Car Batteries N/A Intact
(Expand or contract the table as necessary. Keep the severity at intact or poor.) 
Areas where lead hazards are identified should be washed with a household detergent and rinsed 
with clean rinse water.
Paint identified in poor condition is a lead hazard. Options to reduce lead hazards on sound or 
non-rotting components include, but are not limited to: 
• Wet scraping and repainting 
• On- or off-site paint stripping 
• On- or off-site component planing 
• Covering with an impermeable material, such as vinyl or aluminum coil stock 
• Component replacement
Options to reduce lead hazards on unsound or rotting components include, but are not limited to: 
• Component repair 
• Component replacement
(If bare soil is a lead hazard, use the following sentence. If no bare soil was observed, delete it)
Bare soil may be covered with sod, wood chips, sand or other non-living material after all visible
paint chips are removed from the bare soil area. 
[LIST OUT ANY OTHER UNUSUAL COMPONENTS AND RECOMMENDATIONS FOR 
THEM i.e. The car batteries on the rear porch should be removed to an area where they are 













XRF Testing Results 
Paint Standard 
> 1.0 milligram per square centimeter (> 1.0 mg/cm2) 
If a paint sample equals or exceeds the standard, it is considered a lead hazard. 
Explanation of Column Headings 
(The following items will have to be edited depending on what the XRF print-out looks like)
XRF# - Machine generated sequence number 
Insp/XRF – Initials of the inspector and the serial number of the machine 
Floor – Floor level 
Wall – Wall side of the room starting with A on the street side and going clockwise 
Room – Room being tested 
Structure (and Feature) – What is being tested 
Substrate – The composition of the tested component 
Condition – Condition of the paint 
Color – Color of the paint 
DI – Depth Index – the larger the number the deeper the lead-based paint layer 
Result – The result of the test 
PbC – The total combined lead in the layers of paint














Dust Wipe and Soil Sample Results 
Dust Wipe Standards 
Floor Wipe – 40 micrograms per square foot (µg/ft2) 
Window Sill – 250 µg/ft2 
Window Well – 400 µg/ft2 
If a dust wipe sample equals or exceeds the standard, it is considered a lead hazard.
See the attached City of Minneapolis Public Health Laboratory Chain of Custody Form for 
sampling results. 
(If soil samples were not collected, delete this)
Soil Standard 
100 parts per million (ppm) 
If a soil sample equals or exceeds the standard, it is considered a lead hazard. 
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LEAD POISONING PREVENTION PROGRAM


Primary Prevention Information Form (PPI) 
Instructions:  Fill out the information on the first page using the Referral Form. The information on this 
page will be double-checked beginning on Page 2. 
Child Name: 
Last                                     Middle                                  First 
BLL (if known) at assignment (µg/dL): Test Date: ______/______/______ 
Mother’s BLL (if known) at delivery: Test Date: ______/______/______ 
Child DOB: ______/______/______ Child Age: 
(Days/wks/mos/yrs) 
Instructions:  Prior to conducting the inspection, the primary language for the visit should be determined. If 
necessary, an interpreter from the family, the LPPP office, or the Language Line can be used to assist in 
gathering information. 
Language scheduled: (Instructions: Check the scheduled interview language.) 
� English � Spanish � Russian � Bengali � Hindi 
� Haitian-Creole � Urdu � Other: ___________________________________ 
Interpreter Scheduled: � No � Yes>> 
If yes >> Type of interpreter scheduled: 
� Family member (specify): ________________________________________ � Friend 
� Language line �  LPPP staff � Other: _____________________________ 
NAME OF INSPECTOR: 
INTERVIEW DATE: TIME STARTED: 
A. CONTACT AND DEMOGRAPHIC INFORMATION 
1. Is this the address where [child’s name] currently lives? 
� Yes >> Continue � No >> Stop >> Determine current address 
I would like to find out your name and make sure the information we have in our records is correct. 
2. What is the exact spelling of your name? 
LAST NAME FIRST NAME 
2a. What is your relationship to [child’s name]? 
� Mother � Father � Grandparent    � Legal Guardian    � Foster Parent>> � Other: __________________ 
LP 124 (6/07) Primary Prevention Information Page 1 of 4 
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LI #: 
3. What is the exact spelling of the child’s full name? Instructions: Ask for exact spelling of name. 
LAST NAME FIRST NAME MIDDLE NAME � NA 
3a. Instructions: Enter child’s sex if known. If sex unknown, ask>> 
Is [child’s name] a boy or a girl?    � Male � Female 
3b. How old is [child’s name]?    Age: _______ (days/wks/mos/yrs) 
3c. When is [child’s name]’s date of birth? ______/______/______ 
Month    Day     Year 
4. Please confirm this address. Instructions: Ask for spelling of street and specific apartment #. 
STREET APT. # 
BOROUGH STATE ZIP 
4a. How long has he/she lived at this address? 
_______ mo(s) and _______ day(s) � Since birth 
5. Please tell me the telephone number of this address: 
Telephone number: ( ________ ) __________ – _______________ 
5a. If you have a cell phone, please tell me your cell ( ________ ) __________ – _______________ � Not Provided 
phone number: 
5b. If you work, please tell me your work phone number: ( ________ ) __________ – _______________ � Not Provided 
5c. Which phone number is the best to reach you? � Home � Cell � Work 
5d. Which days of the week are the easiest to reach you? 
� Mon � Tues         � Wed        � Thurs � Fri � Sat � Sun � Any day 
5e. When is the best time of day to reach you? ____________ � AM � PM � Any time 
6. Which of the following best describes your child’s race or ethnicity? I’m going to first read out all the 
categories. You can tell me more than one category. 
Instructions: Read out all categories first. Check as many as reported. Do not read Refused response out loud. 
� African American or Black � Hispanic or Latino 
� American Indian or Alaska Native � Native Hawaiian or Other Pacific Islander 
� Asian � White or Caucasian 
� Other group not listed, Instructions: Ask to describe and write in response 
________________________________________________ 
� Refused 
7. In what country was [child’s name]’s birth mother born? 
� Don’t know � Refused 
7a. In what country was [child’s name]’s birth father born? 
� Don’t know � Refused 
B. ALTERNATE CONTACT INFORMATION 
I would like to ask for a contact person in case we cannot reach you by telephone. 
8. Is there another adult living at this address whom we can contact, in case we cannot reach you? 
� No � Yes>> 
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8a. If yes >> Please tell me his/her name. Instructions: Ask person to spell name. 
ALTERNATE CONTACT LAST NAME ALTERNATE CONTACT FIRST NAME 
� REFUSED 
8b. What is this person’s relationship ot the child? 
� Mother/Father � Sibling � Aunt/Uncle � None 
� Legal Guardian � Foster Parent � Grandparent � Other: _______________________ 
8c. Is there another person, like a family member or friend, who lives at a different address, whom we 
could contact? 
� No � Yes>> 
8d. If yes >> Please tell me his/her name and telephone number. 
ALTERNATE CONTACT LAST NAME ALTERNATE CONTACT FIRST NAME 
HOME NUMBER WORK NUMBER CELL NUMBER 
(             ) (             ) (             ) 
8e. What is this person’s relationship ot the child? 
� Mother/Father � Sibling � Aunt/Uncle 
� Grandparent � Other: _________________________ 
Instructions: Inform interviewee that she/he should notify alternate contacts that we may contact them if we cannot 
get in touch with the interviewee. 
9. Please give me the name and contact information for the landlord or owner? 
Instructions: Ask interviewee to spell landlord’s name and address. 
MANAGEMENT COMPANY 
LAST NAME FIRST NAME 
STREET APT # 
BOROUGH STATE ZIP TELEPHONE NUMBER 
(             ) 
C. PAINT INSPECTION AND DUST SAMPLING 
10. In which rooms in the house does [child’s name] sleep, play or spend time? 
Instructions: Check off all that apply. 
� Child’s bedroom � Parent’s bedroom � Other bedroom(s) (specify) 
� Living room � Kitchen � Other room(s) (specify) 
Instructions: Make a visual inspection of the unit. Perform inspection as per protocol. Show person area(s) that need 
remediation. 
D. INTERVIEW LANGUAGE 
Interview Language: 
� English � Russian � Hindi � Urdu 
� Spanish � Bengali � Haitian-Creole � Other: _______________________ 
Interpreter used: � No � Yes>> 
If yes >> Type of interpreter used: 
� Family member (specify): ___________________________________________________________________________ 
� Friend �  Language line �  LPPP staff        � Other: ___________________________________________ 


























Follow up with your child’s doctor 
□ Blood lead tests are necessary to monitor your child’s exposure to lead. How often these tests need 
to be done depends on your child’s lead level, length of exposure and risk for further exposure. 
□ Generally, the higher the blood lead level and the longer the exposure, the more time it will take for 
the lead to leave your child’s body, and the longer your child will need to be monitored by your 
doctor. 
Reduce your child’s exposure to lead 
□ Keep your child away from the lead paint hazards noted in your home. Consider having your child 
stay somewhere else while hazards are being corrected. 
□ Wash floors and windowsills often using a damp mop or damp cloth. 
□ Wash your child’s hands, toys, pacifiers and bottles often to remove lead dust, especially before your 
child eats or sleeps. 
□ If someone in your home has a job or hobby that involves contact with lead, have them remove their 
shoes before entering your home. Wash their work clothes separately from family laundry. 
□ Avoid using medicines, spices, foods, cosmetics, jewelry, and painted toys from other countries. 
They are more likely to contain lead than products made in the U.S.A. 
□ Avoid using clay pots and dishes from other countries to cook, store or serve food. Do not use 
pottery that is chipped or cracked. 
□ Do not let your child eat or mouth non-food items that may contain lead or lead dust. 
□ Use cold tap water only for making baby formula or baby cereal, and for drinking or cooking. Let 
water run for a few minutes before you use it. Lead can get into water through old plumbing. 
Help your child to eat healthy 
□ It is important for your child to eat a healthy diet with enough calcium, iron and vitamin C. 
□ Talk to your doctor to make sure your child is eating foods with enough calcium, iron, and vitamin C 
in them. 
Get other household members tested for lead 
□ This is especially important for children younger than 6 years of age, children with developmental 
problems and pregnant women. 
□ Older children and adults should be tested if they may have had contact with lead. 
For more information about lead poisoning 
□ Speak with your doctor






□ Call 311 and ask for the BAN-LEAD information line 
□ Go to www.nyc.gov/lead 
Provide information packet. Ask if there are any questions. 
TIME ENDED:		 DATE: 
SUPERVISOR NAME: 
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NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE 
 

LEAD POISONING PREVENTION PROGRAM 

Child Risk Assessment Form (CRA)P P
PRIMARY ADDRESS 
Child Name: 
Last                                     Middle                                  First 
BLL at case assignment (µg/dL): Drawn Date: ______/______/______ 
Child DOB: ______/______/______ 
Information will be confirmed at the inspection. 
Instructions:  In the office, the primary language for the visit should be determined. If necessary, an interpreter from the 
family, the LPPP office, or telephone interpreting services can be used to assist in gathering information. 
Interview language scheduled: (Instructions: Check off the primary language for the visit.) 
� English � Spanish � Russian � Bengali � Hindi 
� Haitian-Creole � Urdu � Other: ___________________________________ 
Interpreter scheduled: � No � Yes >> 
If yes >> Type of interpreter scheduled: 
� Family member (specify): ___________________________________ � Friend 
� Telephone interpreting services                 �  LPPP staff � Other: _____________________________ 
Name of PHS: Time Started: 
A. ENVIRONMENTAL ADDRESS 
Is this the address where [child’s name] currently lives? 
� Yes >> Continue � No >> Go to supplement form 
B. CONTACT INFORMATION 
I would like to find out the child’s name and make sure the information we have in our records is correct. 
1. What is the exact spelling of the child’s full name? Instructions: Ask for middle name. 
LAST NAME FIRST NAME MIDDLE NAME � NA 
1a. Instructions: Enter child’s gender if known. If gender unknown, ask >> 
Is [child’s name] a boy or a girl?    � Male � Female 
1b. What is [child’s name]’s date of birth? ______/______/______ 
Month    Day     Year 
2. Please confirm the child’s address. Instructions: Ask for spelling of street and specific apartment #. 
STREET APT. # 
CITY/BOROUGH STATE ZIP 
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3. What is the exact spelling of your name? 
LAST NAME FIRST NAME 
3a. What is your relationship to [child’s name]? 
� Mother � Father � Aunt � Uncle � Grandmother � Grandfather � Foster Parent>> 
� Other: ___________________________________ 
3b. Instructions: If foster parent, ask for the following information: 
Please tell me the name and telephone number of the foster agency: 
FOSTER AGENCY PHONE NUMBER � NOT PROVIDED 
4. Please tell me the telephone number of this address: 
Environmental address telephone number: (           ) __________ – _______________ � Not Provided 
4a. If you have a cell phone, please tell me your cell number: (          ) _________ – ____________ � Not Provided 
4b. If you work, please tell me your work number: (          ) _________ – ____________ � Not Provided 
4c. Which phone number is the best to reach you?       � Home � Cell � Work 
4d. Which days of the week are the easiest to reach you? 
� Mon � Tues         � Wed        � Thurs � Fri � Sat � Sun � Any day 
4e. When is the best time to reach you? ____________________ � A.M. � P.M.       � Any time 
4f. Do you reside at this address  � No � Yes 
4g. How long has [child’s name] lived at this address? ______ yr(s) ______ mo(s) ______ day(s)  � Since birth >> go to Q. 5 
If more than 3 months at current address >> go to Q. 5
If less than 3 months at current address >> go to Q. 4h 
4h. In the past 3 months, where else has the child lived? 
STREET APT. # 
CITY/BOROUGH STATE ZIP PHONE NUMBER � NOT PROVIDED 
If prior address is in NYC >> Plan to inspect previous address as supplement. 
C. CHILD’S MEDICAL INFORMATION 
I need to write down contact information for [child’s name]’s doctor and for his/her current health insurance. If you 
have a card, letter or bill from the doctor or health insurance, I can copy down the information. 
Instructions: Ask to see card and write down information. If no information shown, ask for spelling of name and address. 
5. What is the contact information for your child’s doctor? 
CLINIC NAME 
DOCTOR’S LAST NAME FIRST NAME 
STREET CITY/BOROUGH STATE ZIP 
TELEPHONE NUMBER 
� DOCUMENTS SHOWN � NO DOCUMENTS SHOWN 
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6. Does [child’s name] currently have any type of health insurance such as Medicaid or Child Health Plus (CHP)? 
� No >> go to Q. 7 � Yes >> � Don’t know >> go to Q. 7 
If yes >> Instructions: Ask to see insurance card and write down information. If no card provided, ask for any 
information available. 
MEDICAID # OTHER PLAN NAME ID # � CARD SHOWN 
___ – ___ – ___ – ___ – ___ – ___ – ___ – ___ � CARD NOT SHOWN 
7. In the past, were you ever told that your child had a high blood lead level or had your child been diagnosed 
with lead poisoning? 
� No >> go to Q. 8 � Yes >> � Don’t know >> go to Q. 8 
If yes >> 
7a. What was the blood lead level? ________________ µg/dL � Don’t know 
7b. In what city and state was the blood test performed?    City: _________________________ State: ________________ 
8. Has a doctor or other health care provider ever told you that [child’s name] has a learning or behavior problem? 
� No � Yes >> Please describe: _________________________________________________________________________ 
� Don’t know 
Early Intervention 
If child < 36 months of age, offer Early Intervention Program Referral and Information.     � Accepted � Rejected 
CHILD 12 MONTHS OR YOUNGER [If child is older than 12 months, go to Section D.] 
9. Is [child’s name] regularly fed infant formula mixed with tap water?     � No � Yes 
10. Are you [child’s name]’s birth mother? � No >> go to Section D � Yes >> 
10a. If yes >> Did you have a blood test for lead � No >> go to Section D 
when you were pregnant with [child’s name]? � Yes >> � Don’t know >> go to Section D 
10b. If yes >> What was the blood lead level? ________________ µg/dL � Told it was high      � Don’t know 
D. COUNTRY OF BIRTH/FOREIGN TRAVEL 
Now I have a few questions about where [child’s name] was born, lived and any trips s/he may have taken outside of 
the U.S. This information can help us identify possible ways your child may have been exposed to lead. I am not 
interested in [child’s name] or your family’s immigration status. 
11. In what country was [child’s name] born? _______________________________________________________________ 
� Don’t know >> go to Q. 12 � Decline to answer >> go to Q. 12 
Instructions: If child was born in Bangladesh, Dominican Republic, Haiti, Mexico, or Pakistan show list at the end of the form 
(Appendix A). 
11a. Where in [Bangladesh, Dominican Republic, Haiti, Mexico, or Pakistan] was [child’s name] born? 
Bangladesh: Dominican Republic: 
Haiti: Mexico: 
Pakistan: 
� Don’t know >> go to Q. 11b 
Instructions:  For ALL children born outside of the U.S. 
11b. How long did s/he live in that country? __________ (in years) 
11c. When (what month and year) did [child’s name] come to the U.S.?   Month: _________ Year: _________ 
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Instructions:  For ALL children, including US-born children. 
12. In the last 12 months, has [child’s name] spent any time outside of the U.S.? This includes any traveling, 
visiting family or friends or living in another country. 
� No >> go to Q. 13 � Yes >> 
If yes >> Instructions: Write down all information about time spent outside the U.S. Ask for all visits. If more than 
3 times, write below. 
#1 #2                                    #3 
Country 
When did s/he stay there? 
_________/_________ _________/_________ _________/_________ 
(start with most recent) Month      Year Month      Year Month      Year 
_________ Week(s) _________ Week(s) _________ Week(s) How long did s/he stay? 
_________ Month(s) _________ Month(s) _________ Month(s) 
Comments: 
(e.g. How often does s/he travel there?) 
13. Which of the following groups best describes your child’s race or ethnicity? First, I’m going to read out all the 
categories. You can tell me more than one category. 
Instructions: Read out all categories first. Check as many as reported. 
� African American or Black � American Indian or Alaska Native 
� Asian � Hispanic or Latino 
� Native Hawaiian or Other Pacific Islander � White or Caucasian 
Instructions: Do not read aloud. 
� Other group not listed – If mentioned, write in response: 
� Declined to answer 
14. In what country was [child’s name]’s birth mother born? 
� Don’t know � Declined to answer 
14a. In what country was [child’s name]’s birth father born? 
� Don’t know � Declined to answer 
E. PAINT HAZARDS 
15. In which rooms in the house does [child’s name] sleep, play or spend time? 
Instructions: Check off all that apply. 
� Child’s bedroom � Parent’s bedroom � Other bedroom(s) (specify) 
� Living room � Kitchen � Other room(s) (specify) 
� Bathroom � All rooms 
16. Does [child’s name] play or spend time in the building basement, hallways, foyers, stairways, or other areas 
in the building? � No >> go to Q. 17 � Yes >> 
16a. If yes >> Please tell me the area(s) inside the building where your child spends time. 
Instructions: Find out floor and specific area(s) inside the building. 
17. Does [child’s name] play outside in locations where there is bare soil, such as the front or backyard, a 
neighborhood playground, or park? 
� No >> go to Q. 18 � Yes >> 
LP 125 (6/07) Child Risk Assessment Inspection Date: _____/_____/_____
244 
CHILD ID: Page 5 of 12 




Plays in bare soil? � Yes      � No � Yes      � No 
Sample Taken � Yes      � No � Yes      � No 
Instructions: See sampling guidelines. Complete Non-Dust Chain of Custody Form. 
18. In the past 12 months, has there been water damage, deteriorated plaster or paint in this home? 
neighborhood playground, or park? 
� No >> go to Q. 19 � Yes >> � Don’t know >> go to Q. 19 
18a. If yes >> Can you please show me and describe the damage? 
When did this occur? 
Location/Room Describe damage (month/year) Current status 
_________/_________ 
Month Year 
19. In the past 12 months, has there been any renovation or repair work in this home? 
� No >> go to Q. 20 � Yes >> � Don’t know >> go to Q. 20 




When was the work done? (month/year) _________ Month _________ Year _________ Month _________ Year 
Current status 
20. In the past 12 months, has there been any renovation or repair work in other areas of the building or in the 
neighborhood where [child’s name] spends time? 
� No >> go to Q. 21 � Yes >> � Don’t know >> go to Q. 21 





When was the work done? (month/year) _________ Month _________ Year _________ Month _________ Year 
Current status 
21. Does [child’s name] currently spend more than five hours a week anywhere other than this home? 
For example, spending time at a day care center, school, babysitter, or another home. 
� No >> go to Q. 22 � Yes >> � Don’t know >> go to Q. 22 
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21a. If yes >> Please tell me the locations. 
#1 #2                                               #3 
Location/Description 
Children less than 6 yrs � No (SNC) � Yes (SC) � No (SNC) � Yes (SC) � No (SNC) � Yes (SC) 








F. IMPORTED PRODUCTS 
Now I am going to ask you about some product(s) [child’s name] may have used or come in contact with, such as 
medications and health remedies, foods or spices. Some of these products may be made in other countries and 
may contain lead. They could be products: 
● sent by friends and family ● bought in local stores 
● brought back from trips you may have taken ● or given to you by friends or family 
I want to find out if [child’s name] used or was given any of these products during the past 12 months. 
Instructions: Ask parent/guardian to show you products in the kitchen and medicine cabinets, Take note of any product(s) that may 
contain lead. If yes to Questions 22-25, ask to see product(s). See sampling guidelines. Complete Non-Dust Chain of Custody Form. 
22. [Imported Medicines] Has your child been given imported... 
Sample 
Product No Yes >> Taken Comments/Observations 
Medicines? (e.g. Remedies for teething, 
 �, stomachaches or diar Yes  �colic, fever hea) No 
Ayurvedics? (e.g. Remedies based on 
� Yes  �traditional Indian medical system) No 
Vitamins? � Yes � No 
Powder or pills? � Yes � No 
Herbs? � Yes � No 
Tea? � Yes � No 
Any other imported remedies?___________ � Yes � No 
23. [Imported Cosmetics] Has your child used any imported... 
Sample 
Product Taken Comments/Observations 
Cosmetics? (e.g. Eye makeup) � Yes � No � Yes � No 
Deodorant? (e,g, Litargirio) � Yes � No � Yes � No 
Any other imported � Yes � No 
� Yes � No 
cosmetics?____________________ 
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24. [Imported Food] Has your child eaten any imported... 
Sample 
Product Taken Comments/Observations 
Spices? (e.g. orange or � Yes � No 
 Yes � No red spices) �
Foods? � Yes � No � Yes � No 
Snacks or candies? (e.g. candy � Yes � No 
spiced with chili or sold in � Yes � No 
clay pots) 
Any other imported � Yes � No 
� Yes � No 
foods?________________________ 
25. [Imported Pottery] Has your child been served food in or eaten from imported, antique or painted... 
Sample 
Product Taken Comments/Observations 
Clay pots? � Yes � No � Yes � No 
Ceramic dishes, bowls, pitchers, � Yes � No � Yes � No 
or cups? 
Any other imported � Yes � No 
� Yes � No 
containers? ___________________ 
G. NON-FOOD ITEMS 
Some products that children play with or wear, such as toys, crayons, jewelry, or candy wrappers, may contain 
lead. If the child puts these items in his/her mouth, she/he can get lead into his/her body. 
Instructions: Be specific when entering responses to ‘How often?’ (e.g. # times per day, week, or month) 
26. Does [child’s name] eat, chew on, or put items in his/her mouth, such as toys, mini-blinds, crayons, candy 
wrappers, jewelry charms or other jewelry? 
� No >> go to Q. 27 � Yes >> � Don’t know >> go to Q. 27 
26a. If yes >> Please show me. 
Country of How Often? Sample 
Item Name/Description Manufacturer (Be specific) Taken Comments/Observations 
_____times per 
#1 � Yes � No 
______________ 
_____times per 
#2 � Yes � No 
______________ 
_____times per 
#3 � Yes � No 
______________ 
_____times per 
#4 � Yes � No 
______________ 
Instructions: See sampling guidelines. Complete Non-Dust Chain of Custody Form. 
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27. Does your child mouth or chew on any surfaces or furniture? For example, windowsills, walls, chairs, or cribs. 
� No >> go to Q. 28 � Yes >> � Don’t know >> go to Q. 28 
27a. If yes >> Please show me. 
How Often? Sample 
Item Name/Description (Be specific) Taken Comments/Observations 
_____times per 
#1 � Yes � No 
______________ 
_____times per 
#2 � Yes � No 
______________ 
_____times per 
#3 � Yes � No 
______________ 
_____times per 
#4 � Yes � No 
______________ 
Instructions: See sampling guidelines. Complete Non-Dust Chain of Custody Form. 
28. Does [child’s name] eat, chew on, or put paint chips, plaster, soil, or clay in his/her mouth? 
� No >> go to Section H � Yes >> � Don’t know >> go to Section H 
28a. If yes >> Please show me. 
How Often? Sample 
Item Name/Description Location/Room (Be specific) Taken Comments/Observations 
_____times per 
#1 � Yes � No 
______________ 
_____times per 
#2 � Yes � No 
______________ 
_____times per 
#3 � Yes � No 
______________ 
_____times per 
#4 � Yes � No 
______________ 
Instructions: See sampling guidelines. Complete Non-Dust Chain of Custody Form. 
H. OCCUPATIONS AND HOBBIES 
Now I’d like to ask you about the jobs, hobbies or activities of people in the houusehold. 
29. In the past 12 months, has anyone in this household done any of the following jobs, hobbies or activities? 
Person’s Time/Period/ 
Relationship How Long? Comments Section/ 
Job/Hobby/Activity to Child (wks/months) Current Status 
________ weeks Bridge painting or repair work � Yes � No 
________ months 
Commercial building renovation � Yes � No ________ weeks 
or demolition ________ months 
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Home renovation, repair or � Yes � No ________ weeks repainting in buildings built 
before 1960 ________ months 
Torch cutting or burning steel, � Yes � No ________ weeks 
welding ________ months 
Cable splicing, soldering, � Yes � No ________ weeks 
electronics repair ________ months 
Metal or car battery recycling; � Yes � No ________ weeks working in a scrap yard; radiator 
repair ________ months 
Working in a firing range; target � Yes � No ________ weeks 
shooting ________ months 
Jobs/Crafts like furniture � Yes � No 
refinishing, jewelry making, stained ________ weeks 
glass, pottery, ceramics, glass blowing; 
making fishing weights, bullets, or lead figures ________ months 
Other: ______________________ ________ weeks � Yes � No 
________ months 
I. HOUSEHOLD INFORMATION 
I’d like to find out about other children in your household because they may also be exposed to lead. 
30. Other than [child’s name], how many children under age 18 live here? __________ 
Instructions: If no other children, go to Section J. 
Please give me the name(s) and age(s) of the other child(ren). Let’s start with the youngest child. 
Instructions: Write in information. If more than 5 children, write below. 
Full Name (ask for spelling) Date of Birth Relationship to child? Date & BLL if available 
LAST:                                 FIRST: � Brother � Sister _____________ µg/dL 
#1 ____/____/____ � Cousin � Twins ____/____/____ 
   Year � ____________ Mo Day Other: Mo   Day   Year 
LAST:                                 FIRST: � Brother � Sister _____________ µg/dL 
#2 � Cousin  ____/____/____ � Twins ____/____/____ 
� Other: ____________ Mo   Day  Year Mo   Day   Year 
LAST:                                 FIRST: � Brother � Sister _____________ µg/dL 
#3 � Cousin � Twins ____/____/____ ____/____/____ 
 Other: ____________ Mo   Day  Year � Mo   Day   Year 
LAST:                                 FIRST: � Brother � Sister _____________ µg/dL 
#4 � Cousin ____/____/____ � Twins ____/____/____ 
� Other: ____________ Mo   Day  Year Mo   Day   Year 
LAST:                                 FIRST: � Brother � Sister _____________ µg/dL 
#5 � Cousin � Twins ____/____/____ ____/____/____ 
� Other: ____________ Mo   Day  Year Mo   Day   Year 
Instructions: Tell parent/guardian that all children should have blood lead tests. 
J. ALTERNATE CONTACT INFORMATION 
Finally, I would like to ask for a contact person in case we cannot reach you by telephone. 
31. Is there another adult living at this address whom we can contact, in case we cannot reach you? 
� No >> go to Q. 32 � Yes >> 
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31a. If yes >> Please tell me his/her name and telephone number. 
Instructions: Ask person to spell name. 
ALTERNATE CONTACT LAST NAME ALTERNATE CONTACT FIRST NAME 
� NOT PROVIDED 
WORK NUMBER CELL NUMBER 
� NOT PROVIDED � NOT PROVIDED 
31b. What is this person’s relationship ot the child? 
� Mother � Father � Grandmother � Grandfather � Brother       � Sister � Aunt 
� Uncle � Family Friend � Foster Parent       � Other: ____________________________________________ 
32. Is there another person, like a family member or friend, who lives at a different address, whom we 
could contact? 
� No >> go to Q. 33 � Yes >> 
32a. If yes >> Please tell me his/her name and telephone number. 
ALTERNATE CONTACT LAST NAME ALTERNATE CONTACT FIRST NAME 
� NOT PROVIDED 
HOME NUMBER � NOT PROVIDED WORK NUMBER � NOT PROVIDED CELL NUMBER � NOT PROVIDED 
32b. What is this person’s relationship ot the child? 
� Mother � Father � Grandmother � Grandfather � Brother       � Sister � Aunt 
� Uncle � Family Friend � Foster Parent       � Other: ____________________________________________ 
Instructions: Inform person that s/he should notify alternate contacts that we may contact them only if we cannot get in touch with him/her. 
K. LANDLORD INFORMATION 
33. Can you please give me the name and contact information for the landlord or owner? 
Instructions: Ask to see rent bill or lease. Ask person to spell landlord’s name and address. 
MANAGEMENT COMPANY 
� NOT PROVIDED 
LAST NAME FIRST NAME 
STREET APT # 
CITY/BOROUGH STATE ZIP 
TELEPHONE NUMBER CELL NUMBER 
� NOT PROVIDED � NOT PROVIDED 
Record where landlord information was obtained from: 
TIME ENDED: 
L. PAINT INSPECTION AND DUST SAMPLING 
INSTRUCTIONS: First conduct a visual inspection of the apartment. After visual inspection, perform an XRF 
inspection, if required, as per protocol. Show the person the area(s) with lead paint violations. 
If lead paint violations are identified, consider obtaining temporary address information AND consider 
obtaining “Request for Safe House Placement” information. 
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Provide the following information: 
34. Lead paint hazards were found in your home. We recommend that [child’s name] not stay at this address 
during repair work. Staying at a temporary address, such as with a friend or with relatives, is advised. Please 
call us to request a visual inspection for lead paint hazards before your child moves to a temporary address. 
If [child’s name] does not have another place to stay and you would like information about staying at a Lead Safe 
House, please call us. The phone number is in the packet with the other materials that I will review with you. 
(The phone number is 212-676-6379). 
Release Supplement/Temporary Address Information 
LAST NAME FIRST NAME 
STREET APT # 
CITY/BOROUGH STATE ZIP 
TEMPORARY ADDRESS PHONE NUMBER 
� NOT PROVIDED 
CONTACT WORK NUMBER CONTACT CELL NUMBER 
� NOT PROVIDED � NOT PROVIDED 
� Safe House Offered           � Safe House Accepted � Safe House Rejected 
35. Is there anything else you would like to tell me about how your child may have been exposed to lead? 
Instructions: Ask if there are any questions. 
M. INTERVIEW LANGUAGE 
Interview Language: (Instructions: Check off the primary language for the visit.) 
� English � Russian � Hindi � Urdu 
� Spanish � Bengali � Haitian-Creole � Other: _______________________ 
Interpreter used: � No � Yes>> 
If yes >> Type of interpreter used: 
� Family member (specify): ____________________________________ � Friend 
� Telephone interpreting services            �  LPPP staff � Other: _______________________ 
N. COUNSELING AND EDUCATION 
Follow up with your child’s doctor � Do not let your child eat or mouth non-food items that may contain 
� Blood lead tests are necessary to monitor your child’s exposure to lead or lead dust. 
lead. How often these tests need to be done depends on your � Use cold tap water only for making baby formula or baby cereal, 
child’s lead level, length of exposure and risk for further exposure. and for drinking or cooking. Let water run for a few minutes before 
� Generally, the higher the blood lead level and the longer the exposure, you use it. Lead can get into water through old plumbing. 
the more time it will take for the lead to leave your child’s body, and Help your child to eat healthy 
the longer your child will need to be monitored by your doctor. � It is important for your child to eat a healthy diet with enough 
Reduce your child’s exposure to lead calcium, iron and vitamin C. 
� Keep your child away from the lead paint hazards noted in your � Talk to your doctor to make sure your child is eating foods with 
home. Consider having your child stay somewhere else while enough calcium, iron, and vitamin C in them. 
hazards are being corrected. Get your household members tested for lead 
� Wash floors and windowsills often using a damp mop or damp cloth. � This is especially important for children younger than 6 years of 
� Wash your child’s hands, toys, pacifiers and bottles often to remove age, children with developmental problems and pregnant women. 
lead dust, especially before your child eats or sleeps. � Older children and adults should be tested if they may have had 
� If someone in your home has a job or hobby that involves contact contact with lead. 
with lead, have them remove their shoes before entering your For more information about lead poisoning 
home. Wash their work clothes separately from family laundry. � Speak with your doctor 
� Avoid using medicines, spices, foods, cosmetics, jewelry, and � Call 311 and ask for the BAN-LEAD information line 
painted toys from other countries. They are more likely to contain � Contact your case manager at 212-676-6379 
lead than products made in the U.S.A. � Go to www.nyc.gov/lead 
� Avoid using clay pots and dishes from other countries to cook, 
Ask if there are any questions. store or serve food. Do not use pottery that is chipped or cracked. 
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APPENDIX A: Questions 11a. Instructions: Please show this list to parent/guardian and ask him/her to tell you/point 
to the area where the child was born. If the area is not on the list, please write in the area and ask for the spelling. 
Mexico � Morelos Haiti 
� Nayarit 
� Aguascalientes � Aribonite (Gonaïves) � Nort-Quest (Port-de-Paix) 
� Nuevo Léon 
� Baja California � Centre (Hinche) � Quest (Port-au-Prince) 
� Oaxaca 
� Baja California Sur � Grand’Anse (Jérémie) � Sud (Les Cayes) 
� Puebla 
� Campeche � Nord (Cap-Haïtien) � Sud-Est (Jacmel) 
� Querétaro (de Arteaga) 
� Chiapas � Nord-Est (Fort Liberté) � Other (specify) _______________ 
� Quintana Roo 
� Chihuahua 
� San Luis Potosí 
� Coahuila (de Zaragoza) 
� Sinaloa 
� Colima Pakistan � Karachi � Rahimyar Khan 
� Sonora 
� Distrito Federal � Kasur � Rawalpindi 
� Tabasco � Bahawalpur 
� Durango � Lahore � Sahiwal 
� Tamaulipas � Faisalabad 
� Guanajuato � Larkana � Sargodha 
� Tlaxcala � Gujranwala 
� Guerrero � Mardan � Shekhupura 
� Verazruz (-Llave) � Gujrat 
� Hidalgo � Multan � Sialkot 
� Yucatán � Hyderabad 
� Jalisco � Okara � Sukkur 
� Zacateca � Islamabad 
� México � Peshawar � Other (specify) 
� Other (specify): � Jhang Maghiana 
� Michoacán (de Ocampo) � Quetta _________________ 
______________________ 
Dominican Republic � Monseñor Nouel Bangladesh � Gaibanda � Madaripur � Panchagarh 
� Monte Cristi � Gazipur � Magura � Pirojpur 
� Azua � Bandarban 
� Monte Plata � Gopalganj � Meherpur � Rangamati 
� ABahoruco � Barguna 
� Pedernales � Habiganj � Manikganj � Rajshahi 
� Barahona � Barisal 
� Peravia (incl. San José � Jamalpur � Munshiganj � Rajbari 
� Dajobón � Begerhat de Ocoa) � Jaipur Hat � Mymensingh � Rajshahi 
� Distrito Nacional � Bhola � Puerto Plata � Jessore � Narayanganj � Rangpur (incl. Santo Domingo) � Bogra � Salcedo � Jhalakhati � Naogaon � Shariatpur � Duarte Brahmanbaria � Samaná � � Jhenida El Seibo � Nator � Sherpur � � Chandpur � San Cristóbal 
Elias Piña � Kishorganj � Narsingdi � Satkhira � � Chuadanga � San Jose � Khagrachari � Narail � Sylhet � Espaillat Chittagong � San Pedro de Macorís � � Khulna � Nawabganj � Sanamganj � Hato Mayor � Comilla � Sánchez Ramírez � Kurigram � Nilphamari Independencia � Sirajganj � Cox’s Bazar � Santiago � � Kushtia � Noakhali Tangail � La Altagracia � � � Dinajpur Santiago Rodriguez � � � � Lalmonir Hat Netrakona Thakurgaon La Romana alverde � � V Dhaka 
� La Vega � Lakshmipur � Pabna � Other (specify) � � Other (specify): Faridpur 
María Trinidad Sánchez � Maulvi Bazar � � Patuakhali _______________ _____________________ � Feni 
NOTES 
Question # Comments/Observations 
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Nutrition Reference Information 
RECOMMENDED INTAKE AND COMMON FOOD SOURCES 
The Dietary Reference Intakes are nutrient reference values established by the Food 
and Nutrition Board of the National Academy of Sciences’ Institute of Medicine (IOM 1997, 
2000, 2001).  Reference values are population specific and vary by sex and life cycle group 
and during pregnancy or lactation.  The type of reference values established differ based on 
the quantity and quality of the research used to establish recommendations.  The
Recommended Dietary Allowance (RDA) is the nutrient intake level that is used as a goal for 
an individual and represents an intake level which is sufficient to meet the nutrient
requirements of nearly all healthy individuals in the population (IOM 1997, 2000, 2001).  If
insufficient clinical data is available to establish an RDA, an Adequate Intake (AI) is 
established.  The AI is a level that is felt to meet the needs of all individuals in the group 
(IOM 1997, 2000, 2001).  Pregnant and lactating women should aim to meet established 
RDA or AI levels for through dietary intake.  Vitamin or mineral supplementation is 
recommended for those women who are unable to meet nutrient requirements through 
dietary sources.  
Calcium 
The Adequate Intake level of calcium is 1,300 mg/day for pregnant and lactating 
women 18 years and younger and 1,000 mg/day for pregnant and lactating women 19 
years and older (IOM 1997).  The richest and most absorbable sources of calcium are dairy 
products including: milk, cheese, and yogurt.  However, many ethnic groups avoid dairy 
products because of lactose intolerance which has been estimated to have a high prevalence 
in Asians (100%), African Americans (75%), Native Americans (100%), and Hispanics 
(53%)(Jackson and Savaiano, 2001).  Calcium-set tofu and calcium-fortified fluids such as
orange juice, soymilk, almond milk, and rice milk, are also rich sources of calcium.  Calcium 
is also found in some vegetables such as broccoli, bok choy, and kale; however, the calcium 
found in plant foods is less bioavailable than the calcium in dairy products and fortified
foods. 
Iron 
The Recommended Dietary Allowance of iron is 27 mg/day for all pregnant women,
10 mg/day for lactating women 18 years and younger, and 9 mg/day for lactating women
19 years and older (IOM 2001).  The amount of iron from food that is absorbed by the body 
is dependent on the source of the iron.  Heme iron is readily absorbed by the body and is 
found in meat, poultry, and fish.  Nonheme iron is found in iron-fortified foods such as
bread, cereal, and grain products, beans/legumes, vegetables, and iron supplements. The 
absorption of nonheme iron is enhanced when eaten at the same time as vitamin C rich 
foods or with an animal product such as meat or poultry.
Selenium
The Recommended Dietary Allowance of Selenium is 60 µg/day for all pregnant
women and 70 µg/day for all lactating women (IOM 2000).  Selenium is found in: meats, 
especially organ meats, seafood, and Brazil nuts. The selenium content of fruits, vegetables, 
nuts, and grains is dependent on soil selenium content and therefore varies substantially 
based on the plant’s origin. 
Zinc
The Recommended Dietary Allowance of zinc is 12 mg/day for pregnant and 13
mg/day for lactating women 18 years and younger and 11 mg/day for pregnant and 12 
mg/day lactating women 19 years and older (IOM 2001).  Red meat and shellfish are rich 
sources of bioavailable zinc. Zinc is also found in: nuts, legumes, fortified cereals, and whole
grains.
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The Recommended Dietary Allowance of vitamin C is 80 mg/day for pregnant and 
115 mg/day for lactating women 18 years and younger and 85 mg/day for pregnant and 
120 mg/day lactating women 19 years and older (IOM 2000).  Vitamin C is found in: plant 
products such as citrus fruits, fruit juice, tomatoes, tomato juice, potatoes, cauliflower, 
broccoli, strawberries, cabbage and spinach. 
Vitamin D
The Recommended Dietary Allowance of vitamin D is 200 IU/day for all pregnant and 
lactating women (IOM 1997).  Recommendations for higher dietary intakes of pre-formed 
vitamin D have also been made (Prentice 2003; Hollis 2005). In nonpregnant adults, daily 
supplementation with 400 IU vitamin D increases 25(OH)D by 7.0 nmol/L (2.8 ng/ml)
(Heaney). Supplementation of a pregnant woman with 400 IU vitamin D, as in prenatal
vitamins, has little effect on her 25(OH)D concentration (Wagner 2008).  The AAP 
recommends that pregnant women maintain a 25(OH)D level of 80 nmol/L (32 ng/ml)
(Wagner 2008).  Dark-skinned individuals require exposures about 5-10 times as long as 
light-skinned individuals to achieve similar levels of cutaneous vitamin D production. (Holick
2004).  At latitudes above 35N and below 35S ultraviolet B photons do not penetrate of 
the earth’s surface in winter months, making cutaneous vitamin D production negligible in
those months; additionally sun exposures outside the peak sun hours of 10 AM to 3 PM in 
the spring, summer and fall has limited impact on cutaneous vitamin D synthesis (Holick 
2003). Clinicians should note that obesity is a risk factor for low 25(OH)D and that 
sunscreen blocks cutaneous production of vitamin D (Holick 2007). The AAP recommends 
that exclusively and partially breastfed infants receive supplements of 400 IU/day of vitamin 
D shortly after birth and continue to receive these supplements until they are weaned and 
consume ≥1,000 mL/day of vitamin D-fortified formula or vitamin D-fortified milk (Wagner).
Food sources of vitamin D (25-hydroxy vitamin D) include: fortified milk, fortified 
orange juice, fortified cereal, some fatty fish (such as salmon and sardines), fish liver oils,
and some eggs.  UV radiation exposure stimulates vitamin D synthesis (through activation
of the pro-vitamin D precursor 7-dehydrocholesterol present in skin), so vitamin D needs
can also be met through sun exposure though dark-skinned women require more time
exposed to sunlight for the same benefits and, thus, more vitamin D to be obtained from 
the diet (Holick, 2004). 
In the United States 98% of fluid milk is estimated to be fortified with vitamin D
(Anderson and Toverud, 1994), however, one study found that only 47.7% of milk samples 
were appropriately fortified with most of the out-of-compliance milk samples being under-
fortified (Murphy et al., 2001). In 2003, the Food and Drug Administration approved food 
fortification with vitamin D of calcium-fortified juices and juice drinks (FDA, 2003). This may
provide enhanced sources of dietary vitamin D to ethnic groups who avoid dairy products
because of lactose intolerance.  Strategies to increase vitamin D intake, especially for non-
Caucasians, emphasize dietary supplements and these vitamin-D enriched non-dairy 
products. 
Vitamin E
The Recommended Dietary Allowance of vitamin E is 15 mg (22.5 IU)/day for all 
pregnant women and 19 mg (28.5)/day for all lactating women (IOM 2000).  Foods rich in 
vitamin E include: vegetable oils (olive, sunflower, and safflower oils), nuts, whole grains, 
green leafy vegetables, and meats. 
ASSESSMENT OF NUTRIENT STATUS AND INTAKE
Biochemical Indicators 
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Blood hemoglobin levels are routinely measured to screen for iron deficiency anemia 
(IOM 2001) and serum concentration of 25(OH)D is the best indicator of vitamin D status 
(IOM 1997). Biochemical assessment of nutrient status is not routinely performed for all 
vitamins and minerals, however, because reliable and valid laboratory tests of nutritional 
status are not available for many nutrients such as zinc and calcium (reference needed).  
In the absence of biochemical assessment options, dietary assessment methods are 
utilized to estimate usual dietary intake and to screen for possible dietary inadequacies.
The most commonly used dietary assessment methods include: 24-hour recalls, food (diary)
records, and food frequency questionnaires.
24-Hour Recall
During a 24-hour recall, an individual is asked to report food and fluid intake 
information for the previous day (Hu 2008). The individual is probed for additional 
information about the food or beverage consumed, including preparation the portion size
eaten. A brief qualitative assessment of the recall is usually conducted by the clinician
performing the assessment.  Common qualitative assessments conducted include: 
estimation of the number of servings of fruits/vegetables eaten or for the inclusion so of
iron-rich or calcium-rich foods.  The 24-hour recall is the dietary assessment method most 
commonly utilized in clinical settings because they can be conducted in a short amount of
time and they do not require advanced preparation or complicated scoring.  Limitations of 
the 24-hour recall include: reliance on memory, difficulty in estimation of portion sizes,
underreporting of food intake, and intentional omission of nutrient-poor foods.  In addition, 
food consumed in the previous day may also not be representative of usual dietary intake.  
Food Record 
The food record (diary) method requires that an individual record in detail all the 
foods and beverages consumed over one or more days (typically between 3 and 7 days) (Hu 
2008).  The individual completing the food record is typically taught about recording 
procedures such as portion size estimation prior to completing the records.  Quantitative 
analysis of completed food records are typically completed by a Registered Dietitian so 
dietary inadequacies and excesses can be identified.  Although food records are typically 
considered the “gold standard” of dietary assessment, there are a number of limitations to 
this approach.  Food records are time and labor intensive to both the individual completing
the record and the individual conducting the dietary analysis.  Individuals may also alter 
their food intake while completing the food record.
Food Frequency Questionnaire
Food Frequency Questionnaires (FFQs) were developed to assess long-term dietary 
intake and are often used in epidemiologic studies (Hu 2008).  Numerous food frequency
questionnaires have been developed and validated for use in specific populations.  A food 
frequency questionnaire consists of a list of food items and beverages.  Individuals are 
asked to report their usual consumption over a specified period of time from a list of 
frequency categories. The average intake over the designated time period of an assortment 
of nutrients is calculated based on the individual’s responses.  FFQs have a number of 
advantages in epidemiologic studies such as minimal respondent burden and low costs. 
However, since FFQs lack the detail of dietary records or 24-hour recalls, they provide less 
accurate estimates of absolute intake. 
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TABLE XII-1 Recommended Dietary Intake and Common Food Sources of
   Selected Nutrients












Plain yogurt, low-fat (12 g protein/8 
415 
oz), 8-oz container 
Soy beverage, calcium fortified, 1 cup 
368 
Fruit yogurt, low-fat (10 g protein/8 
345 
oz), 8-oz container 
Swiss cheese, 1.5 oz
336 
1,300 1,300 
Ricotta cheese, part skim, ½ cup 335 







Cheddar cheese, 1.5 oz





Sardines, Atlantic, in oil, drained, 3 oz 
1% low-fat milk, 1 cup
306 
Low-fat chocolate milk (1%), 1 cup
325 
Whole milk, 1 cup
Tofu, firm, prepared with nigari , ½ 
290 
cup 288 
Spinach, cooked from frozen, ½ cup 276 
253 
146 
Clams, canned, drained, 3 oz
Fortified ready-to-eat cereals
23.8
(various), ~ 1 oz 1.8 -21.1
Oysters, eastern, wild, cooked, moist 







Fortified instant cooked cereals 
(various), 1 packet 
4.9-8.1
Soybeans, mature, cooked, ½ cup 4.4 
White beans, canned, ½ cup
Blackstrap molasses, 1 Tbsp
3.9 
Lentils, cooked, ½ cup
Spinach, cooked from fresh, ½ cup 
3.5 
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Beef, chuck, blade roast, lean, cooked, 
3 oz 
3.3 
Prune juice, ¾ cup 
3.2 
Shrimp, canned, 3 oz 3.1 
Ground beef, 15% fat, cooked, 3 oz 2.3 
2.3 
2.2 
Brazil nuts, dried, unblanched, 1
ounce
Tuna, light, canned in oil, drained, 3
ounces
Beef, cooked, 3½ ounces 
Cod, cooked, 3 ounces 544 
Turkey, light meat, roasted, 3½ 63 
ounces 35 
32 












Egg, whole, 1 medium 12 
Cottage cheese, low fat 2%, 1/2 cup 12 
12 
Oatmeal, instant, fortified, cooked, 1 10 
cup
Rice, white, enriched, long grain, 
cooked, 1/2 cup 
Rice, brown, long-grained, cooked, 
1/2 cup
Bread, enriched, whole wheat, 
commercially prepared, 1 slice
10 
Beef shank, lean only, cooked 3 oz 
Beef tenderloin, lean only, cooked, 3 8.9 
oz 4.8 
3.7 
12 13 Breakfast cereal, complete wheat bran 2.7 







Chicken leg, meat only, roasted, 1 leg 




(>19 (>19 oz 1.4 
years) years) Yogurt, plain, low fat, 1 c 1.3 
1.3 
Baked beans, canned, with pork, 1/2 c 1.1 
Cashews, dry roasted w/out salt, 1 oz 1.1 
Pecans, dry roasted w/out salt, 1 oz
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Raisin bran, 3/4 c 
Chickpeas, mature seeds, canned, 1/2
c 
Mixed nuts, dry roasted w/peanuts, 
w/out salt, 1 oz
Cheese, Swiss, 1 oz 
Red sweet pepper, raw, ½cup 142 
Kiwi fruit, 1 medium 70 
Orange, raw, 1 medium
70 
Orange juice, ¾ cup 













Vegetable juice cocktail, ¾ cup
Strawberries, raw, ½ cup 50-70
(>19 (>19 Brussels sprouts, cooked, ½ cup 50 
years) years) Cantaloupe, ¼ medium




Cod liver oil, 1 tablespoon 1,360
360 
Salmon, cooked, 3.5 ounces 345 
Mackerel, cooked, 3.5 ounces 200 
250 
Tuna fish, canned in oil, 3 ounces 98 
Sardines, canned in oil, drained, 1.75 60 
40 ounces
20 
Vitamin Milk, nonfat, reduced fat, and whole, 15 
D 
(IU)
200 200 vitamin D-fortified, 1 cup
Margarine, fortified, 1 tablespoon
Ready-to-eat cereal, fortified with 
10% of the DV for vitamin D, 0.75-1
cup
Egg, 1 whole (vitamin D is found in
yolk)
Liver, beef, cooked, 3.5 ounces 




15 mg 19 mg
Fortified ready-to-eat cereals, ~1 oz 




















Sunflower oil, 1 Tbsp 
Cottonseed oil, 1 Tbsp
Safflower oil, 1 Tbsp
Hazelnuts (filberts), 1 oz
Mixed nuts, dry roasted, 1 oz
Turnip greens, frozen, cooked, ½ cup 
Peanut butter, 2 Tbsp
Tomato puree, ½ cup
Canola oil, 1 Tbsp 
Wheat germ, toasted, plain, 2 Tbsp 
Peanuts, 1 oz
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Template for Letter to Construction Employer re: Occupational Exposure
TEMPLATE FOR HEALTH CARE PROVIDER LETTER TO EMPLOYER 
Prior to issuing such a letter, the healthcare provider should discuss the contents with the 
affected employee and obtain her authorization.
Physician Provider Letterhead 




City, State XXXXX 
Re: Medical Opinion Regarding Occupational Lead Exposure of [NAME OF PATIENT] 
Dear Employer: 
On [DATE], I conducted a medical evaluation of Ms. [NAME OF PATIENT], who reports being 
an employee of your company.  Based on the information provided by Ms. [NAME OF 
PATIENT], she performs work at your company that may expose her to lead. A  laboratory test 
performed on [DATE] reported a blood lead concentration of [ENTER RESULT] micrograms 
per deciliter (μg/dL). 
My evaluation of Ms. [NAME OF PATIENT] indicates that she is pregnant or planning to 
conceive. Lead exposure has been associated with adverse reproductive outcomes, including an 
increased risk of miscarriage, hypertension during pregnancy, decreased fetal growth, and 
developmental problems in children born to lead-exposed mothers. The U.S. Centers for Disease 
Control and Prevention recommends that women who are or may become pregnant limit their 
exposure to lead. 
In accordance with the OSHA Lead Standards [1910.1025(j)-(k), and 1910.1025 App C – 
Section I. Medical Surveillance and Monitoring Requirements for Workers Exposed to Inorganic 
Lead, or 1926.62(j)-(k)], this letter represents my medical opinion that Ms. [NAME OF 
PATIENT] should be removed from lead exposure at your company. This removal should 
remain in effect until such time that she is no longer pregnant or no longer trying to conceive a 
child. In the interim, Ms. [NAME OF PATIENT] is capable of continuing to work at a job task 
or location associated with her employment that would not be expected to result in a blood lead 
concentration of ≥ 5 μg/dL. I am available to discuss the acceptability of any alternative work 
assignments for the patient with you or one of your representatives. 
I have also attached a brochure that discusses the health effects of lead exposure and outlines 




























   
















You may work with lead if you: 
O   Make or repair radiators 
O   Make or recycle batteries 
O   Recycle scrap metal or electronics 
O   Melt, cast, or grind lead, brass, or bronze 
O   Make or glaze ceramics 
O Work at a shooting range 
O   Remove paint or coatings 
O  Remodel homes and buildings 
O Tear down buildings, bridges, or tanks 
This is not a complete list.  If you are unsure 
if you work with lead, ask your employer. 
Health damage from lead:
Can be permanent. 
Can be occurring even if 
you have no symptoms. 
May not show up until 
many years later. 
If you work with lead you need to: 
k Find out how much lead is in your blood. 
k Talk to your doctor about lead and your health. 
k Take steps to protect yourself at work. 
What health damage can low 
levels of lead cause? 
Studies in recent years show that low levels of lead in 
adults can: 
k increase blood pressure— may increase your 
chances of having a heart attack or stroke. 
k decrease brain function— making it more difficult 
to think, learn, and remember. 
k decrease kidney function— making it more difficult 
to get rid of toxic waste products through your urine. 
k harm the physical and mental development of 
your baby before it’s born. 
k increase chances of having a miscarriage. 
New Health Dangers from Lead 
WORKPLACE  HAZARD  ALERT 








How does lead get into my 
body? 
Lead gets into the body through the air you breathe.
You can also swallow lead without knowing it if 
lead dust gets onto your hands or face or on food 
you eat. 
How do I know how much 
lead is in my body? 
Get a blood lead level test.  This test measures the 
amount of lead in a person’s blood.  Blood lead test 
results are reported as micrograms of lead per 
deciliter of blood (µg/dL or 
mcg/dL). The typical blood 
lead level for adults in the 
U.S. is less than 2 µg/dL.  
Even if you feel fine, you 
should get tested. 
What level of lead is harmful? 
Some of the harmful effects of lead have been seen 
at very low levels.  Scientists and doctors now 
recommend that blood lead 
levels be kept below 
10 µg/dL. Pregnant women 
or women considering 
pregnancy should not have 
a blood lead level above 
5 µg/dL. 
Will my health be damaged? 
No one can predict for sure whether your health 
will be damaged at a low blood lead level.  Your risk 
(chance) of suffering from health damage increases 
with the amount of lead in your blood and the 
length of time you have been exposed.  It will also 
depend on whether you have any health conditions 
that place you at higher risk of damage from lead. 
If your blood lead level has been above 10 µg/dL for 
more than a year, the most important thing you can 
do is take steps to lower your exposure in the future.
Information on how you can protect yourself is on 
pages 4 and 5. 
You should also talk to your personal doctor about 
whether you have any medical conditions that may 
make you more sensitive to the harmful effects of 
lead.
       Know 
your number. 
YES. You take lead dust from your job to your 
family when you wear your work clothes and 
shoes home.  Lead dust can get in your car.  
It can get on furniture, floors, and carpets.  
Your child can swallow this lead dust and 
be poisoned.  The steps you take to protect 
yourself will also keep you from bringing lead 
home to your family.  See pages 4 and 5 for 
more information on what you can do. 
Can lead at work harm my family? 
2 
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What should I tell my doctor? 
Your doctor needs to know if you work with lead.  
Your doctor can order a blood lead level test if you 
need one.  Also, you may have a medical condition 
that makes you more sensitive to the harmful effects 
of lead.  
Tell the doctor: 
k What you do at work. 
k How long you have been at your job. 
k Any lead jobs you’ve had in the past. 
k If you’ve ever had a blood lead level test. 
k If you’ve had to be moved to a different job or 
be off work because your lead level was high. 
k If you think working with lead is making 
you sick. 
Women should also tell their doctor if they are 
pregnant or considering becoming pregnant. 
Ask the doctor if you: 
k Have any medical conditions that may make 
you more sensitive to the effects of lead. 
: High blood pressure 
: Kidney disease 
: Brain or nerve disease 
: Other 
k Need any follow-up medical tests to see if lead 
is affecting your health. 
: Recheck blood pressure 
: Kidney function tests 
: Cognitive evaluation 
: Other 
See the attached clip-off form to fill out and 
take to your doctor. 
My blood lead level has been 
high for years.  Should I find 
other work? 
Whether you continue to work with lead is a 
personal decision. It is often a tough decision to 
make.  When making this decision, consider: 
k Are there steps you can take to lower your 
exposure to lead?  See pages 4 and 5 for steps 
you can take to protect yourself. 
k Do you have any health conditions that may 
make you more sensitive to the harmful effects 
of lead? 
k If you have a medical condition that places you 
at higher risk, can you transfer to another job 
without lead at the same company? 
k If you change jobs will you receive the same 
salary and benefits?  If not, can you and your 
family afford a lower paying job? 
3
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Make sure you don’t accidentally swallow lead. 
k Wash your hands and face with soap and water before eating or drinking 
and before leaving work. 
k Do not eat, drink, or smoke in the work area. 
k Take a shower and wash your hair as soon as 
you get home.  (It’s better to shower at work if 
you can.) 
k Change into clean clothes and shoes at work 
before you go home.  Keep dirty work clothes 
and shoes separate from clean street clothes. 
If you don’t have a storage locker, keep your 
dirty clothes and shoes in a plastic bag. 
k Use wet cleaning methods.  Wet wipe surfaces 
and mop or HEPA vacuum the shop floor daily. 
Do what you can to lower the amount of lead you 
breathe in. 
k If you have local exhaust ventilation, turn it on 
and position it correctly while you work with lead. 
k Ask your employer for a respirator to wear while 
you work with lead.  If you already wear a respirator, 
ask whether there is another type of respirator that 
will protect you better.  If you use a respirator, your 
employer has to pay for a doctor to evaluate 
whether you can wear one safely.  Your employer 
must also provide you with a fit-test to make sure 
that the respirator fits you well. 
Get a blood lead level test at least every 6 months. 
k Ask your employer for a blood lead level test.  
If you have significant lead exposure at work, your 
employer must provide you with a test and pay 
for it. 
k Ask your personal doctor for a test if your 
employer doesn’t provide one. 
For industrial workers 
What can I do to protect myself? 
Get tested 















Make sure you don’t accidentally swallow lead. 
k Wash your hands and face with soap and water before eating
or drinking and before leaving work.  Use a portable plastic 
container with a spigot if running water is not available. 
k Do not eat, drink, or smoke in the work area.  Move to a clean 
area for lunch or breaks. 
k Take a shower and wash your hair as soon as you get home.  
(It’s better to shower at the job site if there are portable showers.) 
k Change into clean clothes and shoes at the job site before you go 
home.  Keep dirty work clothes and shoes separate from clean street 
clothes.  Dirty clothes and shoes can be stored in a plastic bag. 
k Use wet cleaning methods.  Wet wipe surfaces and wet clean or  
HEPA vacuum the work area daily. 
Do what you can to lower the amount of lead you 
breathe in. 
k Use work methods that keep dust and fume levels 
down. 
k Ask your employer for a respirator to wear while you 
work with lead.  If you already wear a respirator, ask 
whether there is another type of respirator that will 
protect you better.  If you use a respirator, your employer 
has to pay for a doctor to evaluate whether you can wear 
one safely.  Your employer must also provide you with a 
fit-test to make sure that the respirator fits you well. 
Get a blood lead level test at least every 6 months. 
k Ask your employer for a blood lead level test.  If you 
have significant lead exposure at work, your employer 
must provide you with a test and pay for it. 
k Ask your personal doctor 
for a test if your employer 
doesn’t provide one. 
For construction workers 
What can I do to protect myself? 
Strip back paint before cutting or welding. 
Attach power tools to a HEPA vacuum. 
Use a long-handled torch and stand upwind. 
Get tested 













Toll-free to California callers. 
O For information about lead safety: 
(866) 627-1587 
O For information about other workplace 
hazards:  (866) 282-5516 
O California Relay Service: 
(800) 735-2929 or 711 
O www.cdph.ca.gov/programs/ohb 
Are there any laws that 
protect me if I work with 
lead? 
Yes.  Your employer must follow special laws to 
protect you from lead hazards on the job.  These 
laws are called the Cal/OSHA Lead Standards. 
The Lead Standards contain many important 
requirements to protect you from lead.  However, 
because they were written many years ago they 
are not based on the most recent scientific 
information.  You can have a blood lead level 
above 10 µg/dL even if your employer follows the 
standards.  That’s why it’s important for workers 
and employers to do everything they can to lower 
the amount of lead in the workplace. 
To find out more about the Cal/OSHA Lead 
Standards, call the Lead in the Workplace Helpline 
(866/ 627-1587) or visit 
www.cdph.ca.gov/programs/olppp . 
Talk to your employer if you think there is a lead 
problem at your job.  If your employer does not fix 
the problem, you can call Cal/OSHA and ask for an 
inspection.  Cal/OSHA will not tell your employer 
who made the call.  Call the Cal/OSHA office in 
your area or call Cal/OSHA headquarters at 
(510) 285-7000. 
California Department of Public Health 
Occupational Health Branch
850 Marina Bay Parkway, Building P, Third Floor 




Arnold Schwarzenegger, Governor 
State of California 
Kimberly Belshé, Secretary 
Health and Human Services Agency 
Mark B. Horton, MD, MSPH, Director 
California Department of Public Health 
To obtain a copy of this document in an alternate format, 
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Worksite Evaluation Form 
What your employer should do to protect you 
The best thing that your employer can do is to get rid of lead and lead-containing materials.  If it’s 
not possible to get rid of the lead, your employer should take steps to keep the amount of lead in 
the workplace as low as possible.  Your employer should: 
Train you to work safely with lead. 
Provide wash-up and shower facilities. 
k If you work in construction these may be portable wash stations and portable showers. 
k Your employer should provide you sufficient time to wash up before breaks, lunch, and 
going home. 
Provide clean areas for eating and changing. 
Provide work clothes and work shoes that stay at the job site. 
Provide a HEPA vacuum or tools for wet cleaning the work area. 
Install local exhaust ventilation whenever possible. 
k If there is already local exhaust ventilation your employer should check it regularly to 
make sure it works well. 
Provide you with the right tools to keep lead dust and fume levels down such as power 
tools attached to a HEPA vacuum and long-handled torches. 
Separate lead work areas from non-lead work areas. 
k In construction, plastic sheeting can be used to isolate dusty work from the surrounding 
area. 
Provide you with a respirator to give you even more protection. 
k If you use a respirator, your employer has to pay for a doctor to evaluate whether you 
can wear one safely.  Your employer must also provide you with a fit-test to make sure 
that the respirator fits you well. 
Provide you with a blood lead level test at least every six months. 
OLPPP 
Occupational Lead Poisoning Prevention Program 
California Department of Public Health, Occupational Health Branch





     
     
 
  
 Lead Health Evaluation Form 
To the worker: 
Fill out the upper part of this form as completely as you can and share the form with your doctor.  The lower part of the 
form has information for your doctor on body systems and health conditions that may be affected by lead.  Talk to your 
doctor about any concerns you have. 
Your name                  Date of birth 
Your employer’s name 
What job do you do now? How long have you been at this job? 
Have you worked with lead at other jobs in the past? 
Have you had a blood lead level test done in the past? (List the date(s) and the test results if you know them.) 
Have you ever had to be moved to a different job or be off work because your blood lead level was high? 
Do you think working with lead is making you sick?  If yes, explain. 
California Department of Public Health, Occupational Health Branch
850 Marina Bay Parkway, Building P, Third Floor, Richmond, CA 94804 
OLPPP 
Occupational Lead Poisoning Prevention Program 

To the healthcare provider: 
Recent studies show that persistent low-level lead exposures are associated with an increased risk of hypertension, 
subtle effects on renal function, subclinical cognitive dysfunction, and adverse female reproductive outcome. Please 
review the following with your patient: 
MAny blood pressure concerns M  Any kidney function concerns       
M  Any brain function concerns M  Pregnancy concerns (for female patients of reproductive age) 
Follow-up recommendations: 
M Recheck blood pressure? M Test kidney function with BUN/Cr?      
M  Cognitive evaluation? M  Other? 
For health care providers with questions about medical management of lead-exposed California workers, please call 
Dr. Ray Meister of the Occupational Lead Poisoning Prevention Program at (510) 620-5731. 
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